{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:30:19Z","timestamp":1792301419601,"version":"4.4.0"},"reference-count":2247,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Clinical Apheresis"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special Issue Writing Committee is charged with reviewing, updating, and categorizing indications for the evidence\u2010based use of therapeutic apheresis (TA) in human disease. As in recent editions, the Tenth Edition of the JCA Special Issue committee has incorporated systematic review and evidence\u2010based approaches in the grading of evidence and categorization of apheresis indications to make recommendations on the use of apheresis in a wide variety of diseases and conditions. This edition has largely maintained the general layout and concept of a fact sheet introduced in the Fourth Edition (2007). Each fact sheet succinctly summarizes the evidence for the use of TA in a specific disease entity or medical condition. The Tenth Edition comprises 93 fact sheets and 183 graded and categorized indications. This includes two new fact sheets and several changes to indications, categorization, or grade on existing fact sheets. The Tenth Edition of the JCA Special Issue seeks to continue to serve as a key resource that guides the utilization of TA in the treatment of human disease.<\/jats:p>","DOI":"10.1002\/jca.70141","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:04:53Z","timestamp":1789567493000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Guidelines on the Use of Therapeutic Apheresis in Clinical Practice\u2014Evidence\u2010Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue"],"prefix":"10.1002","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5776-6400","authenticated-orcid":false,"given":"Nicole D.","family":"Zantek","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology University of Minnesota  Minneapolis Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9352-2585","authenticated-orcid":false,"given":"Caroline R.","family":"Alquist","sequence":"additional","affiliation":[{"name":"Hoxworth Blood Center University of Cincinnati  Cincinnati Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8087-6704","authenticated-orcid":false,"given":"Jan C.","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine University of California San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4105-6660","authenticated-orcid":false,"given":"Reinhard","family":"Klingel","sequence":"additional","affiliation":[{"name":"Apheresis Research Institute, Cologne, and First Dept. Internal Medicine University Hospital Mainz  Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-2301","authenticated-orcid":false,"given":"Yosef","family":"Levenbrown","sequence":"additional","affiliation":[{"name":"Department of Critical Care Nemours Children\u2019s Hospital  Wilmington Delaware USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7266-7101","authenticated-orcid":false,"given":"Oluwatoyosi A.","family":"Onwuemene","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Duke University Medical Center  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9681-3898","authenticated-orcid":false,"given":"Gopal","family":"Patidar","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine All India Institute of Medical Sciences  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2089-8650","authenticated-orcid":false,"given":"Christopher J.","family":"Patriquin","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9835-957X","authenticated-orcid":false,"given":"Jay S.","family":"Raval","sequence":"additional","affiliation":[{"name":"Department of Pathology &amp; Laboratory Medicine, Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, Vermont and the Department of Pathology University of New Mexico Health Sciences Center  Albuquerque New Mexico USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5287-6472","authenticated-orcid":false,"given":"Amber P.","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine University of California San Diego  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1851-7521","authenticated-orcid":false,"given":"Jennifer","family":"Schneiderman","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology\/Neuro\u2010Oncology\/Stem Cell Transplant, Ann &amp; Robert H. Lurie Children\u2019s Hospital of Chicago Northwestern University Feinberg School of Medicine  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7800-3119","authenticated-orcid":false,"given":"Yvette C.","family":"Tanhehco","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cell Biology Columbia University Irving Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9646-6216","authenticated-orcid":false,"given":"Laura","family":"Connelly\u2010Smith","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Fred Hutch Cancer Center &amp; University of Washington Medical Center  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"2","key":"e_1_2_7_2_1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jca.22043","article-title":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice\u2014Evidence\u2010Based Approach From the Writing Committee of the American Society for Apheresis: The Ninth Special Issue","volume":"38","author":"Connelly\u2010Smith L.","year":"2023","journal-title":"Journal of Clinical Apheresis"},{"issue":"1","key":"e_1_2_7_3_1","first-page":"1","article-title":"Clinical Applications of Therapeutic Apheresis. Report of the Clinical Applications Committee, American Society for Apheresis","volume":"3","author":"Klein H. G.","year":"1986","journal-title":"Journal of Clinical Apheresis"},{"key":"e_1_2_7_4_1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/jca.20134","article-title":"The New Approach to Assignment of ASFA Categories\u2014Introduction to the Fourth Special Issue: Clinical Applications of Therapeutic Apheresis","volume":"22","author":"Szczepiorkowski Z. M.","year":"2007","journal-title":"Journal of Clinical Apheresis"},{"key":"e_1_2_7_5_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/jca.20240","article-title":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice: Evidence\u2010Based Approach from the Apheresis Applications Committee of the American Society for Apheresis","volume":"25","author":"Szczepiorkowski J.L.","year":"2010","journal-title":"Journal of Clinical Apheresis"},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/jca.21276","article-title":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice\u2014Evidence\u2010Based Approach From the Writing Committee of the American Society for Apheresis: The Sixth Special Issue","volume":"28","author":"Schwartz J.","year":"2013","journal-title":"Journal of Clinical Apheresis"},{"key":"e_1_2_7_7_1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1378\/chest.129.1.174","article-title":"Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines: Report From an American College of Chest Physicians Task Force","volume":"129","author":"Guyatt G.","year":"2006","journal-title":"Chest"},{"key":"e_1_2_7_8_1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An Emerging Consensus on Rating Quality of Evidence and Strength of Recommendations","volume":"336","author":"Guyatt G. H.","year":"2008","journal-title":"BMJ"},{"key":"e_1_2_7_9_1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma Exchange and Glucocorticoids in Severe ANCA\u2010Associated Vasculitis","volume":"382","author":"Walsh M.","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"e_1_2_7_10_1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/jca.21820","article-title":"Update to the ASFA Guidelines on the Use of Therapeutic Apheresis in ANCA\u2010Associated Vasculitis","volume":"35","author":"Balogun R. A.","year":"2020","journal-title":"Journal of Clinical Apheresis"},{"key":"e_1_2_7_11_1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/jca.10029","article-title":"An Approach to Evidence\u2010Based Therapeutic Apheresis","volume":"17","author":"McLeod B. C.","year":"2002","journal-title":"Journal of Clinical Apheresis"},{"issue":"3","key":"e_1_2_7_12_1","doi-asserted-by":"crossref","DOI":"10.1002\/jca.70038","article-title":"Performance of Total Blood Volume Algorithms in Obesity and Severe Obesity","volume":"40","author":"Raymond C.","year":"2025","journal-title":"Journal of Clinical Apheresis"},{"key":"e_1_2_7_13_1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/jca.21973","article-title":"Hemostatic Effects of Therapeutic Plasma Exchange: A Concise Review","volume":"37","author":"Soares Ferreira Junior A.","year":"2022","journal-title":"Journal of Clinical Apheresis"},{"key":"e_1_2_8_9_1_1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody\u2010associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell B","year":"2023","journal-title":"Lancet Neurol"},{"key":"e_1_2_8_9_2_1","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1177\/0883073814545883","article-title":"Outcomes after early administration of plasma exchange in pediatric central nervous system inflammatory demyelination","volume":"30","author":"Bigi S","year":"2015","journal-title":"J Child Neurol"},{"issue":"7","key":"e_1_2_8_9_3_1","article-title":"Evaluating therapeutic plasma exchange in pediatric acute disseminated encephalomyelitis: a comprehensive review","volume":"16","author":"Bhardwaj T","year":"2024","journal-title":"Cureus"},{"key":"e_1_2_8_9_4_1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/jca.21388","article-title":"Therapeutic plasma exchange in acute disseminated encephalomyelitis in children","volume":"30","author":"Borras\u2010Novell C","year":"2015","journal-title":"J Clin Apher"},{"key":"e_1_2_8_9_5_1","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.4103\/aian.aian_719_22","article-title":"Familial CNS\u2010isolated hemophagocytic lymphohistiocytosis due to a novel PRF1 mutation triggered by SARS\u2010CoV2","volume":"25","author":"Caldito NG","year":"2022","journal-title":"Ann Indian Acad Neurol"},{"key":"e_1_2_8_9_6_1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pediatrneurol.2019.06.017","article-title":"Acute disseminated encephalomyelitis in children: an updated review based on current diagnostic criteria","volume":"100","author":"Cole J","year":"2019","journal-title":"Pediatr Neurol"},{"key":"e_1_2_8_9_7_1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/1744-9987.14059","article-title":"The role of plasmapheresis in severe acute disseminated encephalomyelitis with clinical findings of transverse myelitis","volume":"28","author":"Fjellbirkeland OW","year":"2024","journal-title":"Ther Apher Dial."},{"key":"e_1_2_8_9_8_1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.58.1.143","article-title":"Plasma exchange for severe attacks of CNS demyelination: predictors of response","volume":"58","author":"Keegan M","year":"2002","journal-title":"Neurology"},{"issue":"6","key":"e_1_2_8_9_9_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200323","article-title":"Pediatric MOG\u2010Ab\u2010associated encephalitis: supporting early recognition and treatment","volume":"11","author":"Kim NN","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_2_8_9_10_1","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1212\/WNL.0000000000002723","article-title":"Acute disseminated encephalomyelitis in 228 patients","volume":"86","author":"Koelman DLH","year":"2016","journal-title":"Neurol"},{"key":"e_1_2_8_9_11_1","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00415-015-7694-7","article-title":"Acute disseminated encephalomyelitis: current controversies in diagnosis and outcome","volume":"262","author":"Koelman DL","year":"2015","journal-title":"J Neurol"},{"key":"e_1_2_8_9_12_1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immune\u2010mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp LB","year":"2013","journal-title":"Mult Scler"},{"key":"e_1_2_8_9_13_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.870867","article-title":"Clinical presentation and outcomes of acute disseminated encephalomyelitis in adults worldwide: systematic review and meta\u2010analysis","volume":"13","author":"Li K","year":"2022","journal-title":"Front Immunol"},{"key":"e_1_2_8_9_14_1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.0b013e3181b879be","article-title":"Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6\u2009months","volume":"73","author":"Llufriu S","year":"2009","journal-title":"Neurology"},{"key":"e_1_2_8_9_15_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001080","article-title":"Acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalitis following COVID\u201019: systematic review and meta\u2010synthesis","volume":"8","author":"Manzano GS","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_2_8_9_16_1","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1177\/1352458520929627","article-title":"Acute disseminated encephalomyelitis in children and adults: a focused review emphasizing new developments","volume":"27","author":"Otallah S.","year":"2021","journal-title":"Mult Scler"},{"key":"e_1_2_8_9_17_1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1542\/hpeds.2019-0129","article-title":"Variation in treatment and outcomes of children with acute disseminated encephalomyelitis","volume":"10","author":"Press AC","year":"2020","journal-title":"Hosp Pediatr"},{"key":"e_1_2_8_9_18_1","doi-asserted-by":"crossref","first-page":"1557046","DOI":"10.3389\/fnins.2025.1557046","article-title":"Acute hemorrhagic leukoencephalitis with gradual symptom onset: case report and literature review","volume":"19","author":"Sannes I","year":"2025","journal-title":"Front Neurosci"},{"key":"e_1_2_8_9_19_1","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1212\/WNL.56.10.1313","article-title":"Acute disseminated encephalomyelitis. A follow\u2010up study of 40 adult patients","volume":"56","author":"Schwartz S","year":"2001","journal-title":"Neurology"},{"issue":"7","key":"e_1_2_8_9_20_1","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3390\/vaccines11071225","article-title":"The occurrence of acute disseminated encephalomyelitis in SARS\u2010CoV\u20102 infection\/vaccination: our experience and a systematic review of the literature","volume":"11","author":"Stoian A","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"e_1_2_8_9_21_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12288-016-0661-3","article-title":"Therapeutic plasma exchange in patients with neurologic disorders: review of 63 cases","volume":"33","author":"Tombak A","year":"2017","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"4","key":"e_1_2_8_9_22_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200243","article-title":"Life\u2010threatening MOG antibody\u2010associated hemorrhagic ADEM with elevated CSF IL\u20106","volume":"11","author":"Virupakshaiah A","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_2_8_9_23_1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40272-021-00441-7","article-title":"Assessment and management of acute disseminated encephalomyelitis (ADEM) in the pediatric patient","volume":"23","author":"Wang CX","year":"2021","journal-title":"Paediatr Drugs"},{"key":"e_1_2_8_9_24_1","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00415-021-10771-8","article-title":"SARS\u2010CoV\u20102\u2010associated acute disseminated encephalomyelitis: a systematic review of the literature","volume":"269","author":"Wang Y","year":"2022","journal-title":"J Neurol"},{"key":"e_1_2_9_9_1_1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/jca.20064","article-title":"The effect of total plasma exchange on fulminant hepatic failure","volume":"21","author":"Akdogan M","year":"2006","journal-title":"J Clin Apher"},{"key":"e_1_2_9_9_2_1","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s00467-021-05289-0","article-title":"Therapeutic plasma exchange in children with acute liver failure (ALF): is it time for incorporation into the ALF armamentarium?","volume":"37","author":"Alexander EC","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"e_1_2_9_9_3_1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/LVT.0000000000000231","article-title":"Plasma exchange for acute and acute\u2010on\u2010chronic liver failure: a systematic review and meta\u2010analysis","volume":"30","author":"Beran A","year":"2024","journal-title":"Liver Transpl"},{"key":"e_1_2_9_9_4_1","doi-asserted-by":"crossref","DOI":"10.1002\/jca.22130","article-title":"Therapeutic plasma exchange provides native liver survival benefit in children with acute liver failure: a propensity score\u2010matched analysis","volume":"39","author":"Biswas T","year":"2024","journal-title":"J Clin Apher"},{"key":"e_1_2_9_9_5_1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2024.09.034","article-title":"Plasma exchange does not improve overall survival in patients with acute liver failure in a real\u2010world cohort","volume":"82","author":"Burke L","year":"2025","journal-title":"J Hepatol"},{"key":"e_1_2_9_9_6_1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.29488","article-title":"Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure","volume":"67","author":"Cardoso FS","year":"2018","journal-title":"Hepatology"},{"key":"e_1_2_9_9_7_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2024.101934","article-title":"Adverse events and outcomes of high\u2010volume plasma exchange in 50 acute liver failure patients: a monocentric retrospective real\u2010world study","volume":"15","author":"Coirier V","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"e_1_2_9_9_8_1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/hepr.13255","article-title":"High recovery rate of consciousness by high\u2010volume filtrate hemodiafiltration for fulminant hepatitis","volume":"49","author":"Fujiwara K","year":"2019","journal-title":"Hepatol Res"},{"key":"e_1_2_9_9_9_1","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1080\/14767058.2020.1777267","article-title":"Risk factors assessment in patients with acute fatty liver of pregnancy treated without plasma exchange or renal replacement therapy","volume":"35","author":"Gao Q","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"key":"e_1_2_9_9_10_1","first-page":"1323","article-title":"Randomized controlled study of plasma exchange combined with molecular adsorbent re\u2010circulating system for the treatment of liver failure complicated with hepatic encephalopathy","volume":"59","author":"Huang YK","year":"2012","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_9_9_11_1","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1097\/PCC.0000000000000511","article-title":"Continuous veno\u2010venous hemodiafiltration and plasma exchange in infantile acute liver failure","volume":"16","author":"Ide K","year":"2015","journal-title":"Pediatr Crit Care Med"},{"key":"e_1_2_9_9_12_1","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.dld.2015.11.004","article-title":"Italian Association for the Study of the Liver (AISF). AISF position paper on liver disease and pregnancy","volume":"48","year":"2016","journal-title":"Dig Liver Dis"},{"key":"e_1_2_9_9_13_1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/MPG.0000000000003108","article-title":"Safety of high\u2010volume plasmapheresis in children with acute liver failure","volume":"72","author":"J\u00f8rgensen MH","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_9_9_14_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2015.08.018","article-title":"High\u2010volume plasma exchange in patients with acute liver failure: an open randomized controlled trial","volume":"64","author":"Larsen FS","year":"2016","journal-title":"J Hepatol"},{"key":"e_1_2_9_9_15_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12884-023-05503-x","article-title":"The assessment in patients with acute fatty liver of pregnancy (AFLP) treated with plasma exchange: a cohort study of 298 patients","volume":"23","author":"Li L","year":"2023","journal-title":"BMC Pregnancy Childbirth"},{"key":"e_1_2_9_9_16_1","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1016\/j.cgh.2021.01.036","article-title":"Standard\u2010volume plasma exchange improves outcomes in patients with acute liver failure: A randomized controlled trial","volume":"20","author":"Maiwall R","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"e_1_2_9_9_17_1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/AOG.0000000000004289","article-title":"Acute fatty liver of pregnancy","volume":"137","author":"Nelson DB","year":"2021","journal-title":"Obstet Gynecol"},{"key":"e_1_2_9_9_18_1","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/00003246-200107000-00014","article-title":"Usefulness of plasma exchange plus continuous hemodiafiltration to reduce adverse effects associated with plasma exchange in patients with acute liver failure","volume":"29","author":"Sadahiro T","year":"2001","journal-title":"Crit Care Med"},{"key":"e_1_2_9_9_19_1","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1093\/ndt\/gfr115","article-title":"Comparison of Molecular Adsorbents Recirculating System (MARS) dialysis with combined plasma exchange and hemodialysis in children with acute liver failure","volume":"26","author":"Schaefer B","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_9_9_20_1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/00000658-200109000-00015","article-title":"Role of plasmapheresis in the management of acute hepatic failure in children","volume":"234","author":"Singer AL","year":"2001","journal-title":"Ann Surg"},{"key":"e_1_2_9_9_21_1","doi-asserted-by":"crossref","first-page":"E39","DOI":"10.1111\/j.1525-1594.2011.01417.x","article-title":"Effect of plasma exchange on hepatocyte oxidative stress, mitochondria function, and apoptosis in patients with acute fatty liver of pregnancy","volume":"36","author":"Tang W","year":"2012","journal-title":"Artif Organs"},{"key":"e_1_2_9_9_22_1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/jca.21535","article-title":"Therapeutic plasma exchange versus double plasma molecular absorption system in hepatitis B virus\u2010infected acute\u2010on\u2010chronic liver failure treated by entercavir: a prospective study","volume":"32","author":"Wan YM","year":"2017","journal-title":"J Clin Apher"},{"key":"e_1_2_9_9_23_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12871-015-0017-9","article-title":"Therapeutic plasma exchange does not reduce vasopressor requirement in severe acute liver failure: a retrospective case series","volume":"15","author":"Wiersema UF","year":"2015","journal-title":"BMC Anesthesiol"},{"key":"e_1_2_9_9_24_1","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s12072-015-9667-4","article-title":"The effect of plasma exchange on entecavir\u2010treated chronic hepatitis B patients with hepatic de\u2010compensation and acute\u2010on\u2010chronic liver failure","volume":"10","author":"Yue\u2010Meng W","year":"2016","journal-title":"Hepatol Int"},{"key":"e_1_2_10_9_1_1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/10408444.2025.2540432","article-title":"Meta\u2010analysis of the safety and efficacy of fresh frozen plasma exchange in the treatment of organophosphate pesticide poisoning","volume":"55","author":"Cai B","year":"2025","journal-title":"Crit Rev. Toxicol"},{"key":"e_1_2_10_9_2_1","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.ajem.2015.07.016","article-title":"Therapeutic plasma exchange in poisoning: 8\u2009years' experience of a university hospital","volume":"33","author":"Di\u015fel NR","year":"2015","journal-title":"Am J Emerg Med"},{"key":"e_1_2_10_9_3_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40360-017-0187-9","article-title":"Ibuprofen plasma concentration profile in deliberate ibuprofen overdose with circulatory depression treated with therapeutic plasma exchange: a case report","volume":"18","author":"Geith S","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"key":"e_1_2_10_9_4_1","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.kint.2018.03.026","article-title":"Use of extracorporeal treatments in the management of poisonings","volume":"94","author":"Ghannoum M","year":"2018","journal-title":"Kidney Int"},{"key":"e_1_2_10_9_5_1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/MAT.0b013e31819099f8","article-title":"Plasma exchange during cardiopulmonary bypass in patients with severe hemolysis in cardiac surgery","volume":"55","author":"Hei FL","year":"2009","journal-title":"ASAIO J"},{"key":"e_1_2_10_9_6_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jca.21261","article-title":"Medications and therapeutic apheresis procedures: Are we doing our best?","volume":"28","author":"Ibrahim RB","year":"2013","journal-title":"J Clin Apher"},{"key":"e_1_2_10_9_7_1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1525-139X.2011.01030.x","article-title":"Medications in patients treated with therapeutic plasma exchange: prescription dosage, timing, and drug overdose","volume":"25","author":"Ibrahim RB","year":"2012","journal-title":"Semin Dial"},{"key":"e_1_2_10_9_8_1","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.transproceed.2017.11.032","article-title":"Acute liver failure due to Amanita phalloides poisoning: therapeutic approach and outcome","volume":"50","author":"Kieslichova E","year":"2018","journal-title":"Transplant Proc"},{"key":"e_1_2_10_9_9_1","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2215\/CJN.02560319","article-title":"Extracorporeal removal of poisons and toxins","volume":"14","author":"King JD","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"e_1_2_10_9_10_1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.hbpd.2022.01.007","article-title":"The characteristics of liver injury induced by Amanita and clinical value of \u03b1\u2010amanitin detection","volume":"21","author":"Lin LY","year":"2022","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"e_1_2_10_9_11_1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/ckj\/sfab201","article-title":"Development and internal validation of a Wasp Sting Severity Score to assess severity and indicate blood purification in person with Asian wasp stings","volume":"15","author":"Liu Y","year":"2022","journal-title":"Clin Kidney J"},{"key":"e_1_2_10_9_12_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12028-020-00989-1","article-title":"Drug dosing in patients undergoing therapeutic plasma exchange","volume":"34","author":"Mahmoud SH","year":"2021","journal-title":"Neurocrit Care"},{"key":"e_1_2_10_9_13_1","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1080\/15563650.2017.1324164","article-title":"The effect of plasmapheresis on treated disseminated intravascular coagulation (DIC) cause by Hemiscorpius lepturus (Gadim) sting","volume":"55","author":"Mostafazadeh B","year":"2017","journal-title":"Clin Toxicol (Phila)"},{"key":"e_1_2_10_9_14_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008936","article-title":"Snakebite associated thrombotic microangiopathy: a systematic review of clinical features outcomes, and evidence for interventions including plasmapheresis","volume":"14","author":"Noutsos T","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"e_1_2_10_9_15_1","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/jca.21284","article-title":"Therapeutic plasma exchange: an effective treatment in ethylene dibromide poisoning cases","volume":"28","author":"Pahwa N","year":"2013","journal-title":"J Clin Apher"},{"key":"e_1_2_10_9_16_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2015.05.017","article-title":"Developments in extracorporeal therapy for the poisoned patient","volume":"90","author":"Patel N","year":"2015","journal-title":"Adv Drug Deliv Rev."},{"key":"e_1_2_10_9_17_1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.transci.2011.07.015","article-title":"Therapeutic plasma exchange in amitriptyline intoxication: case report and review of the literature","volume":"45","author":"Sari I","year":"2011","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_10_9_18_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1525-139X.2011.01033.x","article-title":"The role of therapeutic plasma exchange in poisonings and intoxications","volume":"25","author":"Schutt RC","year":"2012","journal-title":"Semin Dial."},{"key":"e_1_2_10_9_19_1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/tme.12666","article-title":"Therapeutic whole blood exchange in the management of methaemoglobinemia: case series and systematic review of the literature","volume":"30","author":"Singh P","year":"2020","journal-title":"Transfus Med"},{"key":"e_1_2_10_9_20_1","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018086","article-title":"Extracorporeal treatment in children with acute severe poisoning","volume":"98","author":"Sun X","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"e_1_2_10_9_21_1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s12098-013-1089-5","article-title":"High frequency of acquired ADAMTS13 deficiency after hemolysis in Hemiscorpius lepturus (scorpion) stung children","volume":"81","author":"Valavi E","year":"2014","journal-title":"Indian J Pediatr"},{"key":"e_1_2_10_9_22_1","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ajem.2013.03.016","article-title":"Effectiveness of therapeutic plasma exchange in patients with intermediate syndrome due to organophosphate intoxication","volume":"31","author":"Yilmaz M","year":"2013","journal-title":"Am J Emerg Med"},{"key":"e_1_2_10_9_23_1","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1159\/000530117","article-title":"Efficacy and Safety of Plasma Exchange Combined with Hemoperfusion in the Treatment of Organophosphorus Poisoning: A Meta\u2010Analysis","volume":"52","author":"Yao Z","year":"2023","journal-title":"Blood Purif"},{"key":"e_1_2_10_9_24_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000442740","article-title":"Efficacy of two combinations of blood purification techniques for the treatment of multiple organ failure induced by wasp stings","volume":"42","author":"Yuan H","year":"2016","journal-title":"Blood Purif"},{"key":"e_1_2_10_9_25_1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.transci.2013.03.006","article-title":"Plasma exchange as a complementary approach to snake bite treatment: an academic emergency department's experiences","volume":"49","author":"Zengin S","year":"2013","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_11_9_1_1","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.2013.4997","article-title":"Age\u2010Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega\u20103 fatty acids for age\u2010related macular degeneration: the Age\u2010Related Eye Disease Study 2 (AREDS2) randomized clinical trial","volume":"309","year":"2013","journal-title":"JAMA"},{"key":"e_1_2_11_9_2_1","volume-title":"American Academy of Ophthalmology Retina Vitreous Committee. Preferred practice pattern guidelines. Age\u2010related macular degeneration","year":"2024"},{"key":"e_1_2_11_9_3_1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMcp2102061","article-title":"Age\u2010related macular degeneration","volume":"385","author":"Apte RS","year":"2021","journal-title":"N Engl J Med"},{"key":"e_1_2_11_9_4_1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.atherosclerosissup.2012.10.023","article-title":"Rheohaemapheresis in the treatment of nonvascular age\u2010related macular degeneration","volume":"14","author":"Blaha M","year":"2013","journal-title":"Atheroscler Suppl"},{"key":"e_1_2_11_9_5_1","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.mayocpiqo.2024.05.003","article-title":"Recent updates on the diagnosis and management of age\u2010related macular degeneration","volume":"8","author":"Boopathiraj N","year":"2024","journal-title":"Mayo Clin Proc Inn Qual Out"},{"key":"e_1_2_11_9_6_1","first-page":"483","article-title":"Influence of membrane differential filtration on the natural course of age\u2010related macular degeneration: a randomized trial","volume":"20","author":"Brunner R","year":"2000","journal-title":"Retina"},{"key":"e_1_2_11_9_7_1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/bjophthalmol-2020-318452","article-title":"Treatments for dry age\u2010related macular degeneration: therapeutic avenues, clinical trials and future directions","volume":"106","author":"Cabral de Guimaraes TA","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"e_1_2_11_9_8_1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/jca.21607","article-title":"Seeing is believing: a review of apheresis therapy in the treatment of ophthalmologic disease","volume":"33","author":"Graham BC","year":"2018","journal-title":"J Clin Apher"},{"key":"e_1_2_11_9_9_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ophtha.2024.07.014","article-title":"Oral antioxidant and Lutein\/Zeaxanthin supplements slow geographic atrophy progression to the fovea in age\u2010related macular degeneration","volume":"132","author":"Keenan TDL","year":"2025","journal-title":"Ophthlmology"},{"key":"e_1_2_11_9_10_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1473-0502(03)00101-0","article-title":"Clinical studies to implement rheopheresis for age\u2010related macular degeneration guided by evidence\u2010based\u2010medicine","volume":"29","author":"Klingel R","year":"2003","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_11_9_11_1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1744-9987.2010.00807.x","article-title":"RheoNet registry analysis of rheopheresis for microcirculatory disorders with a focus on age\u2010related macular degeneration","volume":"14","author":"Klingel R","year":"2010","journal-title":"Ther Apher Dial"},{"key":"e_1_2_11_9_12_1","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00417-009-1113-7","article-title":"Prospective, randomized, controlled clinical study evaluating the efficacy of rheopheresis for dry AMD. Dry AMD treatment with Rheopheresis Trial\u2010ART","volume":"247","author":"Koss MJ","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"e_1_2_11_9_13_1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/03913988221086597","article-title":"Rheopheresis: a narrative review","volume":"45","author":"Kosmadakis G.","year":"2022","journal-title":"Int J Artif Organs"},{"key":"e_1_2_11_9_14_1","article-title":"Dynamics of blood count after rheohemapheresis in age\u2010related macular degeneration: possible association with clinical changes","volume":"2014","author":"Ko\u0161\u0165\u00e1l M","year":"2014","journal-title":"Bio Med Res Int"},{"key":"e_1_2_11_9_15_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.31348\/2023\/2","article-title":"Rheopheresis in the treatment of age\u2010related macular degeneration","volume":"79","author":"Langrov\u00e1 H","year":"2022","journal-title":"Cesk Slov Oftalmol"},{"key":"e_1_2_11_9_16_1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1046\/j.1526-0968.2003.00027.x","article-title":"The effect of membrane differential filtration on the colloid osmotic pressure in patients with age\u2010related macular degeneration: significance to visual function","volume":"7","author":"Lueke C","year":"2003","journal-title":"Ther Apher Dial"},{"key":"e_1_2_11_9_17_1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/jca.20047","article-title":"Clinical outcomes and mechanism of action for rheopheresis treatment of age\u2010related macular degeneration (AMD)","volume":"20","author":"Pulido J","year":"2005","journal-title":"J Clin Apher"},{"key":"e_1_2_11_9_18_1","first-page":"221","article-title":"Preliminary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA\u20101) results","volume":"104","author":"Pulido JS","year":"2006","journal-title":"Trans AM Ophthalmol Soc"},{"key":"e_1_2_11_9_19_1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1755-3768.2009.01710.x","article-title":"Haemorheopheresis could block the progression of the dry form of age\u2010related macular degeneration with soft drusen to the neovascular form","volume":"89","author":"Rencov\u00e1 E","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"e_1_2_11_9_20_1","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1111\/j.1755-3768.2012.02503.x","article-title":"Reduction in the drusenoid retinal pigment epithelium detachment area in the dry form of age\u2010related macular degeneration 2.5\u2009years after rheohemapheresis","volume":"91","author":"Rencov\u00e1 E","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"e_1_2_11_9_21_1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1744-9987.2009.00705.x","article-title":"Acute and subacute effect of rheopheresis on microvascular endothelial function in patients suffering from age\u2010related macular degeneration","volume":"13","author":"Rossi M","year":"2009","journal-title":"Ther Apher Dial"},{"key":"e_1_2_11_9_22_1","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/135798","article-title":"Long\u2010term outcomes of rheohaemapheresis in the treatment of dry form of age\u2010related macular degeneration","volume":"2013","author":"Studni\u010dka J","year":"2013","journal-title":"J Ophthalmol"},{"key":"e_1_2_11_9_23_1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/jcm11020325","article-title":"Managing neovascular age\u2010related macular degeneration in clinical practice: systematic review, meta\u2010analysis, and meta\u2010regression","volume":"11","author":"Veritti D","year":"2022","journal-title":"J Clin Med"},{"key":"e_1_2_12_9_1_1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJMp2110468","article-title":"Revisiting FDA approval of aducanumab","volume":"385","author":"Alexander GC","year":"2021","journal-title":"New Engl J Med"},{"key":"e_1_2_12_9_2_1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2174\/0115672050316936240905064215","article-title":"Post hoc assessment of cognitive efficacy in Alzheimer's disease using a latent growth mixture model in AMBAR, a phase 2B randomized controlled trial","volume":"21","author":"Ayasse ND","year":"2025","journal-title":"Curr Alzheimer Res"},{"key":"e_1_2_12_9_3_1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3233\/JAD-160565","article-title":"Efficacy and safety of plasma exchange with 5% albumin to modify cerebrospinal fluid and plasma amyloid\u2010\u03b2 concentrations and cognition outcomes in Alzheimer's disease patients: a multicenter, randomized, controlled clinical trial","volume":"56","author":"Boada M","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"e_1_2_12_9_4_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jca.22026","article-title":"Feasibility, safety, and tolerability of two modalities of plasma exchange with albumin replacement to treat elderly patients with Alzheimer's disease in the AMBAR study","volume":"38","author":"Boada M","year":"2023","journal-title":"J Clin Apher"},{"key":"e_1_2_12_9_5_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.trci.2019.01.001","article-title":"Plasma exchange for Alzheimer's disease management by albumin replacement (AMBAR) trial: study design and progress","volume":"5","author":"Boada M","year":"2019","journal-title":"Alzheimers Dement (NY)"},{"key":"e_1_2_12_9_6_1","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/alz.12137","article-title":"A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: primary results of the AMBAR study","volume":"16","author":"Boada M","year":"2020","journal-title":"Alzheimers Dement"},{"key":"e_1_2_12_9_7_1","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/alz.12477","article-title":"Neuropsychological, neuropsychiatric, and quality\u2010of\u2010life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study","volume":"18","author":"Boada M","year":"2022","journal-title":"Alzheimers Dement"},{"key":"e_1_2_12_9_8_1","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/14737175.2021.1960823","article-title":"Therapeutic plasma exchange with albumin: a new approach to treat Alzheimer's disease","volume":"21","author":"Boada M","year":"2021","journal-title":"Expert Rev. Neurother"},{"key":"e_1_2_12_9_9_1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1358\/dnp.2009.22.6.1395256","article-title":"Amyloid\u2010targeted therapeutics in Alzheimer's disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization","volume":"22","author":"Boada M","year":"2009","journal-title":"Drug News Perspect"},{"key":"e_1_2_12_9_10_1","doi-asserted-by":"crossref","first-page":"1443132","DOI":"10.3389\/fneur.2024.1443132","article-title":"The use of plasma exchange with albumin replacement in the management of Alzheimer's disease: a scoping review","volume":"15","author":"Cantero\u2010Fortiz Y","year":"2024","journal-title":"Front Neurol"},{"key":"e_1_2_12_9_11_1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/14712598.2024.2416947","article-title":"A systematic review of the efficacy and safety of anti\u2010amyloid beta monoclonal antibodies in treatment of Alzheimer's disease","volume":"24","author":"Chhabra A","year":"2024","journal-title":"Expert Opin Biol Ther."},{"key":"e_1_2_12_9_12_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103164","article-title":"Emerging insights into the role of albumin with plasma exchange in Alzheimer's disease management","volume":"60","author":"Costa M","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_12_9_13_1","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1007\/s00259-022-05915-5","article-title":"Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild\u2010to\u2010moderate Alzheimer's disease: additional results from the AMBAR study","volume":"49","author":"Cuberas\u2010Borr\u00f3s G","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"e_1_2_12_9_14_1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13643-022-02115-y","article-title":"Efficacy and safety of blood derivatives therapy in Alzheimer's disease: a systematic review and meta\u2010analysis","volume":"11","author":"Fei Z","year":"2022","journal-title":"Syst Rev."},{"key":"e_1_2_12_9_15_1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer's disease","volume":"378","author":"Honig LS","year":"2018","journal-title":"N Engl J Med"},{"key":"e_1_2_12_9_16_1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000511506","article-title":"Lessons learnt from the second generation of anti\u2010amyloid monoclonal antibodies clinical trials","volume":"49","author":"Hui Kwan AT","year":"2020","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"12004","key":"e_1_2_12_9_17_1","first-page":"1","article-title":"Perspective: is therapeutic plasma exchange a viable option for treating Alzheimer's disease?","volume":"6","author":"Imbimbo BP","year":"2020","journal-title":"Alzheimers Dement"},{"key":"e_1_2_12_9_18_1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA\u2010AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack CR","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"459","key":"e_1_2_12_9_19_1","first-page":"1","article-title":"AMBAR, an encouraging Alzheimer's trial that raises questions","volume":"11","author":"Loeffler DA","year":"2020","journal-title":"Front Neurol"},{"key":"e_1_2_12_9_20_1","first-page":"CD001747","article-title":"Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment","volume":"11","author":"Lim AWY","year":"2024","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_12_9_21_1","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.62347\/PIYV4216","article-title":"Prognostic value of plasma A\u03b21\u201040 for Alzheimer's disease","volume":"16","author":"Lv H","year":"2024","journal-title":"Am J Transl Res."},{"key":"e_1_2_12_9_22_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101661","article-title":"Effects of interventions on cerebral perfusion in the Alzheimer's disease spectrum: a systematic review","volume":"79","author":"Marcolini S","year":"2022","journal-title":"Aging Res Rev."},{"issue":"1117","key":"e_1_2_12_9_23_1","article-title":"Therapeutic approach to Alzheimer's disease: current treatments and new perspectives","volume":"14","author":"Pardo\u2010Moreno T","year":"2022","journal-title":"Pharmaceutics"},{"key":"e_1_2_12_9_24_1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1474-4422(24)00236-9","article-title":"Y\u2010Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross\u2010sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN\u2010OBS)","volume":"23","author":"Schultz SA","year":"2024","journal-title":"Lancet Neurol"},{"key":"e_1_2_12_9_25_1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/13872877251375430","article-title":"A real\u2010world study on the safety and efficacy of therapeutic plasma exchange in patients with Alzheimer's disease","volume":"108","author":"Taragano F","year":"2025","journal-title":"J Alzheimers Dis"},{"key":"e_1_2_13_9_1_1","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/1744-9987.13749","article-title":"The Japanese Society for Apheresis clinical practice guideline for therapeutic apheresis","volume":"25","author":"Abe T","year":"2021","journal-title":"Ther Apher Dial"},{"key":"e_1_2_13_9_2_1","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1046\/j.1523-1755.2003.00235.x","article-title":"Effect of \u00df 2\u2010microglobulin adsorption column on dialysis\u2010related amyloidosis","volume":"64","author":"Abe T","year":"2003","journal-title":"Kidney Int"},{"key":"e_1_2_13_9_3_1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1525-139X.2009.00584.x","article-title":"Beta2\u2010microglobulin","volume":"22","author":"Dr\u00fceke TB","year":"2009","journal-title":"Semin Dial"},{"key":"e_1_2_13_9_4_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1744-9987.2012.01130.x","article-title":"Survey of the effects of a column for adsorption of \u03b22\u2010microglobulin in patients with dialysis\u2010related amyloidosis in Japan","volume":"17","author":"Gejyo F","year":"2013","journal-title":"Ther Apher Dial"},{"key":"e_1_2_13_9_5_1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1525-1594.2004.47260.x","article-title":"Arresting dialysis\u2010related amyloidosis: a prospective multicenter controlled trial of direct hemoperfusion with a \u00df 2\u2010microglobulin adsorption column","volume":"28","author":"Gejyo F","year":"2004","journal-title":"Artificial Organs"},{"key":"e_1_2_13_9_6_1","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/ckj\/sfaa155","article-title":"Beta\u20102 microglobulin and all\u2010cause mortality in the era of high\u2010flux hemodialysis: Results from the Dialysis Outcomes and Practice Patterns Study","volume":"14","author":"Kanda E","year":"2020","journal-title":"Clin Kidney J"},{"key":"e_1_2_13_9_7_1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/sdi.12720","article-title":"Hemodialysis\u2010related amyloidosis: Is it still relevant?","volume":"31","author":"Kaneko S","year":"2018","journal-title":"Semin Dial"},{"key":"e_1_2_13_9_8_1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000330332","article-title":"Effectiveness of \u03b2(2)\u2010microglobulin adsorption column in treating dialysis\u2010related amyloidosis: a multicenter study","volume":"32","author":"Kuragano T","year":"2011","journal-title":"Blood Purif"},{"key":"e_1_2_13_9_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000547964"},{"key":"e_1_2_13_9_10_1","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/ndt\/gfn706","article-title":"Characteristics of dialysis\u2010related amyloidosis in patients on hemodialysis for more than 30\u2009years","volume":"24","author":"Otsubo S","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_13_9_11_1","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.34067\/KID.0004922020","article-title":"Beta\u20102 microglobulin amyloidosis: past, present, and future","volume":"1","author":"Portales\u2010Castillo I","year":"2020","journal-title":"Kidney360"},{"key":"e_1_2_13_9_12_1","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/ndt\/gfx311","article-title":"Beta\u20102 microglobulin clearance in high\u2010flux dialysis and convection dialysis modalities: A meta\u2010analysis of published studies","volume":"33","author":"Roumelioti M","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_13_9_13_1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2147\/IJNRD.S84784","article-title":"Dialysis\u2010related amyloidosis: challenges and solutions","volume":"9","author":"Scarpioni R","year":"2016","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"e_1_2_13_9_14_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256421","article-title":"Association of dialysis\u2010related amyloidosis with lower quality of life in patients undergoing hemodialysis for more than 10\u2009years: The Kyushu Dialysis\u2010Related Amyloidosis Study","volume":"16","author":"Tsuruya K","year":"2021","journal-title":"PLoS ONE"},{"key":"e_1_2_13_9_15_1","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar AD","year":"2016","journal-title":"Lancet"},{"key":"e_1_2_13_9_16_1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/13506129.2024.2315148","article-title":"Mass spectrometry\u2010based protemic analysis of proteins adsorbed by hexadecyl\u2010immobilized cellulose bead column for the treatment of dialysis related amyloidosis","volume":"31","author":"Yamamoto S","year":"2024","journal-title":"Amyloid"},{"key":"e_1_2_13_9_17_1","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1744-9987.2011.00937.x","article-title":"Long\u2010term efficacy and safety of the small\u2010sized \u03b22\u2010microglobulin adsorption column for dialysis\u2010related amyloidosis","volume":"15","author":"Yamamoto Y","year":"2011","journal-title":"Ther Apher Dial"},{"key":"e_1_2_14_9_1_1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.ajkd.2020.11.023","article-title":"Concurrent anti\u2010glomerular basement membrane antibody disease and membranous nephropathy: a case series","volume":"78","author":"Ahmad SB","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_14_9_2_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.transci.2018.02.007","article-title":"The treatment of ANCA\u2010associated rapidly\u2010progressive glomerulonephritis and Goodpasture syndrome with therapeutic apheresis","volume":"57","author":"Apaydin S.","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_14_9_3_1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.akdh.2024.04.007","article-title":"Anti\u2010glomerular basement membrane disease: recent updates","volume":"31","author":"Bharati J","year":"2024","journal-title":"Adv Kidney Dis Health"},{"key":"e_1_2_14_9_4_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103568","article-title":"Long\u2010term outcome of anti\u2010glomerular basement membrane antibody disease treated with immunoadsorption","volume":"9","author":"Biesenbach P","year":"2014","journal-title":"Plos One"},{"key":"e_1_2_14_9_5_1","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.3390\/vaccines11071152","article-title":"Subsequent COVID\u201019 prophylaxis in COVID\u201019 associated glomerulopathies","volume":"11","author":"Boyle T","year":"2023","journal-title":"Vaccines"},{"key":"e_1_2_14_9_6_1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1159\/000523713","article-title":"Predictors of kidney outcomes of anti\u2010glomerular basement membrane disease in a large Chinese cohort","volume":"53","author":"Jia XY","year":"2022","journal-title":"Am J Nephrol"},{"key":"e_1_2_14_9_7_1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00005792-198507000-00003","article-title":"Therapy of anti\u2010glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors","volume":"64","author":"Johnson JP","year":"1985","journal-title":"Medicine (Baltimore)"},{"key":"e_1_2_14_9_8_1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3390\/jcm9020455","article-title":"In patient burden and mortality of Goodpasture's syndrome in the United States: nationwide inpatient sample 2003\u20132014","volume":"9","author":"Kaewput W","year":"2020","journal-title":"J Clin Med"},{"key":"e_1_2_14_9_9_1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.23876\/j.krcp.24.143","article-title":"Renal transplantation in Alport syndrome","volume":"44","author":"Kim S","year":"2025","journal-title":"Kidney Res Clin Pract"},{"key":"e_1_2_14_9_10_1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/md.0b013e318067da56","article-title":"Alveolar hemorrhage in anti\u2010basement membrane antibody disease: a series of 28 cases","volume":"86","author":"Lazor R","year":"2007","journal-title":"Medicine"},{"key":"e_1_2_14_9_11_1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.7326\/0003-4819-134-11-200106050-00009","article-title":"Long\u2010term outcome of anti\u2010glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression","volume":"134","author":"Levy JB","year":"2001","journal-title":"Ann Intern Med"},{"key":"e_1_2_14_9_12_1","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3389\/fimmu.2019.01665","article-title":"Prognostic factors in anti\u2010glomerular basement membrane disease: a multicenter study of 119 patients","volume":"10","author":"Marques C","year":"2019","journal-title":"Front Immunol"},{"key":"e_1_2_14_9_13_1","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.2215\/CJN.01380217","article-title":"Anti\u2010glomerular basement membrane disease","volume":"12","author":"McAdoo SP","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"e_1_2_14_9_14_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ajt.2023.09.007","article-title":"Recurrent atypical antiglomerular basement membrane nephritis in the kidney transplant","volume":"24","author":"Mignano SE","year":"2024","journal-title":"Am J Transplant"},{"key":"e_1_2_14_9_15_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103212","article-title":"Anti\u2010Glomerular basement membrane vasculitis","volume":"22","author":"Ponticelli C","year":"2023","journal-title":"Autoimmun Rev."},{"key":"e_1_2_14_9_16_1","volume-title":"Goodpasture Syndrome. [Updated 2024 Jun 1]. In: StatPearls [Internet]","author":"Rout P","year":"2025"},{"key":"e_1_2_14_9_17_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin BH","year":"2021","journal-title":"Kidney Int."},{"key":"e_1_2_14_9_18_1","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/ndt\/gfy327","article-title":"Anti\u2010glomerular basement membrane disease: an update on subgroups, pathogenesis and therapies","volume":"34","author":"Segelmark M","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_14_9_19_1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/1744-9987.13718","article-title":"Anti\u2010glomerular basement membrane disease (Goodpasture disease): from pathogenesis to plasma exchange to IdeS","volume":"26","author":"Shin JI","year":"2022","journal-title":"Ther Apher Dial"},{"key":"e_1_2_14_9_20_1","first-page":"301","article-title":"Plasma exchange in Goodpasture's syndrome","volume":"2","author":"Simpson IJ","year":"1982","journal-title":"Am J Nephrol"},{"key":"e_1_2_14_9_21_1","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.kint.2019.06.019","article-title":"The IgG\u2010degrading enzyme of \n                     Streptococcus pyogenes\n                   causes rapid clearance of anti\u2010glomerular basement membrane antibodies in patients with refractory anti\u2010glomerular basement membrane disease","volume":"96","author":"Soveri I","year":"2019","journal-title":"Kidney Int"},{"key":"e_1_2_14_9_22_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/ndt\/gfad132","article-title":"Using imlifidase to elucidate the characteristics and importance of anti\u2010GBM antibodies produced after start of treatment","volume":"39","author":"Tyrberg L","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_14_9_23_1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1681\/ASN.2021111460","article-title":"Endopeptidase cleavage of anti\u2010glomerular basement membrane antibodies in vivo in severe kidney disease: an open\u2010label phase 2a study","volume":"33","author":"Uhlin F","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_14_9_24_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/j.ajkd.2023.12.019","article-title":"Use of immunoadsorption and plasma exchange for treating anti\u2010glomerular basement membrane disease: clinical experience in Germany","volume":"84","author":"Samson\u2010Himmelstjerna FA","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_14_9_25_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.qjmed.a067830","article-title":"Clinical and morphological aspects of the management of crescentic anti\u2010glomerular basement membrane antibody (anti\u2010GBM) nephritis\/Goodpasture's syndrome","volume":"54","author":"Walker RG","year":"1985","journal-title":"Q J Med"},{"key":"e_1_2_14_9_26_1","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1471-2369-15-128","article-title":"Comparison of double filtration plasmapheresis with immunoadsorption therapy in patients with anti\u2010glomerular basement membrane nephritis","volume":"15","author":"Zhang Y","year":"2014","journal-title":"BMC Nephrology"},{"key":"e_1_2_15_9_1_1","first-page":"14","article-title":"Recent advances in atopic dermatitis","volume":"66","author":"Ahn K","year":"2020","journal-title":"Curr Opin Dermatol"},{"key":"e_1_2_15_9_2_1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1684\/ejd.2014.2383","article-title":"Apheresis in the treatment of recalcitrant atopic dermatitis: case series and review of the literature","volume":"24","author":"Chiricozzi A","year":"2014","journal-title":"Eur J Dermatol"},{"key":"e_1_2_15_9_3_1","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","volume":"132","author":"Chu DK","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"e_1_2_15_9_4_1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/1744-9987.12267","article-title":"Repetitive immunoadsorption cycles for treatment of severe atopic dermatitis","volume":"19","author":"Daeschlein G","year":"2015","journal-title":"Ther Apher Dial"},{"key":"e_1_2_15_9_5_1","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies","volume":"90","author":"Davis DMR","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_15_9_6_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2024.100989","article-title":"A systematic review of guidelines for the management of atopic dermatitis in children","volume":"17","author":"Deva M","year":"2024","journal-title":"World Allergy Organ J"},{"key":"e_1_2_15_9_7_1","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jamadermatol.2024.2192","article-title":"Systematic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta\u2010analysis update","volume":"160","author":"Drucker AM","year":"2024","journal-title":"JAMA Dermatol"},{"key":"e_1_2_15_9_8_1","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1097\/DER.0000000000000835","article-title":"Impact of extracorporeal photopheresis on blood parameters of atopic dermatitis patients","volume":"33","author":"Gambichler T","year":"2022","journal-title":"Dermatitis"},{"key":"e_1_2_15_9_9_1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.821871","article-title":"Treatment guidelines for atopic dermatitis since the approval of dupilumab: a systematic review and quality appraisal using AGREE\u2010II","volume":"9","author":"Ghazal S","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"e_1_2_15_9_10_1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fimmu.2018.00254","article-title":"Targeting IgE antibodies by immunoadsorption in atopic dermatitis","volume":"9","author":"Kasperkiewicz M","year":"2018","journal-title":"Front Immunol"},{"key":"e_1_2_15_9_11_1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/1744-9987.12047","article-title":"Double\u2010filtration plasmapheresis for the treatment of patients with recalcitrant atopic dermatitis","volume":"17","author":"Kim JY","year":"2013","journal-title":"Ther Apher Dial"},{"key":"e_1_2_15_9_12_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jdv.16889","volume":"35","author":"Knobler R","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_15_9_13_1","first-page":"33","article-title":"Cyclosporine and extracorporeal photopheresis are equipotent in treating severe atopic dermatitis: a randomized cross\u2010over study comparing two efficient treatment modalities","volume":"1","author":"Koppelhus U","year":"2014","journal-title":"Front Med (Lausanne)"},{"key":"e_1_2_15_9_14_1","first-page":"145","article-title":"Clinical practice guidelines for the diagnosis and management of atopic dermatitis","volume":"39","author":"Kulthanan K","year":"2021","journal-title":"Asian Pac J Allergy Immunol"},{"key":"e_1_2_15_9_15_1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/jca.21759","article-title":"Single\u2010use IgE\u2010selective immunoadsorber column for the treatment of severe atopic dermatitis","volume":"35","author":"Meyersburg D","year":"2020","journal-title":"J Clin Apher"},{"key":"e_1_2_15_9_16_1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jid.2018.09.020","article-title":"IgE\u2010selective immunoadsorption reduces peripheral and skin\u2010bound IgE and modulates cutaneous IL\u201013 expression in severe atopic dermatitis","volume":"139","author":"Reich K","year":"2019","journal-title":"J Invest Dermatol"},{"key":"e_1_2_15_9_17_1","article-title":"Efficacy of dupilumab in two patients with severe and recalcitrant atopic dermatitis previously treated with extracorporeal photopheresis","volume":"33","author":"Russo F","year":"2020","journal-title":"Dermatol The."},{"key":"e_1_2_15_9_18_1","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/jdv.17351","article-title":"Comparative efficacy and safety of systemic therapies used in moderate\u2010to\u2010severe atopic dermatitis: a systematic literature review and network meta\u2010analysis","volume":"35","author":"Silverberg JI","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_15_9_19_1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40257-023-00785-5","article-title":"Efficacy and safety of abrocitinib in patients with severe and\/or difficult\u2010to\u2010treat atopic dermatitis: a post hoc analysis of the randomized phase 3 JADE COMPARE trial","volume":"24","author":"Simpson EL","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"e_1_2_15_9_20_1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra2023911","article-title":"Atopic dermatitis","volume":"384","author":"St\u00e4nder S.","year":"2021","journal-title":"N Engl J Med"},{"key":"e_1_2_15_9_21_1","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.3390\/ijms25053011","article-title":"Extracorporeal photopheresis in dermatological diseases","volume":"25","author":"Terhaar H","year":"2024","journal-title":"Int J Mol Sci."},{"key":"e_1_2_15_9_22_1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jdv.14891","article-title":"Consensus\u2010based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part 1","volume":"32","author":"Wollenberg A","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_15_9_23_1","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.14888","article-title":"Consensus\u2010based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part 2","volume":"32","author":"Wollenberg A","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_15_9_24_1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jdv.19426","article-title":"The safety of systemic janus kinase inhibitors in atopic dermatitis: a systematic review and meta\u2010analysis of randomized controlled trails","volume":"38","author":"Yoon S","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_15_9_25_1","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/all.16368","article-title":"Long\u2010term efficacy and safety of stapokibart for moderate\u2010to\u2010severe atopic dermatitis: 52\u2010week results from a phase 3 trial","volume":"80","author":"Zhao Y","year":"2025","journal-title":"Allergy"},{"key":"e_1_2_16_9_1_1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jadohealth.2017.08.004","article-title":"Reports of postural orthostatic tachycardia syndrome after human papillomavirus vaccination in the vaccine adverse event reporting system","volume":"61","author":"Arana J","year":"2017","journal-title":"J Adolesc Health"},{"key":"e_1_2_16_9_2_1","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.mayocp.2012.08.013","article-title":"Postural tachycardia syndrome: a heterogeneous and multifactorial disorder","volume":"87","author":"Benarroch EE","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_16_9_3_1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12026-021-09185-5","article-title":"Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID\u201019 infection: a case series of 20 patients","volume":"69","author":"Blitshteyn S","year":"2021","journal-title":"Immunol Res"},{"key":"e_1_2_16_9_4_1","doi-asserted-by":"crossref","first-page":"1647203","DOI":"10.3389\/fcimb.2025.1647203","article-title":"Immunotherapies for postural orthostatic tachycardia syndrome, other common autonomic disorders, and long COVID: current state and future direction","volume":"15","author":"Blitshteyn S","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"key":"e_1_2_16_9_5_1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41380-021-01148-4","article-title":"Chronic post\u2010COVID\u201019 syndrome and chronic fatigue syndrome: is there a role for extracorporeal apheresis?","volume":"27","author":"Bornstein SR","year":"2022","journal-title":"Mol Psychiatry"},{"key":"e_1_2_16_9_6_1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jneuroim.2018.11.009","article-title":"Rituximab treatment in seronegative autoimmune autonomic neuropathy and autoimmune autonomic ganglionopathy: case\u2010report and literature review","volume":"326","author":"Bouxin M","year":"2019","journal-title":"J Neuroimmunol"},{"key":"e_1_2_16_9_7_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.o1671","article-title":"Long Covid patients travel abroad for expensive and experimental \u201cblood washing","volume":"378","author":"Davies M.","year":"2022","journal-title":"BMJ"},{"key":"e_1_2_16_9_8_1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","article-title":"Long COVID: major findings, mechanisms, and recommendations","volume":"21","author":"Davis HE","year":"2023","journal-title":"Nat Rev. Microbiol"},{"issue":"5","key":"e_1_2_16_9_9_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103071","article-title":"The autonomic aspects of the post\u2010COVID19 syndrome","volume":"21","author":"Dotan A","year":"2022","journal-title":"Autoimmun Rev."},{"key":"e_1_2_16_9_10_1","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/s41467-025-57198-7","article-title":"Plasma exchange therapy for the post COVID\u201019 condition: a phase II, double\u2010blind, placebo\u2010controlled, randomized trial","volume":"16","author":"Espana\u2010Cueto S","year":"2025","journal-title":"Nat Commun"},{"key":"e_1_2_16_9_11_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562864221110048","article-title":"Effectiveness of treatment for 31 patients with seropositive autoimmune autonomic ganglionopathy in Japan","volume":"15","author":"Hayashi T","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"key":"e_1_2_16_9_12_1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/WCO.0000000000001103","article-title":"Small fiber neuropathies: expanding their etiologies","volume":"35","author":"Hoeijmakers JG","year":"2022","journal-title":"Curr Opin Neurol"},{"key":"e_1_2_16_9_13_1","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1212\/WNL.0b013e3181a92b52","article-title":"Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy","volume":"72","author":"Iodice V","year":"2009","journal-title":"Neurology"},{"key":"e_1_2_16_9_14_1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00415-022-11344-z","article-title":"Immunotherapy with subcutaneous immunoglobulin or plasmapheresis in patients with postural orthostatic tachycardia syndrome (POTS)","volume":"270","author":"Kesterson K","year":"2023","journal-title":"J Neurol"},{"key":"e_1_2_16_9_15_1","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1055\/a-2445-8593","article-title":"A single\u2010center pilot study of therapeutic apheresis in patients with severe post\u2010COVID syndrome","volume":"56","author":"Korth J","year":"2024","journal-title":"Horm Metab Res"},{"key":"e_1_2_16_9_16_1","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1515\/revneuro-2024-0027","article-title":"The role of antibodies in small fiber neuropathy: a review of currently available evidence","volume":"35","author":"Morelli L","year":"2024","journal-title":"Rev. Neurosci"},{"key":"e_1_2_16_9_17_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2024.103967","article-title":"Immunological and therapeutic insights in autoimmune autonomic ganglionopathy: what is the position of apheresis in immunotherapy?","volume":"63","author":"Nakane S","year":"2024","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_16_9_18_1","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.3390\/ijms25042296","article-title":"Autoimmune autonomic neuropathy: from pathogenesis to diagnosis","volume":"25","author":"Nakane S","year":"2024","journal-title":"Int J Mol Sci"},{"key":"e_1_2_16_9_19_1","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.3390\/jcm14113802","article-title":"The effect on quality of life of therapeutic plasmapheresis and intravenous immunoglobulins on a population of myalgic encephalomyelitis\/chronic fatigue syndrome patients with elevated \u03b2\u2010adrenergic and M3\u2010muscarinic receptor antibodies\u2014a pilot study","volume":"14","author":"Oesch\u2010Regeni B","year":"2025","journal-title":"J Clin Med"},{"key":"e_1_2_16_9_20_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jca.21944","article-title":"Therapeutic plasma exchange for peripheral neuropathy associated with trisulfated heparan disaccharide IgM antibodies: a case series of 17 patients","volume":"37","author":"Olsen GM","year":"2022","journal-title":"J Clin Apher"},{"key":"e_1_2_16_9_21_1","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1186\/s12889-024-19951-3","article-title":"Utilization frequency and patient\u2010reported effectiveness of symptomatic therapies in post\u2010COVID syndrome","volume":"24","author":"Reuner M","year":"2024","journal-title":"BMC Public Health"},{"issue":"3","key":"e_1_2_16_9_22_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193672","article-title":"Immunoadsorption to remove \u03b22 adrenergic receptor antibodies in chronic fatigue syndrome CFS\/ME","volume":"13","author":"Scheibenbogen C","year":"2019","journal-title":"PLoS ONE"},{"key":"e_1_2_16_9_23_1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.amjmed.2023.01.043","article-title":"Plasma exchange improves cognitive function in long\u2010COVID\u2010related postural orthostatic tachycardia syndrome and autoimmune neurological dysfunction","volume":"138","author":"Seeley MC","year":"2025","journal-title":"Am J Med"},{"issue":"49","key":"e_1_2_16_9_24_1","article-title":"Efficacy of repeated immunoadsorption in patients with post\u2010COVID myalgic encephalomyelitis\/chronic fatigue syndrome and elevated \u03b22\u2010adrenergic receptor autoantibodies: a prospective cohort study","volume":"12","author":"Stein E","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"e_1_2_16_9_25_1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10286-024-01020-9","article-title":"Randomized controlled trial of intravenous immunoglobulin for autoimmune postural orthostatic tachycardia syndrome (iSTAND)","volume":"34","author":"Vernino S","year":"2024","journal-title":"Clin Auton Res"},{"key":"e_1_2_16_9_26_1","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.mayocp.2018.01.025","article-title":"Efficacy of therapies for postural tachycardia syndrome: a systematic review and meta\u2010analysis","volume":"93","author":"Wells R","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_16_9_27_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.amjmed.2019.10.016","article-title":"Plasma exchange therapy in postural tachycardia syndrome: a novel long\u2010term approach?","volume":"133","author":"Wells R","year":"2020","journal-title":"Am J Med"},{"key":"e_1_2_16_9_28_1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s40265-018-0931-5","article-title":"Postural orthostatic tachycardia syndrome: prevalence, pathophysiology, and management","volume":"78","author":"Zadourian A","year":"2018","journal-title":"Drugs"},{"key":"e_1_2_17_9_1_1","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/trf.17445","article-title":"Outcomes of therapeutic plasma exchange in severe autoimmune hemolytic anemia hospitalizations: an analysis of the National Inpatient Sample","volume":"63","author":"Abdelhay A","year":"2023","journal-title":"Transfusion"},{"key":"e_1_2_17_9_2_1","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/petr.12101","article-title":"Refractory autoimmune hemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitor","volume":"17","author":"Acquazzino MA","year":"2013","journal-title":"Pediatr Transplant"},{"key":"e_1_2_17_9_3_1","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/trf.13932","article-title":"Therapeutic plasma exchange in refractory warm autoimmune hemolytic anemia","volume":"57","author":"Anani W","year":"2017","journal-title":"Transfusion"},{"key":"e_1_2_17_9_4_1","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jtcvs.2013.03.009","article-title":"Cold agglutinins in patients undergoing cardiac surgery requiring cardiopulmonary bypass","volume":"146","author":"Barbara DW","year":"2013","journal-title":"J Thorac Cardiovasc Surg"},{"key":"e_1_2_17_9_5_1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/asheducation-2016.1.226","article-title":"Cold agglutinin disease","volume":"2","author":"Berentsen S.","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"e_1_2_17_9_6_1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2017-04-778175","article-title":"Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial","volume":"130","author":"Berentsen S","year":"2017","journal-title":"Blood"},{"key":"e_1_2_17_9_7_1","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1111\/j.1537-2995.2012.03608.x","article-title":"Plasma exchange and rituximab treatment for lenalidomide\u2010associated cold agglutinin disease","volume":"52","author":"Brauer DL","year":"2012","journal-title":"Transfusion"},{"key":"e_1_2_17_9_8_1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000478991","article-title":"Acute kidney injury and hemolytic anemia secondary to \n                     Mycoplasma pneumoniae\n                   infection","volume":"132","author":"Carrara C","year":"2017","journal-title":"Nephron"},{"key":"e_1_2_17_9_9_1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/jca.21790","article-title":"Efficacy of therapeutic plasma exchange for treatment of autoimmune hemolytic anemia: a systematic review and meta\u2010analysis of randomized controlled trials","volume":"35","author":"Deng J","year":"2020","journal-title":"J Clin Apher"},{"key":"e_1_2_17_9_10_1","doi-asserted-by":"crossref","first-page":"E149","DOI":"10.1002\/ajh.24047","article-title":"Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias","volume":"90","author":"Fattizzo B","year":"2015","journal-title":"Am J Hematol"},{"key":"e_1_2_17_9_11_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting","volume":"41","author":"J\u00e4ger U","year":"2020","journal-title":"Blood Rev."},{"key":"e_1_2_17_9_12_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.861719","article-title":"Efficacy of whole\u2010blood exchange transfusion in refractory severe autoimmune haemolytic anemia secondary to systemic lupus erythematosus: a real\u2010world observational retrospective study","volume":"13","author":"Jiang Y","year":"2022","journal-title":"Front Immunol"},{"key":"e_1_2_17_9_13_1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/petr.12391","article-title":"Autoantibodies to red blood cell antigens occur frequently with hemolysis among pediatric small bowel transplant recipients: clinical implications and management","volume":"19","author":"Koepsell SA","year":"2015","journal-title":"Pediatr Transplant"},{"key":"e_1_2_17_9_14_1","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1111\/trf.13122","article-title":"Retrospective analysis of 30 severe autoimmune hemolytic anemia patients treated by whole blood exchange transfusion","volume":"55","author":"Li BJ","year":"2015","journal-title":"Transfusion"},{"key":"e_1_2_17_9_15_1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1537-2995.2011.03254.x","article-title":"Autoimmune hemolytic anemia in pediatric liver or combined liver and small bowel transplant patients: a case series and review of the literature","volume":"52","author":"Li M","year":"2012","journal-title":"Transfusion"},{"key":"e_1_2_17_9_16_1","first-page":"1","article-title":"Refractory IgG warm autoimmune hemolytic anemia treated with eculizumab: novel application of anticomplement therapy","author":"Ma K","year":"2016","journal-title":"Case Rep Hematol"},{"key":"e_1_2_17_9_17_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.24570","article-title":"A randomized and double\u2010blind controlled trial evaluating the safety and efficacy of rituximab for warm auto\u2010immune hemolytic anemia in adults (the RAIHA study)","volume":"92","author":"Michel M","year":"2016","journal-title":"Am J Hematology"},{"key":"e_1_2_17_9_18_1","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/MOH.0b013e3282c8ca66","article-title":"Evidence based therapeutic apheresis in autoimmune and other hemolytic anemias","volume":"14","author":"McLeod BC","year":"2007","journal-title":"Current Opin Hematol"},{"key":"e_1_2_17_9_19_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.tmrv.2015.09.001","article-title":"Sirolimus for refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: a case report and literature review of the treatment of post\u2010transplant autoimmune hemolytic anemia","volume":"30","author":"Park JA","year":"2016","journal-title":"Transfus Med Rev."},{"key":"e_1_2_17_9_20_1","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1182\/blood.2021014955","article-title":"Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo\u2010controlled phase 3 CADENZA trial","volume":"140","author":"R\u00f6th A","year":"2022","journal-title":"Blood"},{"key":"e_1_2_17_9_21_1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/jca.20096","article-title":"Plasma exchanges do not increase red blood cell transfusion efficiency in severe autoimmune hemolytic anemia: a retrospective case\u2013control study","volume":"21","author":"Ruivard M","year":"2006","journal-title":"J Clin Apher"},{"key":"e_1_2_17_9_22_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103245","article-title":"Hemolytic anemia and plasma exchange","volume":"60","author":"Serin I","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_17_9_23_1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.14503\/THIJ-15-5672","article-title":"Use of an intravascular warming catheter during off\u2010pump coronary artery bypass surgery in a patient with severe cold hemagglutinin disease","volume":"43","author":"Tholpady A","year":"2016","journal-title":"Tex Heart Inst J"},{"key":"e_1_2_17_9_24_1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.dld.2016.12.006","article-title":"Autoimmune cytopenias associated with inflammatory bowel diseases: insights from a multicenter retrospective cohort","volume":"49","author":"Uzzan M","year":"2016","journal-title":"Dig Liver Dis"},{"key":"e_1_2_17_9_25_1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jca.21460","article-title":"Successful renal transplantation in a patient with cold agglutinin disease","volume":"32","author":"Vilayur E","year":"2017","journal-title":"J Clin Apher"},{"key":"e_1_2_18_9_1_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/9869323","article-title":"A case of babesiosis in a pregnant patient treated with red blood cell exchange transfusion","volume":"2019","author":"Abittan B","year":"2019","journal-title":"Case Rep Obstet Gynecol"},{"key":"e_1_2_18_9_2_1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/jca.21492","article-title":"Babesia parasitemia rebound after red blood cell exchange","volume":"32","author":"Alquist CR","year":"2017","journal-title":"J Clin Apher"},{"key":"e_1_2_18_9_3_1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.transci.2019.04.026","article-title":"Heavy parasitemia in babesiosis treated without adjunctive red cell exchange","volume":"58","author":"Cervera\u2010Hernandez ME","year":"2019","journal-title":"Transfus Apher Sci"},{"issue":"10","key":"e_1_2_18_9_4_1","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01268-22","article-title":"Transfusion\u2010transmitted Babesia spp.: a changing landscape of epidemiology, regulation, and risk mitigation","volume":"61","author":"Drews SJ","year":"2023","journal-title":"J Clin Microbiol"},{"key":"e_1_2_18_9_5_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofz311","article-title":"Babesiosis: a retrospective review of 38 cases in the upper Midwest","volume":"6","author":"Fida M","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"e_1_2_18_9_6_1","article-title":"Two recent cases of babesiosis in the United States with a difference in severity and response to therapy","volume":"12","author":"Gasimova U","year":"2020","journal-title":"Cureus"},{"key":"e_1_2_18_9_7_1","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.4744","article-title":"The unusual case of babesiosis causing disseminated intravascular coagulation with hemophagocytic lymphohistiocytosis","volume":"9","author":"Goodman A","year":"2021","journal-title":"Clin Case Rep"},{"key":"e_1_2_18_9_8_1","doi-asserted-by":"crossref","first-page":"674","DOI":"10.4103\/0972-5229.194017","article-title":"Exchange transfusion for babesiosis when, how, and how long?","volume":"20","author":"Guru PK","year":"2016","journal-title":"Indian J Crit Care Med"},{"key":"e_1_2_18_9_9_1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/QCO.0000000000001038","article-title":"Babesiosis in immunosuppressed hosts: Pathogenesis, diagnosis and management","volume":"37","author":"Heller HM","year":"2024","journal-title":"Curr Opin Infect Dis"},{"key":"e_1_2_18_9_10_1","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s15010-013-0526-8","article-title":"Human babesiosis in Europe: what clinicians need to know?","volume":"41","author":"Hildebrandt A","year":"2013","journal-title":"Infection"},{"key":"e_1_2_18_9_11_1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3201\/eid2608.191293","article-title":"Rise in babesiosis cases, Pennsylvania, USA, 2005\u20132018","volume":"26","author":"Ingram D","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"e_1_2_18_9_12_1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12941-017-0198-9","article-title":"Babesiosis in Long Island: review of 62 cases focusing on treatment with azithromycin and atovaquone","volume":"16","author":"Kletsova EA","year":"2017","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"e_1_2_18_9_13_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/cid\/ciaa1216","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America (IDSA): 2020 guideline on diagnosis and management of Babesiosis","volume":"72","author":"Krause PJ","year":"2021","journal-title":"Clin Infect Dis"},{"key":"e_1_2_18_9_14_1","first-page":"1","volume":"11","author":"Kumar M","year":"2019","journal-title":"Triple tick attack. Cureus"},{"key":"e_1_2_18_9_15_1","first-page":"1","article-title":"Case report: Overwhelming babesia parasitemia successfully treated promptly with RBC apheresis and triple therapy with clindamycin, azithromycin, and atovaquone","volume":"7","author":"Li Y","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"e_1_2_18_9_16_1","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1111\/trf.15346","article-title":"Adjunctive treatment of clinically severe babesiosis with red blood cell exchange: a case series of nineteen patients","volume":"59","author":"Nixon CP","year":"2019","journal-title":"Transfusion"},{"key":"e_1_2_18_9_17_1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/jca.21853","article-title":"Parasite burden and red blood cell exchange transfusion for babesiosis","volume":"36","author":"O'Bryan J","year":"2021","journal-title":"J Clin Apher"},{"key":"e_1_2_18_9_18_1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.transci.2019.07.010","article-title":"Repeat exchange transfusion for treatment of severe babesiosis","volume":"58","author":"Radcliffe C","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_18_9_19_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.14740\/jh820","article-title":"Autoimmune hemolytic anemia associated with human babesiosis","volume":"10","author":"Rajapakse P","year":"2021","journal-title":"J Hematol"},{"key":"e_1_2_18_9_20_1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/jca.21429","article-title":"Apheresis for babesiosis: therapeutic parasite reduction or removal of harmful toxins or both?","volume":"31","author":"Saifee NH","year":"2016","journal-title":"J Clin Apher"},{"key":"e_1_2_18_9_21_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tmrv.2021.06.004","article-title":"Red cell exchange as adjunctive therapy for babesiosis: Is it really effective?","volume":"35","author":"Tannous T","year":"2021","journal-title":"Transfus Med Rev."},{"key":"e_1_2_18_9_22_1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.idc.2022.02.009","article-title":"Human Babesiosis","volume":"36","author":"Waked R","year":"2022","journal-title":"Infect Dis Clin N Am"},{"key":"e_1_2_19_9_1_1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/jbcr\/irad125","article-title":"American Burn Association Clinical Practice Guidelines on burn shock resuscitation","volume":"45","author":"Cartotto R","year":"2024","journal-title":"J Burn Care Res"},{"key":"e_1_2_19_9_2_1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00004630-198505000-00007","article-title":"Effect of plasma exchange therapy on circulating fibronectin in burned patients","volume":"6","author":"Dobke M","year":"1985","journal-title":"J Burn Care Rehabil"},{"key":"e_1_2_19_9_3_1","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/jbcr\/irae049","article-title":"Pathophysiology of severe burn injuries: New therapeutic opportunities from a systems perspective","volume":"45","author":"Dobson PD","year":"2024","journal-title":"J Burn Care Res"},{"key":"e_1_2_19_9_4_1","first-page":"215","article-title":"Prophylactic plasma exchange in burn treatment","volume":"9","author":"Donati L","year":"1987","journal-title":"Int J Tissue React"},{"key":"e_1_2_19_9_5_1","unstructured":"European Burns Association. European Practice Guidelines for Burn Care ver 42\u2009017; European Burn Association Hertogenbosch The Netherlands."},{"key":"e_1_2_19_9_6_1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/BCR.0b013e318198a30d","article-title":"The beneficial effects of plasma exchange after severe burn injury","volume":"30","author":"Klein MB","year":"2009","journal-title":"J Burn Care Res"},{"key":"e_1_2_19_9_7_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00004630-198901000-00004","article-title":"A randomized trial of plasma exchange in the treatment of burn shock","volume":"10","author":"Kravitz M","year":"1989","journal-title":"J Burn Care Rehabil"},{"key":"e_1_2_19_9_8_1","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.burns.2014.01.013","article-title":"Extracorporeal blood purification in burns: a review","volume":"40","author":"Linden K","year":"2014","journal-title":"Burns"},{"key":"e_1_2_19_9_9_1","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1097\/00005373-198409001-00009","article-title":"Is there a role for plasmapheresis\/exchange transfusion in the treatment of the septic burn patient?","volume":"24","author":"McManus WF","year":"1984","journal-title":"J Trauma"},{"key":"e_1_2_19_9_10_1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4103\/JCAS.JCAS_173_21","article-title":"Therapeutic plasma exchange therapy in burns","volume":"16","author":"Mohan PB","year":"2023","journal-title":"J Cutan Aesthet Surg"},{"key":"e_1_2_19_9_11_1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/BCR.0b013e318283d18c","article-title":"Use of therapeutic plasma exchange in the burn unit: a review of the literature","volume":"34","author":"Mosier MJ","year":"2013","journal-title":"J Burn Care Res"},{"key":"e_1_2_19_9_12_1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.burns.2009.05.006","article-title":"The use of therapeutic plasma exchange (TPE) in the setting of refractory burn shock","volume":"36","author":"Neff LP","year":"2010","journal-title":"Burns"},{"key":"e_1_2_19_9_13_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archsurg.1984.01390130023004","article-title":"The effect of plasma exchange on lymphocyte suppression after burn","volume":"119","author":"Ninnemann JL","year":"1984","journal-title":"Arch Surg"},{"key":"e_1_2_19_9_14_1","doi-asserted-by":"crossref","first-page":"s6","DOI":"10.5603\/AIT.a2015.0063","article-title":"An overview on fluid resuscitation and resuscitation endpoints in burns: Past, present and future. Part 1\u2010 historical background, resuscitation fluid and adjunctive treatment","volume":"47","author":"Peeters Y","year":"2015","journal-title":"Anaesthesiol Intensive Ther"},{"key":"e_1_2_19_9_15_1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/BCR.0b013e31815f3876","article-title":"American Burn Association practice guidelines burn shock resuscitation","volume":"29","author":"Pham TN","year":"2008","journal-title":"J Burn Care Res"},{"key":"e_1_2_19_9_16_1","unstructured":"RotondoM CribariC SmithRS. (Eds)Resources for the Optimal Care of Injured Patient 2014: American College of Surgeons Chicago IL."},{"key":"e_1_2_19_9_17_1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00004630-198605000-00006","article-title":"Plasma exchange for failure of early resuscitation in thermal injuries","volume":"7","author":"Schnarrs RH","year":"1986","journal-title":"J Burn Care Rehabil"},{"key":"e_1_2_19_9_18_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00005373-198601000-00002","article-title":"Immunologic parameters in burned patients: effects of therapeutic interventions","volume":"26","author":"Stratta RJ","year":"1986","journal-title":"J Trauma"},{"key":"e_1_2_19_9_19_1","first-page":"40\u2009429\u2013432","article-title":"Plasma\u2010exchange therapy during burn shock","author":"Stratta RJ","year":"1983","journal-title":"Curr Surg"},{"key":"e_1_2_19_9_20_1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00000658-197503000-00019","article-title":"Suppression of leukocyte chemotaxis in vitro by chemotherapeutic agents used in the management of thermal injuries","volume":"181","author":"Warden GD","year":"1975","journal-title":"Ann Surg"},{"key":"e_1_2_19_9_21_1","first-page":"321","article-title":"The effect of exchange therapy on postburn lymphocyte suppression","volume":"96","author":"Warden GD","year":"1984","journal-title":"Surgery"},{"key":"e_1_2_19_9_22_1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/00005373-198310000-00018","article-title":"Plasma exchange therapy in patients failing to resuscitate from burn shock","volume":"23","author":"Warden GD","year":"1983","journal-title":"J Trauma"},{"key":"e_1_2_20_9_1_1","first-page":"67","article-title":"Sj\u00f6gren's syndrome diagnosed in pregnancy: a case report","volume":"50","author":"Aslan E","year":"2005","journal-title":"J Reprod Med"},{"key":"e_1_2_20_9_2_1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1471-0528.1987.tb03107.x","article-title":"Successful pregnancy following steroid therapy and plasma exchange in a woman with anti\u2010Ro (SS\u2010A) antibodies","volume":"94","author":"Barclay CS","year":"1987","journal-title":"Case report. Br J Obstet Gynaecol"},{"key":"e_1_2_20_9_3_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12016-009-8190-6","article-title":"Pregnancy outcomes in patients with autoimmune diseases and anti\u2010Ro\/SSA antibodies","volume":"40","author":"Brucato A","year":"2011","journal-title":"Clin Rev. Allergy Immunology"},{"key":"e_1_2_20_9_4_1","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00296-005-0101-4","article-title":"Identification and management of fetuses at risk for, or affected by, congenital heart block associated with autoantibodies to SSA (Ro), SSB (La), or an HsEg5\u2010like autoantigen","volume":"26","author":"Claus R","year":"2006","journal-title":"Rheumatol Int"},{"key":"e_1_2_20_9_5_1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/1471-2393-13-220","article-title":"Antenatal and postnatal combined therapy for autoantibody\u2010related congenital atrioventricular block","volume":"13","author":"Di Mauro A","year":"2013","journal-title":"BMC Pregnancy Childbirth"},{"key":"e_1_2_20_9_6_1","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1161\/01.cir.0000437597.44550.5d","article-title":"Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association","volume":"129","author":"Donofrio MT","year":"2014","journal-title":"Circulation"},{"key":"e_1_2_20_9_7_1","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/art.27308","article-title":"Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open\u2010label clinical trial","volume":"62","author":"Friedman DM","year":"2010","journal-title":"Arthritis Rheum"},{"key":"e_1_2_20_9_8_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13075-023-03246-w","article-title":"Autoimmune congenital heart block: a case report and review of the literature related to pathogenesis and pregnancy management","volume":"26","author":"Huang Y","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"e_1_2_20_9_9_1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/CIRCULATIONAHA.111.089268","article-title":"Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti\u2010SSA\/Ro\u2010associated cardiac manifestations of neonatal lupus","volume":"126","author":"Izmirly P","year":"2012","journal-title":"Circulation"},{"key":"e_1_2_20_9_10_1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jacc.2020.05.045","article-title":"Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of anti\u2010SSA\/Ro\u2010positive mothers","volume":"76","author":"Izmirly P","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_20_9_11_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12969-023-00920-w","article-title":"Reverse complete heart block using transcutaneous pacing and repeated plasmapheresis in a neonate with lupus: a case report","volume":"21","author":"Liu Y","year":"2023","journal-title":"Pediatr Rheumatol J Online"},{"key":"e_1_2_20_9_12_1","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/00016340701343024","article-title":"Effect of steroid administration and plasmapheresis to prevent fetal congenital heart block in patients with systemic lupus erythematosus and\/or Sj\u00f6gren's syndrome","volume":"86","author":"Makino S","year":"2007","journal-title":"Acta Obstet Gynecol Scand"},{"key":"e_1_2_20_9_13_1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.autrev.2015.01.005","article-title":"The effect of a triple therapy on maternal anti\u2010Ro\/SS\u2010A levels associated to fetal cardiac manifestations","volume":"14","author":"Martinez\u2010Sanchez N","year":"2015","journal-title":"Autoimmun Rev."},{"key":"e_1_2_20_9_14_1","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/art.27350","article-title":"Failure of intravenous immunoglobulin to prevent congenital heart block: findings of a multicenter, prospective, observational study","volume":"62","author":"Pisoni CN","year":"2010","journal-title":"Arthritis Rheum"},{"key":"e_1_2_20_9_15_1","first-page":"1161","article-title":"Short and long term outcomes of children with autoimmune congenital heart block treated with a combined maternal\u2010neonatal therapy","volume":"42","author":"Ruffatti A","year":"2022","journal-title":"A comparison study. J Perinatol"},{"key":"e_1_2_20_9_16_1","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1177\/0961203311430969","article-title":"A combination therapy to treat second\u2010degree anti\u2010Ro\/La\u2010related congenital heart block: a strategy to avoid stable third\u2010degree heart block?","volume":"21","author":"Ruffatti A","year":"2012","journal-title":"Lupus"},{"key":"e_1_2_20_9_17_1","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.autrev.2013.01.002","article-title":"A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti\u2010Ro\/La related congenital atrioventricular block. A case series and review of the literature","volume":"12","author":"Ruffatti A","year":"2013","journal-title":"Autoimmun Rev."},{"key":"e_1_2_20_9_18_1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12872-020-01637-4","article-title":"Neonatal lupus with left bundle branch block and cardiomyopathy: a case report","volume":"20","author":"Rumancik B","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"e_1_2_20_9_19_1","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/1529-0131(199911)42:11<2335::AID-ANR12>3.0.CO;2-3","article-title":"Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody\u2010associated congenital heart block: retrospective review of the research registry for neonatal lupus","volume":"42","author":"Saleeb S","year":"1999","journal-title":"Arthritis Rheum"},{"key":"e_1_2_20_9_20_1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/CRD.0000000000000026","article-title":"Prevention and treatment in utero of autoimmune\u2010associated congenital heart block","volume":"22","author":"Saxena A","year":"2014","journal-title":"Cardiol Rev."},{"key":"e_1_2_20_9_21_1","first-page":"848","article-title":"Anti\u2010Ro\/SSA\u2010p200 antibodies in the prediction of congenital heart block. An Italian multicentre cross sectional study on behalf of the \u2018Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA) Group","volume":"32","author":"Scarsi M","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_20_9_22_1","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/trf.13046","article-title":"Plasma exchange effectively removes 52\u2010 and 60\u2010kDa anti\u2010Ro\/SSA and anti\u2010La\/SSB antibodies in pregnant women with congenital heart block","volume":"55","author":"Tonello M","year":"2015","journal-title":"Transfusion"},{"key":"e_1_2_20_9_23_1","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/pd.1970141019","article-title":"Successful outcome of pregnancy after treatment of maternal anti\u2010Ro (SSA) antibodies with immunosuppressive therapy and plasmapheresis","volume":"14","author":"Leij JN","year":"1994","journal-title":"Prenat Diagn"},{"key":"e_1_2_20_9_24_1","first-page":"365","article-title":"Successful preventive treatment of congenital heart block during pregnancy in a woman with systemic lupus erythematosus and anti\u2010Sjogren's syndrome A\/Ro antibody","volume":"38","author":"Yang CH","year":"2005","journal-title":"J Microbiol Immunol Infect"},{"key":"e_1_2_21_9_1_1","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya M","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_21_9_2_1","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/rheumatology\/kew040","article-title":"Complement is a crucial pathogenic factor in catastrophic antiphospholipid syndrome","volume":"55","author":"Barratt\u2010Due A","year":"2016","journal-title":"Rheumatology"},{"key":"e_1_2_21_9_3_1","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman H","year":"2013","journal-title":"Autoimmun Rev."},{"key":"e_1_2_21_9_4_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.autrev.2013.10.004","article-title":"Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the \u201cCAPS Registry","volume":"13","author":"Berman H","year":"2014","journal-title":"Autoimmun Rev."},{"key":"e_1_2_21_9_5_1","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/art.22018","article-title":"Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients","volume":"54","author":"Bucciarelli S","year":"2006","journal-title":"Arthritis Rheum"},{"key":"e_1_2_21_9_6_1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/17474086.2017.1300522","article-title":"Diagnosis and management of catastrophic antiphospholipid syndrome","volume":"10","author":"Carmi O","year":"2017","journal-title":"Expert Rev. Hematol"},{"key":"e_1_2_21_9_7_1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jaut.2009.02.008","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the \u201cCAPS Registry","volume":"32","author":"Cervera R","year":"2009","journal-title":"J Autoimmun"},{"key":"e_1_2_21_9_8_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review","volume":"92","author":"Cervera R","year":"2018","journal-title":"J Autoimmun"},{"key":"e_1_2_21_9_9_1","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/0961203320951260","article-title":"16th International congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome","volume":"29","author":"Cervera R","year":"2020","journal-title":"Lupus"},{"key":"e_1_2_21_9_10_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/1744-9987.14199","article-title":"Therapeutic apheresis treatment in rheumatic diseases: Insights from a single\u2010center experience","volume":"29","author":"\u00c7imen G\u00fcne\u015f E","year":"2025","journal-title":"Ther Apher Dial"},{"key":"e_1_2_21_9_11_1","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1007\/s10067-010-1506-3","article-title":"Successful plasma exchange combined with rituximab therapy in aggressive APS\u2010related cutaneous necrosis","volume":"32","author":"Costa R","year":"2013","journal-title":"Clin Rheumatol"},{"key":"e_1_2_21_9_12_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/(SICI)1098-1101(1999)14:4<171::AID-JCA3>3.0.CO;2-5","article-title":"Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: \u00df2\u2010 glycoprotein I antibodies as a marker of response to therapy","volume":"14","author":"Flamholz R","year":"1999","journal-title":"J Clin Apher"},{"key":"e_1_2_21_9_13_1","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/jth.14192","article-title":"McMaster RARE\u2010Best practices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome","volume":"16","author":"Legault K","year":"2018","journal-title":"J Thromb Haemost"},{"key":"e_1_2_21_9_14_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103055","article-title":"Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): descriptive analysis from the \u201cCAPS Registry","volume":"21","author":"L\u00f3pez\u2010Benjume B","year":"2022","journal-title":"Autoimmun Rev."},{"key":"e_1_2_21_9_15_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2796.2008.01942.x","article-title":"Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement","volume":"264","author":"Marson P","year":"2008","journal-title":"J Intern Med"},{"key":"e_1_2_21_9_16_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152439","article-title":"CAPS Registry Project Group\/European Forum on Antiphospholipid Antibodies (supplementary material 1). Cardiac involvement in the catastrophic antiphospholipid syndrome (CAPS): Lessons from the \u201cCAPS registry","volume":"66","author":"Pons I","year":"2024","journal-title":"Semin Arthritis Rheum."},{"key":"e_1_2_21_9_17_1","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.medcli.2024.02.011","article-title":"Catastrophic antiphospholipid syndrome: lessons from the \u201cCAPS registry","volume":"163","author":"Rodriguez\u2010Pint\u00f3 I","year":"2024","journal-title":"Medicina Clinica"},{"key":"e_1_2_21_9_18_1","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1093\/rheumatology\/kead556","article-title":"What we know and what we don't know about catastrophic antiphospholipid syndrome","volume":"63","author":"Rodriguez\u2010Pint\u00f3 I","year":"2024","journal-title":"Rheumatology"},{"key":"e_1_2_21_9_19_1","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/rheumatology\/key082","article-title":"The effect of triple therapy on the mortality of catastrophic anti\u2010phospholipid syndrome patients","volume":"57","author":"Rodr\u00edguez\u2010Pint\u00f3 I","year":"2018","journal-title":"Rheumatology"},{"key":"e_1_2_21_9_20_1","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.autrev.2016.09.010","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry","volume":"15","author":"Rodr\u00edguez\u2010Pint\u00f3 I","year":"2016","journal-title":"Autoimmun Rev."},{"key":"e_1_2_21_9_21_1","first-page":"124","article-title":"Catastrophic antiphospholipid syndrome: lessons from 14 cases successfully treated in a single center","volume":"93","author":"Ruffatti A","year":"2018","journal-title":"A narrative report. J Autoimmun"},{"key":"e_1_2_21_9_22_1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/hematology.2024000544","article-title":"Catastrophic antiphospholipid syndrome: a CAPS\u2010tivating hematologic disease","author":"Salter BM","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"e_1_2_22_9_1_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eplepsyres.2008.03.007","article-title":"Autoantibodies to Munc18, cerebral plasma cells and B\u2010lymphocytes in Rasmussen encephalitis","volume":"80","author":"Alvarez\u2010Baron E","year":"2008","journal-title":"Epilepsy Res"},{"key":"e_1_2_22_9_2_1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1212\/WNL.46.1.242","article-title":"Plasmapheresis in Rasmussen's encephalitis","volume":"46","author":"Andrews PI","year":"1996","journal-title":"Neurology"},{"key":"e_1_2_22_9_3_1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1528-1157.1997.tb01096.x","article-title":"Clinical and electroencephalographic correlates in Rasmussen's encephalitis","volume":"38","author":"Andrews PI","year":"1997","journal-title":"Epilepsia"},{"key":"e_1_2_22_9_4_1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1212\/WNL.51.1.302","article-title":"Long\u2010term selective IgG immuno\u2010adsorption improves Rasmussen's encephalitis","volume":"51","author":"Antozzi C","year":"1998","journal-title":"Neurology"},{"key":"e_1_2_22_9_5_1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/brain\/awh415","article-title":"Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement","volume":"128","author":"Bien CG","year":"2005","journal-title":"Brain"},{"key":"e_1_2_22_9_6_1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/epi.12042","article-title":"Rasmussen encephalitis: incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins","volume":"54","author":"Bien CG","year":"2013","journal-title":"Epilepsia"},{"key":"e_1_2_22_9_7_1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.seizure.2020.10.008","article-title":"Rasmussen's encephalitis and central precocious puberty. Neuroendocrinological characterization of 3 cases","volume":"83","author":"Cantarin\u2010Extremera V","year":"2020","journal-title":"Seizure"},{"key":"e_1_2_22_9_8_1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3389\/fneur.2017.00564","article-title":"A case series of adult\u2010onset Rasmussen's encephalitis: diagnostic and therapeutic challenges","volume":"25","author":"Castellano JF","year":"2017","journal-title":"Front Neurol"},{"key":"e_1_2_22_9_9_1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.autrev.2017.05.022","article-title":"Late\u2010onset Rasmussen encephalitis: a literature appraisal","volume":"16","author":"Dupont S","year":"2017","journal-title":"Autoimmunity Rev."},{"key":"e_1_2_22_9_10_1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/epi.17131","article-title":"Rasmussen encephalitis: Predisposing factors and their potential role in unilaterality","volume":"63","author":"Fauser S","year":"2022","journal-title":"Epilepsia"},{"key":"e_1_2_22_9_11_1","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1212\/01.WNL.0000099074.04539.E0","article-title":"Experience with immunomodulatory treatments in Rasmussen's encephalitis","volume":"61","author":"Granata T","year":"2003","journal-title":"Neurology"},{"key":"e_1_2_22_9_12_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pediatrneurol.2023.05.003","article-title":"Early intravenous immunoglobulins in halting clinical and radiographic disease progression in Rasmussen encephalitis","volume":"145","author":"Jaafar F","year":"2023","journal-title":"Pediatr Neurol"},{"key":"e_1_2_22_9_13_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebr.2022.100540","article-title":"Rituximab in Rasmussen's encephalitis: a single center experience and review of the literature","volume":"18","author":"Jagtap SA","year":"2022","journal-title":"Epilepsy Behavior Rep"},{"key":"e_1_2_22_9_14_1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.spen.2014.08.002","article-title":"Focal epilepsies: immunologic and inflammatory mechanisms","volume":"21","author":"Khurana DS","year":"2014","journal-title":"Semin Pediatr Neurol"},{"key":"e_1_2_22_9_15_1","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/epi.13387","article-title":"Anti\u2010tumor necrosis factor alpha therapy (adalimumab) in Rasmussen's encephalitis: an open pilot study","volume":"57","author":"Lagarde S","year":"2016","journal-title":"Epilepsia"},{"key":"e_1_2_22_9_16_1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.neurol.2022.01.007","article-title":"Medical treatment of Rasmussen's encephalitis: a systematic review","volume":"178","author":"Lagarde S","year":"2022","journal-title":"Rev. Neurol (Paris)"},{"key":"e_1_2_22_9_17_1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.seizure.2020.07.023","article-title":"Rasmussen's encephalitis: from immune pathogenesis toward targeted therapy","volume":"81","author":"Orsini A","year":"2020","journal-title":"Seizure"},{"issue":"2","key":"e_1_2_22_9_18_1","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1212\/WNL.0000000000011004","article-title":"Immunomodulation with azathioprine therapy in Rasmussen syndrome: a multimodal evaluation","volume":"96","author":"Pellegrin S","year":"2021","journal-title":"Neurology"},{"key":"e_1_2_22_9_19_1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1212\/WNL.8.6.435","article-title":"Focal seizures due to chronic localized encephalitis","volume":"8","author":"Rasmussen T","year":"1958","journal-title":"Neurology"},{"key":"e_1_2_22_9_20_1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1126\/science.8036512","article-title":"Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis","volume":"265","author":"Rogers SW","year":"1994","journal-title":"Science"},{"key":"e_1_2_22_9_21_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebr.2020.100360","article-title":"Posterior\u2010onset Rasmussen's encephalitis with ipsilateral cerebellar atrophy and uveitis resistant to rituximab","volume":"14","author":"Sansevere AJ","year":"2020","journal-title":"Epilepsy Behav Rep"},{"key":"e_1_2_22_9_22_1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.seizure.2024.09.001","article-title":"Current practices in the diagnosis and treatment of Rasmussen syndrome: results of an international survey","volume":"122","author":"Stredny CM","year":"2024","journal-title":"Seizure"},{"key":"e_1_2_22_9_23_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040622320971413","article-title":"Rasmussen's encephalitis: mechanisms update and potential therapy target","volume":"11","author":"Tang C","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"key":"e_1_2_22_9_24_1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1474-4422(13)70260-6","article-title":"Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances","volume":"13","author":"Varadkar S","year":"2014","journal-title":"Lancet Neurol"},{"key":"e_1_2_22_9_25_1","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.neurol.2022.03.012","article-title":"Rasmussens encephalitis: early diagnostic criteria in children","volume":"78","author":"Villeneuve N","year":"2022","journal-title":"Rev. Neurol"},{"key":"e_1_2_23_9_1_1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40272-024-00646-6","article-title":"Pediatric chronic inflammatory demyelinating polyneuropathy: challenges in diagnosis and therapeutic strategies","volume":"26","author":"Alawneh I","year":"2024","journal-title":"Paediatr Drugs"},{"key":"e_1_2_23_9_2_1","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculopathy (AHERE): a multicentre, randomized\u2010withdrawal, double\u2010blind, placebo\u2010controlled, phase 2 trial","volume":"23","author":"Allen JA","year":"2024","journal-title":"Lancet Neurol"},{"key":"e_1_2_23_9_3_1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/jca.21953","article-title":"Immunoadsorption and plasma exchange\u2014Efficient treatment options for neurological autoimmune diseases","volume":"37","author":"Boedecker SC","year":"2022","journal-title":"J Clin Apher"},{"key":"e_1_2_23_9_4_1","first-page":"CD001797","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"2","author":"Bus SR","year":"2024","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_23_9_5_1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.qjmed.a069092","article-title":"Long\u2010term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin","volume":"88","author":"Choudhary PP","year":"1995","journal-title":"QJM"},{"key":"e_1_2_23_9_6_1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ped4.70008","article-title":"Clinical characteristics of anti\u2010neurofascin 155 antibody\u2010positive autoimmune nodopathy in children","volume":"9","author":"Cui L","year":"2025","journal-title":"Pediatr Investig"},{"key":"e_1_2_23_9_7_1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s13311-022-01210-1","article-title":"Autoimmune neurological disorders with IgG4 antibodies: a distinct disease spectrum with unique IgG4 functions responding to anti\u2010B cell therapies","volume":"19","author":"Dalakas MC","year":"2022","journal-title":"Neurotherapeutics"},{"key":"e_1_2_23_9_8_1","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16190","article-title":"Impact of 2021 European Academy of Neurology\/Peripheral Nerve Society diagnostic criteria on diagnosis and therapy of chronic inflammatory demyelinating polyradiculoneuropathy variants","volume":"31","author":"De Lorenzo A","year":"2024","journal-title":"Eur J Neurol"},{"key":"e_1_2_23_9_9_1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/WCO.0000000000000979","article-title":"Atypical chronic inflammatory demyelinating polyradiculoneuropathy: recent advances on classification, diagnosis, and pathogenesis","volume":"34","author":"Doneddu PE","year":"2021","journal-title":"Curr Opin Neurol"},{"key":"e_1_2_23_9_10_1","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.3390\/jcm9092874","article-title":"Safety and tolerability of plasma exchange and immunoadsorption in neuroinflammatory diseases","volume":"9","author":"Dorst J","year":"2020","journal-title":"J Clin Med"},{"key":"e_1_2_23_9_11_1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJM198602203140801","article-title":"Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"314","author":"Dyck PJ","year":"1986","journal-title":"N Engl J Med"},{"key":"e_1_2_23_9_12_1","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ana.410360607","article-title":"A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"3","author":"Dyck PJ","year":"1994","journal-title":"Annals Neurol"},{"key":"e_1_2_23_9_13_1","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.neurol.2022.06.004","article-title":"French recommendations for the management of adult and pediatric chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)","volume":"178","author":"Fargeot G","year":"2022","journal-title":"Rev. Neurol (Paris)"},{"key":"e_1_2_23_9_14_1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s42466-020-00088-8","article-title":"Comprehensive approaches for diagnosis, monitoring and treatment of chronic inflammatory demyelinating polyneuropathy","volume":"2","author":"Fisse AL","year":"2020","journal-title":"Neurol Res Pract"},{"key":"e_1_2_23_9_15_1","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","article-title":"Plasma\u2010exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double\u2010blind, sham\u2010controlled, cross\u2010over study","volume":"119","author":"Hahn AF","year":"1996","journal-title":"Brain"},{"key":"e_1_2_23_9_16_1","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/jca.21546","article-title":"A prospective study comparing tryptophan immunoadsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinating polyneuropathy","volume":"32","author":"Lieker I","year":"2017","journal-title":"J Clin Apher"},{"key":"e_1_2_23_9_17_1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12883-025-04294-2","article-title":"Extracorporeal therapy procedures (plasma exchange and immunoadsorption) in chronic inflammatory demyelinating polyneuropathies (CIDP)\u2014a database analysis","volume":"25","author":"Mahlberg M","year":"2025","journal-title":"BMC Neurol"},{"key":"e_1_2_23_9_18_1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2012.09.008","article-title":"Childhood chronic inflammatory demyelinating polyradiculoneuropathy: combined analysis of a large cohort and eleven published series","volume":"23","author":"McMillan HJ","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"e_1_2_23_9_19_1","first-page":"CD010369","article-title":"Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews","author":"Oaklander AL","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_23_9_20_1","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.3390\/jcm13195721","article-title":"Antibody\u2010mediated nodo\u2010 and paranodopathies","volume":"13","author":"Quinot V","year":"2024","journal-title":"J Clin Med"},{"key":"e_1_2_23_9_21_1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/ITT.S388151","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: current therapeutic approaches and future outlooks","volume":"13","author":"Rajabally YA","year":"2024","journal-title":"Immunotargets Ther"},{"key":"e_1_2_23_9_22_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27046","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy\u2014Diagnostic pitfalls and treatment approach","volume":"63","author":"Stino AM","year":"2021","journal-title":"Muscle Nerve"},{"key":"e_1_2_23_9_23_1","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory polyradiculoneuropathy: report of a joint Task Force\u2014Second revision","volume":"28","author":"Van den Bergh PYK","year":"2021","journal-title":"Eur J Neurol"},{"key":"e_1_2_23_9_24_1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/TCRM.S360249","article-title":"Challenges in the early diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy in adults: current perspectives","volume":"20","author":"Van Doorn IN","year":"2024","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_2_23_9_25_1","doi-asserted-by":"crossref","DOI":"10.1111\/jns.70017","article-title":"CIDP treatment outcomes correlation with first nerve conduction changes: ascertainment of initial and long\u2010term responders","volume":"30","author":"Wannarong T","year":"2025","journal-title":"J Peripher Nerv Syst"},{"key":"e_1_2_23_9_26_1","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1111\/ene.15857","article-title":"Efficacy of hematopoietic stem cell transplantation treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta\u2010analysis","volume":"30","author":"Zheng Y","year":"2023","journal-title":"Eur J Neurol"},{"key":"e_1_2_24_9_1_1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/jca.21532","article-title":"Therapeutic plasma exchange for perioperative management of patients with congenital factor XI deficiency","volume":"32","author":"Alsammak MS","year":"2017","journal-title":"J Clin Apher"},{"key":"e_1_2_24_9_2_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103176","article-title":"Management of factor XI deficiency in oncological liver and colorectal surgery by therapeutic plasma exchange: a case report","volume":"60","author":"Burgos Pratx LD","year":"2021","journal-title":"Transfus Apher Sci"},{"issue":"3","key":"e_1_2_24_9_3_1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/hae.14986","article-title":"Rare bleeding disorders: advances in management","volume":"30","author":"Casini A","year":"2024","journal-title":"Hemophilia"},{"key":"e_1_2_24_9_4_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/hae.14194","article-title":"Real\u2010world evidence on health resource use among patients with hemophilia and inhibitor exhibiting severe bleeding episodes","volume":"27","author":"Chuansamrit A","year":"2021","journal-title":"Hemophilia"},{"key":"e_1_2_24_9_5_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2012-02-409185","article-title":"Immunosuppression for acquired hemophilia A: results from the European Acquired Hemophilia Registry (EACH2)","volume":"120","author":"Collins P","year":"2012","journal-title":"Blood"},{"key":"e_1_2_24_9_6_1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1055\/s-0031-1297372","article-title":"Bleeding and thrombosis in multiple myeloma and related plasma cell disorders","volume":"37","author":"Coppola A","year":"2011","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_24_9_7_1","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jtha.2024.09.040","article-title":"Acquired hemophilia A: a narrative review and management in the emicizumab era","volume":"23","author":"Ellsworth P","year":"2025","journal-title":"J Thromb Haemost"},{"key":"e_1_2_24_9_8_1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0033-1334867","article-title":"Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update","volume":"39","author":"Federici AB","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_24_9_9_1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1055\/s-0032-1305779","article-title":"Acquired inhibitors of coagulation factors: part II","volume":"38","author":"Franchini M","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_24_9_10_1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1055\/s-0029-1214150","article-title":"Extracorporeal immunoadsorption for the treatment of coagulation inhibitors","volume":"35","author":"Franchini M","year":"2009","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_24_9_11_1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/10245332.2017.1319115","article-title":"Acquired hemophilia A: a review of recent data and new therapeutic options","volume":"22","author":"Franchini M","year":"2017","journal-title":"Hematology"},{"key":"e_1_2_24_9_12_1","first-page":"244","article-title":"Kinetic aspects of the removal of IgG and inhibitors in hemophiliacs using protein A immunoadsorption","volume":"61","author":"Gjorstrup P","year":"1991","journal-title":"Vox Sang"},{"key":"e_1_2_24_9_13_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.atherosclerosissup.2015.02.015","article-title":"Treatment of minor severe acquired hemophilia. Is there a rationale for immunoadsorption?","volume":"18","author":"Goldman G","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"e_1_2_24_9_14_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1365-2141.2001.02510.x","article-title":"Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig\u2010Therasorb)","volume":"112","author":"Jansen M","year":"2001","journal-title":"Br J Haematol"},{"key":"e_1_2_24_9_15_1","first-page":"124","article-title":"Immunoadsorption for the treatment of acquired hemophilia: new observational data, systematic review, and meta\u2010analysis","volume":"35","author":"Pereira ME","year":"2021","journal-title":"Transfus Med Rev."},{"key":"e_1_2_24_9_16_1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1365-2141.1981.tb02687.x","article-title":"The role of intensive plasma exchange in the prevention and management of hemorrhage in patients with inhibitors to factor VIII","volume":"47","author":"Slocombe GW","year":"1981","journal-title":"Br J Haematol"},{"key":"e_1_2_24_9_17_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/bloodadvances.2021005126","article-title":"Idiopathic purpura fulminans associated with anti\u2010protein S antibodies in children: a multicenter case series and systematic review","volume":"6","author":"Theron A","year":"2022","journal-title":"Blood Adv"},{"key":"e_1_2_24_9_18_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tmrv.2016.04.001","article-title":"Acquired factor XIII inhibitor in hospitalized and perioperative patients: a systematic review of case reports and case series","volume":"30","author":"Tone KJ","year":"2016","journal-title":"Transfusion Med Rev."},{"key":"e_1_2_24_9_19_1","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026587","article-title":"Feasibility of therapeutic plasma exchange\u2010based combination therapy in the treatment of acquired hemophilia A\u2014A retrospective 6 case series","volume":"100","author":"Wang LY","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"e_1_2_24_9_20_1","first-page":"233","article-title":"Treatment of congenital and acquired hemophilia patients by extracorporeal removal of antibodies to coagulation factors: a review of US clinical studies 1987\u20131990","volume":"13","author":"Watt RM","year":"1992","journal-title":"Hemophilia Study Group. Transfus Sci"},{"key":"e_1_2_24_9_21_1","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1136\/bmj.281.6252.1388","article-title":"Plasma exchange and human factor VIII concentrate in managing hemophilia A with factor VIII inhibitors","volume":"281","author":"Wensley RT","year":"1980","journal-title":"Br Med J"},{"key":"e_1_2_24_9_22_1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000505770","article-title":"Plasma exchange as an initial treatment for severe bleeding induced by acquired factor V deficiency: a case report and mini literature review","volume":"144","author":"Yanagiya R","year":"2021","journal-title":"Acta Haemtaol"},{"key":"e_1_2_24_9_23_1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.atherosclerosissup.2012.10.033","article-title":"Long term outcome of patients with acquired hemophilia\u2014A monocentre interim analysis of 82 patients","volume":"14","author":"Zeitler H","year":"2013","journal-title":"Atheroscler Suppl"},{"key":"e_1_2_24_9_24_1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000341913","article-title":"Extracorporeal treatment for the acute and long\u2010term outcome of patients with life\u2010threatening acquired Hemophilia","volume":"39","author":"Zeitler H","year":"2012","journal-title":"Transfus Med Hemother"},{"key":"e_1_2_25_9_1_1","first-page":"383","article-title":"Plasma exchange therapy in patients with complex regional pain syndrome","volume":"18","author":"Aradillas E","year":"2015","journal-title":"Pain Physician"},{"key":"e_1_2_25_9_2_1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ejp.572","article-title":"Improvement of complex regional pain syndrome after plasmapheresis","volume":"19","author":"Blaes F","year":"2015","journal-title":"Eur J Pain"},{"key":"e_1_2_25_9_3_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2730","article-title":"Complex regional pain syndrome","volume":"351","author":"Bruehl S.","year":"2015","journal-title":"BMJ"},{"key":"e_1_2_25_9_4_1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/SPC.0000000000000211","article-title":"Autoantibodies and pain","volume":"10","author":"Dawes JM","year":"2016","journal-title":"Curr Opin Support Palliat Care"},{"key":"e_1_2_25_9_5_1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/j.pain.2014.09.022","article-title":"Longstanding complex regional pain syndrome is associated with activating autoantibodies against alpha\u20101a adrenoceptors","volume":"155","author":"Dubuis E","year":"2014","journal-title":"Pain"},{"key":"e_1_2_25_9_6_1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12630-018-1091-5","article-title":"Treatment of complex regional pain syndrome: an updated systematic review and narrative synthesis","volume":"65","author":"Duong S","year":"2019","journal-title":"Can J Anaesth"},{"key":"e_1_2_25_9_7_1","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1097\/j.pain.0000000000002245","article-title":"The Valencia consensus\u2010based adaptation of the IASP complex regional pain syndrome diagnostic criteria","volume":"162","author":"Goebel A","year":"2021","journal-title":"Pain"},{"key":"e_1_2_25_9_8_1","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1111\/pme.12601","article-title":"Treatment of long\u2010standing complex regional pain syndrome with therapeutic plasma exchange: a preliminary case series of patients treated in 2008\u20132014","volume":"15","author":"Goebel A","year":"2014","journal-title":"Pain Medicine"},{"key":"e_1_2_25_9_9_1","doi-asserted-by":"crossref","first-page":"476","DOI":"10.7326\/M17-0509","article-title":"Low\u2010dose intravenous immunoglobulin treatment for long\u2010standing complex regional pain syndrome: A randomized trial","volume":"167","author":"Goebel A","year":"2017","journal-title":"Ann Intern Med"},{"key":"e_1_2_25_9_10_1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.pain.2010.04.030","article-title":"Validation of proposed diagnostic criteria (the \u201cBudapest Criteria\u201d) for complex regional pain syndrome","volume":"150","author":"Harden RN","year":"2010","journal-title":"Pain"},{"key":"e_1_2_25_9_11_1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/pm\/pnac046","article-title":"Complex regional pain syndrome: practical diagnostic and treatment guidelines","volume":"23","author":"Harden RN","year":"2022","journal-title":"Pain Med"},{"key":"e_1_2_25_9_12_1","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jca.21407","article-title":"Complex regional pain syndrome and dysautonomia in a 14\u2010year\u2010old girl responsive to therapeutic plasma exchange","volume":"31","author":"Hendrickson JE","year":"2016","journal-title":"J Clin Apher"},{"key":"e_1_2_25_9_13_1","first-page":"253","article-title":"Complex regional pain syndrome: an updated comprehensive review","volume":"47","author":"Kessler A","year":"2020","journal-title":"Neuro Rehabilitation"},{"key":"e_1_2_25_9_14_1","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1474-4422(24)00076-0","article-title":"Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment","volume":"23","author":"Ferraro MC","year":"2024","journal-title":"Lancet Neurol"},{"issue":"17","key":"e_1_2_25_9_15_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12967-019-1833-3","article-title":"Exosome microRNA signatures in patients with complex regional pain syndrome undergoing plasma exchange","volume":"14","author":"Ramanathan S","year":"2019","journal-title":"J Transl Med."},{"key":"e_1_2_25_9_16_1","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1002\/ejp.2025","article-title":"Glucocorticoid treatments in patients with complex regional pain syndrome: a systematic review","volume":"26","author":"Van den Berg C","year":"2022","journal-title":"Eur J Pain"},{"key":"e_1_2_26_9_1_1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archderm.139.3.391","article-title":"Leg ulcers associated with cryoglobulinemia: clinical study of 15 patients and response to treatment","volume":"13","author":"Auzerie V","year":"2003","journal-title":"Arch Dermatol"},{"key":"e_1_2_26_9_2_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1537-2995.1980.20280169957.x","article-title":"Use of plasmapheresis and partial plasma exchange in the management of patients with cryoglobulinemia","volume":"20","author":"Berkman EM","year":"1980","journal-title":"Transfusion"},{"key":"e_1_2_26_9_3_1","first-page":"33","article-title":"Recurrent mixed cryoglobulinemia (MCS): a case report and literature review","volume":"98","author":"Bhattarai M","year":"2015","journal-title":"R I Med J"},{"key":"e_1_2_26_9_4_1","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.amjmed.2015.02.017","article-title":"Cryoglobulinemia vasculitis","volume":"128","author":"Cacoub P","year":"2015","journal-title":"Am J Med"},{"key":"e_1_2_26_9_5_1","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2016.06.009","article-title":"Plasmapheresis for the treatment of kidney diseases","volume":"90","author":"Clark WF","year":"2016","journal-title":"Kidney Int"},{"key":"e_1_2_26_9_6_1","first-page":"255","article-title":"The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements","volume":"232","author":"Dammacco F","year":"2023","journal-title":"Clin Exp Med"},{"key":"e_1_2_26_9_7_1","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","article-title":"A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis","volume":"64","author":"De Vita S","year":"2012","journal-title":"Arthritis Rheum"},{"key":"e_1_2_26_9_8_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1526-0968.2002.00400.x","article-title":"Apheresis in cryoglobulinemia complicating hepatitis C and in other renal diseases","volume":"6","author":"Dominguez JH","year":"2002","journal-title":"Ther Apher"},{"key":"e_1_2_26_9_9_1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.14309\/ajg.0000000000001667","article-title":"Relapse of HCV\u2010cryoglobulinemic vasculitis following sustained viral response after interferon\u2010free direct\u2010acting antivirals","volume":"117","author":"Fayed A","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_26_9_10_1","first-page":"67","article-title":"HCV\u2010unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian Group for the Study of Cryoglobulinaemias (GISC)","volume":"35","author":"Galli M","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_26_9_11_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.rdc.2014.09.008","article-title":"Cold hard facts of cryoglobulinemia: updates on clinical features and treatment advances","volume":"41","author":"Ghetie D","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"e_1_2_26_9_12_1","doi-asserted-by":"crossref","first-page":"794","DOI":"10.2174\/1389450116666150825112105","article-title":"Treatment of HCV\u2010related mixed cryoglobulinemia","volume":"18","author":"Giuggioli D","year":"2017","journal-title":"Curr Drug Targets"},{"key":"e_1_2_26_9_13_1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1053\/j.ackd.2014.01.008","article-title":"Plasma exchange for kidney disease: what is the best evidence?","volume":"21","author":"Hildebrand AM","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"e_1_2_26_9_14_1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.transci.2018.06.005","article-title":"Apheresis treatment of cryoglobulinemic vasculitis: a multicentre cohort study of 159 patients","volume":"57","author":"Marson P","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_26_9_15_1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.23736\/S0026-4806.20.07120-7","article-title":"Hepatitis C virus\u2010related cryoglobulinemic vasculitis","volume":"112","author":"Mazzaro C","year":"2021","journal-title":"Minerva Med"},{"key":"e_1_2_26_9_16_1","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/v13061032","article-title":"Hepatitis B virus\u2010related cryoglobulinemic vasculitis: review of the literature and long\u2010term follow\u2010up analysis of 18 patients treated with nucleos(t)ide analogues from the Italian study group of cryoglobulinemia (GISC)","volume":"13","author":"Mazzaro C","year":"2021","journal-title":"Viruses"},{"key":"e_1_2_26_9_17_1","first-page":"CD011403","article-title":"Treatment for hepatitis C virus\u2010associated mixed cryoglobulinaemia","volume":"5","author":"Montero N","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_26_9_18_1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/jca.21414","article-title":"Successful use of cryocrit for monitoring response to therapeutic plasma exchange in type 1 cryoglobulinemia","volume":"31","author":"Olson N","year":"2016","journal-title":"J Clin Apher"},{"key":"e_1_2_26_9_19_1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.transci.2010.03.001","article-title":"Plasma exchange for treating cryoglobulinemia: a descriptive analysis","volume":"42","author":"Rockx MA","year":"2010","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_26_9_20_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/j.gastro.2017.03.006","article-title":"Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV\u2010associated cryoglobulinemia vasculitis","volume":"153","author":"Saadoun D","year":"2017","journal-title":"Gastroenterology"},{"key":"e_1_2_26_9_21_1","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/art.34322","article-title":"A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus\u2010associated cryoglobulinemic vasculitis","volume":"64","author":"Sneller MC","year":"2012","journal-title":"Arthritis Rheum"},{"key":"e_1_2_26_9_22_1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/jca.20222","article-title":"Immunoadsorption apheresis and immunosuppressive drug therapy in the treatment of complicated HCV\u2010related cryoglobulinemia","volume":"24","author":"Stefanutti C","year":"2009","journal-title":"J Clin Apher"},{"key":"e_1_2_26_9_23_1","doi-asserted-by":"crossref","first-page":"5996","DOI":"10.1182\/blood-2011-12-396028","article-title":"Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey","volume":"119","author":"Terrier B","year":"2012","journal-title":"Blood"},{"key":"e_1_2_26_9_24_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaut.2015.08.008","article-title":"Non HCV\u2010related infectious cryoglobulinemia vasculitis: results from the French nationwide CryoVas survey and systematic review of the literature","volume":"65","author":"Terrier B","year":"2015","journal-title":"J Autoimmun"},{"key":"e_1_2_26_9_25_1","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/816424","article-title":"Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents\u2010based anti\u2010hepatitis C virus therapy","volume":"2015","author":"Urraro T","year":"2015","journal-title":"Case Reports Immunol"},{"key":"e_1_2_27_9_1_1","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/hon.3229","article-title":"Early intervention of extracorporeal photopheresis for advancing\/progressing cutaneous T\u2010cell lymphoma","volume":"41","author":"Aires D","year":"2023","journal-title":"Hematological Oncology"},{"key":"e_1_2_27_9_2_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/bjh.14537","article-title":"The role of extracorporeal photopheresis in the management of cutaneous T\u2010cell lymphoma, graft\u2010versus\u2010host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society","volume":"177","author":"Alfred A","year":"2017","journal-title":"Br J Haematol"},{"key":"e_1_2_27_9_3_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/cancers14010145","article-title":"Contemporary treatment patterns and response in relapsed\/refractory cutaneous T\u2010cell lymphoma (CTCL) across five European countries","volume":"14","author":"Assaf C","year":"2021","journal-title":"Cancers (Basel)"},{"key":"e_1_2_27_9_4_1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.tracli.2017.05.001","article-title":"Extracorporeal photochemotherapy in mycosis fungoides","volume":"24","author":"Atilla E","year":"2017","journal-title":"Transfus Clin Biol"},{"key":"e_1_2_27_9_5_1","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1182\/bloodadvances.2023011041","article-title":"International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies","volume":"7","author":"Campbell BE","year":"2023","journal-title":"Blood Advances"},{"key":"e_1_2_27_9_6_1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2230.2004.01525.x","article-title":"A randomized cross\u2010over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides","volume":"29","author":"Child FJ","year":"2004","journal-title":"Clin Exp Dermatol."},{"key":"e_1_2_27_9_7_1","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood.2019000765","article-title":"Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sezary syndrome","volume":"134","author":"Gao C","year":"2019","journal-title":"Blood"},{"key":"e_1_2_27_9_8_1","doi-asserted-by":"crossref","first-page":"2360658","DOI":"10.1080\/09546634.2024.2360568","article-title":"Chart review of real\u2010world clinical outcomes in patients with cutaneous T\u2010cell lymphoma treated with ECP in the US in 2017\u20132019","volume":"35","author":"Girardi M","year":"2024","journal-title":"J Dermatol Treat"},{"key":"e_1_2_27_9_9_1","doi-asserted-by":"crossref","first-page":"eaaz1580","DOI":"10.1126\/sciadv.aaz1580","article-title":"Platelet P\u2010selectin initiates cross\u2010presentation and dendritic cell differentiation in blood monocytes","volume":"6","author":"Han P","year":"2020","journal-title":"Sci Adv"},{"key":"e_1_2_27_9_10_1","doi-asserted-by":"crossref","first-page":"E491","DOI":"10.1002\/ajh.24564","article-title":"A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome","volume":"91","author":"Hanel W","year":"2016","journal-title":"Am J Hematol"},{"key":"e_1_2_27_9_11_1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.26760","article-title":"Cutaneous T\u2010cell lymphomas: 2023 update on diagnosis, risk\u2010stratification, and management","volume":"98","author":"Hristov AC","year":"2023","journal-title":"Am J Hematol"},{"key":"e_1_2_27_9_12_1","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1111\/jdv.16890","article-title":"European dermatology forum\u2014updated guidelines on the use of extracorporeal photopheresis 2020\u2014part 1","volume":"34","author":"Knobler R","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_27_9_13_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/09546634.2019.1587144","article-title":"Real\u2010world use of extracorporeal photopheresis for patients with cutaneous T\u2010cell lymphoma in the United States: 2010\u20132015","volume":"31","author":"Ling YL","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"e_1_2_27_9_14_1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1600-0781.2007.00300.x","article-title":"Review of extracorporeal photopheresis in early\u2010stage (IA, IB, and IIA) cutaneous T\u2010cell lymphoma","volume":"23","author":"Miller JD","year":"2007","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"e_1_2_27_9_15_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/cancers16010141","article-title":"Mogamulizumab combined with extracorporeal photopheresis as novel therapy in erythrodermic cutaneous T\u2010cell lymphoma","volume":"16","author":"Ninosu N","year":"2024","journal-title":"Cancers"},{"key":"e_1_2_27_9_16_1","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen E","year":"2007","journal-title":"Blood"},{"key":"e_1_2_27_9_17_1","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer","volume":"29","author":"Olsen EA","year":"2011","journal-title":"J Clin Oncol"},{"key":"e_1_2_27_9_18_1","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.clml.2024.07.011","article-title":"On the way to curing advanced\u2010stage mycosis fungoides\/Sezary syndrome","volume":"24","author":"Purnak S","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"e_1_2_27_9_19_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/labmed\/lmy034","article-title":"Iron deficiency anemia in patients undergoing extracorporeal photopheresis for cutaneous T\u2010cell lymphoma","volume":"50","author":"Sanford KW","year":"2019","journal-title":"Lab Med"},{"key":"e_1_2_27_9_20_1","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41375-024-02479-1","article-title":"Dimethyl fumarate and extracorporeal photopheresis combination\u2010therapy synergize in inducing specific cell death and long\u2010term remission in cutaneous T cell lymphoma","volume":"39","author":"Sener OC","year":"2025","journal-title":"Leukemia"},{"key":"e_1_2_27_9_21_1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clml.2011.03.003","article-title":"Multicenter photopheresis intervention trial in early\u2010stage mycosis fungoides","volume":"11","author":"Talpur R","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"e_1_2_27_9_22_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organization for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014update 2017","volume":"77","author":"Trautinger F","year":"2017","journal-title":"Eur J Cancer"},{"key":"e_1_2_27_9_23_1","first-page":"CD008946","article-title":"Interventions for mycosis fungoides","volume":"7","author":"Valipour A","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_27_9_24_1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/jca.21382","article-title":"Successful implementation of a rural extracorporeal photopheresis program for the treatment of cutaneous T\u2010cell lymphoma and chronic graft\u2010versus\u2010host disease in a rural hospital","volume":"30","author":"Weber LL","year":"2015","journal-title":"J Clin Apher"},{"key":"e_1_2_27_9_25_1","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaad.2020.12.026","article-title":"The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: current and future approaches","volume":"84","author":"Weiner DM","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_28_9_1_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00395-016-0569-y","article-title":"Changes of myocardial gene expression and protein composition in patients with dilated cardiomyopathy after immunoadsorption with subsequent immunoglobulin substitution","volume":"111","author":"Ameling S","year":"2016","journal-title":"Basic Res Cardiol"},{"key":"e_1_2_28_9_2_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jprot.2016.09.001","article-title":"Endomyocardial proteomic signature corresponding to the response of patients with dilated cardiomyopathy to immunoadsorption therapy","volume":"150","author":"Bhardwaj G","year":"2017","journal-title":"J Proteomics"},{"key":"e_1_2_28_9_3_1","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026475","article-title":"Immunoadsorption treatment for dilated cardiomyopathy: a PRISMA\u2010compliant systematic review and meta\u2010analysis","volume":"100","author":"Bian R","year":"2021","journal-title":"Medicine"},{"key":"e_1_2_28_9_4_1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1590\/1806-9282.20220784","article-title":"Immunoadsorption therapy in refractory heart failure patients with dilated cardiomyopathy: a potential therapeutic option","volume":"69","author":"Cavusoglu Y","year":"2023","journal-title":"Rev. Assoc Med Bras."},{"key":"e_1_2_28_9_5_1","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/eurjhf\/hfs123","article-title":"Long\u2010term benefits of immunoadsorption in beta(1)\u2010adrenoceptor autoantibody\u2010positive transplant candidates with dilated cardiomyopathy","volume":"14","author":"Dandel M","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"e_1_2_28_9_6_1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.atherosclerosissup.2015.02.023","article-title":"Immunoadsorption can improve cardiac function in transplant candidates with non\u2010ischemic dilated cardiomyopathy associated with diabetes mellitus","volume":"18","author":"Dandel M","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"e_1_2_28_9_7_1","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0735-1097(00)00568-4","article-title":"Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three\u2010month results from a randomized study","volume":"35","author":"Felix SB","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_28_9_8_1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s10198-003-0202-5","article-title":"Economic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy","volume":"5","author":"Hessel FP","year":"2004","journal-title":"Eur J Health Econ"},{"key":"e_1_2_28_9_9_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00380-016-0830-1","article-title":"Outcomes of plasma exchange for severe dilated cardiomyopathy in children","volume":"32","author":"Koizumi K","year":"2017","journal-title":"Heart Vessels"},{"key":"e_1_2_28_9_10_1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s10047-017-0956-7","article-title":"Plasma exchange for the patients with dilated cardiomyopathy in children is safe and effective in improving both cardiac function and daily activities","volume":"20","author":"Moriguchi T","year":"2017","journal-title":"J Artif Organs"},{"key":"e_1_2_28_9_11_1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.CIR.101.4.385","article-title":"Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy","volume":"101","author":"M\u00fcller J","year":"2000","journal-title":"Circulation"},{"key":"e_1_2_28_9_12_1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jjcc.2016.07.014","article-title":"Therapeutic effect of immunoadsorption and subsequent immunoglobulin substitution in patients with dilated cardiomyopathy: results from the observational prospective Bad Berka Registry","volume":"69","author":"Ohlow MA","year":"2017","journal-title":"J Cardiol"},{"key":"e_1_2_28_9_13_1","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure. Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski P","year":"2016","journal-title":"Eur Heart J"},{"key":"e_1_2_28_9_14_1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/jca.21364","article-title":"The effect of a repeated immunoadsorption in patients with dilated cardiomyopathy after recurrence of severe heart failure symptoms","volume":"30","author":"Reinthaler M","year":"2015","journal-title":"J Clin Apher"},{"key":"e_1_2_28_9_15_1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ejhf.1461","article-title":"Heart failure in cardiomyopathies: A position paper from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovi\u0107 PM","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"712","key":"e_1_2_28_9_16_1","first-page":"e1","article-title":"Immunoadsorption in dilated cardiomyopathy: 6\u2010month results from a randomized study","volume":"152","author":"Staudt A","year":"2006","journal-title":"Am Heart J"},{"key":"e_1_2_28_9_17_1","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1161\/01.CIR.103.22.2681","article-title":"Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution","volume":"103","author":"Staudt A","year":"2001","journal-title":"Circulation"},{"key":"e_1_2_28_9_18_1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1744-9987.2006.00343.x","article-title":"Effects of immunoadsorption on the nt\u2010BNP and nt\u2010ANP plasma levels of patients suffering from dilated cardiomyopathy","volume":"10","author":"Staudt A","year":"2006","journal-title":"Ther Apher Dial"},{"key":"e_1_2_28_9_19_1","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3389\/fphys.2019.01436","article-title":"The giant protein titin's role in cardiomyopathy: genetic, transcriptional, and post\u2010translational modifications of TTN and their contributions to cardiac disease","volume":"10","author":"Tharp CA","year":"2019","journal-title":"Front Physiol"},{"key":"e_1_2_28_9_20_1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/jca.20264","article-title":"Therapeutic plasma exchange a potential strategy for patients with advanced heart failure","volume":"25","author":"Torre\u2010Amione G","year":"2010","journal-title":"J Clin Apher"},{"key":"e_1_2_28_9_21_1","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1016\/j.jacc.2019.03.478","article-title":"ACC\/AHA versus ESC guidelines on heart failure: JACC Guideline Comparison","volume":"73","author":"Van der Meer P","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_28_9_22_1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/jca.21355","article-title":"National Heart, Lung, and Blood Institute State of the Science Symposium in Therapeutic Apheresis\u2010Therapeutic apheresis in cardiovascular disease","volume":"30","author":"Winters JL","year":"2015","journal-title":"J Clin Apher"},{"key":"e_1_2_28_9_23_1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/jca.21446","article-title":"Immunoadsorption therapy for dilated cardiomyopathy using tryptophan column\u2010A prospective, multicenter, randomized, within\u2010patient and parallel\u2010group comparative study to evaluate efficacy and safety","volume":"31","author":"Yoshikawa T","year":"2016","journal-title":"J Clin Apher"},{"key":"e_1_2_29_9_1_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.transci.2006.03.001","article-title":"Cytapheresis in the treatment of cell\u2010affected blood disorders and abnormalities","volume":"35","author":"Balint B","year":"2006","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_29_9_2_1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.transci.2012.07.017","article-title":"Investigation of the influence of body weight index to the result of therapeutic erythrocytapheresis in patients with polycythemia vera","volume":"47","author":"Bai J","year":"2012","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_29_9_3_1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.htct.2023.07.003","article-title":"Evaluation of erythrocytapheresis compared to phlebotomy in polycythaemia vera patients","volume":"46","author":"Cabibbo S","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"key":"e_1_2_29_9_4_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/jca.21241","article-title":"Automated double red\u2010cell phlebotomy for the treatment of erythrocytosis","volume":"27","author":"Choe WH","year":"2012","journal-title":"J Clin Apher"},{"key":"e_1_2_29_9_5_1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.wem.2020.07.006","article-title":"Therapeutic erythrocytapheresis is effective in treating high altitude polycythemia on the Qinghai\u2010Tibet plateau","volume":"31","author":"Dong Y","year":"2020","journal-title":"Wilderness Environ Med"},{"key":"e_1_2_29_9_6_1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jca.21303","article-title":"The efficiency of therapeutic erythrocytapheresis compared to phlebotomy: a mathematical tool for predicting response in hereditary hemochromatosis, polycythemia vera, and secondary erythrocytosis","volume":"29","author":"Evers D","year":"2014","journal-title":"J Clin Apher"},{"key":"e_1_2_29_9_7_1","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa\u20102b versus standard therapy for polycythaemia vera (PROUD\u2010PV and CONTINUATION\u2010PV): a randomized, non\u2010inferiority, phase 3 trial and its extension study [published correction]","volume":"7","author":"Gisslinger H","year":"2020","journal-title":"Lancet Haematol"},{"key":"e_1_2_29_9_8_1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1744-9987.1997.tb00028.x","article-title":"Advantages of isovolemic large\u2010volume erythrocytapheresis as a rapidly effective and long\u2010lasting treatment modality for red blood cell depletion in patients with polycythemia vera","volume":"1","author":"Kaboth U","year":"1997","journal-title":"Ther Apher"},{"key":"e_1_2_29_9_9_1","first-page":"29","article-title":"The efficacy of erythrocyte apheresis for treatment of secondary erythrocytosis: an observational study","volume":"103","author":"Ma J","year":"2024","journal-title":"Medicine"},{"key":"e_1_2_29_9_10_1","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon\u2010\u03b1 vs. hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas J","year":"2022","journal-title":"Blood."},{"key":"e_1_2_29_9_11_1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli R","year":"2013","journal-title":"N Engl J Med"},{"key":"e_1_2_29_9_12_1","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1056\/NEJMoa1208500","article-title":"Treatment target in polycythemia vera","volume":"368","author":"Marchioli R","year":"2013","journal-title":"N Engl J Med"},{"key":"e_1_2_29_9_13_1","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1080\/14656566.2024.2387681","article-title":"The evolving landscape of polycythemia vera therapies","volume":"25","author":"Martinez J","year":"2024","journal-title":"Expert Pharmacother"},{"key":"e_1_2_29_9_14_1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2141.2005.05535.x","article-title":"Guidelines for the diagnosis, investigation and management of polycythaemia\/erythrocytosis","volume":"130","author":"McMullin MF","year":"2005","journal-title":"Br J Haematol"},{"key":"e_1_2_29_9_15_1","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/imj.16313","article-title":"A comparison between erythrocytapheresis and venesection for the treatment of JAK2\u2010mutated polycythaemia","volume":"54","author":"Ngo TQ","year":"2024","journal-title":"Intern Med J"},{"key":"e_1_2_29_9_16_1","first-page":"26","article-title":"Safety and efficacy of therapeutic erythrocytapheresis treatment in chronic mountain sickness patients in Shigatse, Tibet, China","author":"Niu M","year":"2020","journal-title":"Med Sci Monit"},{"key":"e_1_2_29_9_17_1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3109\/09537104.2011.633178","article-title":"Evaluation of hemostatic balance in blood from patients with polycythemia vera by means of thromboelastography: the effect of isovolemic erythrocytapheresis","volume":"23","author":"Rusak T","year":"2012","journal-title":"Platelets"},{"key":"e_1_2_29_9_18_1","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.thromres.2014.04.025","article-title":"Platelet\u2010related fibrinolysis resistance in patients suffering from PV. Impact of clot retraction and isovolemic erythrocytapheresis","volume":"134","author":"Rusak T","year":"2014","journal-title":"Thromb Res"},{"key":"e_1_2_29_9_19_1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1179\/102453310X12719010991740","article-title":"Treatment related changes in antifibrinolytic activity in patients with polycythemia vera","volume":"15","author":"Sonmez M","year":"2010","journal-title":"Hematology"},{"key":"e_1_2_29_9_20_1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.6004\/jnccn.2015.0058","article-title":"Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms","volume":"13","author":"Stein BL","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"e_1_2_29_9_21_1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12032-007-9008-0","article-title":"Triple\u2010way therapeutic approach for paraganglioma\u2010dependent erythrocytosis: drugs and surgery plus \u201cmulti\u2010manner\u201d apheresis","volume":"25","author":"Todorovic M","year":"2008","journal-title":"Med Oncol"},{"key":"e_1_2_29_9_22_1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0955-3886(00)00042-4","article-title":"Clinical application of therapeutic erythrocytapheresis (TEA)","volume":"22","author":"Valbonesi M","year":"2000","journal-title":"Transfus Sci"},{"key":"e_1_2_29_9_23_1","first-page":"20","article-title":"A comparison of the results obtained with traditional phlebotomy and with therapeutic erythrocytapheresis in patients with erythrocytosis","volume":"5","author":"Vecchio S","year":"2007","journal-title":"Blood Transfus"},{"key":"e_1_2_29_9_24_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2025.104159","article-title":"Clinical application of erythrocytapheresis in the treatment of erythrocytosis","volume":"64","author":"Yi Z","year":"2025","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_29_9_25_1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1055\/s-2003-44560","article-title":"Correction of hyperviscosity by apheresis","volume":"29","author":"Zarkovic M","year":"2003","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_30_9_1_1","first-page":"1009","article-title":"Liver disease in erythropoietic protoporphyria: insights and implications for management","volume":"56","author":"Anstey AV","year":"2007","journal-title":"Gut"},{"key":"e_1_2_30_9_2_1","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/lt.25632","article-title":"Management of patients with erythropoietic protoporphyria\u2010related progressive liver disease","volume":"25","author":"Ardalan ZS","year":"2019","journal-title":"Liver Transpl"},{"key":"e_1_2_30_9_3_1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ymgme.2019.01.020","article-title":"Erythropoietic protoporphyria and X\u2010linked protoporphyria: pathophysiology, genetics, clinical manifestations, and management","volume":"128","author":"Balwani M.","year":"2019","journal-title":"Mol Genet Metab"},{"key":"e_1_2_30_9_4_1","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1056\/NEJMra1608634","article-title":"Bonkovsky HL Porphyria","volume":"377","author":"Bisell DM","year":"2017","journal-title":"N Eng J Med"},{"key":"e_1_2_30_9_5_1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00007890-200202150-00024","article-title":"Benefits of chronic plasmapheresis and intravenous hemealbumin in erythropoietic protoporphyria after orthotopic liver transplantation","volume":"73","author":"Do KD","year":"2002","journal-title":"Transplantation"},{"key":"e_1_2_30_9_6_1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/lt.21049","article-title":"Erythropoietic protoporphyria and pretransplantation treatment with nonbiological liver assist devices","volume":"13","author":"Eefsen M","year":"2007","journal-title":"Liver Transpl"},{"key":"e_1_2_30_9_7_1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1537-2995.2004.04190.x","article-title":"Red blood cell exchange transfusion in two patients with advanced erythropoietic protoporphyria","volume":"45","author":"Eichbaum QG","year":"2005","journal-title":"Transfusion"},{"key":"e_1_2_30_9_8_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-1172-4-19","article-title":"Erythropoietic protoporphyria","volume":"4","author":"Lecha M","year":"2009","journal-title":"Orphanet J Rare Dis"},{"key":"e_1_2_30_9_9_1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/HEP.0000000000000546","article-title":"Evidence\u2010based consensus guidelines for the diagnosis and management of protoporphyria\u2010related liver dysfunction in erythropoietic protoporphyria and X\u2010linked protoporphyria","volume":"79","author":"Levy C","year":"2024","journal-title":"Hepatology"},{"key":"e_1_2_30_9_10_1","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13966","article-title":"Hematopoietic cell transplant for reversal of liver fibrosis in a pediatric patient with erythropoietic protoporphyria","volume":"25","author":"Hashmi SK","year":"2021","journal-title":"Pediatric Transplantation"},{"key":"e_1_2_30_9_11_1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12328-014-0501-7","article-title":"A second attack of cholestasis associated with erythropoietic protoporphyria was successfully treated by plasma exchange and blood transfusion","volume":"7","author":"Honda Y","year":"2014","journal-title":"Clin J Gastrolenterol"},{"key":"e_1_2_30_9_12_1","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16027","article-title":"Erythropoietic protoporphyrias: pathogenesis, diagnosis and management","volume":"45","author":"Minder AE","year":"2025","journal-title":"Liver Int."},{"key":"e_1_2_30_9_13_1","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1053\/j.gastro.2019.05.053","article-title":"A rare complication of a rare disease","volume":"157","author":"Nayak LJ","year":"2019","journal-title":"Gastroenterol"},{"key":"e_1_2_30_9_14_1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000341111","article-title":"Photosensitivity and acute liver insufficiency in late\u2010onset erythropoietic protoporphyria with a chromosome 18q abnormality","volume":"4","author":"Oshikawa Y","year":"2012","journal-title":"Case Rep Dermatol"},{"key":"e_1_2_30_9_15_1","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jca.21249","article-title":"Plasma and red cell exchange transfusions for erythropoietic protoporphyria: a case report and review of the literature","volume":"27","author":"Pagano MB","year":"2012","journal-title":"J Clin Apher"},{"key":"e_1_2_30_9_16_1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/jca.21337","article-title":"Therapeutic plasma exchange in a patient with erythropoietic protoporphyria status post orthotopic liver transplantation as a bridge to hematopoietic stem cell transplantation","volume":"29","author":"Pham HP","year":"2014","journal-title":"J Clin Apher"},{"key":"e_1_2_30_9_17_1","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/00007890-199903270-00023","article-title":"The value of intravenous heme\u2010albumin and plasmapheresis in reducing postoperative complications of orthothopic liver transplantation for erythropoietic protoporphyria","volume":"67","author":"Reichheld JH","year":"1999","journal-title":"Transplantation"},{"key":"e_1_2_30_9_18_1","first-page":"211","article-title":"Erythropoietic protoporphyria: therapeutic response to combined erythrocyte exchange and plasmapheresis","volume":"1","author":"Spiva DA","year":"1984","journal-title":"Photodermatol"},{"key":"e_1_2_30_9_19_1","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/BF01535955","article-title":"Blood exchange and transfusion therapy for acute cholestasis in protoporphyria","volume":"33","author":"Wijk HJ","year":"1988","journal-title":"Dig Dis Sci"},{"key":"e_1_2_30_9_20_1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/bmt.2009.132","article-title":"The role for BMT in erythropoietic protoporphyria","volume":"45","author":"Wahlin S","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_30_9_21_1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S2468-1253(18)30357-1","article-title":"Red plasma and ascites under ultraviolet A","volume":"4","author":"Wakabayashi S","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"e_1_2_30_9_22_1","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29231","article-title":"Hematopoietic stem cell transplant for erythropoietic porphyrias in pediatric patients","volume":"68","author":"Wang YM","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_30_9_23_1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/0004563216667965","article-title":"Best practice guidelines on first\u2010line laboratory testing for porphyria","volume":"54","author":"Woolf J","year":"2017","journal-title":"Ann Clin Biochem"},{"key":"e_1_2_30_9_24_1","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.2169\/internalmedicine.0673-17","article-title":"Erythropoietic protoporphyria\u2010related hepatopathy successfully treated with phlebotomy","volume":"57","author":"Yoshida A","year":"2018","journal-title":"Intern Med"},{"key":"e_1_2_30_9_25_1","doi-asserted-by":"crossref","first-page":"966","DOI":"10.4254\/wjh.v16.i6.966","article-title":"Successful treatment of severe hepatic impairment in erythropoietic protoporphyria: a case report and review of literature","volume":"16","author":"Zeng T","year":"2024","journal-title":"World J Hepatol"},{"key":"e_1_2_31_9_1_1","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0735-1097(96)00388-9","article-title":"Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease","volume":"28","author":"Aengevaeren WR","year":"1996","journal-title":"JACC"},{"key":"e_1_2_31_9_2_1","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jacl.2019.10.003","article-title":"Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: results of the randomized, controlled, open\u2010label DE LAVAL study","volume":"13","author":"Baum SJ","year":"2019","journal-title":"J Clin Lipidol"},{"key":"e_1_2_31_9_3_1","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","volume":"75","author":"Beheshti SO","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_31_9_4_1","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 Update on European Atherosclerosis Society Consensus Statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel M","year":"2023","journal-title":"Eur Heart J"},{"key":"e_1_2_31_9_5_1","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/eurjpc\/zwab229","article-title":"Efficacy and safety of lomitapide in homozygous familial hypercholersterolaemia: the pan\u2010European retrospective observational study","volume":"29","author":"D'Erasmo L","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"e_1_2_31_9_6_1","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the American Heart Association","volume":"44","author":"Gianos E","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"e_1_2_31_9_7_1","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/0002-9149(92)90352-Y","article-title":"Treatment of refractory familial hypercholesterolemia by low\u2010density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system","volume":"70","author":"Gordon B","year":"1992","journal-title":"Am J Cardiol"},{"key":"e_1_2_31_9_8_1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0002-9149(97)00947-8","article-title":"Long\u2010term effects of low\u2010density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system","volume":"81","author":"Gordon B","year":"1998","journal-title":"Am J Cardiol"},{"key":"e_1_2_31_9_9_1","first-page":"e1082","volume":"139","author":"Grundy SM","year":"2019","journal-title":"Circulation"},{"key":"e_1_2_31_9_10_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/2047487319870007","article-title":"Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia","volume":"27","author":"Kolovou G","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"e_1_2_31_9_11_1","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/01.CIR.93.10.1826","article-title":"LDL\u2010apheresis atherosclerosis regression study (LAARS)","volume":"93","author":"Kroon AA","year":"1996","journal-title":"Circulation"},{"key":"e_1_2_31_9_12_1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.7326\/0003-4819-125-12-199612150-00001","article-title":"Effect of apheresis of low\u2010density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease","volume":"125","author":"Kroon AA","year":"1996","journal-title":"Ann Intern Med"},{"key":"e_1_2_31_9_13_1","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0002-9149(98)00692-4","article-title":"Long\u2010term efficacy of low\u2010density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia","volume":"82","author":"Mabuchi H","year":"1998","journal-title":"Am J Cardiol"},{"key":"e_1_2_31_9_14_1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach F","year":"2020","journal-title":"Eur Heart J"},{"key":"e_1_2_31_9_15_1","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","article-title":"Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: The ODYSSEY ESCAPE trial","volume":"37","author":"Moriarty PM","year":"2016","journal-title":"Eur Heart J"},{"key":"e_1_2_31_9_16_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119234","article-title":"Evinacumab and reduced lipoprotein apheresis in pediatric homozygous familial hypercholesterolemia: a retrospective study on LDL\u2010C","volume":"406","author":"Nigmann C","year":"2025","journal-title":"Atherosclerosis"},{"key":"e_1_2_31_9_17_1","first-page":"e771","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"151","author":"Rao SV","year":"2025","journal-title":"Circulation"},{"key":"e_1_2_31_9_18_1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCULATIONAHA.123.067241","article-title":"LDL\u2010C\u2010lowering therapies for adults and children with homozygous familial hypercholesterolemia: challenges and successes","volume":"149","author":"Santos RD","year":"2024","journal-title":"Circulation"},{"key":"e_1_2_31_9_19_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.118601","volume":"398","author":"Schettler V","year":"2024","journal-title":"Atherosclerosis"},{"key":"e_1_2_31_9_20_1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/jca.21695","article-title":"Real\u2010world study: escalating targeted lipid\u2010lowering treatment with PCSK9\u2010inhibitors and lipoprotein apheresis","volume":"34","author":"Spitth\u00f6ver R","year":"2019","journal-title":"J Clin Apher"},{"key":"e_1_2_31_9_21_1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.amjcard.2020.09.015","article-title":"Cardiovascular outcome of pediatric patients with bi\u2010allelic (homozygous) familial hypercholesterolemia before and after initiation of multimodal lipid lowering therapy including lipoprotein apheresis","volume":"136","author":"Taylan C","year":"2020","journal-title":"Am J Cardiol"},{"key":"e_1_2_31_9_22_1","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx317","article-title":"Survival in homozygous familial hypercholesterolemia is determined by the on\u2010treatment level of serum cholesterol","volume":"39","author":"Thompson GR","year":"2018","journal-title":"Eur Heart J"},{"key":"e_1_2_31_9_23_1","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0140-6736(95)92961-4","article-title":"Familial hypercholesterolemia regression study: a randomized trial of low\u2010density\u2010lipoprotein apheresis","volume":"345","author":"Thompson GR","year":"1995","journal-title":"Lancet"},{"key":"e_1_2_31_9_24_1","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41569-023-00892-0","article-title":"International Atherosclerosis Society guidance for implementing best practices in the care of familial hypercholesterolaemia","volume":"20","author":"Watts GF","year":"2023","journal-title":"Nat Rev. Cardiol"},{"issue":"9","key":"e_1_2_31_9_25_1","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"148","author":"Virani SS","year":"2023","journal-title":"Circulation"},{"key":"e_1_2_32_9_1_1","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1097\/TP.0000000000002008","article-title":"Rituximab and therapeutic plasma exchange in recurrent focal segmental glomerulosclerosis post kidney transplantation","volume":"102","author":"Alasfar S","year":"2018","journal-title":"Transplantation"},{"key":"e_1_2_32_9_2_1","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/ndt\/gfx214","article-title":"Treatment by immunoadsorption for recurrent focal segmental glomerulosclerosis after pediatric kidney transplantation: a multicentre French cohort","volume":"33","author":"Allard L","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_32_9_3_1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5500\/wjt.v11.i7.303","article-title":"Rituximab or plasmapheresis for prevention of recurrent focal segmental glomerulosclerosis after kidney transplantation: a systematic review and meta\u2010analysis","volume":"11","author":"Boonpheng B","year":"2021","journal-title":"World J Transplant"},{"key":"e_1_2_32_9_4_1","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1007\/s00467-024-06452-z","article-title":"Clinical characteristics and favorable treatment responses of recurrent focal segmental glomerulosclerosis or steroid\u2010resistant nephrotic syndrome in children after kidney transplantation","volume":"39","author":"Dharnidharka VR","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"e_1_2_32_9_5_1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/jca.21985","article-title":"Efficacy of intravenous combined immunosuppression with plasmapheresis in adult patients with refractory primary focal segmental glomerulosclerosis","volume":"37","author":"Dirim AB","year":"2022","journal-title":"J Clin Apher"},{"key":"e_1_2_32_9_6_1","first-page":"348","article-title":"Recurrence of nephrotic proteinuria in children with focal segmental glomerulosclerosis: early treatment with plasmapheresis and immunoadsorption should be associated with better prognosis","volume":"68","author":"Fencl F","year":"2016","journal-title":"Minerva Pediatrica"},{"key":"e_1_2_32_9_7_1","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf058","article-title":"Use of rituximab and plasma exchange in treatment and prophylaxis of recurrent FSGS","volume":"18","author":"Gharaei S","year":"2025","journal-title":"Clin Kidney J"},{"key":"e_1_2_32_9_8_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5414\/CN110134","article-title":"Efficacy of abatacept treatment for focal segmental glomerulosclerosis and minimal change disease: a systematic review of case reports, case series, and observational studies","volume":"94","author":"Hansrivijit P","year":"2020","journal-title":"Clin Nephrol"},{"key":"e_1_2_32_9_9_1","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1053\/j.ajkd.2003.08.012","article-title":"A combined low\u2010density lipoprotein apheresis and prednisone therapy for steroid\u2010resistant primary focal segmental glomerulosclerosis in children","volume":"42","author":"Hattori M","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_32_9_10_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12882-016-0322-7","article-title":"The role of plasma exchange in treating post\u2010transplant focal segmental glomerulosclerosis: a systematic review and meta\u2010analysis of 77 case\u2010reports and case\u2010series","volume":"17","author":"Kashgary A","year":"2016","journal-title":"BMC Nephrology"},{"issue":"1","key":"e_1_2_32_9_11_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12882-023-03098-1","article-title":"Post\u2010operative recurrence of focal segmental glomerulosclerosis according to pre\u2010transplant treatment after kidney transplantation","volume":"24","author":"Kwon HE","year":"2023","journal-title":"BMC Nephrology"},{"key":"e_1_2_32_9_12_1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3109\/0886022X.2015.1015366","article-title":"Individualized scheme of immunoadsorption for the recurrence of idiopathic focal segmental glomerulosclerosis in the graft: a single center experience","volume":"37","author":"Lionaki S","year":"2015","journal-title":"Ren Fail"},{"issue":"1","key":"e_1_2_32_9_13_1","doi-asserted-by":"crossref","first-page":"2176694","DOI":"10.1080\/0886022X.2023.2176694","article-title":"Efficacy of extracorporeal plasma therapy for adult native kidney patients with primary FSGS: a systematic review","volume":"45","author":"Miao J","year":"2023","journal-title":"Renal Failure"},{"key":"e_1_2_32_9_14_1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10157-014-0996-8","article-title":"Immediate therapeutic efficacy of low\u2010density lipoprotein apheresis for drug\u2010resistant nephrotic syndrome: evidence from the short\u2010term results from the POLARIS study","volume":"19","author":"Muso E","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"e_1_2_32_9_15_1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000437338","article-title":"A prospective observational survey on the long\u2010term effect of LDL apheresis on drug\u2010resistant nephrotic syndrome","volume":"5","author":"Muso E","year":"2015","journal-title":"Nephron Extra"},{"key":"e_1_2_32_9_16_1","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000504244","article-title":"Immunoadsorption for recurrent primary focal segmental glomerulosclerosis on kidney allografts: a single\u2010center experience and literature review","volume":"49","author":"Naciri Bennani H","year":"2020","journal-title":"Blood Purify"},{"issue":"3","key":"e_1_2_32_9_17_1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.kint.2023.10.017","article-title":"Post\u2010transplant recurrence of focal segmental glomerular sclerosis: consensus statements","volume":"105","author":"Raina R","year":"2024","journal-title":"Kidney Int"},{"key":"e_1_2_32_9_18_1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3389\/fped.2019.00454","article-title":"Dextran\u2010sulfate plasma adsorption lipoprotein apheresis in drug resistant primary focal segmental glomerulosclerosis patients: results from a prospective, multicenter, single\u2010arm intervention study","volume":"7","author":"Raina R","year":"2019","journal-title":"Front Pediatr"},{"key":"e_1_2_32_9_19_1","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1007\/s00467-019-04296-6","article-title":"LDL\u2010apheresis\u2010induced remission of focal segmental glomerulosclerosis recurrence in pediatric renal transplant patients","volume":"34","author":"Shah L","year":"2019","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"e_1_2_32_9_20_1","doi-asserted-by":"crossref","DOI":"10.1002\/jca.70041","article-title":"Report of the ASFA Apheresis Registry Study on focal segmental glomerulosclerosis","volume":"40","author":"Srivaths P","year":"2025","journal-title":"J Clin Apher"},{"key":"e_1_2_32_9_21_1","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/j.transproceed.2017.10.001","article-title":"Long\u2010term outcomes of kidney transplant recipients with primary idiopathic focal segmental glomerulosclerosis","volume":"49","author":"Staeck O","year":"2017","journal-title":"Transplant Proc"},{"key":"e_1_2_32_9_22_1","first-page":"1414","article-title":"Long\u2010term apheresis in the management of patients with recurrent focal segmental glomerulosclerosis after kidney transplantation","volume":"7","author":"Uffing A","year":"2022","journal-title":"Kidney Int Rep"},{"key":"e_1_2_32_9_23_1","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2215\/CJN.00280121","article-title":"Recurrent glomerular disease after kidney transplantation: diagnostic and management dilemmas","volume":"16","author":"Uffing A","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"e_1_2_32_9_24_1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2215\/CJN.08970719","article-title":"Recurrence of FSGS after kidney transplantation in adults","volume":"15","author":"Uffing A","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"e_1_2_32_9_25_1","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13154","article-title":"The effect of peri\u2010transplant plasmapheresis in the prevention of recurrent FSGS","volume":"22","author":"Verghese PS","year":"2018","journal-title":"Pediatr Transplant."},{"key":"e_1_2_33_9_1_1","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.bbmt.2014.05.017","article-title":"Extracorporeal photopheresis in steroid\u2010refractory acute or chronic graft\u2010versus\u2010host disease: results of a systematic review of prospective studies","volume":"20","author":"Abu\u2010Dalle I","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_33_9_2_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5114\/ceji.2018.75831","article-title":"Higher response rates in patients with severe chronic skin graft\u2010versus\u2010host disease treated with extracorporeal photopheresis","volume":"44","author":"Afram G","year":"2019","journal-title":"Cent Eur J Immunol"},{"key":"e_1_2_33_9_3_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/bjh.14537","article-title":"The role of extracorporeal photopheresis in the management of cutaneous T\u2010cell lymphoma, graft\u2010versus\u2010host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society","volume":"177","author":"Alfred A","year":"2017","journal-title":"Br J Haematol"},{"key":"e_1_2_33_9_4_1","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41409-019-0544-y","article-title":"Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft\u2010versus\u2010host disease after allogeneic hematopoietic cell transplantation","volume":"54","author":"Axt L","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_33_9_5_1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/jca.21901","article-title":"Extracorporeal photopheresis vs. standard therapies for steroid\u2010refractory chronic graft\u2010vs\u2010host disease: pharmacoeconomic assessment of hospital resource use in Spain","volume":"36","author":"Boluda B","year":"2021","journal-title":"J Clin Apher"},{"key":"e_1_2_33_9_6_1","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1111\/trf.15384","article-title":"Efficacy and safety of one\u2010day offline extracorporeal photopheresis schedule processing one total blood volume for treating patients with graft\u2010versus\u2010host disease","volume":"59","author":"Cid J","year":"2019","journal-title":"Transfusion"},{"issue":"1","key":"e_1_2_33_9_7_1","doi-asserted-by":"crossref","DOI":"10.1002\/jca.22104","article-title":"Real\u2010world evidence of heparin and citrate use in extracorporeal photopheresis: a hypothesis\u2010generating data review of device settings and performance","volume":"39","author":"Connelly\u2010Smith LS","year":"2024","journal-title":"J Clin Apher"},{"key":"e_1_2_33_9_8_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103243","article-title":"Extracorporeal photopheresis in steroid\u2010refractory chronic graft\u2010versus\u2010host disease: a retrospective multicenter study","volume":"60","author":"Dal MS","year":"2021","journal-title":"Transfus Apher Sci"},{"issue":"2","key":"e_1_2_33_9_9_1","article-title":"Systematic review and meta\u2010analysis of extracorporeal photopheresis for the treatment of steroid\u2010refractory chronic graft\u2010versus\u2010host disease","volume":"31","author":"DeFilipp Z","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"e_1_2_33_9_10_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.transci.2016.12.010","article-title":"Extracorporeal photopheresis for bronchiolitis obliterans syndrome after allogeneic stem cell transplant: an emerging therapeutic approach?","volume":"56","author":"Del Fante C","year":"2017","journal-title":"Transfus Apher Sci"},{"issue":"4","key":"e_1_2_33_9_11_1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/1744666X.2023.2295405","article-title":"Recent insights into extracorporeal photopheresis for graft\u2010versus\u2010host disease","volume":"20","author":"Del Fante C","year":"2024","journal-title":"Expert Rev. Clin Immunol"},{"key":"e_1_2_33_9_12_1","doi-asserted-by":"crossref","first-page":"1500177","DOI":"10.3389\/fimmu.2024.1500177","volume":"15","author":"Farid KMN","year":"2024","journal-title":"Front Immunol"},{"key":"e_1_2_33_9_13_1","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2008-03-141481","article-title":"A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft\u2010versus\u2010host disease","volume":"112","author":"Flowers ME","year":"2008","journal-title":"Blood"},{"key":"e_1_2_33_9_14_1","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.bbmt.2011.05.004","volume":"17","author":"Greinix HT","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_33_9_15_1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41409-023-02153-7","article-title":"The potential association between extracorporeal photopheresis and thrombosis","volume":"59","author":"Jacobs JW","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_33_9_16_1","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1182\/bloodadvances.2019000145","article-title":"Randomized controlled study of ECP with methoxsalen as first\u2010line treatment of patients with moderate to severe cGVHD","volume":"3","author":"Jagasia M","year":"2019","journal-title":"Blood Adv"},{"key":"e_1_2_33_9_17_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2016-07-686642","article-title":"Classification systems for chronic graft\u2010versus\u2010host disease","volume":"129","author":"Lee SJ","year":"2017","journal-title":"Blood"},{"key":"e_1_2_33_9_18_1","article-title":"Initiation of extracorporeal photopheresis in lung transplant patients with mild to moderate refractory BOS: a single\u2010center real\u2010life experience","volume":"81","author":"Leroux J","year":"2022","journal-title":"Respir Med Res"},{"key":"e_1_2_33_9_19_1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/bmt.2010.152","article-title":"Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo\u2010SCT","volume":"46","author":"Lucid CE","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_33_9_20_1","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1097\/TP.0000000000001466","article-title":"Extracorporeal photopheresis (ECP) for treatment of acute and chronic graft versus host disease: an Italian multicentric retrospective analysis on 94 patients on behalf of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)","volume":"100","author":"Malagola M","year":"2016","journal-title":"Transplantation"},{"key":"e_1_2_33_9_21_1","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/s41409-020-01188-4","article-title":"Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD","volume":"56","author":"Mehta RS","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_33_9_22_1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41409-018-0262-x","article-title":"Extracorporeal photopheresis is a valuable treatment option in steroid\u2010refractory or steroid\u2010dependent acute graft versus host disease\u2014experience with three different approaches","volume":"54","author":"Nygaard M","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_33_9_23_1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/ejh.13381","article-title":"Extracorporeal photopheresis for graft\u2010vs\u2010host disease: a literature review and treatment guidelines proposed by the Nordic ECP Quality Group","volume":"104","author":"Nygaard M","year":"2020","journal-title":"Eur J of Haematol"},{"key":"e_1_2_33_9_24_1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.bbmt.2019.12.769","article-title":"Retrospective multicenter study of extracorporeal photopheresis in steroid\u2010refractory acute and chronic graft\u2010versus\u2010host disease","volume":"26","author":"Oarbeascoa G","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_33_9_25_1","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem\u2010cell transplantation for hematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack O","year":"2020","journal-title":"Lancet Haematol"},{"key":"e_1_2_34_9_1_1","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16365","article-title":"Guillain\u2010Berr\u00e9\u2010Syndrome: a comprehensive review","volume":"31","author":"Bellanti R","year":"2024","journal-title":"Eur J Neurol"},{"key":"e_1_2_34_9_2_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s41983-024-00820-0","volume":"60","author":"Balili K","year":"2024","journal-title":"Egypt J Neurol Psychiatry Neurosurg"},{"key":"e_1_2_34_9_3_1","first-page":"CD001789","article-title":"Plasma exchange for Guillian Barr\u00e9 syndrome","volume":"2","author":"Chevret S","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_34_9_4_1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1526-0968.2004.00183.x","article-title":"Plasmapheresis treatment in Guillain\u2010Barr\u00e9 syndrome: potential benefit over IVIg in patients with axonal involvement","volume":"8","author":"Dada MA","year":"2004","journal-title":"Ther Apher Dial"},{"key":"e_1_2_34_9_5_1","first-page":"CD008630","article-title":"Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain\u2010Barr\u00e9 syndrome","volume":"1","author":"Doets AY","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_34_9_6_1","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1016\/j.vaccine.2023.08.014","article-title":"Vaccine patterns among patients diagnosed with Guillain\u2010Barr\u00e9 Syndrome and matched counterparts in a Medicare supplemental population, 2000\u20132020","volume":"41","author":"Eiffert SR","year":"2023","journal-title":"Vaccine"},{"key":"e_1_2_34_9_7_1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/ana.410220612","article-title":"French Cooperative Group on Plasma Exchange in Guillain\u2010Barr\u00e9 syndrome. Efficiency of plasma exchange in Guillain\u2010Barr\u00e9 syndrome: role of replacement fluids","volume":"22","year":"1987","journal-title":"Ann Neurol"},{"key":"e_1_2_34_9_8_1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/NRL.0000000000000342","article-title":"Treatment options for COVID\u201019\u2010related Guillain\u2010Barr\u00e9 syndrome: a systematic review of the literature","volume":"26","author":"Goudarzi S","year":"2021","journal-title":"Neurologist"},{"key":"e_1_2_34_9_9_1","first-page":"203","article-title":"Long\u2010term outcomes of plasma exchange versus intravenous immunoglobulin for the treatment of Guillain\u2010Barr\u00e9 Syndrome: a double\u2010blind, randomized clinical trial","volume":"41","author":"Haridy NA","year":"2023","journal-title":"Restor Neurol Neurosci"},{"key":"e_1_2_34_9_10_1","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain\u2010Barr\u00e9 syndrome","volume":"19","author":"Hughes RA","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_34_9_11_1","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.61.6.736","volume":"61","author":"Hughes RAC","year":"2003","journal-title":"Neurology."},{"key":"e_1_2_34_9_12_1","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027351","article-title":"Efficacy of therapies in the treatment of Guillain\u2010Barr\u00e9 syndrome: a network analysis","volume":"100","author":"Lin J","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"e_1_2_34_9_13_1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1744-9987.2009.00730.x","article-title":"Guillain\u2010Barre syndrome treated by membrane plasma exchange and\/or immunoadsorption","volume":"13","author":"Marn Pernat A","year":"2009","journal-title":"Ther Apher Dial"},{"key":"e_1_2_34_9_14_1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/jca.21646","article-title":"Cost\u2010minimization analysis in the Indian subcontinent for treating Guillain Barre Syndrome patients with therapeutic plasma exchange as compared to intravenous immunoglobulin","volume":"33","author":"Maheshwari A","year":"2018","journal-title":"J Clin Apher"},{"key":"e_1_2_34_9_15_1","article-title":"Treatment efficacy of plasmapheresis versus intravenous immunoglobulin in Guillain\u2010Barr\u00e9 Syndrome management: a systematic review","volume":"16","author":"Nandeesha SS","year":"2024","journal-title":"Cureus"},{"key":"e_1_2_34_9_16_1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/08830738221089476","article-title":"Modified zipper method, a promising treatment option in severe pediatric immune\u2010mediated neurologic disorders","volume":"37","author":"Nikolaus M","year":"2022","journal-title":"J Child Neurol"},{"key":"e_1_2_34_9_17_1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CND.0b013e3181f3dbbf","article-title":"Plasma exchange after initial intravenous immunoglobulin treatment in Guillain\u2010Barr\u00e9 syndrome: critical reassessment of effectiveness and cost\u2010efficiency","volume":"12","author":"Oczko\u2010Walker M","year":"2010","journal-title":"J Clin Neuromuscul Dis"},{"key":"e_1_2_34_9_18_1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.transci.2017.08.013","article-title":"Immunoadsorption in neurological disorders","volume":"56","author":"Oji S","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_34_9_19_1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1526-0968.2004.00138.x","article-title":"Tryptophan\u2010immobilized column\u2010based immunoadsorption as the choice method for plasmapheresis in Guillain\u2010Barr\u00e9 syndrome","volume":"8","author":"Okamiya S","year":"2004","journal-title":"Ther Apher Dial"},{"key":"e_1_2_34_9_20_1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain\u2010Barre syndrome","volume":"349","author":"Plasma Exchange\/Sandoglobulin Guillain\u2010Barre Syndrome Trial Group","year":"1997","journal-title":"Lancet"},{"key":"e_1_2_34_9_21_1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.clineuro.2004.12.019","article-title":"Factors influencing outcome in Guillain\u2010Barr\u00e9 syndrome: comparison of plasma adsorption against other treatments","volume":"107","author":"Seta T","year":"2005","journal-title":"Clin Neurol Neurosurg"},{"key":"e_1_2_34_9_22_1","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/mus.28265","volume":"70","author":"Stino AM","year":"2024","journal-title":"Muscle Nerve"},{"key":"e_1_2_34_9_23_1","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.35.8.1096","article-title":"Plasmapheresis and acute Guillain\u2010Barre syndrome","volume":"35","author":"The Guillain\u2010Barre syndrome Study Group","year":"1985","journal-title":"Neurology"},{"key":"e_1_2_34_9_24_1","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain\u2010Barre syndrome. Dutch Guillain\u2010Barre Study Group","volume":"326","author":"Meche FG","year":"1992","journal-title":"N Engl J Med"},{"key":"e_1_2_34_9_25_1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/jns.12594","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain\u2010Barr\u00e9\u2010syndrome","volume":"28","author":"Doorn PA","year":"2023","journal-title":"J Periph Nerv Syst"},{"key":"e_1_2_35_9_1_1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00043426-199602000-00009","article-title":"Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients","volume":"18","author":"Adams DM","year":"1996","journal-title":"J Pediatr Hematol Oncol"},{"key":"e_1_2_35_9_2_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2257.1986.tb00097.x","article-title":"A study on the value of red cell exchange transfusion in transfusion dependent anaemias","volume":"8","author":"Berdoukas VA","year":"1986","journal-title":"Clin Lab Haematol"},{"key":"e_1_2_35_9_3_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1537-2995.1997.37297203514.x","article-title":"A moderate transfusion regimen may reduce iron loading in beta\u2010thalassemia major without producing excessive expansion of erythropoiesis","volume":"37","author":"Cazzola M","year":"1997","journal-title":"Transfusion"},{"issue":"580","key":"e_1_2_35_9_4_1","first-page":"128","article-title":"Improved preprocedure hematocrit in chronic RBC exchange patients following splenectomy: a case report","volume":"9","author":"Chandrasekar AP","year":"2025","journal-title":"Case Rep Hematol"},{"issue":"8","key":"e_1_2_35_9_5_1","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000732","article-title":"2021 Thalassemia International Federation Guidelines for the management of transfusion\u2010dependent thalassemia","volume":"6","author":"Farmakis D","year":"2022","journal-title":"Hemasphere"},{"key":"e_1_2_35_9_6_1","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s00431-023-04900-w","article-title":"Therapeutic perspective for children and young adults living with thalassemia and sickle cell disease","volume":"182","author":"Ferraresi M","year":"2023","journal-title":"Eur J Pediatr"},{"issue":"3","key":"e_1_2_35_9_7_1","article-title":"Red blood cell exchange in a patient with extramedullary hematopoiesis and cor pulmonale secondary to beta thalassemia","volume":"13","author":"Kopparthy P","year":"2021","journal-title":"Cureus"},{"key":"e_1_2_35_9_8_1","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1111\/trf.16640","article-title":"The transfusion management of beta thalassemia in the United States","volume":"61","author":"Lal A","year":"2021","journal-title":"Transfusion"},{"key":"e_1_2_35_9_9_1","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1046\/j.1537-2995.1997.37797369445.x","article-title":"The presurgical management with erythrocytapheresis of a patient with high\u2010oxygen\u2010affinity, unstable Hb variant (Hb Bryn Mawr)","volume":"37","author":"Larson PJ","year":"1997","journal-title":"Transfusion"},{"key":"e_1_2_35_9_10_1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.tracli.2025.05.005","article-title":"Red blood cell exchange in Hemoglobin Evans: a novel therapeutic avenue for a rare hemoglobinopathy","volume":"32","author":"Meher R.","year":"2025","journal-title":"Transfus Clin Biol"},{"key":"e_1_2_35_9_11_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101165","article-title":"Alpha\u2010thalassemia: a practical overview","volume":"64","author":"Musallam KM","year":"2024","journal-title":"Blood Rev."},{"key":"e_1_2_35_9_12_1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3109\/03630269.2015.1136935","volume":"40","author":"Oliveira A","year":"2016","journal-title":"Hemoglobin"},{"key":"e_1_2_35_9_13_1","first-page":"124","article-title":"Thalassemia intermedia: the role of erythroexchange in the treatment of an indolent wound","volume":"12","author":"Pignatti M","year":"2014","journal-title":"Blood Transfus"},{"issue":"3","key":"e_1_2_35_9_14_1","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2022-252885","article-title":"Methaemalbumin: a diagnostic surrogate for methaemoglobinaemia and treatment with red cell exchange in a patient with thalassemia","volume":"16","author":"Prus\u2010Czarnecka Z","year":"2023","journal-title":"BMJ Case Rep"},{"key":"e_1_2_35_9_15_1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.14740\/jh2086","article-title":"Novel red blood cell exchange parameters for treatment of transfusion\u2010dependent thalassemia based on experience of five patients","volume":"14","author":"Sevcik K","year":"2025","journal-title":"J Hematol"},{"key":"e_1_2_35_9_16_1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMra2021838","article-title":"Beta\u2010thalassemias","volume":"384","author":"Taher AT","year":"2021","journal-title":"N Engl J Med"},{"key":"e_1_2_35_9_17_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102619","article-title":"Global, regional, and national burden of thalassemia, 1990\u20132021: a systematic analysis for the global burden of disease study 2024","volume":"72","author":"Tuo Y","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"19","key":"e_1_2_35_9_18_1","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.3390\/jcm12196287","article-title":"Erythrocytapheresis in children and young adults with hemoglobinopathies and iron overload in need of iron chelation therapy","volume":"12","author":"Van Hattem J","year":"2023","journal-title":"J Clin Med"},{"key":"e_1_2_35_9_19_1","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/trf.17419","article-title":"Complications of red cell exchange for anemia management in patients with transfusion\u2010dependent thalassemia","volume":"63","author":"Wall E","year":"2023","journal-title":"Transfusion"},{"key":"e_1_2_35_9_20_1","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/jca.22086","article-title":"The first reported use of red blood cell exchange to treat hemoglobin Evans with secondary methemoglobinemia","volume":"38","author":"Williams LA","year":"2023","journal-title":"J Clin Apher"},{"issue":"1","key":"e_1_2_35_9_21_1","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.1089","article-title":"Erythrocytapheresis as a strategy to manage anemia and iron overload in nondeletional hemoglobin H disease","volume":"6","author":"Zhang K","year":"2025","journal-title":"eJHaem"},{"key":"e_1_2_36_9_1_1","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00296-016-3545-9","article-title":"Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus","volume":"36","author":"Aytac S","year":"2016","journal-title":"Rheumatol Int"},{"key":"e_1_2_36_9_2_1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.transci.2016.09.015","article-title":"Therapeutic plasma exchange in primary hemophagocytic lymphohistiocytosis: reports of two cases and a review of the literature","volume":"55","author":"Bosnak M","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_36_9_3_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152043","article-title":"Efficacy of plasma exchange on top of standard immunosuppressive therapy in adult autoimmune inflammatory rheumatic diseases\u2010associated macrophage activation syndrome, a single center real\u2010world analysis","volume":"55","author":"Chen Y","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"e_1_2_36_9_4_1","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/cc11256","article-title":"Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis\/sepsis\/multiple organ dysfunction syndrome\/macrophage activation syndrome: what is the treatment?","volume":"16","author":"Demirkol D","year":"2012","journal-title":"Crit Care"},{"key":"e_1_2_36_9_5_1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.blre.2016.05.001","article-title":"Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: a systematic scoping review","volume":"30","author":"Hayden A","year":"2016","journal-title":"Blood Rev."},{"key":"e_1_2_36_9_6_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2022.103603","article-title":"PD\u20101 blockader\u2010associated atypical hemophagocytic lymphohistiocytosis: a cautionary case report","volume":"62","author":"He L","year":"2023","journal-title":"Trans Apher Sci"},{"key":"e_1_2_36_9_7_1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH\u20102004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter J\u2010I","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_36_9_8_1","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood.2024025077","article-title":"Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited","volume":"144","author":"Henter J\u2010I","year":"2024","journal-title":"Blood"},{"key":"e_1_2_36_9_9_1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/CCM.0000000000005361","article-title":"Consensus\u2010based guidelines for the recognition, diagnosis, and management of hemophagocytic lymphohistiocytosis in critically ill children and adults","volume":"50","author":"Hines MR","year":"2022","journal-title":"Crit Care Med"},{"key":"e_1_2_36_9_10_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.2019-3197","volume":"145","author":"Huang P","year":"2020","journal-title":"Pediatrics"},{"key":"e_1_2_36_9_11_1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s13054-020-02941-3","article-title":"Hemophagocytic lymphohistiocytosis in critically ill patients: diagnostic reliability of HLH\u20102024 criteria and HScore","volume":"24","author":"Knaak C","year":"2020","journal-title":"Crit Care"},{"key":"e_1_2_36_9_12_1","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood.V60.4.814.814","article-title":"Immunologic and clinical effects of repeated blood exchange in familial erythrophagocytic lymphohistiocytosis","volume":"60","author":"Ladisch S","year":"1982","journal-title":"Blood"},{"key":"e_1_2_36_9_13_1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/1744-9987.14141","article-title":"Therapeutic plasma exchange in critically ill children: a single center experience","volume":"28","author":"Ozkaya PY","year":"2024","journal-title":"Ther Apher Dial"},{"key":"e_1_2_36_9_14_1","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos\u2010Casals M","year":"2014","journal-title":"Lancet"},{"key":"e_1_2_36_9_15_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-3-031-59815-9_3","article-title":"The history of macrophage activation syndrome in autoimmune diseases","volume":"1448","author":"Silverman ED","year":"2024","journal-title":"Adv Exp Med Biol"},{"key":"e_1_2_36_9_16_1","first-page":"249","article-title":"Efficacy of plasma exchange in children with severe hemophagocytic syndrome: a prospective randomized controlled trial","volume":"24","author":"Yuan Y\u2010H","year":"2022","journal-title":"Chin J Contemp Pediatr"},{"issue":"1","key":"e_1_2_37_9_1_1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/hematology.2024000564","article-title":"Approaches to management of HIT is complex scenarios, including cardiac surgery","volume":"2024","author":"Adeoye O","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"e_1_2_37_9_2_1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjh.19180","article-title":"BSH Committee. Diagnosis and management of heparin\u2010induced thrombocytopenia","volume":"204","author":"Arachhillage DJ","year":"2024","journal-title":"Br J Haematol"},{"key":"e_1_2_37_9_3_1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0049-3848(88)90111-9","article-title":"Treatment of serious heparin\u2010induced thrombocytopenia by plasma exchange: report on 4 cases","volume":"51","author":"Bouvier JL","year":"1988","journal-title":"Thromb Res"},{"key":"e_1_2_37_9_4_1","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin\u2010induced thrombocytopenia","author":"Cuker A","year":"2018","journal-title":"Blood Adv"},{"key":"e_1_2_37_9_5_1","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1182\/blood-2012-07-443051","article-title":"Predictive value of the 4Ts scoring system for heparin\u2010induced thrombocytopenia: a systematic review and meta\u2010analysis","volume":"120","author":"Cuker A","year":"2012","journal-title":"Blood"},{"key":"e_1_2_37_9_6_1","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1053\/j.jvca.2024.09.006","article-title":"Efficacy of therapeutic plasma exchange or cangrelor as an adjunctive strategy to facilitate cardiopulmonary bypass in patients with heparin\u2010induced thrombocytopenia: a systematic review and meta\u2010analysis","volume":"38","author":"Del Vecchio A","year":"2024","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"e_1_2_37_9_7_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1213\/ANE.0b013e3181c427d5","article-title":"Plasma exchange for heparin\u2010induced thrombocytopenia: is there enough evidence?","volume":"110","author":"Despotis GJ","year":"2010","journal-title":"Anesth Analg"},{"key":"e_1_2_37_9_8_1","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/S2352-3026(18)30046-2","article-title":"Disease burden, complication rates, and health\u2010care costs of heparin\u2010induced thrombocytopenia in the USA: a population\u2010based study","volume":"5","author":"Dhakal B","year":"2018","journal-title":"Lancet Haematol"},{"key":"e_1_2_37_9_9_1","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/1076029615578167","article-title":"Heparin reexposure in patients with a history of heparin\u2010induced thrombocytopenia","volume":"21","author":"Dhakal P","year":"2015","journal-title":"Clin Appl Thromb Hemost"},{"key":"e_1_2_37_9_10_1","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.pathol.2017.02.005","article-title":"Clinical and laboratory diagnosis of heparin induced thrombocytopenia: an update","volume":"49","author":"Favaloro EJ","year":"2017","journal-title":"Pathology"},{"key":"e_1_2_37_9_11_1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/jca.20289","article-title":"Use of plasma exchange in patients with heparin\u2010induced thrombocytopenia: a report of two cases and a review of the literature","volume":"26","author":"Jaben EA","year":"2011","journal-title":"J Clin Apher"},{"key":"e_1_2_37_9_12_1","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2017-08-803031","article-title":"Normal plasma IgG inhibits HIT\u2010antibody mediated platelet activation: implications for plasma exchange","volume":"131","author":"Jones CG","year":"2018","journal-title":"Blood"},{"key":"e_1_2_37_9_13_1","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.athoracsur.2006.09.038","article-title":"Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin\u2010induced thrombocytopenia and heparin antibodies: results of the CHOOSE\u2010ON trial","volume":"83","author":"Koster A","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"e_1_2_37_9_14_1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/vox.13008","article-title":"Clinical outcomes of cardiac surgery patients undergoing therapeutic plasma exchange for heparin\u2010induced thrombocytopenia","volume":"116","author":"Moreno\u2010Duarte I","year":"2021","journal-title":"Vox Sang"},{"key":"e_1_2_37_9_15_1","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.3390\/jcm13164686","article-title":"Management of heparin\u2010induced thrombocytopenia: a contemporary review","volume":"13","author":"Ng JY","year":"2024","journal-title":"J Clin Med"},{"key":"e_1_2_37_9_16_1","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1111\/trf.16018","article-title":"Therapeutic plasma exchange and intravenous immune globulin in the treatment of heparin\u2010induced thrombocytopenia: A systematic review","volume":"60","author":"Onuoha C","year":"2020","journal-title":"Transfusion"},{"key":"e_1_2_37_9_17_1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/jca.21709","article-title":"Therapeutic plasma exchange for management of heparin\u2010induced thrombocytopenia: Results of an international practice survey","volume":"34","author":"Onwuemene OA","year":"2019","journal-title":"J Clin Apher"},{"key":"e_1_2_37_9_18_1","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.chest.2017.03.050","article-title":"IVIg for treatment of severe refractory heparin\u2010induced thrombocytopenia","volume":"152","author":"Padmanabhan A","year":"2017","journal-title":"Chest"},{"key":"e_1_2_37_9_19_1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1056\/NEJM200008173430718","article-title":"Use of heparin during cardiopulmonary bypass in patients with a history of heparin\u2010induced thrombocytopenia","volume":"343","author":"P\u00f6tzsch B","year":"2000","journal-title":"N Engl J Med"},{"key":"e_1_2_37_9_20_1","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/jca.21876","article-title":"Use of therapeutic plasma exchange in heparin\u2010induced thrombocytopenia: a population\u2010based study","volume":"36","author":"Soares Ferreira J\u00fanior A","year":"2021","journal-title":"J Clin Apher"},{"key":"e_1_2_37_9_21_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1213\/ANE.0b013e3181c3c1cd","article-title":"Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin\u2010induced thrombocytopenia","volume":"110","author":"Welsby IJ","year":"2010","journal-title":"Anesth Analg"},{"key":"e_1_2_37_9_22_1","first-page":"6921","article-title":"Autoimmune heparin\u2010induced thrombocytopenia. J","volume":"12","author":"Warkentin TE","year":"2023","journal-title":"Clin Med"},{"key":"e_1_2_37_9_23_1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/17474086.2019.1636645","article-title":"High\u2010dose intravenous immunoglobulin for the treatment and prevention of heparin\u2010induced thrombocytopenia: a review","volume":"12","author":"Warkentin TE","year":"2019","journal-title":"Expert Rev. Hematol"},{"key":"e_1_2_37_9_24_1","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood-2017-04-778993","article-title":"Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review","volume":"130","author":"Warkentin TE","year":"2017","journal-title":"Blood"},{"key":"e_1_2_37_9_25_1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2014-07-590844","article-title":"Plasma exchange to remove HIT antibodies: dissociation between enzyme\u2010immunoassay and platelet activation test reactivities","volume":"125","author":"Warkentin TE","year":"2015","journal-title":"Blood"},{"key":"e_1_2_38_8_1_1","first-page":"CD011647","article-title":"Interventions for hereditary haemochromatosis: an attempted network meta\u2010analysis","volume":"3","author":"Buzzetti E","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_38_8_2_1","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.htct.2024.05.011","article-title":"Performance and safety of therapeutic erythrocytapheresis in polycythemia and hemochromatosis treatment: single centre experience","volume":"46","author":"Burna\u0107 IL","year":"2024","journal-title":"Hematol Transfus Cell Ther."},{"key":"e_1_2_38_8_3_1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s12072-015-9608-2","article-title":"Recent advances in hemochromatosis: a 2015 update: a summary of proceedings of the 2014 conference held under the auspices of Hemochromatosis Australia","volume":"9","author":"Ekanayake D","year":"2015","journal-title":"Hepatol Int"},{"key":"e_1_2_38_8_4_1","first-page":"409","article-title":"Comparison between phlebotomy and erythrocytapheresis of iron overload in patients with HFE gene mutations","volume":"127","author":"Fernandez\u2010Mosteirin N","year":"2006","journal-title":"Med Clin"},{"key":"e_1_2_38_8_5_1","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/trf.12949","article-title":"Iron depletion with a novel apheresis system in patients with hemochromatosis","volume":"55","author":"Grabmer C","year":"2015","journal-title":"Transfusion"},{"key":"e_1_2_38_8_6_1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s41669-023-00463-6","article-title":"Health economic evaluations of hemochromatosis screening and treatment: a systematic review","volume":"8","author":"Hoxha M","year":"2024","journal-title":"Pharmacoecon Open"},{"key":"e_1_2_38_8_7_1","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/hep4.2012","volume":"6","author":"Hsu CC","year":"2022","journal-title":"Iron overload disorders. Hepatol Commun"},{"key":"e_1_2_38_8_8_1","doi-asserted-by":"crossref","first-page":"1362941","DOI":"10.3389\/fmed.2024.1362941","article-title":"Blood donation for iron removal in individuals with HFE mutations: study of efficacy and safety and short review on hemochromatosis and blood donation","volume":"11","author":"Infanti L","year":"2024","journal-title":"Front Med (Lausanne)."},{"key":"e_1_2_38_8_9_1","first-page":"263","article-title":"Hereditary hemochromatosis: rapid evidence review","volume":"104","author":"Kane SF","year":"2021","journal-title":"Am Fam Physician"},{"key":"e_1_2_38_8_10_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1423-0410.2000.7910040.x","article-title":"Erythrocytapheresis with recombinant human erythropoietin in hereditary hemochromatosis therapy: a new alternative","volume":"79","author":"Kohan A","year":"2000","journal-title":"Vox Sang"},{"key":"e_1_2_38_8_11_1","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.14309\/ajg.0000000000000315","article-title":"ACG clinical guideline: hereditary hemochromatosis","volume":"114","author":"Kowdley KV","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_38_8_12_1","first-page":"717","article-title":"Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage","volume":"90","author":"Mariani R","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_38_8_13_1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/jca.10024","article-title":"In hereditary hemochromatosis, red cell apheresis removes excess iron twice as fast as manual whole blood phlebotomy","volume":"17","author":"Muncunill J","year":"2002","journal-title":"J Clin Apher"},{"key":"e_1_2_38_8_14_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/vox.12896","article-title":"Diagnosis and management of hereditary haemochromatosis","volume":"115","author":"Murphree CR","year":"2020","journal-title":"Vox Sang"},{"key":"e_1_2_38_8_15_1","doi-asserted-by":"crossref","first-page":"e607","DOI":"10.1016\/S2352-3026(17)30214-4","article-title":"Reduction of body iron in HFE\u2010related haemochromatosis and moderate iron overload (Mi\u2010Iron): a multicentre, participant\u2010blinded, randomized controlled trial","volume":"4","author":"Ong SY","year":"2017","journal-title":"Lancet Haematol"},{"key":"e_1_2_38_8_16_1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/trf.16308","article-title":"How do I\u2026perform therapeutic phlebotomy?","volume":"61","author":"Peedin AR","year":"2021","journal-title":"Transfusion"},{"key":"e_1_2_38_8_17_1","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMra031573","volume":"350","author":"Pietrangelo A.","year":"2004","journal-title":"N Engl J Med"},{"key":"e_1_2_38_8_18_1","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1002\/hep.31405","article-title":"Systematic review of the clinical outcomes of iron reduction in hereditary hemochromatosis","volume":"72","author":"Prabhu A","year":"2020","journal-title":"Hepatology"},{"key":"e_1_2_38_8_19_1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/jca.21956","article-title":"Patients with hereditary hemochromatosis reach safe range of transferrin saturation sooner with erythrocytaphereses than with phlebotomies","volume":"37","author":"Rombout\u2010Sestrienkova E","year":"2022","journal-title":"J Clin Apher"},{"key":"e_1_2_38_8_20_1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/jca.21451","article-title":"Course of iron parameters in HFE\u2010hemochromatosis patients during initial treatment with erythrocytapheresis compared to phlebotomy","volume":"31","author":"Rombout\u2010Sestrienkova E","year":"2016","journal-title":"J Clin Apher"},{"key":"e_1_2_38_8_21_1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1537-2995.2011.03292.x","article-title":"Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial","volume":"52","author":"Rombout\u2010Sestrienkova E","year":"2012","journal-title":"Transfusion"},{"key":"e_1_2_38_8_22_1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/trf.13328","article-title":"Erythrocytapheresis versus phlebotomy in the maintenance treatment of HFE hemochromatosis patients: results from a randomized crossover trial","volume":"56","author":"Rombout\u2010Sestrienkova E","year":"2016","journal-title":"Transfusion"},{"key":"e_1_2_38_8_23_1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/jca.21867","article-title":"A predictive model for estimating the number of erythrocytapheresis or phlebotomy treatments for patients with na\u00efve hereditary hemochromatosis","volume":"36","author":"Rombout\u2010Sestrienkova E","year":"2021","journal-title":"J Clin Apher."},{"key":"e_1_2_38_8_24_1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1159\/000504144","article-title":"Red blood cells: exchange, transfuse, or deplete","volume":"46","author":"Stussi G","year":"2019","journal-title":"Transfus Med Hemother"},{"key":"e_1_2_38_8_25_1","first-page":"s84","article-title":"Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis","volume":"12","author":"Sundic T","year":"2014","journal-title":"Blood Transfus"},{"key":"e_1_2_39_9_1_1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/MPH.0000000000000490","article-title":"Early complications of hyperleukocytosis and leukapheresis in childhood acute leukemias","volume":"38","author":"Abla O","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"key":"e_1_2_39_9_2_1","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1111\/trf.15994","volume":"60","author":"Bewersdorf JP","year":"2020","journal-title":"Transfusion"},{"key":"e_1_2_39_9_3_1","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/ajh.20939","article-title":"Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: no impact on early mortality and intracranial hemorrhage","volume":"82","author":"Chang MC","year":"2007","journal-title":"Am J Hematol"},{"key":"e_1_2_39_9_4_1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/trf.14329","article-title":"The effect of therapeutic leukapheresis on early complications and outcomes in patients with acute leukemia and hyperleukocytosis: a propensity score\u2010matched study","volume":"58","author":"Choi MH","year":"2018","journal-title":"Transfusion"},{"key":"e_1_2_39_9_5_1","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/cncr.34751","article-title":"Clinical characteristics and outcomes of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis managed with different cytoreductive methods","volume":"129","author":"Christakopoulos GE","year":"2023","journal-title":"Cancer"},{"key":"e_1_2_39_9_6_1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner H","year":"2016","journal-title":"Blood"},{"key":"e_1_2_39_9_7_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/MPH.0000000000002225","article-title":"Management of hyperleukocytosis in childhood acute leukemia without leukapheresis and rasburicase prophylaxis","volume":"44","author":"Gelen SA","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"key":"e_1_2_39_9_8_1","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/ajh.21006","article-title":"Increased cerebral blood flow after leukapheresis for acute myelogenous leukemia","volume":"82","author":"Kasner MT","year":"2007","journal-title":"Am J Hematol"},{"key":"e_1_2_39_9_9_1","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/bjh.13146","article-title":"A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukemia presenting with hyperleucocytosis","volume":"168","author":"Kuo KH","year":"2015","journal-title":"Br J Haematol"},{"key":"e_1_2_39_9_10_1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/jca.22090","article-title":"Effectiveness of leukapheresis on early survival in acute myeloid leukemia: an observational propensity score matching cohort study","volume":"38","author":"Lee H","year":"2023","journal-title":"J Clin Apher"},{"key":"e_1_2_39_9_11_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/pbc.20178","article-title":"Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis","volume":"45","author":"Lowe EJ","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_39_9_12_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/trf.15006","article-title":"Apheresis principles in a patient with chronic myeloid leukemia during pregnancy: challenges in cell separation and assessing transcript levels","volume":"59","author":"Lund K","year":"2019","journal-title":"Transfusion"},{"key":"e_1_2_39_9_13_1","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1080\/10428194.2022.2056178","article-title":"Hyperleukocytosis and leukostasis in acute and chronic leukemias","volume":"63","author":"Macaron W","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_39_9_14_1","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood.2023021895","article-title":"Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis","volume":"143","author":"Mack EA","year":"2024","journal-title":"Blood"},{"key":"e_1_2_39_9_15_1","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1080\/10428194.2016.1277386","volume":"58","author":"Nan X","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_39_9_16_1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1600-0609.2005.00421.x","article-title":"Grading of symptoms in hyperleukocytic leukemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome","volume":"74","author":"Novotny JR","year":"2005","journal-title":"Eur J Haematol"},{"key":"e_1_2_39_9_17_1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.leukres.2014.01.004","article-title":"Leukapheresis and low\u2010dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta\u2010analysis","volume":"38","author":"Oberoi S","year":"2014","journal-title":"Leuk Res"},{"key":"e_1_2_39_9_18_1","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2147\/JBM.S312140","volume":"12","author":"Rinaldi I","year":"2021","journal-title":"J Blood Med"},{"issue":"1","key":"e_1_2_39_9_19_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/16078454.2021.2024939","article-title":"Comparison of early mortality between leukapheresis and non\u2010leukapheresis in adult acute myeloid leukemia patients with hyperleukocytosis: a systematic review and meta\u2010analysis","volume":"27","author":"Rinaldi I","year":"2022","journal-title":"Hematology"},{"key":"e_1_2_39_9_20_1","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/trf.14512","article-title":"Hyperleukocytosis in infant acute leukemia: a role for manual exchange transfusion for leukoreduction","volume":"58","author":"Runco DV","year":"2018","journal-title":"Transfusion"},{"key":"e_1_2_39_9_21_1","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1038\/s41375-020-0783-3","article-title":"Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short\u2010 and long\u2010term clinical outcomes: a large, retrospective, multi\u2010center, international study","volume":"34","author":"Stahl M","year":"2020","journal-title":"Leukemia"},{"key":"e_1_2_39_9_22_1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/trf.14448","article-title":"Management of chronic myeloid leukemia in the setting of pregnancy: when is leukapheresis appropriate? A case report and review of the literature","volume":"58","author":"Staley EM","year":"2018","journal-title":"Transfusion"},{"key":"e_1_2_39_9_23_1","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29457","article-title":"Outcomes of children and young adults with T\u2010cell acute lymphoblastic leukemia\/lymphoma who present in critical status","volume":"69","author":"Wayne NJ","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_39_9_24_1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/bjh.14692","volume":"178","author":"Zeller B","year":"2017","journal-title":"Br J Haematol"},{"key":"e_1_2_39_9_25_1","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.3324\/haematol.2024.285285","article-title":"Management of hyperleukocytosis in pediatric acute myeloid leukemia using immediate chemotherapy without leukapheresis: results from the NOPHO\u2010DBH AML 2012 protocol","volume":"109","author":"Zeller B","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_40_9_1_1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/MEG.0000000000002025","article-title":"Continuous insulin therapy versus apheresis in patients with hypertriglyceridemia\u2010associated pancreatitis","volume":"34","author":"Araz F","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"e_1_2_40_9_2_1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/gutjnl-2012-302779","article-title":"Classification of acute pancreatitis\u20102012: revision of the Atlanta classification and definitions by international consensus","volume":"62","author":"Banks PA","year":"2013","journal-title":"Gut"},{"key":"e_1_2_40_9_3_1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/jca.21954","article-title":"Rapid reduction in triglyceride levels by therapeutic plasma exchange in patients with hypertriglyceridemic pancreatitis","volume":"37","author":"Chen Z","year":"2022","journal-title":"J Clin Apher"},{"key":"e_1_2_40_9_4_1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.pan.2015.02.010","article-title":"The role of apheresis in hypertriglyceridemia\u2010induced acute pancreatitis: a systematic review","volume":"15","author":"Click B","year":"2015","journal-title":"Pancreatology"},{"key":"e_1_2_40_9_5_1","first-page":"8\u2009850\u2009666\u2009211\u20090","article-title":"Hypertriglyceridemia induced pancreatitis: Plasmapheresis or conservative management?","author":"Dichtwald S","year":"2021","journal-title":"J Intensive Care Med"},{"key":"e_1_2_40_9_6_1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1159\/000506506","article-title":"Relapsing and progressive complications of severe hypertriglyceridemia: effective long\u2010term treatment with double filtration plasmapheresis","volume":"49","author":"Grupp C","year":"2020","journal-title":"Blood Purif"},{"key":"e_1_2_40_9_7_1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jca.21843","article-title":"Potential differences between double\u2010filtration plasmapheresis and therapeutic plasma exchange in the treatment of acute hypertriglyceridemic pancreatitis","volume":"36","author":"Gubensek J.","year":"2021","journal-title":"J Clin Apher"},{"key":"e_1_2_40_9_8_1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.870067","volume":"9","author":"Gubensek J","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"e_1_2_40_9_9_1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12876-023-02957-3","article-title":"The role of apheresis and insulin therapy in hypertriglyceridemic acute pancreatitis\u2014a concise review","volume":"23","author":"Gubensek J.","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"e_1_2_40_9_10_1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/trf.16214","article-title":"Retrospective analysis of outcomes in patients with acute hypertriglyceridemia pancreatitis treated without therapeutic plasma exchange","volume":"61","author":"Hutchison B","year":"2021","journal-title":"Transfusion"},{"key":"e_1_2_40_9_11_1","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/1751-2980.12659","article-title":"Continuous intravenous infusion of insulin and heparin vs. plasma exchange in hypertriglyceridemia\u2010induced acute pancreatitis","volume":"19","author":"Jin M","year":"2019","journal-title":"J Dig Dis"},{"key":"e_1_2_40_9_12_1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41575-019-0158-2","article-title":"New insights in acute pancreatitis","volume":"16","author":"Lee PJ","year":"2019","journal-title":"Nat Rev. Gastroenterol Hepatol"},{"key":"e_1_2_40_9_13_1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/trf.16724","article-title":"Clinical analysis of the therapeutic effect of plasma exchange on hypertriglyceridemic acute pancreatitis: a retrospective study","volume":"62","author":"Lin Y","year":"2022","journal-title":"Transfusion"},{"key":"e_1_2_40_9_14_1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/jca.21811","article-title":"The role of double filtration plasmapheresis in hypertriglyceridemic pancreatitis: a propensity score matching analysis","volume":"35","author":"Lu Z","year":"2020","journal-title":"J Clin Apher"},{"key":"e_1_2_40_9_15_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2024-001620","article-title":"Triglyceride lowering in patients with different severities of hypertriglyceridaemia\u2010associated acute pancreatitis: secondary analysis of a multicentre, prospective cohort study","volume":"12","author":"Luo X","year":"2025","journal-title":"BMJ Open Gastroenterol"},{"key":"e_1_2_40_9_16_1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00134-017-4722-3","article-title":"Plasmapheresis therapy has no triglyceride\u2010lowering effect in patients with hypertriglyceridemic pancreatitis","volume":"43","author":"Miyamoto K","year":"2017","journal-title":"Intensive Care Med"},{"key":"e_1_2_40_9_17_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.transci.2016.10.005","article-title":"Use of the APACHE II score to assess impact of therapeutic plasma exchange for critically ill patients with hypertriglyceride\u2010induced pancreatitis","volume":"56","author":"Nakhoda S","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_40_9_18_1","first-page":"109","article-title":"Efficacy and adverse effects of insulin versus plasmapheresis in patients with hypertriglyceridemia\u20103\u2010induced acute pancreatitis: a systematic review and meta\u2010analysis","volume":"37","author":"Piplani S","year":"2024","journal-title":"Ann Gastroenterol"},{"key":"e_1_2_40_9_19_1","article-title":"Trends and outcomes of US hypertriglyceridemia\u2010induced acute pancreatitis hospitalizations in Hispanic Americans: epidemiology from 2016 to 2020","author":"Reiche WS","year":"2024","journal-title":"J Racial Ethnic Health Disparities"},{"key":"e_1_2_40_9_20_1","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1210\/clinem\/dgae613","article-title":"Comparison of patients with familial chylomicronemia syndrome and multifactorial chylomicronemia syndrome","volume":"110","author":"Spagnuolo CM","year":"2025","journal-title":"J Clin Endocrinol Metabolism"},{"key":"e_1_2_40_9_21_1","first-page":"21","article-title":"Hypertriglyceridemia\u2010induced pancreatitis in pregnancy: case review on the role of therapeutic plasma exchange","volume":"2021","author":"Tan SYT","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"e_1_2_40_9_22_1","first-page":"1255","article-title":"Effect of plasmapheresis versus standard treatment in preventing recurrent acute pancreatitis in Chinese patients with hypertriglyceridemia","volume":"34","author":"Tang S","year":"2021","journal-title":"Pak J Pharm Sci"},{"key":"e_1_2_40_9_23_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163984","article-title":"Relationship between plasma triglyceride level and severity of hypertriglyceridemic pancreatitis","volume":"11","author":"Wang SH","year":"2016","journal-title":"PloS ONE"},{"key":"e_1_2_40_9_24_1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/jca.21922","article-title":"Effect of TPE vs. medical management on patient outcomes in the setting of hypertriglyceridemia\u2010induced acute pancreatitis with severely elevated triglycerides","volume":"36","author":"Webb CB","year":"2021","journal-title":"J Clin Apher"},{"key":"e_1_2_40_9_25_1","first-page":"2427","article-title":"Effects of different triglyceride\u2010lowering therapies in patient with hypertriglyceridemia\u2010induced acute pancreatitis","volume":"19","author":"Yu S","year":"2020","journal-title":"Exp Ther Med"},{"key":"e_1_2_41_9_1_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.seminhematol.2023.03.005","article-title":"Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment\u2010na\u00efve patients","volume":"60","author":"Buske C","year":"2023","journal-title":"Semin Hematol."},{"key":"e_1_2_41_9_2_1","first-page":"1","article-title":"The spectrum of ocular manifestations in patients with Waldenstr\u00f6m's macroglobulinemia","volume":"16","author":"Dammacco R","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"e_1_2_41_9_3_1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s12288-015-0603-5","article-title":"Immunoglobulin M \u201cflare\u201d seen in a case of Waldenstrom's nacroglobulinemia: successfully managed by therapeutic plasma exchange","volume":"32","author":"Datta SS","year":"2016","journal-title":"Indian J Hematol Blood Transfus"},{"key":"e_1_2_41_9_4_1","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","article-title":"Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low\u2010dose dexamethasone, and rituximab (BDR): long\u2010term results of a phase 2 study of the European Myeloma Network (EMN)","volume":"122","author":"Dimopoulos MA","year":"2013","journal-title":"Blood"},{"key":"e_1_2_41_9_5_1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood-2018-06-846816","article-title":"Acute hyperviscosity: syndromes and management","volume":"132","author":"Gertz MA","year":"2018","journal-title":"Blood."},{"key":"e_1_2_41_9_6_1","first-page":"335","article-title":"Hyperviscosity syndrome: efficacy and comparison of plasma exchange by plasma separation and cascade filtration in patients with immunocytoma of Waldenstrom's type","volume":"43","author":"Hoffkes HG","year":"1995","journal-title":"Clin Nephrol"},{"key":"e_1_2_41_9_7_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.transci.2013.05.019","article-title":"Waldenstr\u00f6m's macroglobulinemia: treatment approaches for newly diagnosed and relapsed disease","volume":"49","author":"Hodge LS","year":"2013","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_41_9_8_1","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.3324\/haematol.2015.124149","article-title":"Competing risk survival analysis in patients with symptomatic Waldenstr\u00f6m Macroglobulinemia: the impact of disease unrelated mortality and of rituximab\u2010based primary therapy","volume":"100","author":"Kastritis E","year":"2015","journal-title":"Haematologica"},{"key":"e_1_2_41_9_9_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/CH-131691","article-title":"Hyperviscosity in plasma cell dyscrasias","volume":"55","author":"Kwaan HC","year":"2013","journal-title":"Clin Hemorheol Microcirc"},{"key":"e_1_2_41_9_10_1","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamaoncol.2016.5763","article-title":"Diagnosis and management of Waldenstr\u00f6m's macroglobulinemia: Mayo stratification of macroglobulinemia and risk\u2010adapted therapy (mSMART) guidelines 2016","volume":"3","author":"Kapoor P","year":"2017","journal-title":"JAMA Oncol"},{"key":"e_1_2_41_9_11_1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jca.21529","article-title":"Plasma exchange in the intensive care unit: technical aspects and complications","volume":"32","author":"Lemaire A","year":"2017","journal-title":"J Clin Apher"},{"key":"e_1_2_41_9_12_1","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1167\/iovs.07-1254","article-title":"Effect of plasmapheresis on hyperviscosity\u2010related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia","volume":"49","author":"Menke MN","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_41_9_13_1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/jca.21655","article-title":"Prediction of immunoglobulin M reduction via simple dose of therapeutic plasma exchange and double filtration plasmapheresis using membrane separation in patients with hyperviscosity syndrome caused by Waldenstrom macroglobulinemia","volume":"33","author":"Miyamoto Y","year":"2018","journal-title":"J Clin Apher"},{"key":"e_1_2_41_9_14_1","first-page":"69","article-title":"Plasmapheresis for hyperviscosity syndrome in macroglobulinemia Waldenstrom and multiple myeloma: influence on blood rheology and the microcirculation","volume":"119","author":"Reinhart WH","year":"1992","journal-title":"J Lab Clin Med"},{"key":"e_1_2_41_9_15_1","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1182\/blood-2011-04-347690","article-title":"Evidence\u2010based focused review of management of hyperviscosity syndrome","volume":"119","author":"Stone MJ","year":"2012","journal-title":"Blood"},{"key":"e_1_2_41_9_16_1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clml.2013.02.013","article-title":"Role of plasmapheresis in Waldenstr\u00f6m's macroglobulinemia","volume":"13","author":"Stone MJ","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"e_1_2_41_9_17_1","first-page":"721","volume":"126","author":"Treon SP","year":"2015","journal-title":"How I treat Waldenstr\u00f6m macroglobulinemia. Blood"},{"key":"e_1_2_41_9_18_1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/039139888500800312","article-title":"Efficacy of discontinuous flow centrifugation compared with cascade filtration in Waldenstrom's macroglobulinemia: a pilot study","volume":"8","author":"Valbonesi M","year":"1985","journal-title":"Int J Artif Organs"},{"key":"e_1_2_41_9_19_1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3389\/fonc.2020.00815","article-title":"Hyperviscosity syndrome in paraprotein secreting conditions including Waldenstrom macroglobulinemia","volume":"10","author":"Weaver A","year":"2020","journal-title":"Front Oncol"},{"key":"e_1_2_41_9_20_1","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1016\/S2352-3026(21)00056-9","article-title":"Polyclonal hypergammaglobulinaemia: assessment, clinical interpretation, and management","volume":"8","author":"Zhao EJ","year":"2021","journal-title":"Lancet Haematol"},{"key":"e_1_2_42_9_1_1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/rheumatology\/kez357","article-title":"Successful treatment of anti\u2010MDA5 antibody\u2010positive refractory interstitial lung disease with plasma exchange therapy","volume":"59","author":"Abe Y","year":"2020","journal-title":"Rheumatol"},{"key":"e_1_2_42_9_2_1","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal R","year":"2022","journal-title":"N Engl J Med"},{"key":"e_1_2_42_9_3_1","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","article-title":"Different phenotypes in dermatomyositis associated with anti\u2010MDA5 antibody","volume":"95","author":"Allenbach Y","year":"2020","journal-title":"Neurology"},{"key":"e_1_2_42_9_4_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102941","article-title":"Efficacy of plasma exchange in patients with anti\u2010MDA5 rapidly progressive interstitial lung disease","volume":"133","author":"Bay P","year":"2022","journal-title":"J Autoimmun"},{"key":"e_1_2_42_9_5_1","first-page":"47","article-title":"Plasmapheresis for macrophage activation syndrome and multiorgan failure as first presentation of juvenile dermatomyositis","volume":"77","author":"Bustos BR","year":"2012","journal-title":"An Pediatr Barc"},{"issue":"13","key":"e_1_2_42_9_6_1","first-page":"1","article-title":"Successful treatment of severe interstitial pneumonia by removal of circulating autoantibodies: a case series","volume":"21","author":"Eller P","year":"2021","journal-title":"BMC Pulm Med"},{"issue":"10","key":"e_1_2_42_9_7_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100802","article-title":"Efficacy of JAK inhibitor combined with protein A immunoadsorption in MDA5+ dermatomyositis with RPILD: A real\u2010world study","volume":"6","author":"Fu Y","year":"2025","journal-title":"Med"},{"key":"e_1_2_42_9_8_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2022.101767","volume":"36","author":"Galindo\u2010Feria AS","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"e_1_2_42_9_9_1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jca.21968","article-title":"Therapeutic plasma exchange for the treatment of refractory necrotizing myopathy","volume":"37","author":"Kruse RL","year":"2022","journal-title":"J Clin Apher"},{"key":"e_1_2_42_9_10_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103286","article-title":"Immune\u2010mediated necrotizing myopathy: A comprehensive review of the pathogenesis, clinical features, and treatments","volume":"148","author":"Li C","year":"2024","journal-title":"J Autoimmun"},{"key":"e_1_2_42_9_11_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","article-title":"The EuroMyositis registry: an international collaborative tool to facilitate myositis research","volume":"77","author":"Lilleker JB","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_42_9_12_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2022.101769","article-title":"Management of interstitial lung disease (ILD) in myositis syndromes: a practical guide for clinicians","volume":"36","author":"Mehta P","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"e_1_2_42_9_13_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2020.101503","article-title":"Clinical manifestations and treatment of antisynthetase syndrome","volume":"34","author":"Marco JL","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"e_1_2_42_9_14_1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3390\/jpm14050461","article-title":"Plasma exchange in anti\u2010signal recognition particle myopathy: a systematic review and combined analysis of patient individual data","volume":"14","author":"Mart\u00ednez\u2010Rodr\u00edguez P","year":"2024","journal-title":"J Pers Med"},{"key":"e_1_2_42_9_15_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.151959","article-title":"Management of MDA\u20105 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review","volume":"53","author":"McPherson M","year":"2022","journal-title":"Sem Arthritis Rheumatism"},{"key":"e_1_2_42_9_16_1","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJM199205213262102","article-title":"Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis","volume":"326","author":"Miller FW","year":"1992","journal-title":"N Engl J Med"},{"key":"e_1_2_42_9_17_1","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti\u2010MDA5\u2010positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment","volume":"59","author":"Shirakashi M","year":"2020","journal-title":"Rheumatol"},{"key":"e_1_2_42_9_18_1","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/BOR.0000000000000836","article-title":"Differential diagnosis of necrotizing myopathy","volume":"33","author":"Selva\u2010O'Callaghan A","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"e_1_2_42_9_19_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152564","article-title":"One\u2010year survival benefits of plasma exchange in idiopathic inflammatory myositis patients with progressive interstitial lung disease\u2010a systemic review and meta\u2010analysis","volume":"69","author":"Tangborwornweerakul B","year":"2024","journal-title":"Semin Artritis Rheum"},{"key":"e_1_2_42_9_20_1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high\u2010dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti\u2013melanoma differentiation\u2013associated gene 5\u2013positive dermatomyositis","volume":"72","author":"Tsuji H","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_42_9_21_1","first-page":"1","article-title":"Clinical features and outcome of patients with acute respiratory failure revealing anti\u2010synthetase or anti\u2010MDA5 dermato\u2010pulmonary syndrome: a French multicenter retrospective study","volume":"8","author":"Vuillard C","year":"2018","journal-title":"Ann Int Care"},{"key":"e_1_2_42_9_22_1","doi-asserted-by":"crossref","first-page":"2311605","DOI":"10.1080\/07853890.2024.2411605","article-title":"Short\u2010term efficiency of plasma exchange in combination with immunosuppressants and\/or biologics in the treatment of idiopathic inflammatory myopathy with rapidly progressive interstitial lung disease: a systematic review and meta\u2010analysis","volume":"56","author":"Yang Y","year":"2024","journal-title":"Ann Med"},{"key":"e_1_2_42_9_23_1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.55563\/clinexprheumatol\/8xj0b9","article-title":"Defining anti\u2010synthetase syndrome: a systematic literature review","volume":"40","author":"Zanframundo G","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_42_9_24_1","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s13311-022-01220-z","article-title":"Antibody therapies in autoimmune inflammatory myopathies","volume":"19","author":"Zeng R","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"928861","key":"e_1_2_42_9_25_1","first-page":"1","article-title":"Myocardial involvement is not rare in anti\u2010melanoma differentiation\u2010associated gene 5 antibody\u2010positive dermatomyositis\/clinically amyopathic dermatomyositis: a retrospective study","volume":"13","author":"Zhou S","year":"2022","journal-title":"Front Immunol"},{"key":"e_1_2_43_9_1_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000521582","article-title":"IgA nephropathy and atypical anti\u2010GBM disease: a rare dual pathology in a pediatric rapidly progressive glomerulonephritis","volume":"2","author":"Bajaj V","year":"2022","journal-title":"Glomerular Ds"},{"key":"e_1_2_43_9_2_1","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s00467-021-05381-5","article-title":"Specific immune biomarker monitoring in two children with severe IgA nephropathy and successful therapy with immunoadsorption in a rapidly progressive case","volume":"37","author":"Cambier A","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"e_1_2_43_9_3_1","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032698","article-title":"High\u2010frequency plasma exchange therapy for immunocompromised, type I crescentic glomerulonephritis complicated with IgA nephropathy: a case report and literature review","volume":"102","author":"Chen H","year":"2023","journal-title":"Medicine."},{"key":"e_1_2_43_9_4_1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted\u2010release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double\u2010blind, randomized, placebo\u2010controlled phase 2b trial","volume":"389","author":"Fellstr\u00f6m BC","year":"2017","journal-title":"Lancet"},{"key":"e_1_2_43_9_5_1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.kint.2018.10.018","article-title":"Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference","volume":"95","author":"Floege J","year":"2019","journal-title":"Kidney Int"},{"key":"e_1_2_43_9_6_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.transproceed.2023.11.023","article-title":"Immunoglobulin A deposits in renal allografts: a prospective longitudinal single\u2010center study","volume":"56","author":"Ganesh K","year":"2024","journal-title":"Transplant Proc"},{"key":"e_1_2_43_9_7_1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/ckj\/sfv008","article-title":"What is new in the management of rapidly progressive glomerulonephritis?","volume":"8","author":"Greenhall GH","year":"2015","journal-title":"Clin Kidney J"},{"key":"e_1_2_43_9_8_1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/s41581-021-00466-8","article-title":"Unconventional T cells and kidney disease","volume":"17","author":"Kaminski H","year":"2021","journal-title":"Nat Rev. Nephrol"},{"key":"e_1_2_43_9_9_1","first-page":"24","article-title":"Coexistence of atypical hemolytic uremic syndrome and crescentic IgA nephropathy treated with eculizumab: a case report","volume":"4","author":"Matsumura D","year":"2016","journal-title":"Clin Nephrol Case Stud"},{"key":"e_1_2_43_9_10_1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000485194","article-title":"Atypical hemolytic uremic syndrome associated with complement Factor H mutation and IgA nephropathy: a case report successfully treated with Eculizumab","volume":"138","author":"Nakamura H","year":"2018","journal-title":"Nephron"},{"key":"e_1_2_43_9_11_1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0272-6386(85)80134-7","article-title":"Malignant IgA nephropathy","volume":"5","author":"Nicholls K","year":"1985","journal-title":"Am J Kid Dis"},{"key":"e_1_2_43_9_12_1","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.3390\/ijms24043977","article-title":"Efficacy and safety of plasma exchange as an adjunctive therapy for rapidly progressive IgA nephropathy and Henoch\u2010Sch\u00f6nlein Purpura nephritis: a systematic review","volume":"24","author":"Nguyen B","year":"2023","journal-title":"Int J Mol Sci"},{"key":"e_1_2_43_9_13_1","first-page":"15","article-title":"Acute kidney injury and diffuse pulmonary hemorrhage secondary to IgA nephropathy and Henoch\u2010Sch\u00f6nlein Purpura: a case report","author":"Razack RA","year":"2023","journal-title":"Cureus"},{"key":"e_1_2_43_9_14_1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fimmu.2019.00504","article-title":"The emerging role of complement proteins as a target for therapy of IgA nephropathy","volume":"10","author":"Rizk DV","year":"2019","journal-title":"Front Immunol"},{"key":"e_1_2_43_9_15_1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin BH","year":"2021","journal-title":"Kidney Int"},{"key":"e_1_2_43_9_16_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/iji.12561","article-title":"Immunological drivers of IgA nephropathy: exploring the mucosa\u2010kidney link","volume":"49","author":"Selvaskandan H","year":"2022","journal-title":"Int J of Immunogenet"},{"key":"e_1_2_43_9_17_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000448767","article-title":"Plasma exchange as an adjunctive therapy for crescentic IgA nephropathy","volume":"44","author":"Xie X","year":"2016","journal-title":"Am J Nephrol"},{"key":"e_1_2_44_10_1_1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/scitranslmed.3003130","article-title":"The PDL1\u2010PD1 axis converts human TH1 cells into regulatory T cells","volume":"3","author":"Amarnath S","year":"2011","journal-title":"Sci Transl Med"},{"key":"e_1_2_44_10_2_1","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/art.41604","article-title":"Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors","volume":"73","author":"Aldrich J","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_44_10_3_1","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune\u2010related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer JR","year":"2018","journal-title":"J Clin Oncol"},{"key":"e_1_2_44_10_4_1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ccell.2025.01.004","article-title":"Adiponectin reduces immune checkpoint inhibitor\u2010induced inflammation without blocking anti\u2010tumor immunity","volume":"43","author":"Braun LM","year":"2025","journal-title":"Cancer Cell"},{"key":"e_1_2_44_10_5_1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/07357907.2021.1913502","article-title":"Real\u2010world incidence and management of immune\u2010related adverse events from immune checkpoint inhibitors: retrospective claims\u2010based analysis","volume":"39","author":"Brown VT","year":"2021","journal-title":"Cancer Invest"},{"key":"e_1_2_44_10_6_1","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.727445","article-title":"Case report: Cardiac toxicity associated with immune checkpoint inhibitors","volume":"8","author":"Chen R","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"e_1_2_44_10_7_1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar FB","year":"2016","journal-title":"Kidney Int"},{"key":"e_1_2_44_10_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000002330"},{"key":"e_1_2_44_10_9_1","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s10072-021-05561-z","article-title":"Characterization and management of neurological adverse events during immune\u2010checkpoint inhibitors treatment: an Italian multicentric experience","volume":"43","author":"Diamanti L","year":"2022","journal-title":"Neurol Sci"},{"key":"e_1_2_44_10_10_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115049","article-title":"Extracorporeal photopheresis vs. systemic immunosuppression for immune\u2010related adverse events: Interim analysis of a prospective two\u2010arm study","volume":"212","author":"Ertl C","year":"2024","journal-title":"Eur J Cancer."},{"key":"e_1_2_44_10_11_1","first-page":"119","volume":"116","author":"Heinzerling L","year":"2019","journal-title":"Checkpoint inhibitors. Dtsch Arztebl Int"},{"key":"e_1_2_44_10_12_1","doi-asserted-by":"crossref","first-page":"ltac012","DOI":"10.1093\/immadv\/ltac012","article-title":"Plasma exchange for severe immune\u2010related adverse events from checkpoint inhibitors: an early window of opportunity?","volume":"2","author":"Katsumoto TR","year":"2022","journal-title":"Immunother Adv"},{"key":"e_1_2_44_10_13_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000750","article-title":"Checkpoint inhibitor\u2010related renal vasculitis and use of rituximab","volume":"8","author":"Mamlouk O","year":"2020","journal-title":"J Immunother Cancer"},{"key":"e_1_2_44_10_14_1","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1111\/trf.17114","article-title":"Therapeutic plasma exchange in the management of immune checkpoint inhibitor\u2010associated immune\u2010related adverse effects: a review","volume":"62","author":"Onwuemene OA","year":"2022","journal-title":"Transfusion."},{"key":"e_1_2_44_10_15_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001113","article-title":"Therapeutic plasma exchange clears circulating soluble PD\u2010L1 and PD\u2010L1\u2010positive extracellular vesicles","volume":"8","author":"Orme JJ","year":"2020","journal-title":"J Immunother Cancer"},{"key":"e_1_2_44_10_16_1","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.1007\/s00415-024-12660-2","article-title":"Immune checkpoint inhibitors\u2010associated cranial nerves involvement: a systematic literature review on 136 patients","volume":"1","author":"Pichon S","year":"2024","journal-title":"J Neurol."},{"key":"e_1_2_44_10_17_1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune\u2010related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","journal-title":"N Engl J Med"},{"key":"e_1_2_44_10_18_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114028","article-title":"Second\u2010line therapies for steroid\u2010refractory immune\u2010related adverse events in patients treated with immune checkpoint inhibitors","volume":"203","author":"Ruf T","year":"2024","journal-title":"Eur J Cancer"},{"key":"e_1_2_44_10_19_1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa H","year":"2019","journal-title":"J Immunother Cancer"},{"key":"e_1_2_44_10_20_1","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune\u2010related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update","volume":"39","author":"Schneider BJ","year":"2021","journal-title":"J Clin Oncol"},{"key":"e_1_2_44_10_21_1","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei SC","year":"2018","journal-title":"Cancer Discov"},{"key":"e_1_2_44_10_22_1","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/jnnp-2020-323055","article-title":"Central nervous system complications associated with immune checkpoint inhibitors","volume":"91","author":"Vogrig A","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_44_10_23_1","doi-asserted-by":"crossref","first-page":"1275254","DOI":"10.3389\/fimmu.2023.1275254","article-title":"Immune checkpoint inhibitor\u2010associated myocarditis: a systematic analysis of case reports","volume":"14","author":"Wang C","year":"2023","journal-title":"Front Immunol"},{"key":"e_1_2_44_10_24_1","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta\u2010analysis","volume":"4","author":"Wang DY","year":"2018","journal-title":"JAMA Oncol"},{"issue":"31","key":"e_1_2_44_10_25_1","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000043552","article-title":"Immune checkpoint inhibitors associated inflammatory disease of central nervous system: case report and systemic review","volume":"104","author":"Yang TT","year":"2025","journal-title":"Medicine (Baltimore)."},{"key":"e_1_2_45_9_1_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103246","article-title":"A multicenter retrospective analysis on therapeutic plasma exchange in immune thrombocytopenic purpura","volume":"60","author":"Basturk A","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_45_9_2_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.transci.2008.07.006","article-title":"Immunoadsorption method using immunoglobulin Adsopak in adult cases with ITP resistant to splenectomy and other medical therapies","volume":"39","author":"Bilgir O","year":"2008","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_45_9_3_1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1046\/j.1537-2995.1984.24585017826.x","article-title":"Intensive plasma exchange therapy in ten patients with idiopathic thrombocytopenic purpura","volume":"24","author":"Blanchette VS","year":"1984","journal-title":"Transfusion"},{"key":"e_1_2_45_9_4_1","first-page":"295","article-title":"The Canadian experience using plasma exchange for immune thrombocytopenic purpura","volume":"19","author":"Buskard N","year":"1998","journal-title":"Canadian Apheresis Group. Transfus Sci"},{"key":"e_1_2_45_9_5_1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1046\/j.1365-2141.1998.00568.x","article-title":"Protein A immunoadsorption in chronic refractory ITP reverses increased platelet activation but fails to achieve sustained clinical benefit","volume":"100","author":"Cahill MR","year":"1998","journal-title":"Br J Haematol"},{"key":"e_1_2_45_9_6_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1423-0410.1983.tb01905.x","article-title":"Plasma exchange in autoimmune thrombocytopenic purpura","volume":"45","author":"Cotter FE","year":"1983","journal-title":"Vox Sang"},{"key":"e_1_2_45_9_7_1","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood-2016-03-603365","article-title":"How I treat refractory immune thrombocytopenia","volume":"28","author":"Cuker A","year":"2016","journal-title":"Blood"},{"key":"e_1_2_45_9_8_1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.transci.2013.06.019","article-title":"Combined plasma exchange and platelet transfusion in immune\u2010mediated thrombocytopenic emergencies","volume":"49","author":"Finn L","year":"2013","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_45_9_9_1","first-page":"1","article-title":"Protein A columns for the treatment of patients with idiopathic thrombocytopenic purpura and other indications","author":"Handelsman H.","year":"1990","journal-title":"Health Technol Assess Rep"},{"key":"e_1_2_45_9_10_1","first-page":"3","article-title":"Immune thrombocytopenia purpura: a pilot study of staphylococcal protein A immunomodulation in refractory patients","volume":"26","author":"Guthrie TH","year":"1989","journal-title":"Semin Hematol"},{"key":"e_1_2_45_9_11_1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.transci.2013.04.005","article-title":"Refractory idiopathic thrombocytopenic purpura treated with immunoadsorption using tryptophan column","volume":"48","author":"Kurtoglu E","year":"2013","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_45_9_12_1","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-03-754119","article-title":"Clinical updates in adult immune thrombocytopenia","volume":"129","author":"Lambert MP","year":"2017","journal-title":"Blood"},{"key":"e_1_2_45_9_13_1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/jca.22000","article-title":"Therapeutic plasma exchange practices in immune thrombocytopenia related hospitalizations: Results from a nationally representative sample","volume":"37","author":"Makhani SS","year":"2022","journal-title":"J Clin Apher"},{"key":"e_1_2_45_9_14_1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1046\/j.1537-2995.1984.24585017826.x","article-title":"One\u2010year follow\u2010up of plasma exchange therapy in 14 patients with idiopathic thrombocytopenic purpura","volume":"24","author":"Marder VJ","year":"1984","journal-title":"Transfusion"},{"key":"e_1_2_45_9_15_1","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1053\/j.seminhematol.2013.03.008","article-title":"Immune thrombocytopenia nomenclature, consensus reports, and guidelines: what are the consequences for daily practice and clinical research?","volume":"50","author":"Michel M.","year":"2013","journal-title":"Semin Hematol"},{"key":"e_1_2_45_9_16_1","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert C","year":"2019","journal-title":"Blood Adv"},{"key":"e_1_2_45_9_17_1","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/bloodadvances.2023012541","article-title":"The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia","volume":"8","author":"Neunert CE","year":"2024","journal-title":"Blood Adv"},{"key":"e_1_2_45_9_18_1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1600-0609.1987.tb00177.x","article-title":"Plasmapheresis for idiopathic thrombocytopenic purpura unresponsive to intravenous immunoglobulin","volume":"39","author":"Pettersson T","year":"1987","journal-title":"Eur J Haematol"},{"key":"e_1_2_45_9_19_1","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan D","year":"2019","journal-title":"Blood Adv"},{"key":"e_1_2_45_9_20_1","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1537-2995.2004.04333.x","article-title":"On the mechanism of staphylococcal protein A immunomodulation","volume":"45","author":"Silverman GJ","year":"2005","journal-title":"Transfusion"},{"key":"e_1_2_45_9_21_1","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41591-021-01408-4","article-title":"First\u2010dose ChAdOx1 and BNT162b2 COVID\u201019 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland","volume":"27","author":"Simpson CR","year":"2021","journal-title":"Nat Med"},{"key":"e_1_2_45_9_22_1","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1097\/00002030-199110000-00017","article-title":"Use of protein A immunoadsorption as a treatment for thrombocytopenia in HIV\u2010infected homosexual men: a retrospective evaluation of 37 cases","volume":"5","author":"Snyder HW","year":"1991","journal-title":"AIDS"},{"key":"e_1_2_45_9_23_1","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood.V79.9.2237.2237","article-title":"Experience with protein A immunoadsorption in treatment\u2010resistant adult immune thrombocytopenic purpura","volume":"79","author":"Snyder HW","year":"1992","journal-title":"Blood"},{"key":"e_1_2_45_9_24_1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1526-0968.2003.00004.x","article-title":"Plasmapheresis in immune hematology: review of clinical outcome data with respect to evidence\u2010based medicine and clinical experience","volume":"7","author":"Von Baeyer H.","year":"2003","journal-title":"Ther Apher Dial"},{"key":"e_1_2_46_9_1_1","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/1744-9987.13749","article-title":"The Japanese Society for Apheresis clinical practice guideline for therapeutic apheresis","volume":"25","author":"Abe T","year":"2021","journal-title":"Ther Apher Dial"},{"key":"e_1_2_46_9_2_1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/ibd.20833","article-title":"Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open\u2010label pilot study","volume":"15","author":"Abreu MT","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"e_1_2_46_9_3_1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/jca.21299","article-title":"Effects of preoperative leukocytapheresis on inflammatory cytokines following surgery for ulcerative colitis: a prospective randomized study","volume":"29","author":"Bamba T","year":"2014","journal-title":"J Clin Apher"},{"issue":"27","key":"e_1_2_46_9_4_1","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3748\/wjg.v27.i10.908","article-title":"Use of granulocyte\/monocytapheresis in ulcerative colitis: a practical review from a European perspective","volume":"14","author":"Dom\u00e8nech E","year":"2021","journal-title":"World J Gastroenterol"},{"key":"e_1_2_46_9_5_1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.5009\/gnl.2012.6.4.427","article-title":"Adsorptive granulocyte\/monocyte apheresis for the maintenance of remission in patients with ulcerative colitis: a prospective randomized, double blind, sham\u2010controlled clinical trial","volume":"6","author":"Fukunaga K","year":"2012","journal-title":"Gut Liver"},{"key":"e_1_2_46_9_6_1","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10620-009-0845-x","article-title":"Clinical effectiveness of selective granulocyte, monocyte adsorptive apheresis with the Adacolumn device in ulcerative colitis","volume":"55","author":"Habermalz B","year":"2010","journal-title":"Dig Dis Sci"},{"key":"e_1_2_46_9_7_1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000479502","article-title":"Adsorptive depletion of myeloid lineage leucocytes as remission induction therapy in patients with ulcerative colitis after failure of first\u2010line medications: results from a three\u2010year real world, clinical practice","volume":"96","author":"Iida T","year":"2017","journal-title":"Digestion"},{"key":"e_1_2_46_9_8_1","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/1744-9987.13594","article-title":"Factors associated with the outcomes in ulcerative colitis patients undergoing granulocyte and monocyte adsorptive apheresis as remission induction therapy: a multicenter cohort study","volume":"25","author":"Ishiguro Y","year":"2021","journal-title":"Ther Apher Dial"},{"key":"e_1_2_46_9_9_1","first-page":"1","article-title":"Exploratory study of the effectiveness of granulocyte and monocyte adsorptive apheresis before initiation of steroids in patients with active ulcerative colitis (EXPECT study): a multicenter prospective clinical trial","volume":"2","author":"Kakimoto K","journal-title":"Crohns Colitis"},{"issue":"11","key":"e_1_2_46_9_10_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-042374","article-title":"Granulocyte and monocyte apheresis as an adjunctive therapy to induce and maintain clinical remission in ulcerative colitis: a systematic review and meta\u2010analysis","volume":"1","author":"Kiss S","year":"2021","journal-title":"BMJ Open"},{"key":"e_1_2_46_9_11_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000431149","volume":"92","author":"Kruis W","year":"2015","journal-title":"Digestion"},{"key":"e_1_2_46_9_12_1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000505484","article-title":"Adsorptive granulocyte and monocyte apheresis is effective in ulcerative colitis patients both with and without concomitant prednisolone","volume":"5","author":"Matsuda K","year":"2020","journal-title":"Inflam Intest Dis"},{"key":"e_1_2_46_9_13_1","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s00535-019-01651-0","article-title":"Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open\u2010label prospective multicenter randomized controlled trial","volume":"55","author":"Naganuma M","year":"2020","journal-title":"J Gastroenterol"},{"key":"e_1_2_46_9_14_1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.tmrv.2014.09.004","article-title":"National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: scientific opportunities in extracorporeal photopheresis","volume":"29","author":"Ratcliffe N","year":"2015","journal-title":"Transfus Med Rev."},{"key":"e_1_2_46_9_15_1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ibd.23012","article-title":"Extracorporeal photopheresis (ECP) in patients with steroid\u2010dependent Crohn's disease: an open\u2010label, multicenter, prospective trial","volume":"19","author":"Reinisch W","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"e_1_2_46_9_16_1","doi-asserted-by":"crossref","first-page":"e692","DOI":"10.1016\/j.crohns.2013.06.012","article-title":"Granulocytapheresis in steroid\u2010dependent and steroid\u2010resistant patients with inflammatory bowel disease: a prospective observational study","volume":"7","author":"Sacco R","year":"2013","journal-title":"J Crohns Colitis"},{"key":"e_1_2_46_9_17_1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/MEG.0b013e3282f5e9a4","article-title":"Comparison of the efficacy of granulocyte and monocyte\/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study","volume":"20","author":"Sakata Y","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"e_1_2_46_9_18_1","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1136\/gutjnl-2011-300995","article-title":"A randomized, double\u2010blind, sham\u2010controlled study of granulocyte\/monocyte apheresis for moderate to severe Crohn's disease","volume":"62","author":"Sands BE","year":"2013","journal-title":"Gut"},{"key":"e_1_2_46_9_19_1","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.gastro.2008.04.023","article-title":"A randomized, double\u2010blind, sham\u2010controlled study of granulocyte\/monocyte apheresis for active ulcerative colitis","volume":"135","author":"Sands BE","year":"2008","journal-title":"Gastroenterology"},{"key":"e_1_2_46_9_20_1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000495503","article-title":"Shorter relapse\u2010free period after leukocyte removal therapy in younger than older patients with ulcerative colitis","volume":"100","author":"Yamasaki S","year":"2019","journal-title":"Digestion"},{"key":"e_1_2_46_9_21_1","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.crohns.2014.01.027","article-title":"A large\u2010scale, prospective, observational study of leukocytapheresis for ulcerative colitis: treatment outcomes of 847 patients in clinical practice","volume":"8","author":"Yokoyama Y","year":"2014","journal-title":"J Crohns Colitis"},{"key":"e_1_2_46_9_22_1","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jcyt.2015.02.007","article-title":"Factors associated with treatment outcome, and long\u2010term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study","volume":"17","author":"Yokoyama Y","year":"2015","journal-title":"Cytotherapy"},{"key":"e_1_2_46_9_23_1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.dld.2013.10.011","article-title":"Efficacy and safety of granulocyte and monocyte adsorption apheresis for ulcerative colitis: a meta\u2010analysis","volume":"46","author":"Yoshino T","year":"2014","journal-title":"Dig Liver Dis"},{"key":"e_1_2_46_9_24_1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12876-015-0390-3","article-title":"An open\u2010label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active Crohn's disease","volume":"15","author":"Yoshimura N","year":"2015","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"e_1_2_46_9_25_1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3390\/biomedicines11030747","article-title":"Exploring the pipeline of novel therapies for inflammatory bowel disease; state of the art review","volume":"11","author":"Zurba Y","year":"2023","journal-title":"Biomedicines."},{"key":"e_1_2_47_9_1_1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/mus.25520","article-title":"Lambert\u2010Eaton myasthenic syndrome: epidemiology and therapeutic response in the national Veterans Affairs population","volume":"56","author":"Abenroth DC","year":"2017","journal-title":"Muscle Nerve"},{"key":"e_1_2_47_9_2_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jneuroim.2008.05.026","article-title":"Effect of IgG immunoadsorption on serum cytokines in MG and LEMS patients","volume":"201","author":"Baggi F","year":"2008","journal-title":"J Neuroimmunol"},{"key":"e_1_2_47_9_3_1","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","article-title":"Effects of intravenous immunoglobulin on muscle weakness and calcium\u2010channel autoantibodies in the Lambert\u2010Eaton myasthenic syndrome","volume":"47","author":"Bain PG","year":"1996","journal-title":"Neurology"},{"key":"e_1_2_47_9_4_1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.12998\/wjcc.v3.i3.293","article-title":"Voltage gated calcium channel antibody\u2010related neurological diseases","volume":"3","author":"Bekircan\u2010Kurt CE","year":"2015","journal-title":"World J Clin Cases"},{"key":"e_1_2_47_9_5_1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ncl.2020.09.007","article-title":"Update in the management of myasthenia gravis and Lambert\u2010Eaton myasthenic syndrome","volume":"39","author":"Bodkin C","year":"2021","journal-title":"Neurol Clin"},{"key":"e_1_2_47_9_6_1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10072-014-1637-4","article-title":"Italian recommendations for Lambert\u2010Eaton myasthenic syndrome (LEMS) management","volume":"35","author":"Evoli A","year":"2014","journal-title":"Neurol Sci"},{"key":"e_1_2_47_9_7_1","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3390\/brainsci11081035","article-title":"Presynaptic paraneoplastic disorders of the neuromuscular junction: an update","volume":"11","author":"Giannoccaro MP","year":"2021","journal-title":"Brain Sci"},{"issue":"6","key":"e_1_2_47_9_8_1","article-title":"A rare case of Lambert\u2010Eaton Myasthenia Syndrome with dysphasia and dysarthria","volume":"17","author":"Harimohan H","year":"2025","journal-title":"Cureus."},{"key":"e_1_2_47_9_9_1","first-page":"1","volume-title":"NCBI Bookshelf (National Library of Medicine, National Institutes of Health), StatPearls [Internet]. Treasure Island","author":"Jayarangaiah A","year":"2023"},{"key":"e_1_2_47_9_10_1","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1212\/WNL.0000000000008747","article-title":"Long\u2010term follow\u2010up, quality of life, and survival of patients with Lambert\u2010Eaton myasthenic syndrome","volume":"94","author":"Lipka AF","year":"2020","journal-title":"Neurology"},{"key":"e_1_2_47_9_11_1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40120-015-0034-0","article-title":"The European LEMS Registry: baseline demographics and treatment approaches","volume":"4","author":"Mantegazza R","year":"2015","journal-title":"Neurol Ther"},{"key":"e_1_2_47_9_12_1","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s40120-022-00354-8","volume":"11","author":"Meisel A","year":"2022","journal-title":"Neurol Ther"},{"key":"e_1_2_47_9_13_1","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","article-title":"Treatment of concomitant myasthenia gravis and Lambert\u2010Eaton myasthenic syndrome with autologous CD19\u2010targeted CAR T cells","volume":"112","author":"Motte J","year":"2024","journal-title":"Neuron"},{"key":"e_1_2_47_9_14_1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1212\/WNL.34.4.480","article-title":"Plasma exchange and immunosuppressive drug treatment in the Lambert\u2010Eaton myasthenic syndrome","volume":"34","author":"Newsom\u2010Davis J","year":"1984","journal-title":"Neurology"},{"key":"e_1_2_47_9_15_1","first-page":"S17","article-title":"Lambert\u2010Eaton myasthenic syndrome: electro\u2010physiological evidence for a humoral factor","volume":"5","author":"Newsom\u2010Davis J","year":"1982","journal-title":"Muscle Nerve"},{"key":"e_1_2_47_9_16_1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/WCO.0000000000000972","article-title":"Neuromuscular junction disorders beyond myasthenia gravis","volume":"34","author":"Oh SJ","year":"2021","journal-title":"Curr Opin Neurol"},{"key":"e_1_2_47_9_17_1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3988\/jcn.2024.0018","article-title":"Amifampridines are the most effective drugs for treating Lambert\u2010Eaton myasthenic syndrome with a focus on pediatric Lambert\u2010Eaton myasthenic syndrome","volume":"20","author":"Oh SJ","year":"2024","journal-title":"J Clin Neurol"},{"key":"e_1_2_47_9_18_1","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1744-9987.2010.00806.x","article-title":"A case report of the efficient reduction of calcium channel antibodies by tryptophan ligand immunoadsorption in a patient with Lambert\u2010Eaton syndrome","volume":"14","author":"Sauter M","year":"2010","journal-title":"Ther Apher Dial"},{"key":"e_1_2_47_9_19_1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s13760-024-02657-z","article-title":"Severe progression of a young\u2010onset nonparaneoplastic Lambert\u2010Eaton myasthenic syndrome","volume":"125","author":"Sch\u00f6n M","year":"2025","journal-title":"Acta Neurol Belg"},{"key":"e_1_2_47_9_20_1","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1007\/s00415-017-8541-9","article-title":"Lambert\u2010Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer","volume":"264","author":"Schoser B","year":"2017","journal-title":"J Neurol"},{"key":"e_1_2_47_9_21_1","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie GO","year":"2010","journal-title":"Eur J Neurol"},{"key":"e_1_2_47_9_22_1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s12035-014-8887-2","article-title":"Synaptic pathophysiology and treatment of Lambert\u2010Eaton myasthenic syndrome","volume":"52","author":"Tarr TB","year":"2015","journal-title":"Mol Neurobiol"},{"key":"e_1_2_47_9_23_1","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1749-6632.1998.tb11024.x","article-title":"Lambert\u2010Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients","volume":"841","author":"Tim RW","year":"1998","journal-title":"Ann NY Acad Sci"},{"key":"e_1_2_47_9_24_1","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","article-title":"Lambert\u2010Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies","volume":"10","author":"Titulaer MJ","year":"2011","journal-title":"Lancet Neurol"},{"key":"e_1_2_47_9_25_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562864231213240","article-title":"Guidelines for the management of myasthenic syndromes","volume":"16","author":"Wiendl H","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"e_1_2_48_9_1_1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab an lipoprotein(a) and cardiovascular risk after acute coronary syndromes","volume":"75","author":"Bittner VA","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_48_9_2_1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1744-9987.2009.00667.x","article-title":"Single lipoprotein apheresis session improves cardiac microvascular function in patients with elevated lipoprotein(a): detection by stress\/rest perfusion magnetic resonance imaging","volume":"13","author":"Bohl S","year":"2009","journal-title":"Ther Apher Dial"},{"key":"e_1_2_48_9_3_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.atherosclerosissup.2017.05.011","article-title":"Association of lipoprotein(a) level with short\u2010 and long\u2010term outcomes after CABG: the role of lipoprotein apheresis","volume":"30","author":"Ezhov MV","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"e_1_2_48_9_4_1","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the American Heart Association","volume":"44","author":"Gianos E","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"e_1_2_48_9_5_1","first-page":"e1082","volume":"139","author":"Grundy SM","year":"2019","journal-title":"Circulation"},{"key":"e_1_2_48_9_6_1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.atherosclerosissup.2015.02.013","article-title":"Efficacy, safety, and tolerability of long\u2010term lipoprotein apheresis in patients with LDL\u2010 or Lp(a) hyperlipoproteinemia: findings gathered from more than 36\u2009000 treatments at one center in Germany","volume":"18","author":"Heigl F","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"e_1_2_48_9_7_1","first-page":"229","article-title":"Longitudinal cohort study of the effectiveness of lipid apheresis treatment to reduce high lipoprotein (a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger BR","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"e_1_2_48_9_8_1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3390\/antiox10010132","article-title":"Oxidized LDL and anti\u2010oxidized LDL antibodies are reduced by lipoprotein apheresis in a randomized controlled trial on patients with refractory angina and elevated lipoprotein(a)","volume":"10","author":"Khan TZ","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"e_1_2_48_9_9_1","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky ML","year":"2024","journal-title":"J Clin Lipidol"},{"key":"e_1_2_48_9_10_1","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg F","year":"2022","journal-title":"Eur Heart J"},{"key":"e_1_2_48_9_11_1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2023.04.012","article-title":"Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society","volume":"374","author":"Kronenberg F","year":"2023","journal-title":"Atherosclerosis"},{"key":"e_1_2_48_9_12_1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11789-017-0082-3","article-title":"Prevention of cardiovascular complications in patients with Lp(a)\u2010hyperlipoproteinemia and progressive cardiovascular disease by long\u2010term lipoprotein apheresis according to German national guidelines","volume":"12","author":"Klingel R","year":"2017","journal-title":"Clin Res Cardiol Suppl"},{"key":"e_1_2_48_9_13_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120508","article-title":"Pro(a)LiFe study group. Lipoprotein apheresis for lipoprotein(a)\u2010associated progressive atherosclerotic cardiovascular disease: 12\u2010years follow\u2010up","volume":"410","author":"Klingel R","year":"2025","journal-title":"Atherosclerosis"},{"key":"e_1_2_48_9_14_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120479","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"409","author":"Mach F","year":"2025","journal-title":"Atherosclerosis"},{"key":"e_1_2_48_9_15_1","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jacl.2019.09.010","article-title":"Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease","volume":"13","author":"Moriarty PM","year":"2019","journal-title":"J Clin Lipidol"},{"key":"e_1_2_48_9_16_1","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard BG","year":"2024","journal-title":"Lancet"},{"key":"e_1_2_48_9_17_1","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue ML","year":"2019","journal-title":"Circulation"},{"key":"e_1_2_48_9_18_1","first-page":"e771","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"151","author":"Rao SV","year":"2025","journal-title":"Circulation"},{"key":"e_1_2_48_9_19_1","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes\u2010Soffer G","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"e_1_2_48_9_20_1","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"Lipoprotein apheresis for lipoprotein(a)\u2010associated cardiovascular disease: prospective 5\u2009years of follow\u2010up and apolipoprotein(a) characterization","volume":"36","author":"Roeseler E","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"e_1_2_48_9_21_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.atherosclerosissup.2012.10.015","article-title":"Effect of lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography","volume":"14","author":"Safarova MS","year":"2013","journal-title":"Atheroscler Suppl"},{"key":"e_1_2_48_9_22_1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.atherosclerosissup.2017.05.047","author":"Schatz U","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"e_1_2_48_9_23_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.118601","volume":"398","author":"Schettler V","year":"2024","journal-title":"Atherosclerosis"},{"key":"e_1_2_48_9_24_1","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jacl.2020.05.002","article-title":"Lipoprotein(a) concentration, genetic variants, apo(a) isoform size, and cellular cholesterol efflux in patients with elevated Lp(a) and coronary heart disease submitted or not to lipoprotein apheresis: an Italian case\u2013control multicenter study on Lp(a)","volume":"14","author":"Stefanutti C","year":"2020","journal-title":"J Clin Lipidol"},{"key":"e_1_2_48_9_25_1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI working group recommendations to reduce lipoprotein(a)\u2010mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas S","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_49_9_1_1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/1475-2875-11-158","article-title":"Automated red blood cell exchange as an adjunctive treatment for severe Plasmodium falciparum malaria at the Vienna General Hospital in Austria: a retrospective cohort study","volume":"11","author":"Auer\u2010Hackenberg L","year":"2012","journal-title":"Malar J"},{"key":"e_1_2_49_9_2_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.transci.2006.03.001","article-title":"Cytapheresis in the treatment of cell\u2010affected blood disorders and abnormalities","volume":"35","author":"Balint B","year":"2006","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_49_9_3_1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1046\/j.1365-3156.1997.d01-375.x","article-title":"Exchange blood transfusion in severe falciparum malaria: retrospective evaluation of 61 patients treated with, compared to 63 patients treated without, exchange transfusion","volume":"2","author":"Burchard GD","year":"1997","journal-title":"Trop Med Int Health"},{"key":"e_1_2_49_9_4_1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12936-016-1264-z","article-title":"The role of red blood cell exchange for severe imported malaria in the artesunate era: a retrospective cohort study in a referral centre","volume":"15","author":"Calvo\u2010Cano A","year":"2016","journal-title":"Malar J"},{"key":"e_1_2_49_9_5_1","article-title":"Optimizing the intensive care treatment of severe and complicated plasmodium falciparum malaria in nonimmune patients","volume":"1628270","author":"Chentsov VB","year":"2020","journal-title":"J Trop Med"},{"key":"e_1_2_49_9_6_1","article-title":"Study of twenty one cases of red cell exchange in a tertiary care hospital in southern India","volume":"10","author":"Daniel MJ","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"e_1_2_49_9_7_1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1179\/000349803225001364","article-title":"Predicting the reduction of parasitaemia following exchange transfusion in severe Plasmodium falciparum malaria: comparison of two mathematical formulae","volume":"97","author":"Kumar S","year":"2003","journal-title":"Ann Trop Med Parasitol"},{"key":"e_1_2_49_9_8_1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jinf.2016.02.001","article-title":"UK malaria treatment guidelines","volume":"72","author":"Lalloo DG","year":"2016","journal-title":"J Infect"},{"key":"e_1_2_49_9_9_1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12936-018-2174-z","article-title":"Manual exchange transfusion for severe imported falciparum malaria: a retrospective study","volume":"17","author":"Lin J","year":"2018","journal-title":"Malar J"},{"key":"e_1_2_49_9_10_1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/00006454-199408000-00006","article-title":"Pediatric Plasmodium falciparium malaria: a ten\u2010year experience from Washington","volume":"13","author":"McCaslin RI","year":"1994","journal-title":"DC. Pediatr Infect Dis J"},{"key":"e_1_2_49_9_11_1","first-page":"208","article-title":"Role of exchange transfusion in patients with severe Falciparum malaria: report of six cases","volume":"86","author":"Molla S","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_49_9_12_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.actatropica.2006.05.003","article-title":"Automated erythrocytapheresis in severe falciparum malaria: a critical appraisal","volume":"98","author":"Nieuwenhuis JA","year":"2006","journal-title":"Acta Trop"},{"key":"e_1_2_49_9_13_1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jinf.2019.09.014","article-title":"Safety and effectiveness of apheresis in the treatment of infectious diseases: a systematic review","volume":"79","author":"Odedra A","year":"2019","journal-title":"J Infect"},{"key":"e_1_2_49_9_14_1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/tmrv.2002.33437","article-title":"Exchange transfusion for malaria and Babesia infection","volume":"16","author":"Powell VI","year":"2002","journal-title":"Transfus Med Rev."},{"key":"e_1_2_49_9_15_1","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1086\/339810","article-title":"Exchange transfusion as an adjunct therapy in severe Plasmodium falciparum malaria: a meta\u2010analysis","volume":"34","author":"Riddle MS","year":"2002","journal-title":"Clin Infect Dis"},{"key":"e_1_2_49_9_16_1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3233\/CH-2010-1354","article-title":"Erythrocytapheresis and sublingual micro\u2010vascular flow in severe malaria","volume":"46","author":"Siegenthaler N","year":"2010","journal-title":"Clin Hemorheol Microcirc"},{"key":"e_1_2_49_9_17_1","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/cid\/cit429","article-title":"Exchange transfusion for severe malaria: evidence base and literature review","volume":"57","author":"Tan KR","year":"2013","journal-title":"Clin Infect Dis"},{"key":"e_1_2_49_9_18_1","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1537-2995.2009.02488.x","article-title":"Efficacy and safety of exchange transfusion as an adjunct therapy for severe Plasmodium falciparum malaria in nonimmune travelers: a 10\u2010year single\u2010center experience with a standardized treatment protocol","volume":"50","author":"Genderen PJ","year":"2010","journal-title":"Transfusion"},{"key":"e_1_2_49_9_19_1","unstructured":"World Health organization guidelines for malaria. 13th August 2025.https:\/\/www.who.int\/publications\/i\/item\/guidelines-for-malaria(accessed Oct 1 2025)."},{"key":"e_1_2_49_9_20_1","volume-title":"World malaria report 2024: addressing inequity in the global malaria response","year":"2024"},{"key":"e_1_2_49_9_21_1","article-title":"Exchange transfusion combined with artesunate (ET\u2010AS) as a safe and effective therapy in severe P. falciparum malaria: a case series","volume":"24","author":"Zhang J","year":"2024","journal-title":"BMC Infect Dis"},{"key":"e_1_2_50_9_1_1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/jca.21953","volume":"37","author":"Boedecker SC","year":"2022","journal-title":"J Clin Apher"},{"key":"e_1_2_50_9_2_1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/jca.21788","article-title":"Double\u2010blind, randomized controlled trial of therapeutic plasma exchanges vs. sham exchanges in moderate\u2010to\u2010severe relapses of multiple sclerosis","volume":"35","author":"Brochet B","year":"2020","journal-title":"J Clin Apher"},{"key":"e_1_2_50_9_3_1","first-page":"441e6","article-title":"Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis","volume":"337","year":"1991","journal-title":"Lancet"},{"key":"e_1_2_50_9_4_1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jamaneurol.2023.0467","article-title":"Is autologous hematopoietic stem cell transplant better than high\u2010efficacy disease\u2010modifying therapies for relapsing multiple sclerosis?","volume":"80","author":"Cohen JA","year":"2023","journal-title":"JAMA Neurol"},{"key":"e_1_2_50_9_5_1","doi-asserted-by":"crossref","unstructured":"CorteseI ChaudhryV SoYT et al.Evidence\u2010based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology2011;76:294\u2013300.","DOI":"10.1212\/WNL.0b013e318207b1f6"},{"key":"e_1_2_50_9_6_1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.eclinm.2019.10.017","article-title":"Safety and efficacy of immunoadsorption versus plasma exchange in steroid\u2010refractory relapse of multiple sclerosis and clinically isolated syndrome: a randomized, parallel\u2010group, controlled trial","volume":"16","author":"Dorst J","year":"2019","journal-title":"EClinicalMedicine"},{"key":"e_1_2_50_9_7_1","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.3390\/jcm9092874","article-title":"Safety and tolerability of plasma exchange and immunoadsorption in neuroinflammatory diseases","volume":"9","author":"Dorst J","year":"2020","journal-title":"J Clin Med"},{"key":"e_1_2_50_9_8_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134583","article-title":"Response to therapeutic plasma exchange as a rescue treatment in clinically isolated syndromes and acute worsening of multiple sclerosis: a retrospective analysis of 90 patients","volume":"10","author":"Ehler J","year":"2015","journal-title":"PLoS One"},{"key":"e_1_2_50_9_9_1","doi-asserted-by":"crossref","first-page":"1531447","DOI":"10.3389\/fimmu.2025.1531447","article-title":"Apheresis for the treatment of relapses in MS and NMOSD: reduced antibody reactivities, gene expression changes and potential clinical response indicators","volume":"16","author":"Hecker M","year":"2025","journal-title":"Front Immunol"},{"key":"e_1_2_50_9_10_1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.atherosclerosissup.2012.10.025","article-title":"Immunoadsorption in steroid\u2010refractory multiple sclerosis: clinical experience in 60 patients","volume":"14","author":"Heigl F","year":"2013","journal-title":"Atheroscler Suppl"},{"key":"e_1_2_50_9_11_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756286418774973","article-title":"Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica","volume":"11","author":"Hoffmann F","year":"2018","journal-title":"Ther Adv Neurol Dis"},{"key":"e_1_2_50_9_12_1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","article-title":"Multiple sclerosis","volume":"403","author":"Jakimovski D","year":"2024","journal-title":"Lancet"},{"key":"e_1_2_50_9_13_1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(05)67102-4","article-title":"Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange","volume":"366","author":"Keegan M","year":"2005","journal-title":"Lancet"},{"key":"e_1_2_50_9_14_1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4172\/2376-0389.1000102","article-title":"Plasma exchange in secondary progressive multiple sclerosis: twenty\u2010five year follow\u2010up study","volume":"1","author":"Khatri BO","year":"2014","journal-title":"J Mult Scler"},{"key":"e_1_2_50_9_15_1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1742-2094-9-80","article-title":"Immunoadsorption therapy in patients with multiple sclerosis with steroid\u2010refractory optical neuritis","volume":"9","author":"Koziolek M","year":"2012","journal-title":"J Neuroinflamm"},{"key":"e_1_2_50_9_16_1","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jca.21686","article-title":"Immunoadsorption or plasma exchange in steroid\u2010refractory multiple sclerosis and neuromyelitis optica","volume":"34","author":"Lipphardt M","year":"2019","journal-title":"J Clin Apher"},{"key":"e_1_2_50_9_17_1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti C","year":"2000","journal-title":"Ann Neurol"},{"key":"e_1_2_50_9_18_1","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/archneurol.2011.34","article-title":"Beneficial plasma exchange response in CNS inflammatory demyelination","volume":"68","author":"Magana SM","year":"2011","journal-title":"Arch Neurol"},{"key":"e_1_2_50_9_19_1","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","article-title":"Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria","volume":"24","author":"Montalban X","year":"2025","journal-title":"Lancet Neurol"},{"key":"e_1_2_50_9_20_1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12974-022-02583-y","article-title":"Immunoadsorption versus double\u2010dose methylprednisolone in refractory multiple sclerosis relapses","volume":"19","author":"Pfeuffer S","year":"2022","journal-title":"J Neuroinflammation"},{"key":"e_1_2_50_9_21_1","unstructured":"Rae\u2010GrantA DayGS MarrieAM et al.Comprehensive systematic review summary: disease\u2010modifying therapies for adults with multiple sclerosis. Report of the guideline development dissemination and implementation subcommittee of the American Academy of Neurology. Neurology2018;90:789\u2013800."},{"key":"e_1_2_50_9_22_1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000447059","article-title":"Escalation therapy of steroid refractory multiple sclerosis relapse with tryptophan immunoadsorption\u2014observational multicenter study with 147 patients","volume":"75","author":"Schimrigk S","year":"2016","journal-title":"Eur Neurol"},{"key":"e_1_2_50_9_23_1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1001\/jamaneurol.2017.4842","article-title":"Differences in the response to apheresis therapy of patients with 3 histopathologically classified immunopathological patterns of multiple sclerosis","volume":"75","author":"Stork L","year":"2018","journal-title":"JAMA Neurol"},{"key":"e_1_2_50_9_24_1","doi-asserted-by":"crossref","first-page":"7749","DOI":"10.3390\/cimb45100489","article-title":"Therapeutic plasma exchange and multiple sclerosis dysregulations: focus on the removal of pathogenic circulatory factors and altering nerve growth factor and sphingosine\u20101\u2010phosphate plasma levels","volume":"45","author":"Tonev D","year":"2023","journal-title":"Curr Issues Mol Biol"},{"key":"e_1_2_50_9_25_1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/jca.2920100402","article-title":"Meta\u2010analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis","volume":"10","author":"Vamvakas EC","year":"1995","journal-title":"J Clin Apheresis"},{"key":"e_1_2_50_9_26_1","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker BG","year":"1999","journal-title":"Ann Neurol"},{"key":"e_1_2_51_9_1_1","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth D","year":"2011","journal-title":"Neurology"},{"key":"e_1_2_51_9_2_1","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMra2312718","volume":"392","author":"Bussel JB","year":"2025","journal-title":"N Engl J Med"},{"key":"e_1_2_51_9_3_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.disamonth.2025.101969","article-title":"Myasthenia gravis: mechanisms, clinical syndromes, and diagnosis","volume":"71","author":"Fecto F.","year":"2025","journal-title":"Dis Mon"},{"key":"e_1_2_51_9_4_1","first-page":"789","volume-title":"Clinical trial of plasma exchange and high\u2010dose intravenous immunoglobulin in myasthenia gravis","author":"Gajdos P","year":"1997"},{"key":"e_1_2_51_9_5_1","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002275","article-title":"Plasma exchange for myasthenia gravis","author":"Gajdos P","year":"2002","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_51_9_6_1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1212\/WNL.45.2.338","article-title":"Treatment of myasthenia gravis by immunoadsorption of plasma","volume":"45","author":"Grob D","year":"1995","journal-title":"Neurology"},{"key":"e_1_2_51_9_7_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/jca.10023","article-title":"Long\u2010term treatment of myasthenia gravis with immunoadsorption","volume":"17","author":"Haas M","year":"2002","journal-title":"J Clin Apher"},{"key":"e_1_2_51_9_8_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.662856","article-title":"Therapeutic plasma exchange in myasthenia gravis: a systematic literature review and mata\u2010analysis of comparative evidence","volume":"12","author":"Ipe TS","year":"2021","journal-title":"Front Neurol"},{"key":"e_1_2_51_9_9_1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/jca.20317","article-title":"A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis","volume":"26","author":"K\u00f6hler W","year":"2011","journal-title":"J Clin Apher"},{"key":"e_1_2_51_9_10_1","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1007\/s00415-021-10603-9","article-title":"MuSK\u2010antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation","volume":"268","author":"K\u00f6nig N","year":"2021","journal-title":"J Neurol"},{"key":"e_1_2_51_9_11_1","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025622","article-title":"Efficacy and safety of double\u2010filtration plasmapheresis treatment of myasthenia gravis: a systematic review and meta\u2010analysis","volume":"100","author":"Liu C","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"e_1_2_51_9_12_1","doi-asserted-by":"crossref","first-page":"1495205","DOI":"10.3389\/fneur.2024.1495205","article-title":"Autoantibodies in neuromuscular disorders: a review of their utility in clinical practice","volume":"15","author":"Loser V","year":"2024","journal-title":"Front Neurol"},{"key":"e_1_2_51_9_13_1","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/mus.21924","article-title":"Outcome of plasmapheresis in myasthenia gravis: delayed therapy is not favorable","volume":"43","author":"Mandawat A","year":"2011","journal-title":"Muscle Nerve"},{"key":"e_1_2_51_9_14_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2025-001076","article-title":"Epidemiology and patient characteristics of the US myasthenia gravis population: real\u2010world evidence from a large insurance claims database","volume":"7","author":"Miller\u2010Wilson LA","year":"2025","journal-title":"BMJ Neurol Open"},{"key":"e_1_2_51_9_15_1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis (2020 update)","volume":"96","author":"Narayanaswami P","year":"2021","journal-title":"Neurology"},{"key":"e_1_2_51_9_16_1","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","article-title":"Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases","volume":"94","author":"Neumann B","year":"2020","journal-title":"Neurology"},{"key":"e_1_2_51_9_17_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CND.0000000000000119","article-title":"Human immunoglobulin versus plasmapheresis in Guillain\u2010Barre syndrome and myasthenia gravis: a meta\u2010analysis","volume":"18","author":"Ortiz\u2010Salas P","year":"2016","journal-title":"J Clin Neuromusc Dis"},{"key":"e_1_2_51_9_18_1","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/icvts\/ivz186","article-title":"Clinical usefulness of prethymectomy plasmapheresis in patients with myasthenia gravis: a systematic review and meta\u2010analysis","volume":"29","author":"Reis TA","year":"2019","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"e_1_2_51_9_19_1","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1111\/ene.15872","article-title":"Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta\u2010analysis and network meta\u2010analysis","volume":"30","author":"Sacc\u00e0 F","year":"2023","journal-title":"Eur J Neurol"},{"key":"e_1_2_51_9_20_1","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1510\/icvts.2007.170894","article-title":"Surgical outcome in thymic tumors with myasthenia gravis after plasmapheresis\u2010a comparative study","volume":"7","author":"Sarkar BK","year":"2008","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"e_1_2_51_9_21_1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/1756285616637046","article-title":"Immunoadsorption versus plasma exchange versus combination for treatment of myasthenic deterioration","volume":"9","author":"Schneider\u2010Gold C","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"key":"e_1_2_51_9_22_1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/jca.21694","article-title":"Excellent response to therapeutic plasma exchange in myasthenia gravis patients irrespective of antibody status","volume":"34","author":"Usmani A","year":"2019","journal-title":"J Clin Apher"},{"key":"e_1_2_51_9_23_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl H","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"e_1_2_51_9_24_1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe GI","year":"2016","journal-title":"N Engl J Med"},{"key":"e_1_2_51_9_25_1","doi-asserted-by":"crossref","first-page":"1479685","DOI":"10.3389\/fneur.2024.1479685","article-title":"Initiation response maximized therapeutic efficacy and post\u2010treatment effects of biological targeted therapies in myasthenia gravis: a systematic review and network meta\u2010analysis","volume":"15","author":"Zhong H","year":"2024","journal-title":"Front Neurol"},{"key":"e_1_2_52_9_1_1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody\u2010associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell B","year":"2023","journal-title":"Lancet Neurol"},{"key":"e_1_2_52_9_2_1","doi-asserted-by":"crossref","unstructured":"Butzkueven H Arkelsten S Comi G et al. Brain health\u2014time matters: multiple sclerosis neuromyelitis optica spectrum disorder (NMOSD) myelin oligodendrocyte glycoprotein antibody\u2010associated disease (MOGAD) and related conditions. 2024 report. Mult Scler Relat Disord 2025;101:106456.","DOI":"10.1016\/j.msard.2025.106456"},{"key":"e_1_2_52_9_3_1","doi-asserted-by":"crossref","first-page":"1605075","DOI":"10.3389\/fneur.2025.1605075","article-title":"Optic neuritis: a comprehensive review of current therapies and emerging treatment strategies","volume":"16","author":"Chaitanuwong P","year":"2025","journal-title":"Front Neurol"},{"key":"e_1_2_52_9_4_1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ajo.2023.02.013","article-title":"Visual outcomes following plasma exchange for optic neuritis: an international multicenter retrospective analysis of 395 optic neuritis attacks","volume":"252","author":"Chen JJ","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"e_1_2_52_9_5_1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti\u2010MOG\u2010associated acquired demyelinating syndromes in children and adults","volume":"26","author":"De Mol CL","year":"2020","journal-title":"Mult Scler"},{"key":"e_1_2_52_9_6_1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12974-022-02420-2","article-title":"Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study","volume":"19","author":"Demuth S","year":"2022","journal-title":"J Neuroinflamm"},{"key":"e_1_2_52_9_7_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106402","article-title":"Clinico\u2010investigational profile, relapse predictors and outcomes of pediatric patients with anti\u2010myelin oligodendrocyte associated disorders: an experience from tertiary centre","volume":"97","author":"Dhar D","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"e_1_2_52_9_8_1","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.neurol.2025.04.012","article-title":"French guidelines for the diagnostic and management of MOG antibody\u2010associated disease","volume":"181","author":"Giorgi L","year":"2025","journal-title":"Rev. Neurol (Paris)"},{"key":"e_1_2_52_9_9_1","doi-asserted-by":"crossref","first-page":"1260358","DOI":"10.3389\/fneur.2023.1260358","article-title":"Epidemiology of myelin oligodendrocyte glycoprotein antibody\u2010associated disease: a review of prevalence and incidence worldwide","volume":"14","author":"Hor JY","year":"2023","journal-title":"Front Neurol"},{"key":"e_1_2_52_9_10_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578709","article-title":"Prolonged corticosteroid therapy and steroid\u2010sparing maintenance immunotherapy lower relapse risk in pediatric and adult MOGAD","volume":"407","author":"Hoshina Y","year":"2025","journal-title":"J Neuroimmunol"},{"key":"e_1_2_52_9_11_1","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1007\/s40123-025-01216-w","article-title":"Therapeutic plasma exchange for severe optic neuritis in a region with a high prevalence of neuromyelitis optica","volume":"14","author":"Jugnet M","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"e_1_2_52_9_12_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105941","article-title":"New insights into the use of high dose corticosteroids and plasmapheresis in persons with MOGAD and NMOSD","volume":"92","author":"Kosior N","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"e_1_2_52_9_13_1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin\u2010oligodendrocyte glycoprotein antibody\u2010associated disease","volume":"20","author":"Marignier R","year":"2021","journal-title":"Lancet Neurol"},{"key":"e_1_2_52_9_14_1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00415-025-13233-7","article-title":"Management and burden of disease in people with myelin oligodendrocyte glycoprotein antibody\u2010associated disease: data from an international, cross\u2010sectional survey","volume":"272","author":"Paul F","year":"2025","journal-title":"J Neurol"},{"key":"e_1_2_52_9_15_1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody\u2010associated demyelination","volume":"89","author":"Ramanathan S","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_52_9_16_1","first-page":"1","article-title":"Autoimmune neuro\u2010ophthalmic disorders: pathophysiologic mechanisms and targeted biologic therapies","volume":"25","author":"Rowe LW","year":"2025","journal-title":"Expert Opin Biol Ther"},{"key":"e_1_2_52_9_17_1","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s00415-025-13245-3","article-title":"MOGAD\u2010related epilepsy: a systematic characterization of age\u2010dependent clinical, fluid, imaging and neurophysiological features","volume":"272","author":"Rubin M","year":"2025","journal-title":"J Neurol"},{"key":"e_1_2_52_9_18_1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2024-334863","article-title":"Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks","volume":"96","author":"Schwake C","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_52_9_19_1","first-page":"1052","article-title":"Continuum (Minneap Minn), Autoimmune","volume":"30","author":"Sechi E. NMOSD","year":"2024","journal-title":"Neurology"},{"key":"e_1_2_52_9_20_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213903","article-title":"Outcomes after acute plasma exchange for myelin oligodendrocyte glycoprotein antibody\u2010associated disease","volume":"105","author":"Thakolwiboon S","year":"2025","journal-title":"Neurology"},{"key":"e_1_2_52_9_21_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103693","article-title":"MOGAD: A comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally","volume":"24","author":"Trewin BP","year":"2025","journal-title":"Autoimm Rev."},{"key":"e_1_2_52_9_22_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209321","article-title":"Validation of the 2023 international diagnostic criteria for MOGAD in a selected cohort of adults and children","volume":"103","author":"Varley JA","year":"2024","journal-title":"Neurology"},{"key":"e_1_2_52_9_23_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG\u2010IgG\u2010associated disorder with rituximab: An international study of 121 patients","volume":"44","author":"Whittam DH","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"e_1_2_52_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744\u20109987.14228"},{"key":"e_1_2_52_9_25_1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/1744-9987.70063","article-title":"Immunoabsorption therapy for myelin oligodendrocyte glycoprotein antibody\u2010associated disease: a retrospective study","volume":"29","author":"Wang D","year":"2025","journal-title":"Ther Apher Dial"},{"issue":"1","key":"e_1_2_53_9_1_1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/jha2.620","article-title":"What can we do about patients presenting with myeloma and severe renal failure? Observations from the UK MERIT plasma exchange trial","volume":"4","author":"Behrens J","year":"2022","journal-title":"EJHaem."},{"key":"e_1_2_53_9_2_1","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.20.00298","article-title":"Randomized trial comparing double versus triple bortezomib\u2010based regimen in patients with multiple myeloma and acute kidney injury due to cast nephropathy","volume":"23","author":"Bridoux F","year":"2020","journal-title":"J Clin Oncol"},{"key":"e_1_2_53_9_3_1","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.kint.2020.11.010","article-title":"Management of acute kidney injury in symptomatic multiple myeloma","volume":"3","author":"Bridoux F","year":"2021","journal-title":"Kidney Int."},{"key":"e_1_2_53_9_4_1","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1056\/NEJMc1101834","article-title":"Renal improvement in myeloma with bortezomib plus plasma exchange","volume":"364","author":"Burnette BL","year":"2011","journal-title":"N Engl J Med"},{"key":"e_1_2_53_9_5_1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-143-11-200512060-00005","article-title":"Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial","volume":"143","author":"Clark WF","year":"2005","journal-title":"Ann Intern Med"},{"key":"e_1_2_53_9_6_1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1537-2995.2006.01143.x","article-title":"Light\u2010chain removal by plasmapheresis in myeloma\u2010associated renal failure","volume":"47","author":"Cserti C","year":"2007","journal-title":"Transfusion"},{"issue":"7","key":"e_1_2_53_9_7_1","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma\u2010related renal impairment: recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos MA","year":"2023","journal-title":"Lancet Oncol."},{"key":"e_1_2_53_9_8_1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/sj.thj.6200312","article-title":"Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation","volume":"4","author":"Durie BG","year":"2003","journal-title":"Hematol J"},{"key":"e_1_2_53_9_9_1","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40620-016-0347-9","article-title":"Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology","volume":"29","author":"Fabbrini P","year":"2016","journal-title":"J Nephrol"},{"key":"e_1_2_53_9_10_1","doi-asserted-by":"crossref","unstructured":"Finkel KW Cohen EP Shirali A Abudayyeh A American Society of Nephrology Onco\u2010Nephrology Forum.Paraprotein\u2010related kidney disease: evaluation and treatment of myeloma cast nNephropathy. Clin J Am Soc Nephrol2016;11:2273\u20132279.","DOI":"10.2215\/CJN.01640216"},{"key":"e_1_2_53_9_11_1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1542-4758.2010.00481.x","article-title":"Role of plasmapheresis in the management of myeloma kidney: a systematic review","volume":"14","author":"Gupta D","year":"2010","journal-title":"Hemodial Int"},{"key":"e_1_2_53_9_12_1","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(19)30014-6","article-title":"High cutoff versus high\u2010flux hemodialysis for myeloma cast nephropathy in patients receiving bortezomib\u2010based chemotherapy (EuLITE): a phase 2 randomized controlled trial","volume":"6","author":"Hutchison CA","year":"2019","journal-title":"Lancet Haematol"},{"key":"e_1_2_53_9_13_1","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/archinte.1990.00390160111022","article-title":"Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy","volume":"150","author":"Johnson WJ","year":"1990","journal-title":"Arch Intern Med"},{"key":"e_1_2_53_9_14_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103244","article-title":"Efficacy and safety of plasmapheresis in symptomatic hyperviscosity and cast nephropathy: a multicenter experience in Turkey","volume":"5","author":"Kalpakci Y","year":"2021","journal-title":"Transf and Apher Science"},{"key":"e_1_2_53_9_15_1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1034\/j.1600-0609.2000.90221.x","article-title":"Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group","volume":"65","author":"Knudsen LM","year":"2000","journal-title":"Eur J Haematol"},{"key":"e_1_2_53_9_16_1","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/ki.2008.108","article-title":"Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains","volume":"73","author":"Leung N","year":"2008","journal-title":"Kidney Int"},{"key":"e_1_2_53_9_17_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000013424","article-title":"Plasma exchange in rapidly progressive renal failure due to multiple myeloma. A retrospective case series","volume":"19","author":"Moist L","year":"1999","journal-title":"Am J Nephrol"},{"key":"e_1_2_53_9_18_1","first-page":"27","article-title":"Plasma exchange therapy in rapidly progressive renal failure due to multiple myeloma","volume":"8","author":"Pasquali S","year":"1985","journal-title":"Int J Artif Organs"},{"key":"e_1_2_53_9_19_1","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/ki.2008.138","article-title":"Approach to acute renal failure in biopsy proven myeloma cast nephropathy: is there still a role for plasmapheresis?","volume":"74","author":"Pillon L","year":"2008","journal-title":"Kidney Int"},{"key":"e_1_2_53_9_20_1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/1744-9987.12606","article-title":"Role of plasmapheresis in the management of acute kidney injury in patients with multiple myeloma: should we abandon it?","volume":"22","author":"Premuzic V","year":"2018","journal-title":"Ther Apher Dial"},{"key":"e_1_2_53_9_21_1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40620-018-0492-4","article-title":"Myeloma light chain cast nephropathy, a review","volume":"32","author":"Sathick IJ","year":"2019","journal-title":"J of Nephrol"},{"key":"e_1_2_53_9_22_1","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/nep.12979","article-title":"Plasma exchange in the management of new onset multiple myeloma with cast nephropathy treated with bortezomib based chemotherapy","volume":"22","author":"Sethi J","year":"2017","journal-title":"Nephrology"},{"key":"e_1_2_53_9_23_1","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/ckj\/sfaa220","article-title":"Effect of high cut\u2010off dialysis for acute kidney injury secondary to cast nephropathy in patients with multiple myeloma: a systematic review and meta\u2010analysis","volume":"14","author":"Tarragon B","year":"2020","journal-title":"Clin Kidney J"},{"key":"e_1_2_53_9_24_1","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/ki.1988.127","article-title":"Controlled plasma exchange trial in acute renal failure due to multiple myeloma","volume":"33","author":"Zucchelli P","year":"1988","journal-title":"Kidney Int"},{"key":"e_1_2_54_9_1_1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1148\/radiol.2019182916","article-title":"A systematic review of 639 patients with biopsy\u2010confirmed nephrogenic systemic fibrosis","volume":"292","author":"Attari H","year":"2019","journal-title":"Radiology"},{"key":"e_1_2_54_9_2_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/BOR.0b013e328333bf3d","article-title":"Nephrogenic systemic fibrosis","volume":"22","author":"Bardin T","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"e_1_2_54_9_3_1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/00000372-200306000-00004","article-title":"Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis","volume":"25","author":"Baron PW","year":"2003","journal-title":"Am J Dermatopathol"},{"key":"e_1_2_54_9_4_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5527\/wjn.v10.i3.29","article-title":"Nephrogenic systemic fibrosis: a frivolous entity","volume":"10","author":"Bhargava V","year":"2021","journal-title":"World J Nephrol"},{"key":"e_1_2_54_9_5_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/IJNRD.S392231","article-title":"The clinical manifestations and efficacy of different treatments used for nephrogenic systemic fibrosis: a systematic review","volume":"16","author":"Farooqi S","year":"2023","journal-title":"International Journal of Nephrology and Renovascular Disease"},{"key":"e_1_2_54_9_6_1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2133.2005.06434.x","article-title":"Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis","volume":"152","author":"Gilliet M","year":"2005","journal-title":"Br J Dermatol"},{"key":"e_1_2_54_9_7_1","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/00003072-200411000-00004","article-title":"Two patients with abnormal skeletal muscle uptake of Tc\u201099\u2009m hydroxymethylene diphosphonate following liver transplant: nephrogenic fibrosing dermopathy and graft vs. host disease","volume":"29","author":"Gremmels JM","year":"2004","journal-title":"Clin Nucl Med"},{"key":"e_1_2_54_9_8_1","first-page":"12","article-title":"Nephrogenic fibrosing dermopathy: response to plasma exchange","volume":"20","author":"Hofmann JC","year":"2005","journal-title":"J Clin Apher"},{"key":"e_1_2_54_9_9_1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2133.2003.05181.x","article-title":"Scleromyxoedema\u2010like changes in four renal dialysis patients","volume":"148","author":"Hubbard V","year":"2003","journal-title":"Br J Dermatol"},{"key":"e_1_2_54_9_10_1","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.3390\/ijerph18063000","article-title":"Nephrogenic systemic fibrosis as a complication after gadolinium\u2010containing contrast agents: a rapid review","volume":"18","author":"Lange S","year":"2021","journal-title":"In t J Environ Res Public Health."},{"key":"e_1_2_54_9_11_1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000077321","article-title":"Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis","volume":"208","author":"Lauchli S","year":"2004","journal-title":"Dermatology"},{"key":"e_1_2_54_9_12_1","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jvir.2022.11.022","article-title":"Adverse events associated with intra\u2010arterial administration of gadolinium\u2010based contrast agents: A systematic review and meta\u2010analysis","volume":"34","author":"MacLeod CA","year":"2023","journal-title":"J Vasc Interv Radiol"},{"key":"e_1_2_54_9_13_1","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1111\/j.1600-6143.2006.01420.x","article-title":"Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update","volume":"6","author":"Maloo M","year":"2006","journal-title":"Am J Transplant"},{"key":"e_1_2_54_9_14_1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/jca.20170","article-title":"Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy\/nephrogenic systemic fibrosis: three case reports and review of literature","volume":"23","author":"Mathur K","year":"2008","journal-title":"J Clin Apher"},{"key":"e_1_2_54_9_15_1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1148\/rg.2020190110","article-title":"Gadolinium deposition and nephrogenic systemic fibrosis: a radiologist's primer","volume":"40","author":"Mathur M","year":"2020","journal-title":"Radiographics"},{"key":"e_1_2_54_9_16_1","first-page":"13","article-title":"Extracorporeal photopheresis (ECP), a promising treatment for nephrogenic fibrosing dermopathy (NFD)","volume":"21","author":"Pesek GD","year":"2006","journal-title":"J Clin Apher"},{"key":"e_1_2_54_9_17_1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jca.21253","article-title":"The treatment of nephrogenic systemic fibrosis with therapeutic plasma exchange","volume":"28","author":"Poisson JL","year":"2013","journal-title":"J Clin Apher"},{"key":"e_1_2_54_9_18_1","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/archderm.143.8.1025","article-title":"Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis","volume":"143","author":"Richmond H","year":"2007","journal-title":"Arch Dermatol"},{"key":"e_1_2_54_9_19_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1525-139X.2007.00405.x","article-title":"Dialytic therapies to prevent NSF following gadolinium exposure in high\u2010risk patients","volume":"21","author":"Rodby RA","year":"2008","journal-title":"Semin Dial."},{"key":"e_1_2_54_9_20_1","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jaad.2009.03.040","volume":"61","author":"Schieren G","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_54_9_21_1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1177\/039139880803101009","article-title":"Combination treatment with plasmapheresis and sirolimus does not seem to benefit nephrogenic systemic fibrosis","volume":"31","author":"Tsagalis G","year":"2008","journal-title":"Int J Artif Organs"},{"key":"e_1_2_54_9_22_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3174\/ajnr.A8501","article-title":"State of practice: ASNR statement on gadolinium\u2010based contrast agent use in patients with chronic kidney disease","volume":"46","author":"Welker KM","year":"2025","journal-title":"AJNR Am J Neuroradiol"},{"key":"e_1_2_54_9_23_1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jaad.2017.02.003","article-title":"Nephrogenic systemic fibrosis: a 15\u2010year retrospective study at a single tertiary care center","volume":"77","author":"Wilson J","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_54_9_24_1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/jamainternmed.2019.5284","article-title":"Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium\u2010based contrast agent: a systematic review and meta\u2010analysis","volume":"180","author":"Woolen SA","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"240","key":"e_1_2_54_9_25_1","first-page":"287","article-title":"Photopheresis provides significant long\u2010lasting benefit in nephrogenic systemic fibrosis","volume":"3","author":"Zhang R","year":"2017","journal-title":"Case Rep Dermatol Med"},{"key":"e_1_2_54_9_26_1","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.jcmg.2011.08.013","article-title":"Nephrogenic systemic fibrosis: review of 370 biopsy\u2010confirmed cases","volume":"4","author":"Zou Z","year":"2011","journal-title":"J Am Coll Cardiol Img"},{"key":"e_1_2_55_9_1_1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud H","year":"2016","journal-title":"Mult Scler"},{"key":"e_1_2_55_9_2_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.msard.2017.02.015","article-title":"Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: case series and review of the literature","volume":"13","author":"Aungsumart S","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"e_1_2_55_9_3_1","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan M","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_55_9_4_1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ajo.2023.02.013","article-title":"Visual outcomes following plasma exchange for optic neuritis: an international multicenter retrospective analysis of 395 optic neuritis attacks","volume":"252","author":"Chen JJ","year":"2023","journal-title":"Am J Ophthalmol."},{"issue":"208","key":"e_1_2_55_9_5_1","first-page":"1","article-title":"Neuromyelitis spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Contentti EC","year":"2021","journal-title":"J Neuroinflamm"},{"key":"e_1_2_55_9_6_1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/1756285616646332","article-title":"Immunoadsorption in patients with neuromyelitis optica spectrum disorder","volume":"9","author":"Faissner S","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"key":"e_1_2_55_9_7_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104020","article-title":"Treatment outcomes of first\u2010ever episode of severe optic neuritis","volume":"66","author":"Galetta K","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"e_1_2_55_9_8_1","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/1744-9987.13844","article-title":"Therapeutic plasma exchange for optic neuritis attacks in patients with neuromyelitis optica spectrum disorders","volume":"26","author":"Gonzales C","year":"2022","journal-title":"Ther Apher Dial"},{"key":"e_1_2_55_9_9_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562864221150314","article-title":"Immunoadsorption as maintenance therapy for refractory neuromyelitis optica spectrum disorder","volume":"16","author":"Heigl F","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"e_1_2_55_9_10_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jca.21754","article-title":"Therapeutic plasma exchange for neuromyelitis optica spectrum disorder: a multicenter retrospective study by the ASFA neurologic subcommittee","volume":"35","author":"Ipe TS","year":"2019","journal-title":"J Clin Apher"},{"key":"e_1_2_55_9_11_1","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","volume":"270","author":"Jarius S","year":"2023","journal-title":"J Neurol"},{"key":"e_1_2_55_9_12_1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/jca.21215","article-title":"Maintenance plasma exchange therapy for steroid\u2010refractory neuromyelitis optica","volume":"27","author":"Khatri BO","year":"2012","journal-title":"J Clin Apher"},{"key":"e_1_2_55_9_13_1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses","volume":"79","author":"Kleiter I","year":"2016","journal-title":"Ann Neurol"},{"key":"e_1_2_55_9_14_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter I","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_2_55_9_15_1","doi-asserted-by":"crossref","first-page":"1575613","DOI":"10.3389\/fimmu.2025.1575613","article-title":"Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late\u2010onset neuromyelitis optica spectrum disorders (COPTER\u2010LO study)","volume":"16","author":"Kretschmer JR","year":"2025","journal-title":"Front Immunol"},{"key":"e_1_2_55_9_16_1","first-page":"141","volume":"271","author":"Kumpfel T","year":"2024","journal-title":"Part II: Attack therapy and long\u2010term management J Neurol"},{"key":"e_1_2_55_9_17_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e06811","article-title":"PLEX: the best first\u2010line treatment in NMOSD attacks experience at a single center in Colombia","volume":"7","author":"Restrepo\u2010Aristizabal C","year":"2021","journal-title":"Heliyon"},{"issue":"101506","key":"e_1_2_55_9_18_1","first-page":"1","article-title":"A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add\u2010on plasma exchange (PLEX) versus simultaneous IVMP and PLEX","volume":"38","author":"Songthammawat T","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"e_1_2_55_9_19_1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/1744-9987.13595","article-title":"Sequential intermittent therapeutic plasma exchange: a possible induction and maintenance therapy in the management of adult patients with neuromyelitis optica spectrum disorder","volume":"25","author":"Visvanathan S","year":"2021","journal-title":"Ther Apher Dial"},{"key":"e_1_2_55_9_20_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40120-021-00295-8","article-title":"Network meta\u2010analysis of Food and Drug Administration\u2010approved treatment options for adults with aquaporin\u20104 immunoglobulin G\u2010positive neuromyelitis optica spectrum disorder","volume":"11","author":"Wingerchuk DM","year":"2022","journal-title":"Neurol Ther"},{"key":"e_1_2_55_9_21_1","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14780","article-title":"Efficacy and safety of apheresis therapy in AQP4 antibody\u2010positive NMOSD attack: a propensity score\u2010matched cohort study","volume":"30","author":"Xu Y","year":"2024","journal-title":"CNS Neurosci Ther."},{"key":"e_1_2_55_9_22_1","doi-asserted-by":"crossref","first-page":"175628642513282","DOI":"10.1177\/17562864251328276","article-title":"Advances in the treatment of neuromyelitis optic spectrum disorders","volume":"18","author":"Yang X","year":"2025","journal-title":"Ther Adv Neurol Disord."},{"key":"e_1_2_55_9_23_1","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1177\/11206721211065218","article-title":"Efficacy and safety of plasma exchange or immunoadsorption for the treatment of optic neuritis in demyelinating diseases: a systematic review and meta\u2010analysis","volume":"32","author":"Zhang J","year":"2022","journal-title":"Eur J Ophthalmol."},{"key":"e_1_2_55_9_24_1","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.21037\/apm-21-177","article-title":"The efficacy of therapeutic apheresis in patients with refractory neuromyelitis optica spectrum disorders: a single\u2010center retrospective study","volume":"10","author":"Zhang L","year":"2021","journal-title":"Ann Palliat Med"},{"key":"e_1_2_55_9_25_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562864231162420","article-title":"Therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single\u2010center observational study","volume":"16","author":"Zhang W","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"e_1_2_56_8_1_1","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1474-4422(18)30244-8","article-title":"Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis","volume":"17","author":"Armangue T","year":"2018","journal-title":"Lancet Neurol"},{"key":"e_1_2_56_8_2_1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jocn.2018.11.033","article-title":"Abnormal level of consciousness predicts outcomes of patients with anti\u2010NMDA encephalitis","volume":"62","author":"Aungsumart S","year":"2019","journal-title":"J Clin Neurosci"},{"key":"e_1_2_56_8_3_1","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody\u2010mediated encephalitis","volume":"378","author":"Dalmau J","year":"2018","journal-title":"N Engl J Med"},{"key":"e_1_2_56_8_4_1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/jca.21363","article-title":"Intravenous methylprednisolone versus therapeutic plasma exchange for treatment of anti\u2010n\u2010methyl\u2010d\u2010aspartate receptor antibody encephalitis: a retrospective review","volume":"30","author":"DeSena AD","year":"2015","journal-title":"J Clin Apher"},{"key":"e_1_2_56_8_5_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000207","article-title":"Immunoadsorption therapy in autoimmune encephalitides","volume":"3","author":"Dogan\u2010Onugoren M","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_2_56_8_6_1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1474-4422(13)70282-5","article-title":"Antibody titres at diagnosis and during follow\u2010up of anti\u2010NMDA receptor encephalitis: a retrospective study","volume":"13","author":"Gresa\u2010Arribas N","year":"2014","journal-title":"Lancet Neurol"},{"key":"e_1_2_56_8_7_1","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s00415-016-8277-y","article-title":"Immunoadsorption or plasma exchange in the treatment of autoimmune encephalitis: a pilot study","volume":"263","author":"Heine J","year":"2016","journal-title":"J Neurol"},{"key":"e_1_2_56_8_8_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2025.100318","article-title":"Clinical efficacy and immunomodulation of double\u2010filtration plasmapheresis in autoimmune encephalitis: A prospective study highlighting the importance of timely initiation","volume":"11","author":"Hongyan L","year":"2025","journal-title":"J Transl Autoimmun"},{"key":"e_1_2_56_8_9_1","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1007\/s00415-016-8282-1","article-title":"Clinical characteristics and outcomes between children and adults with anti\u2010N\u2010methyl\u2010D\u2010aspartate receptor encephalitis","volume":"263","author":"Huang Q","year":"2016","journal-title":"J Neurol"},{"key":"e_1_2_56_8_10_1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/ene.12389","article-title":"Tryptophan immunoadsorption for the treatment of autoimmune encephalitis","volume":"22","author":"K\u00f6hler W","year":"2015","journal-title":"Eur J Neurol"},{"key":"e_1_2_56_8_11_1","doi-asserted-by":"crossref","first-page":"112796","DOI":"10.1016\/j.intimp.2024.112796","article-title":"A short\u2010term functional recovery comparison of therapeutic plasma exchange and immunoadsorption in severe acute neuroimmune disease","volume":"140","author":"Leng B","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"e_1_2_56_8_12_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.tracli.2021.03.006","article-title":"Variable response to therapeutic plasma exchange in pediatric anti\u2010NMDA receptor encephalitis","volume":"28","author":"Naik A","year":"2021","journal-title":"Transfus Clin Biol"},{"key":"e_1_2_56_8_13_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/IJGM.S397429","article-title":"Anti\u2010NMDA receptor autoimmune encephalitis: diagnosis and management strategies","volume":"16","author":"Nguyen L","year":"2023","journal-title":"Int J Gen Med."},{"issue":"4","key":"e_1_2_56_8_14_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00415-025-13032-0","article-title":"Intravenous immunoglobulin as first\u2010line acute treatment in adults with autoimmune encephalitis caused by antibodies to NMDAR, LG1 and CASPR2","volume":"272","author":"Rittel JC","year":"2025","journal-title":"J Neurol"},{"key":"e_1_2_56_8_15_1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/WNL.0000000000003536","article-title":"Bortezomib for treatment of therapy\u2010refractory anti\u2010NMDA receptor encephalitis","volume":"88","author":"Scheibe F","year":"2017","journal-title":"Neurology"},{"key":"e_1_2_56_8_16_1","first-page":"1","article-title":"Short delay to initiate plasma exchange or immunoadsorption as synergistic therapies for patients in the acute phase of anti\u2010NMDAR encephalitis","volume":"17","author":"Su M","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"e_1_2_56_8_17_1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.braindev.2016.01.009","article-title":"Plasma exchange in pediatric anti\u2010NMDAR encephalitis: a systematic review","volume":"38","author":"Suppiej A","year":"2019","journal-title":"Brain Dev"},{"key":"e_1_2_56_8_18_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long\u2010term outcome in patients with anti\u2010NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer MJ","year":"2013","journal-title":"Lancet Neurol"},{"key":"e_1_2_56_8_19_1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12974-021-02293-x","article-title":"Molecular mimicry of NMDA receptors may contribute to neuropsychiatric symptoms in severe COVID\u201019 cases","volume":"18","author":"Vasilevska V","year":"2021","journal-title":"J Neuroinflammation"},{"key":"e_1_2_56_8_20_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577527","article-title":"Efficacy and safety of bortezomib in rituximab\u2010resistant anti\u2010N\u2010methyl\u2010d\u2010aspartate receptor (anti\u2010NMDAR) encephalitis as well as the clinical characteristics: an observational study","volume":"354","author":"Wang T","year":"2021","journal-title":"J Neuroimmunol"},{"key":"e_1_2_56_8_21_1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.brs.2018.11.016","article-title":"Electroconvulsive therapy for anti\u2010N\u2010methyl\u2010d\u2010aspartate (NMDA) receptor encephalitis: a systematic review of cases","volume":"12","author":"Warren N","year":"2019","journal-title":"Brain Stimul"},{"key":"e_1_2_56_8_22_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000633","article-title":"Anti\u2010NMDAR encephalitis: a single\u2010center, longitudinal study in China","volume":"7","author":"Xu X","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_2_56_8_23_1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejpn.2023.10.001","article-title":"Analysis of the relation between cerebrospinal fluid antibody titers and clinical characteristics in pediatric patients with anti\u2010N\u2010methyl\u2010D\u2010aspartate receptor encephalitis","volume":"47","author":"Yang H","year":"2023","journal-title":"Eur J Paediatr Neurol"},{"key":"e_1_2_56_8_24_1","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00415-015-7781-9","article-title":"Treatment and outcome of children and adolescents with N\u2010methyl\u2010D\u2010aspartate receptor encephalitis","volume":"262","author":"Zekeridou A","year":"2015","journal-title":"J Neurol"},{"key":"e_1_2_56_8_25_1","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s13311-019-00725-4","article-title":"Efficacy of therapeutic plasma exchange in patients with severe refractory anti\u2010NMDA receptor encephalitis","volume":"16","author":"Zhang Y","year":"2019","journal-title":"Neurotherapeutics"},{"key":"e_1_2_57_9_1_1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3892\/ol.2023.13894","article-title":"Intravenous rituximab and oral cyclophosphamide for the treatment of cancer\u2010associated retinopathy in a patient with epithelial ovarian cancer: a case report","volume":"16","author":"Andrikopoulou A","year":"2023","journal-title":"Oncol Lett."},{"key":"e_1_2_57_9_2_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoc.2022.101349","article-title":"Bilateral diffuse uveal melanocytic proliferation: report of a novel optical coherence tomography finding and clinical response to plasmapheresis","volume":"25","author":"Antaki F","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"e_1_2_57_9_3_1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.oret.2023.05.002","article-title":"Treatment of cancer\u2010associated retinopathy: a systematic literature review","volume":"7","author":"Brossard\u2010Barbosa N","year":"2023","journal-title":"Ophthalmol Retina."},{"key":"e_1_2_57_9_4_1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ajo.2017.04.019","article-title":"Outcomes of autoimmune retinopathy patients treated with rituximab","volume":"180","author":"Davoudi S","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"e_1_2_57_9_5_1","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archophthalmol.2009.24","article-title":"Management of autoimmune retinopathies with immunosuppression","volume":"127","author":"Ferreyra HA","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"e_1_2_57_9_6_1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/jca.21607","article-title":"Seeing is believing: a review of apheresis therapy in the treatment of ophthalmologic disease","volume":"33","author":"Graham BC","year":"2018","journal-title":"J Clin Apher"},{"key":"e_1_2_57_9_7_1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/archopht.1990.01070060075053","article-title":"Bilateral diffuse uveal melanocytic proliferation in patients with occult carcinoma","volume":"108","author":"Gass JD","year":"1990","journal-title":"Arch Ophthalmol"},{"key":"e_1_2_57_9_8_1","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/ICB.0000000000001081","article-title":"Triple therapy with rituximab, intravenous immunoglobulin, and intravitreal corticosteroids for melanoma\u2010associated retinopathy: ttriic does the trick","volume":"16","author":"Hamdan SA","year":"2022","journal-title":"Retin Cases Brief Rep"},{"key":"e_1_2_57_9_9_1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12886-018-0948-2","article-title":"Cancer\u2010associated retinopathy preceding the diagnosis of cancer","volume":"18","author":"Hoogewoud F","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"e_1_2_57_9_10_1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/jca.20310","article-title":"The potential role of plasma exchange as a treatment for bilateral diffuse uveal melanocytic proliferation: a report of two cases","volume":"26","author":"Jaben EA","year":"2011","journal-title":"J Clin Apher"},{"key":"e_1_2_57_9_11_1","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/bjophthalmol-2014-305893","article-title":"Early diagnosis and successful treatment of paraneoplastic melanocytic proliferation","volume":"99","author":"Jansen JCG","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"e_1_2_57_9_12_1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/jamaophthalmol.2019.0284","article-title":"Outcomes associated with sustained\u2010release intraocular fluocinolone implants in a case of melanoma\u2010associated retinopathy treated without systemic immunosuppression","volume":"137","author":"Karatsai E","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"e_1_2_57_9_13_1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00041327-200109000-00004","article-title":"Clinical and immunologic characteristics of melanoma\u2010associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases","volume":"21","author":"Keltner JL","year":"2001","journal-title":"J Neuroophthalmol"},{"key":"e_1_2_57_9_14_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.exer.2019.04.006","article-title":"Heterogeneity of cultured melanocyte elongation and proliferation factor in bilateral diffuse uveal melanocytic proliferation","volume":"184","author":"Lavine JA","year":"2019","journal-title":"Exp Eye Res"},{"key":"e_1_2_57_9_15_1","first-page":"885","article-title":"Effects of cytotoxic T lymphocyte antigen 4 (CTLA4) signaling and locally applied steroid on retinal dysfunction by recoverin, cancer\u2010associated retinopathy antigen","volume":"12","author":"Maeda A","year":"2006","journal-title":"Mol Vis"},{"key":"e_1_2_57_9_16_1","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1001\/archophthalmol.2011.277","article-title":"Bilateral diffuse uveal melanocytic proliferation with a positive ophthalmoscopic and visual response to plasmapheresis","volume":"129","author":"Mets RB","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"e_1_2_57_9_17_1","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1097\/IAE.0b013e3182618bab","article-title":"A factor found in the IgG fraction of serum of patients with paraneoplastic bilateral diffuse uveal melanocytic proliferation causes proliferation of cultured human melanocytes","volume":"32","author":"Miles SL","year":"2012","journal-title":"Retina"},{"key":"e_1_2_57_9_18_1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/IIO.0000000000000156","article-title":"Comprehensive review of treatments for bilateral diffuse uveal melanocytic proliferation: a focus on plasmapheresis","volume":"57","author":"Moreno TA","year":"2017","journal-title":"Int Ophthalmol Clin"},{"key":"e_1_2_57_9_19_1","first-page":"490","volume":"8","author":"Przezdziecka\u2010Dolyk J","year":"2020","journal-title":"Ocular paraneoplastic syndromes. Biomedicines"},{"key":"e_1_2_57_9_20_1","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/eye.2013.131","article-title":"Dermal and conjunctival melanocytic proliferations in diffuse uveal melanocytic proliferation","volume":"27","author":"Pulido JS","year":"2013","journal-title":"Eye (Lond)"},{"key":"e_1_2_57_9_21_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.658407","volume":"11","author":"Rafei\u2010Shamsabadi D","year":"2021","journal-title":"Front Oncol"},{"key":"e_1_2_57_9_22_1","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00417-021-05409-4","article-title":"Autoimmune retinopathy: clinical, electrophysiological, and immunological features in nine patients with long\u2010term follow\u2010up","volume":"160","author":"Safadi K","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"e_1_2_57_9_23_1","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/s41433-021-01676-x","article-title":"Paraneoplastic ocular syndrome: a Pandora's box of underlying malignancies","volume":"36","author":"Sarkar P","year":"2022","journal-title":"Eye (Lond)"},{"key":"e_1_2_57_9_24_1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/ICB.0000000000000104","article-title":"Bilateral diffuse uveal melanocytic proliferation with good clinical response to plasmapheresis and treatment of the primary tumor","volume":"9","author":"Schelvergem KV","year":"2015","journal-title":"Retin Cases Brief Rep"},{"key":"e_1_2_57_9_25_1","doi-asserted-by":"crossref","first-page":"107327482211444","DOI":"10.1177\/10732748221144458","article-title":"Ocular paraneoplastic syndromes: a critical review of diffuse uveal melanocytic proliferation and autoimmune retinopathy","volume":"29","author":"Weppelmann TA","year":"2022","journal-title":"Cancer Control"},{"key":"e_1_2_58_9_1_1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12028-019-00875-5","article-title":"Treatment of movement disorder emergencies in autoimmune encephalitis in the neurosciences ICU","volume":"32","author":"Ali F","year":"2020","journal-title":"Neurocrit Care"},{"key":"e_1_2_58_9_2_1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1023\/A:1006136219490","article-title":"Immunoadsorption therapy for paraneoplastic syndromes","volume":"40","author":"Batchelor TT","year":"1998","journal-title":"J Neurooncol"},{"key":"e_1_2_58_9_3_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/practneurol-2021-003073","article-title":"Paraneoplastic neurological syndromes: a practical approach to diagnosis and management","volume":"22","author":"Binks S","year":"2022","journal-title":"Pract Neurol"},{"issue":"15","key":"e_1_2_58_9_4_1","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.3390\/diagnostics13152589","article-title":"Autoimmune encephalitis with antibodies: Anti\u2010NMDAR, Anti\u2010AMPAR, Anti\u2010GQ1b, Anti\u2010DPPX, Anti\u2010CASPR2, Anti\u2010LGI1, Anti\u2010RI, Anti\u2010Yo, Anti\u2010Hu, Anti\u2010CV2 and Anti\u2010GABAAR, in the course of psychoses, neoplastic diseases, and paraneoplastic syndromes","volume":"13","author":"Braczkowski M","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"e_1_2_58_9_5_1","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/1097-0142(19950401)75:7<1678::AID-CNCR2820750719>3.0.CO;2-2","article-title":"Therapy for paraneoplastic neurologic syndromes in six patients with protein A column immunoadsorption","volume":"75","author":"Cher LM","year":"1995","journal-title":"Cancer"},{"key":"e_1_2_58_9_6_1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neurol.2021.12.001","article-title":"Immunomodulation of the acute phase of autoimmune encephalitis","volume":"178","author":"Ciano\u2010Peterson NL","year":"2022","journal-title":"Rev. Neurol (Paris)"},{"key":"e_1_2_58_9_7_1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00005792-199203000-00001","article-title":"Anti\u2010Hu\u2010associated paraneoplastic encephalomyelitis\/sensory neuronopathy. A clinical study of 71 patients","volume":"71","author":"Dalmau J","year":"1992","journal-title":"Medicine"},{"key":"e_1_2_58_9_8_1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archneurol.2009.341","article-title":"Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers","volume":"67","author":"Giometto B","year":"2010","journal-title":"Arch Neurol"},{"key":"e_1_2_58_9_9_1","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1212\/WNL.42.3.536","article-title":"Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies","volume":"42","author":"Graus F","year":"1992","journal-title":"Neurology"},{"key":"e_1_2_58_9_10_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes","volume":"8","author":"Graus F","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_2_58_9_11_1","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1007\/s00415-022-11247-z","article-title":"Paraneoplastic syndrome in neuroophthalmology","volume":"269","author":"Kang L.","year":"2022","journal-title":"J Neurol"},{"key":"e_1_2_58_9_12_1","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.3534","article-title":"Antibody\u2010positive autoimmune encephalitis and paraneoplastic neurological syndrome: a Swedish case series","volume":"14","author":"Kosek S","year":"2024","journal-title":"Brain Behav"},{"key":"e_1_2_58_9_13_1","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2217\/fon-2020-0080","article-title":"Diagnosis and treatment of limbic encephalitis in the cancer patients","volume":"16","author":"Kyritsis AP","year":"2020","journal-title":"Future Oncol"},{"key":"e_1_2_58_9_14_1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s00415-018-9153-8","article-title":"Patient characteristic and outcome associations in AMPA receptor encephalitis","volume":"266","author":"Laurido\u2010Soto O","year":"2019","journal-title":"J Neurol"},{"key":"e_1_2_58_9_15_1","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3390\/jcm13030824","article-title":"Paraneoplastic neurological syndromes as initial presentation of tumors: an eight\u2010year single\u2010center experience","volume":"13","author":"Melanis K","year":"2024","journal-title":"J Clin Med"},{"key":"e_1_2_58_9_16_1","doi-asserted-by":"crossref","first-page":"1466704","DOI":"10.3389\/fimmu.2024.1466704","article-title":"Long term survival and outcomes in patients with paraneoplastic neurologic syndromes","volume":"15","author":"Mucha SB","year":"2024","journal-title":"Front Immunol"},{"key":"e_1_2_58_9_17_1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s12311-021-01363-3","article-title":"Novelties in autoimmune and paraneoplastic cerebellar ataxias: twenty year of progress","volume":"21","author":"Mu\u00f1iz\u2010Castrillo S","year":"2022","journal-title":"Cerebellum"},{"key":"e_1_2_58_9_18_1","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1212\/WNL.55.5.713","article-title":"Long\u2010term clinical outcome of paraneoplastic cerebellar degeneration and anti\u2010Yo antibodies","volume":"55","author":"Rojas I","year":"2000","journal-title":"Neurology"},{"key":"e_1_2_58_9_19_1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.lungcan.2017.07.026","article-title":"Autoimmune paraneoplastic syndromes associated to lung cancer: a systematic review of the literature: Part 5: Neurological auto\u2010antibodies, discussion, flow chart, conclusions","volume":"111","author":"Sculier C","year":"2017","journal-title":"Lung Cancer"},{"key":"e_1_2_58_9_20_1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.transci.2013.02.043","article-title":"Therapeutic plasma exchange in treatment of neuroimmunologic disorders: review of 92 cases","volume":"49","author":"Sorgun MH","year":"2013","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_58_9_21_1","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s004150050419","article-title":"Acquired neuromyotonia: superiority of plasma exchange over high\u2010dose intravenous human immunoglobulin","volume":"246","author":"Berg JS","year":"1999","journal-title":"J Neurol"},{"key":"e_1_2_58_9_22_1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1055\/s-0043-1777353","article-title":"Updates in the Management of Paraneoplastic Syndrome","volume":"44","author":"Verma N","year":"2024","journal-title":"Semin Neurol"},{"key":"e_1_2_58_9_23_1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1215\/S1152851703000395","article-title":"Immunomodulatory treatment trial for paraneoplastic neurological disorders","volume":"6","author":"Vernino S","year":"2004","journal-title":"Neuro Oncol"},{"key":"e_1_2_58_9_24_1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygyno.2017.06.025","article-title":"Paraneoplastic syndromes associated with gynecological cancers: a systematic review","volume":"146","author":"Viau M","year":"2017","journal-title":"Gynecol Oncol"},{"key":"e_1_2_58_9_25_1","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27776","article-title":"An upfront immunomodulatory therapy protocol for pediatric opsoclonus\u2010myoclonus syndrome","volume":"66","author":"Wilbur C","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"e_1_2_59_9_1_1","volume":"15","author":"Aguirre AS","year":"2023","journal-title":"Efficacy of rituximab in CANOMAD. Cureus"},{"key":"e_1_2_59_9_2_1","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16249","article-title":"Prevalence and clinical profiles of anti\u2010myelin\u2010associated glycoprotein neuropathy in Japan: A nationwide survey study of 133 patients","volume":"31","author":"Aotsuka Y","year":"2024","journal-title":"Eur J Neurol"},{"key":"e_1_2_59_9_3_1","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/s00415-017-8502-3","article-title":"Plasma exchanges for severe acute neurological deterioration in patients with IgM anti\u2010myelin\u2010associated glycoprotein (anti\u2010MAG) neuropathy","volume":"264","author":"Baron M","year":"2017","journal-title":"J Neurol"},{"key":"e_1_2_59_9_4_1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.nrl.2021.02.010","volume":"36","author":"Bertr\u00e1n Recasens B","year":"2021","journal-title":"Neurologia (Engl Ed)"},{"key":"e_1_2_59_9_5_1","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.mayocp.2017.02.003","article-title":"Monoclonal gammopathy\u2010associated peripheral neuropathy: diagnosis and management","volume":"92","author":"Chaudhry HM","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_59_9_6_1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/jca.21530","article-title":"Therapeutic plasma exchange in chronic dysimmune peripheral neuropathies: a 10\u2010year retrospective study","volume":"32","author":"Cordon P","year":"2017","journal-title":"J Clin Apher"},{"key":"e_1_2_59_9_7_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28870","article-title":"Time course of the autoantibody response to therapy in anti\u2010MAG neuropathy: TWO case REPORTS","volume":"10","author":"Cornejo AC","year":"2024","journal-title":"Heliyon."},{"key":"e_1_2_59_9_8_1","doi-asserted-by":"crossref","unstructured":"CorteseI ChaudhryV SoYT et al.Evidence\u2010based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology2011;76:294\u2013300.","DOI":"10.1212\/WNL.0b013e318207b1f6"},{"key":"e_1_2_59_9_9_1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejpn.2024.12.005","article-title":"Immunoadsorption is equally effective as plasma exchange in pediatric neuroimmunological disorders\u2014A retrospective multicentre study","volume":"54","author":"Cramer P","year":"2025","journal-title":"Eur J Paediatr Neurol."},{"key":"e_1_2_59_9_10_1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","article-title":"Placebo\u2010controlled trial of rituximab in IgM anti\u2010myelin\u2010associated glycoprotein antibody demyelinating neuropathy","volume":"65","author":"Dalakas MC","year":"2009","journal-title":"Ann Neurol"},{"key":"e_1_2_59_9_11_1","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/mus.1069","article-title":"Treatment experience in patients with anti\u2010myelin\u2010associated glycoprotein neuropathy","volume":"24","author":"Gorson KC","year":"2001","journal-title":"Muscle Nerve"},{"key":"e_1_2_59_9_12_1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1529-8027.2010.00278.x","volume":"15","author":"Joint Task Force of the EFNS and the PNS","year":"2010","journal-title":"J Peripher Nerv Syst"},{"key":"e_1_2_59_9_13_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41572-018-0027-2","volume":"4","author":"Kieseier BC","year":"2018","journal-title":"Immune\u2010mediated neuropathies. Nat Rev. Dis Primers"},{"key":"e_1_2_59_9_14_1","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1182\/blood.2020007092","article-title":"CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B\u2010cell\u2010targeted therapies","volume":"136","author":"Le Cann M","year":"2020","journal-title":"Blood"},{"key":"e_1_2_59_9_15_1","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","article-title":"On behalf of RIMAG Study Group (France and Switzerland). Placebo\u2010controlled trial of rituximab in IgM anti\u2010myelin\u2010associated glycoprotein neuropathy","volume":"80","author":"L\u00e9ger JM","year":"2013","journal-title":"Neurology"},{"key":"e_1_2_59_9_16_1","doi-asserted-by":"crossref","first-page":"1495205","DOI":"10.3389\/fneur.2024.1495205","article-title":"Autoantibodies in neuromuscular disorders: a review of their utility in clinical practice","volume":"15","author":"Loser V","year":"2024","journal-title":"Front Neurol"},{"key":"e_1_2_59_9_17_1","first-page":"CD002827","article-title":"Immunotherapy for IgM anti\u2010myelin\u2010associated glycoprotein paraprotein\u2010associated peripheral neuropathies","volume":"10","author":"Lunn MP","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_59_9_18_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000453390","article-title":"Immune\u2010mediated neuropathies following autologous stem cell transplantation for multiple myeloma: Case series and review of the literature","volume":"137","author":"Mohyuddin GR","year":"2017","journal-title":"Acta Haematol"},{"key":"e_1_2_59_9_19_1","first-page":"587","article-title":"Autoimmune polyneuropathies. Handbook of Clinical Neurology, Vol. 195 (3rd series), Motor System Disorders, Part I: Normal Physiology and Function and Neuromuscular Disorders. D.S. Younger, Editor","author":"Naum R","year":"2023","journal-title":"Elsevier B.V."},{"key":"e_1_2_59_9_20_1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/jnnp.59.3.243","article-title":"Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM\u2010associated Polyneuropathy Study Group","volume":"59","author":"Oksenhendler E","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_59_9_21_1","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1111\/ene.15553","article-title":"Efficacy of rituximab in anti\u2010myelin\u2010associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2\u2009years of follow\u2010up","volume":"29","author":"Parisi M","year":"2022","journal-title":"Eur J Neurol"},{"key":"e_1_2_59_9_22_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209725","volume":"103","author":"Pascual\u2010Goni E","year":"2024","journal-title":"Neurology"},{"key":"e_1_2_59_9_23_1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/jnnp-2023-332443","article-title":"Excellent response to anti\u2010CD38 therapy with daratumumab in a patient with severe refractory CANOMAD","volume":"95","author":"Pascual\u2010Goni E","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"7288","key":"e_1_2_59_9_24_1","first-page":"1","article-title":"Immune\u2010mediated neuropathies: pathophysiology and management","volume":"24","author":"Shastri A","year":"2023","journal-title":"Int J Mol Sci"},{"key":"e_1_2_59_9_25_1","first-page":"CD005376","article-title":"Treatment for IgG and IgA paraproteinaemic neuropathy","volume":"24","author":"Stork AC","year":"2015","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_59_9_26_1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1212\/WNL.0000000000011324","article-title":"The wide spectrum of pathophysiologic mechanisms of paraproteinemic neuropathy","volume":"96","author":"Vallat J","year":"2021","journal-title":"Neurol"},{"key":"e_1_2_59_9_27_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e10928","article-title":"Anti\u2010myelin\u2010associated\u2010glycoprotein neuropathy successfully treated with tirabrutinib","volume":"8","author":"Yasuda H","year":"2022","journal-title":"Heliyon."},{"issue":"3","key":"e_1_2_60_9_1_1","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2024-070334","article-title":"Pediatric acute\u2010onset neuropsychiatric syndrome (PANS): clinical report","volume":"155","author":"American Academy of Pediatrics, Board of Directors","year":"2025","journal-title":"Pediatrics"},{"key":"e_1_2_60_9_2_1","first-page":"8189067","article-title":"An atypical presentation of pediatric acute neuropsychiatric syndrome responding to plasmapheresis treatment. Case Rep","author":"Barzman DH","year":"2018","journal-title":"Psychiatry"},{"key":"e_1_2_60_9_3_1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1089\/cap.2016.0139","article-title":"Pediatric acute\u2010onset neuropsychiatric syndrome response to oral corticosteroid bursts: An observational study of patients in an academic community\u2010based PANS clinic","volume":"27","author":"Brown K","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"e_1_2_60_9_4_1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1089\/cap.2017.0101","article-title":"Treatment of pediatric acute\u2010onset neuropsychiatric disorder in a large survey population","volume":"28","author":"Calaprice D","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"e_1_2_60_9_5_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/cap.2014.0084","article-title":"Clinical evaluation of youth with pediatric acute\u2010onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS Consensus Conference","volume":"25","author":"Chang K","year":"2015","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"e_1_2_60_9_6_1","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1136\/archdischild-2015-308693","article-title":"Sydenham's chorea: not gone but perhaps forgotten","volume":"100","author":"Crealey M","year":"2015","journal-title":"Arch Dis Child"},{"issue":"4","key":"e_1_2_60_9_7_1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.6792","article-title":"Sydenham's Chorea Systematic Literature Review Working Group. Treatments and outcomes among patients with Sydenham chorea: a meta\u2010analysis","volume":"7","author":"Eyre M","year":"2024","journal-title":"JAMA Netw Open"},{"key":"e_1_2_60_9_8_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/cap.2014.0056","article-title":"Five youth with pediatric acute\u2010onset neuropsychiatric syndrome of differing etiologies","volume":"25","author":"Frankovich J","year":"2015","journal-title":"Child Adolesc Psychopharmacol"},{"key":"e_1_2_60_9_9_1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/dmcn.13349","article-title":"Systematic review of immunoglobulin use in pediatric neurological and neurodevelopmental disorders","volume":"59","author":"Gadian J","year":"2017","journal-title":"Dev Med Child Neurol"},{"issue":"19","key":"e_1_2_60_9_10_1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2147\/NDT.S362202","article-title":"Pediatric acute\u2010onset neuropsychiatric syndrome: current perspectives","volume":"24","author":"Gagliano A","year":"2023","journal-title":"Neuropsychiatr Dis Treat"},{"key":"e_1_2_60_9_11_1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1177\/08830738050200050601","article-title":"Treatment of Sydenham's chorea with intravenous immunoglobulin, plasma exchange, or prednisone","volume":"20","author":"Garvey MA","year":"2005","journal-title":"J Child Neurol"},{"key":"e_1_2_60_9_12_1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11011-015-9681-1","article-title":"Neuropsychological manifestations in children with Sydenham's chorea after adjunct intravenous immunoglobulin and standard treatment","volume":"31","author":"Gregorowski C","year":"2016","journal-title":"Metab Brain Dis"},{"key":"e_1_2_60_9_13_1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/cap.2014.0080","article-title":"Therapeutic plasma apheresis as a treatment for 35 severely ill children and adolescents with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections","volume":"25","author":"Latimer ME","year":"2015","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"e_1_2_60_9_14_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40734-014-0012-1","article-title":"Severe Sydenham's chorea (chorea paralytica) successfully treated with plasmapheresis","volume":"2","author":"Miranda M","year":"2015","journal-title":"J Clin Mov Disord"},{"key":"e_1_2_60_9_15_1","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/jpc.12915","article-title":"Intravenous immunoglobulin in acute Sydenham's chorea: a systematic review","volume":"51","author":"Mohammad SS","year":"2015","journal-title":"J Paediatr Child Health"},{"key":"e_1_2_60_9_16_1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1089\/cap.2016.0190","article-title":"A double\u2010blind randomized placebo\u2010controlled pilot study of azithromycin in youth with acute\u2010onset obsessive\u2010compulsive disorder","volume":"27","author":"Murphy TK","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"e_1_2_60_9_17_1","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/INF.0b013e31829062e2","article-title":"Tonsillectomies and adenoidectomies do not prevent the onset of pediatric autoimmune neuropsychiatric disorder associated with group A streptococcus","volume":"32","author":"Murphy TK","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"e_1_2_60_9_18_1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejpn.2024.08.002","article-title":"Management, treatment, and clinical approach of Sydenham's chorea in children: Italian survey on expert\u2010based experience","volume":"52","author":"Orsini A","year":"2024","journal-title":"Eur J Paediatr Neurol"},{"key":"e_1_2_60_9_19_1","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(98)12297-3","article-title":"Therapeutic plasma exchange and intravenous immunoglobulin for obsessive\u2010compulsive disorder and tic disorders in childhood","volume":"354","author":"Perlmutter SJ","year":"1999","journal-title":"Lancet"},{"key":"e_1_2_60_9_20_1","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/jca.22023","article-title":"Therapeutic plasma exchange in adolescent and adult patients with autoimmune neuropsychiatric disorders associated with streptococcal infections","volume":"37","author":"Prus K","year":"2022","journal-title":"J Clin Apher"},{"key":"e_1_2_60_9_21_1","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.biopsych.2004.12.035","article-title":"Antibiotic prophylaxis with azithromycin or penicillin for childhood\u2010onset neuropsychiatric disorders","volume":"57","author":"Snider LA","year":"2005","journal-title":"Biol Psychiatry"},{"key":"e_1_2_60_9_22_1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1176\/ajp.155.2.264","article-title":"Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases","volume":"155","author":"Swedo SE","year":"1998","journal-title":"Am J Psychiatry"},{"key":"e_1_2_60_9_23_1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/pch\/pxy145","article-title":"PANDAS\/PANS in childhood: controversies and evidence","volume":"24","author":"Wilbur C","year":"2019","journal-title":"Paediatr Child Health"},{"key":"e_1_2_60_9_24_1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.brainres.2014.09.071","article-title":"Post\u2010infectious autoimmune disorders: Sydenham's chorea","volume":"1617","author":"Williams KA","year":"2015","journal-title":"PANDAS and beyond. Brain Res"},{"key":"e_1_2_60_9_25_1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jaac.2016.06.017","article-title":"Randomized, controlled trial of intravenous immunoglobulin for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections","volume":"55","author":"Williams KA","year":"2016","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"e_1_2_61_8_1_1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/jdv.12678","article-title":"An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab","volume":"29","author":"Amber KT","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_61_8_2_1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3892\/etm.2021.10770","article-title":"Comprehensive review on the pathophysiology, clinical variants and management of pemphigus (Review)","volume":"22","author":"Costan VV","year":"2021","journal-title":"Exp Ther Med"},{"key":"e_1_2_61_8_3_1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.atherosclerosissup.2017.05.044","article-title":"Successful and well\u2010tolerated bi\u2010weekly immunoadsorption regimen in pemphigus vulgaris","volume":"30","author":"Dietze J","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"e_1_2_61_8_4_1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/1346-8138.17518","article-title":"Clinical characteristics and outcomes of autoimmune blistering diseases in Japan","volume":"53","author":"Encarnacion MRN","year":"2025","journal-title":"J Dermatol."},{"key":"e_1_2_61_8_5_1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0190-9622(08)80854-7","article-title":"Unresponsive severe generalized pemphigus vulgaris successfully controlled by extracorporeal photopheresis","volume":"28","author":"Gollnick HP","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_61_8_6_1","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/archderm.1988.01670110019004","article-title":"Controlled study of plasma exchange in pemphigus","volume":"124","author":"Guillaume JC","year":"1988","journal-title":"Arch Dermatol"},{"key":"e_1_2_61_8_7_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archderm.1993.01680220061016","article-title":"Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid","volume":"129","author":"Guillaume JC","year":"1993","journal-title":"Arch Dermatol."},{"issue":"1","key":"e_1_2_61_8_8_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2340\/00015555667375","article-title":"Long term plasma exchange therapy in bullous pemphigoid","volume":"66","author":"Guillot B","year":"1986","journal-title":"Acta Derm Venereol."},{"key":"e_1_2_61_8_9_1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.oraloncology.2003.09.020","article-title":"Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non\u2010hematologic malignancy and oral mucosa manifestations","volume":"40","author":"Kaplan I","year":"2004","journal-title":"Oral Oncol"},{"key":"e_1_2_61_8_10_1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2133.2011.10585.x","article-title":"Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine\/mycophenolate mofetil: a pilot study of 23 patients","volume":"166","author":"Kasperkiewicz M","year":"2012","journal-title":"Br J Dermatol"},{"key":"e_1_2_61_8_11_1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jca.21829","article-title":"Double\u2010filtration plasmapheresis combined with immunosuppressive treatment for severe pemphigus: 10\u2009years' experience of a single center in China","volume":"36","author":"Liu Y","year":"2021","journal-title":"J Clin Apher"},{"key":"e_1_2_61_8_12_1","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1046\/j.1365-2133.2003.05513.x","article-title":"Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan\u2010linked polyvinylalcohol adsorber","volume":"149","author":"Luftl M","year":"2003","journal-title":"Br J Dermatol"},{"key":"e_1_2_61_8_13_1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1744-9987.2012.01075.x","article-title":"Immunoadsorption in dermatology","volume":"16","author":"Meyersburg D","year":"2012","journal-title":"Ther Apher Dial"},{"key":"e_1_2_61_8_14_1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/1346-8138.16641","article-title":"Clinical course and outcomes of pemphigus vulgaris and foliaceus: A retrospective study using a nationwide database in Japan","volume":"50","author":"Miyachi H","year":"2023","journal-title":"J Dermatol"},{"key":"e_1_2_61_8_15_1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/archderm.1983.01650270033013","article-title":"Plasma exchange in pemphigus. Uncontrolled study of ten patients","volume":"119","author":"Roujeau JC","year":"1983","journal-title":"Arch Dermatol"},{"key":"e_1_2_61_8_16_1","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0140-6736(84)92565-0","article-title":"Plasma exchange in bullous pemphigoid","volume":"2","author":"Roujeau JC","year":"1984","journal-title":"Lancet."},{"key":"e_1_2_61_8_17_1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2133.1978.tb01630.x","article-title":"Pathogenecity of the intercellular antibodies of pemphigus and their periodic removal from the circulation by plasmapheresis","volume":"98","author":"Ruocco V","year":"1978","journal-title":"Br J Dermatol"},{"key":"e_1_2_61_8_18_1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.transci.2010.10.006","article-title":"Remission of severe autoimmune bullous disorders induced by long\u2010term extracorporeal photochemotherapy","volume":"43","author":"Sanli H","year":"2010","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_61_8_19_1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2340\/0001555575150152","article-title":"The steroid sparing effect of long\u2010term plasmapheresis in pemphigus","volume":"75","author":"Sondergaard K","year":"1995","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_61_8_20_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0190-9622(90)70004-2","article-title":"Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies","volume":"22","author":"Tan\u2010Lim R","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_61_8_21_1","doi-asserted-by":"crossref","first-page":"1363032","DOI":"10.3389\/fimmu.2024.1363032","article-title":"State\u2010of\u2010the\u2010art diagnosis of autoimmune blistering diseases","volume":"15","author":"Van Beek N","year":"2024","journal-title":"Front Immunol"},{"key":"e_1_2_61_8_22_1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/bjd\/ljad489","article-title":"Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA\u2010Pem Study): a multicenter randomized controlled trial","volume":"190","author":"Van Beek N","year":"2024","journal-title":"Br J Dermatol"},{"key":"e_1_2_61_8_23_1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1744-9987.1997.tb00037.x","article-title":"Plasmapheresis for the treatment of pemphigus vulgaris and bullous pemphigoid","volume":"1","author":"Yamada H","year":"1997","journal-title":"Ther Apher"},{"key":"e_1_2_61_8_24_1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jca.21774","article-title":"Safety and efficacy of plasma exchange via direct femoral vein puncture in autoimmune blistering diseases","volume":"35","author":"Yoshida T","year":"2020","journal-title":"J Clin Apher."},{"key":"e_1_2_62_9_1_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.atherosclerosissup.2019.08.025","article-title":"Lipoprotein apheresis in Austria\u2014reduction of cardiovascular events by regular lipoprotein apheresis treatment","volume":"40","author":"Berent T","year":"2019","journal-title":"Atheroscler Suppl"},{"key":"e_1_2_62_9_2_1","first-page":"634","article-title":"Building your peripheral artery disease toolkit: medical management of peripheral artery disease in 2022","volume":"38","author":"Bhagirath VC","year":"2022","journal-title":"Can J Cardiol"},{"key":"e_1_2_62_9_3_1","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1161\/CIR.0000000000001005","article-title":"Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association","volume":"144","author":"Criqui MH","year":"2021","journal-title":"Circulation"},{"key":"e_1_2_62_9_4_1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1744-9987.2007.00497.x","article-title":"Blood flow analysis of the head and lower limbs by the laser Doppler blood flowmeter during LDL apheresis","volume":"11","author":"Ebihara I","year":"2007","journal-title":"Ther Apher Dial"},{"key":"e_1_2_62_9_5_1","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1177\/039139880703001010","article-title":"Rheopheresis in vascular diseases","volume":"30","author":"Ferrannini M","year":"2007","journal-title":"Int J Artif Organs"},{"key":"e_1_2_62_9_6_1","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the American Heart Association","volume":"44","author":"Gianos E","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"e_1_2_62_9_7_1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41569-021-00663-9","article-title":"Update on the pathophysiology and medical treatment of peripheral artery disease","volume":"19","author":"Golledge J.","year":"2022","journal-title":"Nat Rev. Cardiol"},{"issue":"25","key":"e_1_2_62_9_8_1","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1161\/CIRCULATIONAHA.108.191171","article-title":"Atherosclerotic Peripheral Vascular Disease Symposium II: nomenclature for vascular diseases","volume":"118","author":"Hiatt WR","year":"2008","journal-title":"Circulation."},{"key":"e_1_2_62_9_9_1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1526-0968.2003.00077.x","article-title":"Low\u2010density lipoprotein apheresis in the treatment of peripheral arterial disease","volume":"7","author":"Kawashima A.","year":"2003","journal-title":"Ther Apher Dial"},{"key":"e_1_2_62_9_10_1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00001721-199909000-00004","article-title":"Does the production of nitric oxide contribute to the early improvement after a single low\u2010density lipoprotein apheresis in patients with peripheral arterial obstructive disease?","volume":"10","author":"Kizaki Y","year":"1999","journal-title":"Blood Coagul Fibrinolysis"},{"key":"e_1_2_62_9_11_1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1744-9987.2005.00276.x","article-title":"Rheopheresis in patients with critical limb ischemia\u2014results of an open label prospective pilot trial","volume":"9","author":"Klingel R","year":"2005","journal-title":"Ther Apher Dial"},{"key":"e_1_2_62_9_12_1","first-page":"1","volume-title":"Therapeutic Apheresis","author":"Klingel R","year":"2020"},{"key":"e_1_2_62_9_13_1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/jca.20033","article-title":"LDL\u2010apheresis improves peripheral arterial occlusive disease with an implication for anti\u2010inflammatory effects","volume":"20","author":"Kobayashi S","year":"2005","journal-title":"J Clin Apheresis"},{"key":"e_1_2_62_9_14_1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jca.10055","article-title":"LDL\u2010apheresis up\u2010regulates VEGF and IGF\u2010I in patients with ischemic limb","volume":"18","author":"Kobayashi S","year":"2003","journal-title":"J Clin Apher"},{"key":"e_1_2_62_9_15_1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.7326\/0003-4819-125-12-199612150-00001","article-title":"Effect of apheresis of low\u2010density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease","volume":"125","author":"Kroon AA","year":"1996","journal-title":"Ann Intern Med"},{"key":"e_1_2_62_9_16_1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1159\/000108634","article-title":"Efficacy of low\u2010density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment","volume":"27","author":"Morimoto S","year":"2007","journal-title":"Am J Nephrol"},{"key":"e_1_2_62_9_17_1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/1744-9987.12450","article-title":"Beneficial effect of endovascular therapy and low\u2010density lipoprotein apheresis combined treatment in hemodialysis patients with critical limb ischemia due to below\u2010knee arterial lesions","volume":"20","author":"Ohtake T","year":"2016","journal-title":"Ther Apher Dial"},{"key":"e_1_2_62_9_18_1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.atherosclerosissup.2017.05.007","article-title":"Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)\u2010hyperlipoproteinemia: 2\u2010year follow\u2010up of a prospective single center study","volume":"30","author":"Poller WC","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"e_1_2_62_9_19_1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1253\/circj.CJ-24-0830","article-title":"Efficacy of Rheocarna, a novel apheresis device, in patients with no\u2010or\u2010poor\u2010option chronic limb\u2010threatening ischemia","volume":"89","author":"Soga Y","year":"2025","journal-title":"Circ J"},{"key":"e_1_2_62_9_20_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/jca.21955","article-title":"Rheopheresis for severe peripheral arterial disease in hemodialysis patients: a clinical series","volume":"37","author":"Solignac J","year":"2022","journal-title":"J Clin Apher"},{"key":"e_1_2_62_9_21_1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1744-9987.2012.01149.x","article-title":"Therapeutic potential of low\u2010density lipoprotein apheresis in the management of peripheral artery disease in patients with chronic kidney disease","volume":"17","author":"Tamura K","year":"2013","journal-title":"Ther Apher Dial"},{"key":"e_1_2_62_9_22_1","first-page":"287","article-title":"Effect of low\u2010density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P\u2010LAS)","volume":"25","author":"Tsuchida H","year":"2006","journal-title":"Int Angiol"},{"key":"e_1_2_62_9_23_1","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/ATVBAHA.109.200212","article-title":"Sustained inhibition of oxidized low\u2010density lipoprotein is involved in the long\u2010term therapeutic effects of apheresis in dialysis patients","volume":"30","author":"Tsurumi\u2010Ikeya Y","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"e_1_2_62_9_24_1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1525-139X.2011.01036.x","article-title":"A critical review on the use of lipid apheresis and rheopheresis for treatment of peripheral arterial disease and the diabetic foot syndrome","volume":"25","author":"Weiss N.","year":"2012","journal-title":"Semin Dial"},{"key":"e_1_2_62_9_25_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11789-019-00097-1","article-title":"Lipoprotein(a) apheresis in patients with peripheral arterial disease: rationale and clinical results","volume":"14","author":"Weiss N","year":"2019","journal-title":"Clin Res Cardiol Suppl"},{"key":"e_1_2_63_9_1_1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s13256-024-04789-5","article-title":"Dilated cardiomyopathy revealing Refsum disease: a case report","volume":"18","author":"Arous S","year":"2024","journal-title":"J Med Case Rep"},{"key":"e_1_2_63_9_2_1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1469-8749.1989.tb08416.x","article-title":"A child with Refsum's disease: successful treatment with diet and plasma exchange","volume":"31","author":"Dickson N","year":"1989","journal-title":"Dev Med Child Neurol"},{"key":"e_1_2_63_9_3_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/jmd2.12020","article-title":"Pregnancy outcome in Refsum disease: affected fetuses and children born to an affected mother","volume":"46","author":"Dubot P","year":"2019","journal-title":"JIMD Reports"},{"key":"e_1_2_63_9_4_1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0140-6736(79)91005-5","article-title":"Heredopathia atactica polyneuritiformis (Refsum's disease) treated by diet and plasma\u2010exchange","volume":"1","author":"Gibberd FB","year":"1979","journal-title":"Lancet"},{"key":"e_1_2_63_9_5_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.1985.tb01541.x","article-title":"Heredopathia atactica polyneuritiformis: Refsum's disease","volume":"72","author":"Gibberd FB","year":"1985","journal-title":"Acta Neurol Scand"},{"key":"e_1_2_63_9_6_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0955-3886(93)90049-Z","article-title":"Plasma exchange for Refsum's disease","volume":"14","author":"Gibberd FB","year":"1993","journal-title":"Transfus Sci"},{"key":"e_1_2_63_9_7_1","unstructured":"GlobalDare Foundation:https:\/\/www.defeatadultrefsumeverywhere.org\/"},{"key":"e_1_2_63_9_8_1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1600-0404.1996.tb07051.x","article-title":"Lipapheresis: an immunoglobulin\u2010sparing treatment for Refsum's disease","volume":"94","author":"Gutsche HU","year":"1996","journal-title":"Acta Neurol Scand"},{"key":"e_1_2_63_9_9_1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/jnnp.54.7.614","article-title":"Plasma exchange in the treatment of Refsum's disease (heredopathia atactica polyneuritiformis)","volume":"54","author":"Harari D","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_63_9_10_1","first-page":"153","article-title":"Refsum's disease: management by diet and plasmapheresis","volume":"24","author":"Hungerbuhler JP","year":"1985","journal-title":"Eur Neurol"},{"key":"e_1_2_63_9_11_1","unstructured":"KumarR De JesusO.Refsum disease. StatPearls (Internet) Publishing 2022;1\u201311; last update August 1 2022."},{"key":"e_1_2_63_9_12_1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/BF02191145","article-title":"Long\u2010term plasma exchange in a case of Refsum's disease","volume":"241","author":"Leppert D","year":"1991","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"e_1_2_63_9_13_1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.62.6.671-a","article-title":"Refsum's disease: long term treatment preserves sensory nerve action potentials and motor function","volume":"62","author":"Lou JS","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_63_9_14_1","first-page":"309","article-title":"Heredopathia atactica polyneuritiformis (Refsum's disease). Experiences of dietary treatment and plasmapheresis","volume":"8","author":"Lundberg A","year":"1972","journal-title":"Eur Neurol"},{"key":"e_1_2_63_9_15_1","first-page":"491","article-title":"Therapeutic trial of plasmapheresis in Refsum disease and in Fabry disease","volume":"16","author":"Moser HW","year":"1980","journal-title":"Birth Defects Orig Artic Ser"},{"key":"e_1_2_63_9_16_1","first-page":"151","volume-title":"Advances in Neurology","author":"Penovich PE","year":"1978"},{"key":"e_1_2_63_9_17_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/oxfordjournals.ndt.a090825","article-title":"Cascade filtration in Refsum's disease","volume":"10","author":"Siegmund JB","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_63_9_18_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/BF02435981","article-title":"Bone dysplasia associated with phytanic acid accumulation and deficient plasmalogen synthesis: a peroxismoal entitiy amenable to plasmapheresis","volume":"15","author":"Smeitink JAM","year":"1992","journal-title":"J Inherit Metab Dis"},{"key":"e_1_2_63_9_19_1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1473-0502(03)00102-2","article-title":"Membrane differential filtration is safe and effective for the long\u2010term treatment of Refsum syndrome\u2014an update of treatment modalities and pathophysiological cognition","volume":"29","author":"Straube R","year":"2003","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_63_9_20_1","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1007\/s00018-005-5463-y","article-title":"Phytanic acid: production from phytol, its breakdown and role in human disease","volume":"63","author":"Brink DM","year":"2006","journal-title":"Cell Mol Life Sci"},{"key":"e_1_2_63_9_21_1","volume-title":"Adult Refsum Disease. 2021 (original 2006). In: Adam MP, Ardinger HH, Pagon RA, et al. editors. GeneReviews [Internet]","author":"Waterham HR","year":"1993"},{"key":"e_1_2_63_9_22_1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/(SICI)1098-1101(1999)14:4<181::AID-JCA5>3.0.CO;2-Z","article-title":"Phytanic acid storage disease (Refsum's disease): clinical characteristics, pathophysiology and the role of therapeutic apheresis in its management","volume":"14","author":"Weinstein R.","year":"1999","journal-title":"J Clin Apher"},{"key":"e_1_2_63_9_23_1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/qjmed\/94.8.403","article-title":"Refsum's disease","volume":"94","author":"Wills AJ","year":"2001","journal-title":"Q J Med"},{"key":"e_1_2_63_9_24_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1023\/A:1005486913371","article-title":"Transport of phytanic acid on lipoproteins in Refsum disease","volume":"22","author":"Wierzbicki AS","year":"1999","journal-title":"J Inher Metab Dis"},{"key":"e_1_2_63_9_25_1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/jca.21200","article-title":"Long\u2010term strategies for treatment of Refsum's disease using therapeutic apheresis","volume":"27","author":"Zolotov D","year":"2012","journal-title":"J Clin Apher"},{"key":"e_1_2_64_9_1_1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM197411282912205","article-title":"Post\u2010transfusion purpura: immunologic aspects and therapy","volume":"291","author":"Abramson N","year":"1974","journal-title":"N Engl J Med"},{"key":"e_1_2_64_9_2_1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1365-2141.1985.tb02876.x","article-title":"Post\u2010transfusion purpura responding to high dose intravenous IgG: further observations on pathogenesis","volume":"61","author":"Berney S","year":"1985","journal-title":"Br J Haematol"},{"key":"e_1_2_64_9_3_1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ajh.2830300211","article-title":"Apparent response of refractory post\u2010transfusion purpura to splenectomy","volume":"30","author":"Cunningham CC","year":"1989","journal-title":"Am J Hematol"},{"key":"e_1_2_64_9_4_1","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/S0140-6736(15)01313-6","article-title":"Transfusion reactions: prevention, diagnosis, and treatment","volume":"388","author":"Delaney M","year":"2016","journal-title":"Lancet"},{"key":"e_1_2_64_9_5_1","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archinte.1978.03630310076025","article-title":"Posttransfusion purpura. Case report with observation on antibody detection and therapy","volume":"138","author":"Erichson RB","year":"1978","journal-title":"Arch Intern Med"},{"key":"e_1_2_64_9_6_1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/(SICI)1098-1101(2000)15:1\/2<28::AID-JCA4>3.0.CO;2-N","article-title":"Therapeutic apheresis in hematological and oncological diseases","volume":"15","author":"Grima KM","year":"2000","journal-title":"J Clin Apher"},{"issue":"10","key":"e_1_2_64_9_7_1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2147\/JBM.S189176","article-title":"Post transfusion purpura: current perspectives","volume":"9","author":"Hawkins J","year":"2019","journal-title":"J Blood Med"},{"issue":"1","key":"e_1_2_64_9_8_1","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1182\/blood-2023-187525","article-title":"Post\u2010transfusion purpura: a literature review","volume":"142","author":"Hinojosa O","year":"2023","journal-title":"Blood"},{"key":"e_1_2_64_9_9_1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.0954-6820.1978.tb14922.x","article-title":"Post\u2010transfusion purpura treated with plasma exchange by Haemonetics cell separator","volume":"203","author":"Laursen B","year":"1978","journal-title":"A case report. Acta Med Scand"},{"key":"e_1_2_64_9_10_1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ajh.20093","article-title":"Efficacy of HPA\u20101a (PlA1)\u2010negative platelets in a patient with post\u2010transfusion purpura","volume":"76","author":"Loren AW","year":"2004","journal-title":"Am J Hematol"},{"issue":"1","key":"e_1_2_64_9_11_1","doi-asserted-by":"crossref","DOI":"10.1002\/anr3.12279","article-title":"Post\u2010transfusion purpura after cardiac surgery associated with veno\u2010arterial extracorporeal membrane oxygenation","volume":"12","author":"Lovisari F","year":"2024","journal-title":"Anaesth Rep"},{"key":"e_1_2_64_9_12_1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1473-0502(03)00049-1","article-title":"Detection and identification of platelet antibodies in clinical disorders","volume":"28","author":"McFarland JG","year":"2003","journal-title":"Transfus Apher Sci"},{"issue":"55","key":"e_1_2_64_9_13_1","first-page":"284","article-title":"Posttransfusion purpura occurrence and potential risk factors among the inpatient US elderly, as recorded in large Medicare databases during 2011 through 2012","volume":"2015","author":"Menis M","journal-title":"Transfusion"},{"key":"e_1_2_64_9_14_1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/labmed\/lmz004","article-title":"Post\u2010transfusion purpura mimicking idiopathic thrombocytopenic purpura: a case report","volume":"50","author":"Milito C","year":"2019","journal-title":"Laboratory Medicine"},{"key":"e_1_2_64_9_15_1","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2141.1986.tb02198.x","article-title":"Post\u2010transfusion purpura","volume":"64","author":"Mueller\u2010Eckhardt C.","year":"1986","journal-title":"Br J Haematol"},{"issue":"25","key":"e_1_2_64_9_16_1","article-title":"Uncommon presentation of Post\u2010Transfusion Purpura in an Elderly Male: A Case Report and Unique Alloantibody Identification","volume":"9","author":"Owczarzak L","year":"2024","journal-title":"Am J Case Rep."},{"key":"e_1_2_64_9_17_1","first-page":"2013","article-title":"Post\u2010transfusion purpura: a rare and life\u2010threatening etiology of thrombocytopenia","volume":"24","author":"Padhi P","year":"2013","journal-title":"BMJ Case Rep"},{"key":"e_1_2_64_9_18_1","article-title":"Post\u2010transfusion purpura: a case report of an underdiagnosed phenomenon","volume":"9","author":"Rafei H","year":"2017","journal-title":"Cureus"},{"key":"e_1_2_64_9_19_1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/trf.12934","article-title":"Shedding a little light on posttransfusion purpura","volume":"55","author":"Roubinian NH","year":"2015","journal-title":"Transfusion"},{"key":"e_1_2_65_9_1_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001097","article-title":"CCR5 blockade in inflammatory PML and PML\u2010IRIS associated with chronic inflammatory diseases' treatments","volume":"9","author":"Bernard\u2010Valnet R","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"e_1_2_65_9_2_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200281","article-title":"Presentation and outcome in S1P\u2010RM and natalizumab\u2010associated progressive multifocal leukoencephalopathy: a multicenter cohort study","volume":"11","author":"Blant JC","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_2_65_9_3_1","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab\u2010associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford DB","year":"2010","journal-title":"Lancet Neurol"},{"key":"e_1_2_65_9_4_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus\u2010related disease","volume":"17","author":"Cortese I","year":"2021","journal-title":"Net Rev. Neurol"},{"key":"e_1_2_65_9_5_1","first-page":"41","article-title":"Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis","volume":"28","author":"Hoepner R","year":"2014","journal-title":"J Cent Nerv Syst Dis"},{"key":"e_1_2_65_9_6_1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","article-title":"Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function","volume":"72","author":"Khatri BO","year":"2009","journal-title":"Neurology"},{"key":"e_1_2_65_9_7_1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/jca.21616","article-title":"Do we have enough evidence for recommending therapeutic apheresis for natalizumab\u2010associated progressive multifocal leukoencephalopathy patients? Comments on \u201cGuidelines on the use of therapeutic apheresis in clinical practice\u2010evidence\u2010based approach from the writing committee of the American Society for Apheresis: the seventh special issue","volume":"33","author":"Landi D","year":"2018","journal-title":"J Clin Apher"},{"key":"e_1_2_65_9_8_1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/WNL.0000000000003740","article-title":"No evidence of beneficial effects of plasmapheresis in natalizumab\u2010associated PML","volume":"88","author":"Landi D","year":"2017","journal-title":"Neurology"},{"key":"e_1_2_65_9_9_1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa0810316","article-title":"Progressive multifocal leukoencephalopathy after natalizumab monotherapy","volume":"361","author":"Lind\u00e5 H","year":"2009","journal-title":"N Engl J Med"},{"key":"e_1_2_65_9_10_1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12883-022-02839-3","article-title":"Progressive multifocal leukoencephalopathy or immune reconstitution inflammatory syndrome after fingolimod cessation","volume":"22","author":"Mickeviciene D","year":"2022","journal-title":"A case report. BMC Neurol"},{"issue":"103995","key":"e_1_2_65_9_11_1","first-page":"1","article-title":"Use of natalizumab in persons with multiple sclerosis: 2022 update","volume":"65","author":"Morrow SA","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"e_1_2_65_9_12_1","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00415-023-11924-7","article-title":"Long\u2010term outcome of natalizumab\u2010associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study","volume":"271","author":"Moser T","year":"2024","journal-title":"J Neurol"},{"key":"e_1_2_65_9_13_1","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/jca.21617","article-title":"In reply to: Do we have enough evidence for recommending therapeutic plasma exchange for patients with natalizumab\u2010associated progressive multifocal leukoencephalopathy?","volume":"33","author":"Pham HP","year":"2018","journal-title":"J Clin Apher"},{"key":"e_1_2_65_9_14_1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40264-023-01383-4","article-title":"Drug\u2010induced progressive multifocal leukoencephalopathy (PML): a systematic review and meta\u2010analysis","volume":"47","author":"Rindi LV","year":"2024","journal-title":"Drug Safety"},{"key":"e_1_2_65_9_15_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mcp.2014.11.007","article-title":"Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab\u2010treated multiple sclerosis patients","volume":"29","author":"Rossi F","year":"2015","journal-title":"Mol Cell Probes"},{"key":"e_1_2_65_9_16_1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ana.25070","article-title":"To do or not to do? Plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy?","volume":"82","author":"Scarpazza C","year":"2017","journal-title":"Ann Neurol"},{"key":"e_1_2_65_9_17_1","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1212\/WNL.0000000000207622","article-title":"Progressive multifocal leukoencephalopathy: pathogenesis, diagnostic tools, and potential biomarkers of response to therapy","volume":"101","author":"Schweitzer F","year":"2023","journal-title":"Neurology"},{"issue":"443","key":"e_1_2_65_9_18_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120459","article-title":"Progressive multifocal leukoencephalopathy in anti\u2010CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: a review","volume":"15","author":"Sharma K","year":"2022","journal-title":"J Neurol Sci"},{"key":"e_1_2_65_9_19_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577721","article-title":"Disease\u2010modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: a systematic review and meta\u2010analysis","volume":"360","author":"Sriwastava S","year":"2021","journal-title":"J Neuroimmunol"},{"key":"e_1_2_65_9_20_1","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/acn3.776","article-title":"Treatment of natalizumab\u2010associated PML with filgrastim","volume":"6","author":"Stefoski D","year":"2019","journal-title":"Ann Clin Translat Neurol"},{"key":"e_1_2_66_8_1_1","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1159\/000454674","article-title":"Plasmapheresis for refractory pruritus due to drug\u2010induced cholestasis","volume":"10","author":"Al\u2010Azzawi H","year":"2017","journal-title":"Case Rep Gastroenterol"},{"key":"e_1_2_66_8_2_1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1155\/2008\/969826","article-title":"Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports","volume":"22","author":"Alallam A","year":"2008","journal-title":"Can J Gastroenterol"},{"key":"e_1_2_66_8_3_1","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.transci.2013.07.002","article-title":"Twenty\u2010six years of plasma exchange for symptomatic treatment of pruritus in primary biliary cirrhosis","volume":"49","author":"Axelsson CG","year":"2013","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_66_8_4_1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/jca.21573","article-title":"Plasma exchange for the management of refractory pruritus of cholestasis: a report of three cases and review of literature","volume":"33","author":"Chkheidze R","year":"2018","journal-title":"J Clin Apher"},{"key":"e_1_2_66_8_5_1","doi-asserted-by":"crossref","first-page":"4296474","DOI":"10.1155\/2017\/4296474","article-title":"Severe cholestasis and bile cast nephropathy induced by anabolic steroids successfully treated with plasma exchange","volume":"2017","author":"El Khoury C","year":"2017","journal-title":"Case Rep Med"},{"key":"e_1_2_66_8_6_1","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001317","article-title":"Severe elevated bile acids in early pregnancy","volume":"11","author":"Fass L","year":"2024","journal-title":"ACG Case Rep J"},{"key":"e_1_2_66_8_7_1","first-page":"239","article-title":"Treatment of intractable pruritus in patients with cholestatic jaundice by plasma exchange and plasmaperfusion","volume":"21","author":"Geerdink P","year":"1978","journal-title":"Neth J Med"},{"key":"e_1_2_66_8_8_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/jca.21436","article-title":"Therapeutic plasma exchange for intractable pruritus secondary to primary sclerosing cholangitis","volume":"31","author":"Gibson B","year":"2016","journal-title":"J Clin Apher"},{"key":"e_1_2_66_8_9_1","first-page":"102","article-title":"Therapeutic options for the management of the cholestatic phase of viral hepatitis A and E\u2010a systematic review","volume":"15","author":"Giri S","journal-title":"J Clin Exp Hepatol"},{"key":"e_1_2_66_8_10_1","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1002\/hep.30496","article-title":"Effect of plasmapheresis on cholestatic pruritus and autotaxin activity during pregnancy","volume":"69","author":"Heerkens M","year":"2019","journal-title":"Hepatology"},{"key":"e_1_2_66_8_11_1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/liv.13281","article-title":"Plasmapheresis exerts a long\u2010lasting antipruritic effect in severe cholestatic itch","volume":"37","author":"Krawczyk M","year":"2017","journal-title":"Liver Int"},{"key":"e_1_2_66_8_12_1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1159\/000360518","article-title":"Advances in pathogenesis and management of pruritus in cholestasis","volume":"32","author":"Kremer AE","year":"2014","journal-title":"Dig Dis"},{"key":"e_1_2_66_8_13_1","article-title":"Acute renal failure due to bile cast nephropathy: an overlooked cause of kidney injury","volume":"12","author":"Jamshaid MB","year":"2020","journal-title":"Cureus"},{"key":"e_1_2_66_8_14_1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000543619","article-title":"Bilirubin Removal with Therapeutic Plasma Exchange or Molecular Adsorbent Recirculating System as Treatment for Cholemic Nephropathy in Patients with Cirrhosis and Acute\u2010on\u2010Chronic Liver Failure: A Case Series","volume":"54","author":"Jim\u00e9nez\u2010Esquivel N","year":"2025","journal-title":"Blood Purif."},{"key":"e_1_2_66_8_15_1","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-246318","article-title":"Intrahepatic cholestasis of pregnancy resistant to both therapeutic plasma exchange and albumin dialysis","volume":"15","author":"Lia M","year":"2022","journal-title":"BMJ Case Rep"},{"key":"e_1_2_66_8_16_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2024\/5112461","article-title":"Cholestasis linked to bodybuilding supplements: exploring the risks of contamination","author":"Matusak M","year":"2024","journal-title":"Case Reports Hepatol"},{"key":"e_1_2_66_8_17_1","article-title":"Plasma exchange for refractory pruritus due to drug\u2010induced chronic cholestasis following azithromycin misuse in COVID\u201019 infection","volume":"16","author":"Mongare N","year":"2024","journal-title":"Cureus"},{"key":"e_1_2_66_8_18_1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/j.1572-0241.2002.05852.x","article-title":"Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease","volume":"97","author":"Neff GW","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_66_8_19_1","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-229097","article-title":"Severe cholestatic hyperbilirubinaemia secondary to thyrotoxicosis complicated with bile cast nephropathy treated with plasma exchange and hemodialysis","volume":"12","author":"Ocon AJ","year":"2019","journal-title":"BMJ Case Rep"},{"key":"e_1_2_66_8_20_1","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1111\/hepr.12978","article-title":"Prevalence of pruritus in patients with chronic liver disease: a multicenter study","volume":"48","author":"Oeda S","year":"2018","journal-title":"Hepatol Res"},{"key":"e_1_2_66_8_21_1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/jca.21654","article-title":"Therapeutic plasma exchange as a novel treatment for severe intrahepatic cholestasis of pregnancy: case series and mechanism of action","volume":"33","author":"Ovadia C","year":"2018","journal-title":"J Clin Apher"},{"key":"e_1_2_66_8_22_1","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jhep.2006.08.008","article-title":"Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis","volume":"45","author":"Pusl T","year":"2006","journal-title":"J Hepatol"},{"key":"e_1_2_66_8_23_1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/jca.21595","article-title":"Improvement of refractory pruritus after lipoprotein\u2010apheresis in arthrogryposis\u2010renal failure\u2010cholestasis syndrome","volume":"33","author":"Rosales A","year":"2018","journal-title":"J Clin Apher"},{"key":"e_1_2_66_8_24_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cld.2022.08.011","article-title":"Pruritus in chronic liver disease","volume":"27","author":"Selim R","year":"2023","journal-title":"Clin Liver Dis"},{"key":"e_1_2_66_8_25_1","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.3748\/wjg.v23.i19.3418","article-title":"Recent advances in the management of pruritus in chronic liver diseases","volume":"23","author":"Tajiri K","year":"2017","journal-title":"World J Gastroenterol"},{"key":"e_1_2_67_9_1_1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/1346-8138.17667","article-title":"Efficacy of granulocyte and monocyte adsorptive apheresis on skin and joint manifestations of palmoplantar pustulosis with pustulotic arthro\u2010osteitis: a multicentric, prospective, observational study","volume":"52","author":"Abe N","year":"2025","journal-title":"J Dermatol"},{"key":"e_1_2_67_9_2_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.transci.2015.02.005","article-title":"Extracorporeal photopheresis for the treatment of autoimmune diseases","volume":"52","author":"Adamski J","year":"2015","journal-title":"Transfus Apheres Sci"},{"key":"e_1_2_67_9_3_1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong W","year":"2020","journal-title":"JAMA"},{"key":"e_1_2_67_9_4_1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0190-9622(83)70022-8","article-title":"Plasmapheresis in the treatment of psoriasis. A controlled clinical study","volume":"8","author":"Clemmensen OJ","year":"1983","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_67_9_5_1","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/archderm.115.10.1171","article-title":"Resolution of psoriasis during plasmapheresis therapy","volume":"115","author":"Dau PC","year":"1979","journal-title":"Arch Dermatol"},{"key":"e_1_2_67_9_6_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000014311","article-title":"Effects of cascade apheresis in patients with psoriasis and psoriatic arthropathy","volume":"16","author":"J\u00f8rstad S","year":"1998","journal-title":"Blood Purif"},{"key":"e_1_2_67_9_7_1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/1744-9987.12816","article-title":"Generalized pustular psoriasis with CARD14 Variant c.256G>C (p.Asp176His) successfully treated with granulocyte and monocyte adsorption apheresis","volume":"23","author":"Fujii A","year":"2019","journal-title":"Ther Apher Dial"},{"key":"e_1_2_67_9_8_1","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1744-9987.2012.01108.x","article-title":"Adsorptive depletion of CD14(+) CD16(+) proinflammatory monocyte phenotype in patients with generalized pustular psoriasis: clinical efficacy and effects on cytokines","volume":"16","author":"Fujisawa T","year":"2012","journal-title":"Ther Apher Dial"},{"key":"e_1_2_67_9_9_1","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/1744-9987.12342","article-title":"Granulocyte and monocyte adsorption apheresis for generalized pustular psoriasis: therapeutic outcomes in three refractory patients","volume":"19","author":"Fujisawa T","year":"2015","journal-title":"Ther Apher Dial"},{"key":"e_1_2_67_9_10_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF00412488","article-title":"Leukopheresis for treatment of psoriasis: is therapeutical benefit related to reduced activities of neutral proteinases of polymorphonuclear leukocytes?","volume":"278","author":"Gli\u0144ski W","year":"1985","journal-title":"Arch Dermatol Res"},{"key":"e_1_2_67_9_11_1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jaad.2012.09.037","article-title":"Therapeutic depletion of myeloid lineage leukocytes in patients with generalized pustular psoriasis indicates a major role for neutrophils in the immunopathogenesis of psoriasis","volume":"68","author":"Ikeda S","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_67_9_12_1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1744-9987.2006.00369.x","article-title":"Granulocyte and monocyte adsorption apheresis (GCAP) for refractory skin diseases caused by activated neutrophils and psoriatic arthritis: evidence that GCAP removes Mac\u20101\u2010expressing neutrophils","volume":"10","author":"Kanekura T","year":"2006","journal-title":"Ther Apher Dial"},{"key":"e_1_2_67_9_13_1","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/1346-8138.13975","article-title":"Therapeutic depletion of myeloid lineage leukocytes by adsorptive apheresis for psoriatic arthritis: Efficacy of a non\u2010drug intervention for patients refractory to pharmacologics","volume":"44","author":"Kanekura T","year":"2017","journal-title":"J Dermatol"},{"key":"e_1_2_67_9_14_1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/BF00455159","article-title":"Plasma exchange and leukapheresis in psoriasis\u2010\u2010no effect?","volume":"278","author":"Lieden G","year":"1986","journal-title":"Arch Dermatol Res"},{"key":"e_1_2_67_9_15_1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/jca.20079","article-title":"Lymphocytapheresis in the treatment of psoriasis vulgaris","volume":"21","author":"Liumbruno GM","year":"2006","journal-title":"J Clin Apher"},{"key":"e_1_2_67_9_16_1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/1346-8138.12501","article-title":"Case of generalized pustular psoriasis with end\u2010stage renal disease successfully treated with granulocyte monocyte apheresis in combination with hemodialysis","volume":"41","author":"Mabuchi T","year":"2014","journal-title":"J Dermatol"},{"key":"e_1_2_67_9_17_1","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1111\/1346-8138.14357","article-title":"Successful treatment of plaque\u2010type psoriasis by granulocyte and monocyte adsorption apheresis in a patient with psoriatic arthritis","volume":"45","author":"Matsuoka A","year":"2018","journal-title":"J Dermatol."},{"key":"e_1_2_67_9_18_1","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/1346-8138.15569","article-title":"Intensive granulocyte and monocyte adsorption apheresis for generalized pustular psoriasis","volume":"47","author":"Mizutani Y","year":"2020","journal-title":"J Dermatol"},{"key":"e_1_2_67_9_19_1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/1346-8138.16217","article-title":"Clinical characteristics of Japanese pustular psoriasis: a multicenter observational study","volume":"49","author":"Ohata C","year":"2022","journal-title":"J Dermatol"},{"key":"e_1_2_67_9_20_1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/1744-9987.12113","article-title":"Granulocyte and monocyte adsorption apheresis for refractory skin diseases due to activated neutrophils, psoriasis, and associated arthropathy","volume":"17","author":"Sakanoue M","year":"2013","journal-title":"Ther Apher Dial"},{"key":"e_1_2_67_9_21_1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/1744-9987.14118","article-title":"Successful treatment with granulocyte and monocyte adsorption apheresis for plaque\u2010type skin lesions in patients with psoriatic arthritis","volume":"28","author":"Seishima M","year":"2024","journal-title":"Ther Apher Dial"},{"key":"e_1_2_67_9_22_1","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1111\/jdv.12383","article-title":"Generalized pustular psoriasis caused by deficiency of interleukin\u201036 receptor antagonist successfully treated with granulocyte and monocyte adsorption apheresis","volume":"28","author":"Sugiura K","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_67_9_23_1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1744-9987.2012.01109.x","article-title":"Successful treatment of three cases of generalized pustular psoriasis with granulocyte and monocyte adsorption apheresis","volume":"16","author":"Suzuki A","year":"2012","journal-title":"Ther Apher Dial"},{"key":"e_1_2_67_9_24_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000380876","article-title":"A case of old age\u2010onset generalized pustular psoriasis with a deficiency of IL\u201036RN (DITRA) treated by granulocyte and monocyte pheresis","volume":"7","author":"Tominaga C","year":"2015","journal-title":"Case Rep Dermatol"},{"key":"e_1_2_67_9_25_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/IJWH.S125784","article-title":"Pustular psoriasis of pregnancy: current perspectives","volume":"10","author":"Trivedi MK","year":"2018","journal-title":"Int J Womens Health"},{"key":"e_1_2_68_9_1_1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/(SICI)1096-8652(199903)60:3<245::AID-AJH16>3.0.CO;2-4","article-title":"Successful prevention of post\u2010transfusion Rh alloimmunization by intravenous Rho (D) immune globulin (WinRho SD)","volume":"60","author":"Anderson B","year":"1999","journal-title":"Am J Hematol"},{"key":"e_1_2_68_9_2_1","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1111\/j.1537-2995.2008.01800.x","article-title":"Prevention of D sensitization after mismatched transfusion of blood components: toward optimal use of RhIg","volume":"48","author":"Ayache S","year":"2008","journal-title":"Transfusion"},{"key":"e_1_2_68_9_3_1","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1136\/bmj.280.6231.1569","article-title":"Adverse effect of plasma exchange on anti\u2010D production in rhesus immunization owing to removal of inhibitory factors","volume":"28","author":"Barclay GR","year":"1980","journal-title":"Br Med J"},{"key":"e_1_2_68_9_4_1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.transci.2017.05.024","article-title":"Personalized treatment with immunoadsorption and intravenous immunoglobulin in a case of severe Rh alloimmunization during pregnancy unresponsive to plasma exchange","volume":"87","author":"Colpo A","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_68_9_5_1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/jca.21468","article-title":"Therapeutic plasma exchange and pregnancy: a case report and guidelines for performing plasma exchange in a pregnant patient","volume":"32","author":"Cox JL","year":"2017","journal-title":"J Clin Apher"},{"key":"e_1_2_68_9_6_1","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/trf.14547","article-title":"O\u2010 product transfusion, inventory management, and utilization during shortage: the OPTIMUS study","volume":"58","author":"Dunbar NM","year":"2018","journal-title":"Transfusion"},{"key":"e_1_2_68_9_7_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0140-6736(76)92906-8","article-title":"Intensive antenatal plasmapheresis in severe rhesus isoimmunisation","volume":"1","author":"Fraser ID","year":"1976","journal-title":"Lancet"},{"key":"e_1_2_68_9_8_1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejogrb.2017.07.024","article-title":"Successful management of a severe anti\u2010M alloimmunization during pregnancy","volume":"217","author":"Hubinont C","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"e_1_2_68_9_9_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1423-0410.2005.00637.x","article-title":"Prevention of post\u2010transfusion RhD immunization using red cell exchange and intravenous anti\u2010D immunoglobulin","volume":"89","author":"Laspina S","year":"2005","journal-title":"Vox Sang"},{"key":"e_1_2_68_9_10_1","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1111\/trf.16061","article-title":"Impact of red blood cell alloimmunization on fetal and neonatal outcomes: a single center cohort study","volume":"60","author":"Lieberman L","year":"2020","journal-title":"Transfusion"},{"key":"e_1_2_68_9_11_1","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1111\/aogs.14261","article-title":"Management and clinical consequences of red blood cell antibodies in pregnancy: a population\u2010based cohort study","volume":"100","author":"Liu S","year":"2021","journal-title":"Acta Obstet Gynecol Scand"},{"key":"e_1_2_68_9_12_1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/trf.12925","article-title":"A case for stocking O D+ red blood cells in emergency room trauma bays","volume":"55","author":"Meyer E","year":"2015","journal-title":"Transfusion"},{"key":"e_1_2_68_9_13_1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJMoa2314466","article-title":"Nipocalimab in early\u2010onset severe hemolytic disease of the fetus and newborn","volume":"391","author":"Moise KJ","year":"2024","journal-title":"N Engl J Med"},{"key":"e_1_2_68_9_14_1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ajog.2024.11.003","article-title":"Monitoring and management of hemolytic disease of the fetus and newborn based on an international expert Delphi consensus","volume":"232","author":"Mustafa HJ","year":"2025","journal-title":"Am J Obstetrics Gynecology"},{"key":"e_1_2_68_9_15_1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1111\/j.0041-1132.2004.04161.x","article-title":"Prevention of immunization to D+ red blood cells with red blood cell exchange and intravenous Rh immune globulin","volume":"44","author":"Nester TA","year":"2004","journal-title":"Transfusion"},{"key":"e_1_2_68_9_16_1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/trf.14453","article-title":"Successful management of severe red blood cell alloimmunization in pregnancy with a combination of therapeutic plasma exchange, intravenous immune globulin, and intrauterine transfusion","volume":"58","author":"Nwogu L","year":"2018","journal-title":"Transfusion"},{"issue":"138","key":"e_1_2_68_9_17_1","first-page":"e1","article-title":"Combined plasmapheresis and intravenous immune globulin for the treatment of severe maternal red cell alloimmunization","volume":"196","author":"Ruma MS","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"e_1_2_68_9_18_1","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3390\/children12070822","article-title":"Patient\u2010reported disease presentation, interventions, and outcomes in United States pregnancies affected by alloimmunization at risk of hemolytic disease of the fetus and newborn","volume":"12","author":"Sherwood MR","year":"2025","journal-title":"Children"},{"key":"e_1_2_68_9_19_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.21307\/immunohematology-2019-110","article-title":"Transfusion of D+ red blood cells to D\u2010individuals in trauma situations","volume":"30","author":"Tchakarov A","year":"2014","journal-title":"Immunohaematology"},{"key":"e_1_2_68_9_20_1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1515\/jpme.1997.25.1.85","article-title":"High\u2010dose gammaglobulin (IVIG) followed by intrauterine transfusions (IUTs): a new alternative for the treatment of severe fetal hemolytic disease","volume":"25","author":"Voto LS","year":"1997","journal-title":"J Perinat Med"},{"key":"e_1_2_68_9_21_1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/jca.20225","article-title":"Prevention of Rh sensitization in the context of trauma: two case reports","volume":"25","author":"Werch JB","year":"2010","journal-title":"J Clin Apher"},{"key":"e_1_2_68_9_22_1","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1111\/trf.15569","article-title":"It is time to reconsider the risks of transfusing RhD negative females of childbearing potential with RhD positive red blood cells in bleeding emergencies","volume":"59","author":"Yazer MH","year":"2019","journal-title":"Transfusion"},{"key":"e_1_2_68_9_23_1","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/pd.5355","article-title":"The near disappearance of fetal hydrops in relation to current state\u2010of\u2010the\u2010art management of red cell alloimmunization","volume":"38","author":"Zwiers C","year":"2018","journal-title":"Prenat Diagn"},{"key":"e_1_2_68_9_24_1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/17474086.2017.1305265","article-title":"Intrauterine transfusion and non\u2010invasive treatment options for hemolytic disease of the fetus and newborn\u2014review on current management and outcome","volume":"10","author":"Zwiers C","year":"2017","journal-title":"Expert Rev. Hematol"},{"issue":"291","key":"e_1_2_68_9_25_1","first-page":"e1","article-title":"Postponing Early intrauterine Transfusion with Intravenous immunoglobulin Treatment; the PETIT study on severe hemolytic disease of the fetus and newborn","volume":"219","author":"Zwiers C","year":"2018","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"e_1_2_69_9_1_1","doi-asserted-by":"crossref","first-page":"16876","DOI":"10.1038\/s41598-024-67028-3","article-title":"A randomized controlled trial of plasma exchange compared to standard of care in the treatment of severe COVID\u201019 infection (COVIPLEX)","volume":"14","author":"Arulkumaran N","year":"2024","journal-title":"Sci Rep."},{"key":"e_1_2_69_9_2_1","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1007\/s00134-002-1410-7","article-title":"Plasmapheresis in severe sepsis and septic shock: a prospective, randomized, controlled trial","volume":"28","author":"Busund R","year":"2002","journal-title":"Intensive Care Med"},{"key":"e_1_2_69_9_3_1","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.24953\/turkjped.2022.494","article-title":"Management of thrombocytopenia\u2010associated multiple organ failure: plasma infusion vs. plasma exchange","volume":"64","author":"\u00c7ele\u011fen M","year":"2022","journal-title":"Turk J Pediatr"},{"key":"e_1_2_69_9_4_1","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1097\/CCM.0000000000005991","article-title":"Blood purification for adult patients with severe infection or sepsis\/septic shock: a network Meta\u2010analysis of randomized controlled trials","volume":"51","author":"Chen JJ","year":"2023","journal-title":"Crit Care Med"},{"key":"e_1_2_69_9_5_1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fped.2017.00254","article-title":"Use of therapeutic plasma exchange during extracorporeal life support in critically ill cardiac children with thrombocytopenia\u2010associated multi\u2010organ failure","volume":"5","author":"Chong M","year":"2017","journal-title":"Front Pediatr"},{"key":"e_1_2_69_9_6_1","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans L","year":"2021","journal-title":"Intensive Care Med"},{"issue":"5","key":"e_1_2_69_9_7_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106334","article-title":"Therapeutic plasma exchange in patients with life\u2010threatening COVID\u201019: a randomized controlled clinical trial","volume":"57","author":"Faqihi F","year":"2021","journal-title":"Int J Antimicrob Agents."},{"key":"e_1_2_69_9_8_1","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s00134-020-06151-x","article-title":"Incidence and mortality of hospital\u2010 and ICU\u2010treated sepsis: results from an updated and expanded systematic review and meta\u2010analysis","volume":"46","author":"Fleischmann\u2010Struzek C","year":"2020","journal-title":"Intensive Care Med"},{"key":"e_1_2_69_9_9_1","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1097\/CCM.0000000000003559","article-title":"Therapeutic plasma exchange in children with thrombocytopenia\u2010associated multiple organ failure: the Thrombocytopenia\u2010Associated Multiple Organ Failure Network prospective experience","volume":"47","author":"Fortenberry JD","year":"2019","journal-title":"Crit Care Med"},{"key":"e_1_2_69_9_10_1","article-title":"Enhancing survival in septic shock: A systematic review and meta\u2010analysis of the efficacy of plasma exchange therapy","volume":"16","author":"Hernandez GN","year":"2024","journal-title":"Cureus"},{"key":"e_1_2_69_9_11_1","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/aas.14115","article-title":"Mortality and adverse events of hemoadsorption with CytoSorb in critically ill patients: A systematic review and meta\u2010analysis of randomized controlled trials","volume":"66","author":"Heymann M","year":"2022","journal-title":"Acta Anaesthesiol Scand"},{"key":"e_1_2_69_9_12_1","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1186\/s13054-020-03241-6","article-title":"The therapeutic efficacy of adjunct therapeutic plasma exchange for septic shock with multiple organ failure: a single\u2010center experience","volume":"24","author":"Keith PD","year":"2020","journal-title":"Crit Care"},{"key":"e_1_2_69_9_13_1","doi-asserted-by":"crossref","DOI":"10.1002\/jca.22107","article-title":"Improved survival in COVID\u201019 related sepsis and ARDS treated with a unique \u201ctriple therapy\u201d including therapeutic plasma exchange: a single center retrospective analysis","volume":"39","author":"Keith P","year":"2024","journal-title":"J Clin Apher."},{"key":"e_1_2_69_9_14_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13054-023-04795-x","article-title":"Influence of therapeutic plasma exchange treatment on short\u2010term mortality of critically ill adult patients with sepsis\u2010induced organ dysfunction: a systematic review and meta\u2010analysis","volume":"28","author":"Kuklin V","year":"2024","journal-title":"Crit Care"},{"key":"e_1_2_69_9_15_1","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1177\/08850666231170775","article-title":"Survival benefits of therapeutic plasma exchange in severe sepsis and septic shock: a systematic review and meta\u2010analysis","volume":"38","author":"Lee OPE","year":"2023","journal-title":"J Intensive Care Med"},{"key":"e_1_2_69_9_16_1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jcrc.2018.01.028","article-title":"Use of plasma exchange in pediatric severe sepsis in children's hospitals","volume":"45","author":"Lima LM","year":"2018","journal-title":"J Crit Care"},{"key":"e_1_2_69_9_17_1","first-page":"198","article-title":"A randomized controlled trial of plasma filtration in severe pediatric sepsis","volume":"15","author":"Long EJ","year":"2013","journal-title":"Crit Care Resusc"},{"key":"e_1_2_69_9_18_1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jca.22027","article-title":"Chinese Critical Care Nutrition Trials Group. Therapeutic plasma exchange in patients with sepsis: secondary analysis of a cluster\u2010randomized controlled trial","volume":"38","author":"Luo X","year":"2023","journal-title":"J Clin Apher."},{"key":"e_1_2_69_9_19_1","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1097\/CCM.0b013e318186aa49","article-title":"Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs\u201013 activity and reverses organ dysfunction in children with thrombocytopenia\u2010associated multiple organ failure","volume":"36","author":"Nguyen TC","year":"2008","journal-title":"Crit Care Med"},{"key":"e_1_2_69_9_20_1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1186\/s13054-014-0699-2","article-title":"The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta\u2010analysis","volume":"18","author":"Rimmer E","year":"2014","journal-title":"Crit Care"},{"key":"e_1_2_69_9_21_1","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1097\/PCC.0000000000000227","article-title":"Use of therapeutic plasma exchange in children with thrombocytopenia\u2010associated multiple organ failure in the Turkish thrombocytopenia\u2010associated multiple organ failure network","volume":"15","author":"Sevketoglu E","year":"2014","journal-title":"Pediatr Crit Care Med"},{"key":"e_1_2_69_9_22_1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13054-022-04003-2","article-title":"Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial","volume":"26","author":"Stahl K","year":"2022","journal-title":"Crit Care"},{"key":"e_1_2_69_9_23_1","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.3390\/jcm14072285","article-title":"Hemoadsorption in the management of septic shock: a systematic review and meta\u2010analysis","volume":"14","author":"Steindl D","year":"2025","journal-title":"J Clin Med"},{"key":"e_1_2_69_9_24_1","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1097\/PCC.0000000000002198","article-title":"Surviving sepsis campaign international guidelines for the management of septic shock and sepsis\u2010associated organ dysfunction in children","volume":"21","author":"Weiss SL","year":"2020","journal-title":"Pediatr Crit Care Med."},{"key":"e_1_2_69_9_25_1","first-page":"721","article-title":"Therapeutic plasma exchange protects patients with sepsis\u2010associated disseminated intravascular coagulation by improving endothelial function","volume":"36","author":"Weng J","year":"2021","journal-title":"J Clin Apher"},{"key":"e_1_2_69_9_26_1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/SHK.0000000000002254","article-title":"The therapeutic efficacy of plasmapheresis for sepsis with multiple organ failure: a propensity score\u2010matched analysis based on the MIMIC\u2010IV database","volume":"61","author":"Yan D","year":"2024","journal-title":"Shock"},{"key":"e_1_2_70_9_1_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM199807023390102","article-title":"Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography","volume":"339","author":"Adams RJ","year":"1998","journal-title":"N Engl J Med"},{"key":"e_1_2_70_9_2_1","doi-asserted-by":"crossref","first-page":"23132","DOI":"10.1038\/s41598-021-02437-2","article-title":"Nationwide retrospective study of critically ill adults with sickle cell disease in France","volume":"11","author":"Agbakou M","year":"2021","journal-title":"Sci Rep"},{"key":"e_1_2_70_9_3_1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/0300-1652.184073","article-title":"Effect of automated red cell exchanges on oxygen saturation on\u2010air, blood parameters and length of hospitalization in sickle cell disease patients with acute chest syndrome","volume":"57","author":"Aneke JC","year":"2016","journal-title":"Niger Med J"},{"key":"e_1_2_70_9_4_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jca.21394","article-title":"Safety and efficacy of blood exchange transfusion for priapism complicating sickle cell disease","volume":"31","author":"Ballas SK","year":"2016","journal-title":"J Clin Apher"},{"key":"e_1_2_70_9_5_1","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1111\/trf.14806","article-title":"Red blood cell exchange in patients with sickle cell disease\u2010 indications and management: a review and consensus report by the Therapeutic Apheresis Subsection of the AABB","volume":"58","author":"Biller E","year":"2018","journal-title":"Transfusion"},{"key":"e_1_2_70_9_6_1","first-page":"643","article-title":"Sickle cell intrahepatic cholestasis: approach to a difficult problem","volume":"156","author":"Brousse V","year":"2012","journal-title":"Br J Haematol"},{"key":"e_1_2_70_9_7_1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/bloodadvances.2019001143","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support","volume":"4","author":"Chou ST","year":"2020","journal-title":"Blood Adv"},{"key":"e_1_2_70_9_8_1","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1111\/trf.14931","article-title":"Effects of red blood cell (RBC) transfusion on sickle cell disease recipient plasma and RBC metabolism","volume":"58","author":"Culp\u2010Hill R","year":"2018","journal-title":"Transfusion"},{"key":"e_1_2_70_9_9_1","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1182\/bloodadvances.2019001142","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults","volume":"4","author":"DeBaun MR","year":"2020","journal-title":"Blood Adv"},{"key":"e_1_2_70_9_10_1","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.jsxm.2021.07.006","article-title":"Exploring the use of exchange transfusion in the surgical management of priapism in sickle cell disease: A population\u2010based analysis","volume":"18","author":"Ha AS","year":"2021","journal-title":"J Sex Med"},{"key":"e_1_2_70_9_11_1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jpeds.2006.06.037","article-title":"Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia","volume":"149","author":"Hulbert ML","year":"2006","journal-title":"J Pediatr"},{"key":"e_1_2_70_9_12_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.transci.2018.02.011","article-title":"Use of red blood cell exchange for treating acute complications of sickle cell disease","volume":"57","author":"Kozanoglu I","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_70_9_13_1","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1542\/peds.84.3.500","article-title":"Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease","volume":"84","author":"Leikin SL","year":"1989","journal-title":"Pediatrics"},{"key":"e_1_2_70_9_14_1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/trf.14407","article-title":"Case series supporting heme detoxification via therapeutic plasma exchange in acute multiorgan failure syndrome resistant to red blood cell exchange in sickle cell disease","volume":"58","author":"Louie JE","year":"2018","journal-title":"Transfusion"},{"key":"e_1_2_70_9_15_1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/jca.21511","article-title":"Red blood cell exchange: 2015 American Society for Apheresis consensus conference on the management of patients with sickle cell disease","volume":"32","author":"Sarode R","year":"2017","journal-title":"J Clin Apher"},{"key":"e_1_2_70_9_16_1","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1111\/trf.12993","article-title":"Hyperhemolysis syndrome in patients with sickle cell anemia: report of three cases","volume":"55","author":"Santos B","year":"2015","journal-title":"Transfusion"},{"key":"e_1_2_70_9_17_1","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1002\/pbc.24744","article-title":"Comparison of automated red cell exchange transfusion and simple transfusion for the treatment of children with sickle cell disease acute chest syndrome","volume":"60","author":"Saylors RL","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_70_9_18_1","first-page":"2048","article-title":"Sickle cell intrahepatic cholestasis: approach to a difficult problem","volume":"90","author":"Shao SH","year":"1995","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"e_1_2_70_9_19_1","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27588","article-title":"Impact of erythrocytapheresis on natural anticoagulant levels in children with sickle cell disease: a pilot study","volume":"66","author":"Sharma R","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"e_1_2_70_9_20_1","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1111\/bjh.18638","article-title":"Addition of plasma exchange to red cell exchange improves outcomes of fat embolism syndrome in sickle cell disease","volume":"200","author":"Tsitsikas DA","year":"2023","journal-title":"Br J Haematol"},{"key":"e_1_2_70_9_21_1","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/j.1537-2995.2008.02075.x","article-title":"Exchange versus simple transfusion for acute chest syndrome in sickle cell anemia adults","volume":"49","author":"Turner JM","year":"2009","journal-title":"Transfusion"},{"key":"e_1_2_70_9_22_1","unstructured":"US Department of Health and Human Services.Evidence based management of sickle cell disease expert panel report 2014.http:\/\/www.nhlbi.nih.gov\/health-pro\/guidelines\/sickle-cell-disease-guidelines(accessed October 21 2025)."},{"key":"e_1_2_70_9_23_1","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/pbc.22211","article-title":"Erythrocytapheresis in children with sickle cell disease and acute chest syndrome","volume":"53","author":"Velasquez MP","year":"2009","journal-title":"Pediatric Blood Cancer"},{"key":"e_1_2_70_9_24_1","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM200006223422502","article-title":"Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group","volume":"342","author":"Vichinsky EP","year":"2000","journal-title":"N Engl J Med"},{"key":"e_1_2_70_9_25_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11239-013-0914-z","article-title":"Short\u2010term central venous catheter complications in patients with sickle cell disease who undergo apheresis","volume":"37","author":"Yeral M","year":"2014","journal-title":"J Thromb Thrombolysis"},{"key":"e_1_2_71_9_1_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM199807023390102","article-title":"Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography","volume":"339","author":"Adams RJ","year":"1998","journal-title":"N Engl J Med"},{"key":"e_1_2_71_9_2_1","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1056\/NEJMoa050460","article-title":"Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease","volume":"353","author":"Adams RJ","year":"2005","journal-title":"N Engl J Med"},{"key":"e_1_2_71_9_3_1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga KI","year":"2017","journal-title":"N Engl J Med"},{"key":"e_1_2_71_9_4_1","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/pbc.25153","article-title":"Impact of long\u2010term erythrocytapheresis on growth and peak height velocity of children with sickle cell disease","volume":"61","author":"Bavle A","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_71_9_5_1","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1111\/trf.14806","article-title":"Red blood cell exchange in patients with sickle cell disease\u2014indications and management: a review and consensus report by the Therapeutic Apheresis Subsection of the AABB","volume":"58","author":"Biller E","year":"2018","journal-title":"Transfusion"},{"key":"e_1_2_71_9_6_1","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/jca.22004","article-title":"Algorithm\u2010based selection of automated red blood cell exchange procedure goals reduces blood utilization in chronically transfused adults with sickle cell disease","volume":"37","author":"Buban KR","year":"2022","journal-title":"J Clin Apher"},{"key":"e_1_2_71_9_7_1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/bloodadvances.2019001143","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support","volume":"4","author":"Chou ST","year":"2020","journal-title":"Blood Adv"},{"key":"e_1_2_71_9_8_1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1401731","article-title":"Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia","volume":"371","author":"DeBaun MR","year":"2014","journal-title":"N Engl J Med"},{"key":"e_1_2_71_9_9_1","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1182\/bloodadvances.2019001142","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults","volume":"4","author":"DeBaun MR","year":"2020","journal-title":"Blood Adv"},{"key":"e_1_2_71_9_10_1","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul H","year":"2024","journal-title":"NEJM"},{"key":"e_1_2_71_9_11_1","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2017-06-789842","article-title":"Red cell exchange transfusions lower cerebral blood flow and oxygen extraction fraction in pediatric sickle cell anemia","volume":"131","author":"Guilliams KP","year":"2018","journal-title":"Blood"},{"key":"e_1_2_71_9_12_1","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(12)61726-7","article-title":"The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomized, controlled, multicentre clinical trial","volume":"381","author":"Howard J","year":"2013","journal-title":"Lancet"},{"key":"e_1_2_71_9_13_1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jpeds.2006.06.037","article-title":"Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia","volume":"149","author":"Hulbert ML","year":"2006","journal-title":"J Pediatr"},{"key":"e_1_2_71_9_14_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ajh.26741","article-title":"Lovo\u2010cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB\u2010206 study","volume":"98","author":"Kanter J","year":"2023","journal-title":"Am J Hematol"},{"key":"e_1_2_71_9_15_1","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1182\/blood-2015-06-649319","article-title":"Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta\u2010analysis","volume":"126","author":"Malinowski AK","year":"2015","journal-title":"Blood"},{"key":"e_1_2_71_9_16_1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/trf.12875","article-title":"Immunohematologic tolerance of chronic transfusion exchanges with erythrocytapheresis in sickle cell disease","volume":"55","author":"Michot JM","year":"2015","journal-title":"Transfusion"},{"key":"e_1_2_71_9_17_1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1067\/mpd.2001.119593","article-title":"Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle\u2010cell anemia","volume":"139","author":"Miller ST","year":"2001","journal-title":"J Pediatr"},{"key":"e_1_2_71_9_18_1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of L\u2010glutamine in sickle cell disease","volume":"379","author":"Niihara Y","year":"2018","journal-title":"N Engl J Med"},{"key":"e_1_2_71_9_19_1","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1182\/bloodadvances.2024012923","article-title":"Prophylactic exchange transfusion in sickle cell disease pregnancy: a TAPS2 feasibility randomized controlled trial","volume":"8","author":"Oteng\u2010Ntim E","year":"2024","journal-title":"Blood Adv"},{"key":"e_1_2_71_9_20_1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/trf.14495","article-title":"Vascular access for red blood cell exchange","volume":"58","author":"Otrock ZK","year":"2018","journal-title":"Transfusion"},{"key":"e_1_2_71_9_21_1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/jca.21511","article-title":"Red blood cell exchange: 2015 American Society for Apheresis consensus conference on the management of patients with sickle cell disease","volume":"32","author":"Sarode R","year":"2017","journal-title":"J Clin Apher"},{"key":"e_1_2_71_9_22_1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/jca.21393","article-title":"Use of a dual lumen port for automated red cell exchange in adults with sickle cell disease","volume":"30","author":"Shrestha A","year":"2015","journal-title":"J Clin Apher"},{"key":"e_1_2_71_9_23_1","unstructured":"US Department of Health and Human Services.Evidence based management of sickle cell disease expert panel report 2014. Available at:https:\/\/www.nhlbi.nih.gov\/resources\/evidence-based-management-sickle-cell-disease-expert-0(accessed October 21 2025)."},{"key":"e_1_2_71_9_24_1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(15)01041-7","article-title":"Hydroxycarbamide versus chronic transfusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anemia\u2010TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open\u2010label, phase 3, non\u2010inferiority trial","volume":"387","author":"Ware RE","year":"2016","journal-title":"Lancet"},{"key":"e_1_2_71_9_25_1","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/pbc.23145","article-title":"Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): A Phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload","volume":"57","author":"Ware RE","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_72_9_1_1","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1212\/WNL.0b013e3182582fd4","article-title":"Pearls & oysters: Hashimoto encephalopathy","volume":"78","author":"Afshari M","year":"2012","journal-title":"Neurology"},{"key":"e_1_2_72_9_2_1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.pediatrneurol.2011.11.009","article-title":"Hashimoto encephalopathy causing drug\u2010resistant status epilepticus treated with plasmapheresis","volume":"46","author":"Bektas \u00d6","year":"2012","journal-title":"Pediatr Neurol"},{"key":"e_1_2_72_9_3_1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/jnnp.70.1.132","article-title":"Hashimoto's encephalopathy responding to plasmapheresis","volume":"70","author":"Boers PM","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_72_9_4_1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11910-023-01255-5","article-title":"Hashimoto's encephalopathy: case series and literature review","volume":"23","author":"Chaudhuri J","year":"2023","journal-title":"Curr Neurol Neurosci Rep"},{"key":"e_1_2_72_9_5_1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/archneur.60.2.164","article-title":"Hashimoto encephalopathy: syndrome or myth?","volume":"60","author":"Chong JY","year":"2003","journal-title":"Arch Neurol"},{"key":"e_1_2_72_9_6_1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/jca.21353","article-title":"The use of plasma exchange in Hashimoto's encephalopathy: a case report and review of the literature","volume":"30","author":"Cook MK","year":"2015","journal-title":"J Clin Apher"},{"key":"e_1_2_72_9_7_1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.pediatrneurol.2011.09.010","article-title":"Hashimoto's encephalopathy in children and adolescents","volume":"45","author":"Erol I","year":"2011","journal-title":"Pediatr Neurol"},{"key":"e_1_2_72_9_8_1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.atherosclerosissup.2017.05.041","volume":"30","author":"Fassbender C","year":"2017","journal-title":"Immunoadsorption for autoimmune encephalitis. Atheroscler Supp"},{"key":"e_1_2_72_9_9_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.122908","article-title":"Characterization of neurological morbidity associated with thyroid antibodies: Hashimoto's encephalopathy and beyond","volume":"458","author":"Figgie MP","year":"2024","journal-title":"J Neurol Sci"},{"key":"e_1_2_72_9_10_1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3109\/00207454.2013.836706","article-title":"Hashimoto's encephalopathy: four cases and review of literature","volume":"124","author":"Gul Mert G","year":"2014","journal-title":"Int J Neurosci"},{"key":"e_1_2_72_9_11_1","first-page":"1","article-title":"Consensus recommendation on the use of therapeutic plasma exchange for adult neurological diseases in Southeast Asia from the Southeast Asia therapeutic plasma exchange consortium","volume":"13","author":"Hiew FL","year":"2021","journal-title":"J Cent Nerv Syst Dis"},{"key":"e_1_2_72_9_12_1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.seizure.2011.04.011","article-title":"Infectious disease or Hashimoto encephalopathy flares: a case report","volume":"20","author":"Huang W","year":"2011","journal-title":"Seizure"},{"key":"e_1_2_72_9_13_1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1212\/01.WNL.0000148580.98997.C5","article-title":"Effects of prednisone and plasma exchange on cognitive impairment in Hashimoto encephalopathy","volume":"64","author":"Hussain NS","year":"2005","journal-title":"Neurology"},{"key":"e_1_2_72_9_14_1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3389\/fimmu.2019.00324","article-title":"Application of plasma exchange in steroid\u2010responsive encephalopathy","volume":"10","author":"Jiang Y","year":"2019","journal-title":"Front Immunol"},{"key":"e_1_2_72_9_15_1","article-title":"Two perPLEXing cases of Hashimoto's encephalopathy unresponsive to steroid and intravenous immunoglobulin therapy","volume":"14","author":"Karan A","year":"2022","journal-title":"Cureus"},{"key":"e_1_2_72_9_16_1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.braindev.2017.07.008","article-title":"Hashimoto encephalopathy in pediatric patients: homogeneity in clinical presentation and heterogeneity in antibody titers","volume":"40","author":"Lee J","year":"2018","journal-title":"Brain Dev"},{"key":"e_1_2_72_9_17_1","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3390\/biomedicines13030726","article-title":"Hashimoto's encephalopathy: clinical features, therapeutic strategies, and rehabilitation approaches","volume":"13","author":"Manocchio N","year":"2025","journal-title":"Biomedicines"},{"key":"e_1_2_72_9_18_1","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jns.2009.09.030","article-title":"Clinical manifestations, diagnostic criteria and therapy of Hashimoto's encephalopathy: report of two cases","volume":"288","author":"Mijajlovic M","year":"2010","journal-title":"J Neurol Sci"},{"key":"e_1_2_72_9_19_1","first-page":"80","article-title":"Subacute Hashimoto's encephalopathy, treated with plasmapheresis","volume":"104","author":"Nieuwenhuis L","year":"2004","journal-title":"Acta Neurol Belg"},{"key":"e_1_2_72_9_20_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2013.05.009","article-title":"Diagnostic and therapeutic aspects of Hashimoto's encephalopathy","volume":"331","author":"Olmez I","year":"2013","journal-title":"J Neurol Sci"},{"key":"e_1_2_72_9_21_1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00415-013-7228-0","article-title":"A follow\u2010up 18F\u2010FDG brain PET study in a case of Hashimoto's encephalopathy causing drug\u2010resistant status epilepticus treated with plasmapheresis","volume":"261","author":"Pari E","year":"2014","journal-title":"J Neurol"},{"key":"e_1_2_72_9_22_1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.prp.2010.02.015","article-title":"Hashimoto encephalopathy with fulminant myocarditis","volume":"206","author":"Podberezin M","year":"2010","journal-title":"Pathol Res Pract"},{"key":"e_1_2_72_9_23_1","first-page":"1","article-title":"Hashimoto encephalopathy: a literature review and case report with comprehensive neuropsychological evaluation","volume":"18","author":"Schenck LAM","year":"2024","journal-title":"Clin Neuropsychol"},{"key":"e_1_2_72_9_24_1","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/jca.21597","article-title":"Therapeutic plasma exchange for Hashimoto's encephalopathy","volume":"33","author":"Simmons SC","year":"2018","journal-title":"J Clin Apher"},{"key":"e_1_2_72_9_25_1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.transci.2018.05.027","article-title":"Long\u2010term plasma exchange as maintenance therapy for cerebellar\u2010type Hashimoto's encephalopathy, a case report","volume":"57","author":"Tran MH","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_73_9_1_1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.transci.2019.03.015","article-title":"Role of plasma exchange in stiff person syndrome","volume":"58","author":"Albahra S","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_73_9_2_1","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025260","article-title":"Use of subcutaneous immunoglobulin in stiff person syndrome: case series","volume":"100","author":"Aljarallah S","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"e_1_2_73_9_3_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaut.2019.04.007","article-title":"The neurological syndromes associated with glutamic acid decarboxylase antibodies","volume":"101","author":"Baizabal\u2010Carvallo JF","year":"2019","journal-title":"J Autoimmun"},{"key":"e_1_2_73_9_4_1","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1212\/WNL.41.10.1588","article-title":"Autoantibodies to GABAergic neurons and response to plasmapheresis in stiff\u2010man syndrome","volume":"41","author":"Brashear HR","year":"1991","journal-title":"Neurology"},{"key":"e_1_2_73_9_5_1","first-page":"e817","article-title":"Autologous hematopoietic stem cell transplantation for stiff\u2010person spectrum disorder: a clinical trial","volume":"96","author":"Burt RK","year":"2021","journal-title":"Neurology"},{"key":"e_1_2_73_9_6_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200197","article-title":"Successful autologous hematopoietic stem cell transplant in glycine receptor antibody\u2010positive Stiff Person Syndrome: a case report","volume":"11","author":"Celli SI","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_2_73_9_7_1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ncl.2012.09.005","article-title":"Stiff person syndrome","volume":"31","author":"Ciccoto G","year":"2013","journal-title":"Neurol Clin"},{"key":"e_1_2_73_9_8_1","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jamaneurol.2013.4442","article-title":"Childhood onset of stiff\u2010man syndrome","volume":"70","author":"Clardy SL","year":"2013","journal-title":"JAMA Neurol"},{"key":"e_1_2_73_9_9_1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1515\/med-2021-0220","article-title":"Efficacy and safety of therapeutic plasma exchange in stiff person syndrome","volume":"16","author":"Czempik PF","year":"2021","journal-title":"Open Med (Wars)"},{"key":"e_1_2_73_9_10_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200109","article-title":"Therapies in stiff\u2010person syndrome: advances and future prospects based on disease pathophysiology","volume":"10","author":"Dalakas MC","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_2_73_9_11_1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/mds.25167","article-title":"Treatment of stiff\u2010person syndrome with chronic plasmapheresis","volume":"28","author":"De la Casa\u2010Fages B","year":"2013","journal-title":"Mov Disord"},{"key":"e_1_2_73_9_12_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/jca.21342","article-title":"Therapeutic plasma exchange and immunosuppressive therapy in a patient with anti\u2010GAD antibody\u2010related epilepsy: quantification of the antibody response","volume":"30","author":"Farooqi MS","year":"2015","journal-title":"J Clin Apher"},{"key":"e_1_2_73_9_13_1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00415-020-10054-8","article-title":"Autologous hematopoietic stem cell transplantation for refractory stiff\u2010person syndrome: the UK experience","volume":"268","author":"Kass\u2010Iliyya L","year":"2021","journal-title":"J Neurol"},{"key":"e_1_2_73_9_14_1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.htct.2023.11.014","article-title":"Therapeutic role of plasma exchange in the management of stiff person syndrome: experience from a tertiary care centre","volume":"46","author":"Kumawat V","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"key":"e_1_2_73_9_15_1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0025-6196(12)61012-X","article-title":"Stiff\u2010man syndrome","volume":"66","author":"McEvoy KM","year":"1991","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_73_9_16_1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/archneurol.2011.991","article-title":"Stiff\u2010man syndrome and variants: clinical course, treatments and outcomes","volume":"69","author":"McKeon A","year":"2012","journal-title":"Arch Neurol"},{"key":"e_1_2_73_9_17_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.autneu.2021.102910","article-title":"Severe dysautonomia in glycine receptor antibody\u2010positive progressive encephalomyelitis with rigidity and myoclonus (PERM): a case report","volume":"237","author":"Mizutani Y","year":"2022","journal-title":"Auton Neurosci"},{"key":"e_1_2_73_9_18_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562864231180736","article-title":"Therapeutic plasma exchange in the management of stiff person syndrome spectrum disorders: a case series and review of the literature","volume":"16","author":"Mercure\u2010Corriveau N","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"e_1_2_73_9_19_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000696","article-title":"Neurologic syndromes related to anti\u2010GAD65: clinical and serologic response to treatment","volume":"7","author":"Mu\u00f1oz\u2010Lopetegi A","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_2_73_9_20_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577915","article-title":"Stiff person syndrome spectrum disorders; more than meets the eye","volume":"369","author":"Newsome SD","year":"2022","journal-title":"J Neuroimmunol"},{"key":"e_1_2_73_9_21_1","article-title":"Stiff\u2010person syndrome: a treatment update and new directions","volume":"12","author":"Ortiz JF","year":"2020","journal-title":"Cureus"},{"key":"e_1_2_73_9_22_1","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1111\/trf.12573","article-title":"Efficacy of therapeutic plasma exchange for treatment of stiff\u2010person syndrome","volume":"54","author":"Pagano MB","year":"2014","journal-title":"Transfusion"},{"key":"e_1_2_73_9_23_1","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/mus.23234","article-title":"Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes","volume":"45","author":"Rakocevic G","year":"2012","journal-title":"Muscle Nerve"},{"key":"e_1_2_73_9_24_1","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1001\/jamaneurol.2014.1297","article-title":"Autologous stem cell transplantation for stiff person syndrome: two cases from the Ottawa blood and marrow transplant program","volume":"71","author":"Sanders S","year":"2014","journal-title":"JAMA Neurol"},{"key":"e_1_2_73_9_25_1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/vox.13205","article-title":"Profile of the single\u2010use, multiple\u2010pass protein A adsorber column in immunoadsorption","volume":"117","author":"Schossee N","year":"2022","journal-title":"Vox Sang."},{"key":"e_1_2_73_9_26_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562864211003486","article-title":"GAD antibody\u2010spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions","volume":"14","author":"Tsiortou P","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"e_1_2_74_9_1_1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.5301\/IJAO.2011.8548","article-title":"Apheresis as a rescue therapy in a severe case of sudden hearing loss","volume":"34","author":"Alpa M","year":"2011","journal-title":"In J Artif Organs"},{"key":"e_1_2_74_9_2_1","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1007\/s00405-014-3449-9","article-title":"Fibrinogen is not a prognostic factor for response to HELP\u2010apheresis in sudden sensorineural hearing loss (SSHL)","volume":"272","author":"Berger T","year":"2015","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"e_1_2_74_9_3_1","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/lary.20835","article-title":"Treatment with HELP\u2010apheresis in patients suffering from sudden sensorineural hearing loss: a prospective, randomized, controlled trial","volume":"120","author":"Bianchin G","year":"2010","journal-title":"Laryngoscope"},{"key":"e_1_2_74_9_4_1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/0194599819859883","article-title":"Clinical practice guideline: sudden hearing loss (update) executive summary","volume":"161","author":"Chandrasekhar SS","year":"2019","journal-title":"Otolaryngol Head Neck Surg"},{"key":"e_1_2_74_9_5_1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/00016480802495438","article-title":"The influence of cholesterol on the motility of cochlear outer hair cells and the motor protein prestin","volume":"129","author":"Canis M","year":"2009","journal-title":"Acta Otolaryngol"},{"key":"e_1_2_74_9_6_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121025","article-title":"The relationship between serum lipids and sudden sensorineural hearing loss: a systematic review and meta\u2010analysis","volume":"10","author":"Chang IJ","year":"2015","journal-title":"PLoS One"},{"key":"e_1_2_74_9_7_1","first-page":"941","article-title":"Evidence\u2010based practice: management of adult sensorineural hearing loss","volume":"45","author":"Chau JK","year":"2012","journal-title":"Otolaryngol Clin North Am"},{"key":"e_1_2_74_9_8_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/lary.24834","article-title":"Steroids for treatment of sudden sensorineural hearing loss: a meta\u2010analysis of randomized controlled trials","volume":"125","author":"Crane RA","year":"2015","journal-title":"Laryngoscope"},{"key":"e_1_2_74_9_9_1","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/phar.2044","article-title":"Evaluation and treatment of acute and subacute hearing loss: a review of pharmacotherapy","volume":"37","author":"Fazel TM","year":"2017","journal-title":"Pharmacother"},{"key":"e_1_2_74_9_10_1","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.autrev.2011.05.005","article-title":"Sudden sensorineural hearing loss: an autoimmune disease?","volume":"10","author":"Greco A","year":"2011","journal-title":"Autoimmun Rev."},{"key":"e_1_2_74_9_11_1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1567-5688(09)71820-3","article-title":"Fibrinogen\/LDL apheresis as successful second\u2010line treatment of sudden hearing loss: a retrospective study of 217 patients","volume":"10","author":"Heigl F","year":"2009","journal-title":"Atherosclerosis"},{"key":"e_1_2_74_9_12_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5152\/iao.2020.7438","article-title":"Prognostic value of fibrinogen\/HDL ratio in idiopathic sudden sensorineural hearing loss","volume":"17","author":"Hira \u0130","year":"2021","journal-title":"J Int Adv Otol"},{"key":"e_1_2_74_9_13_1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S1567-5688(09)71821-5","article-title":"Rheopheresis for sudden sensorineural hearing loss","volume":"10","author":"Klingel R","year":"2009","journal-title":"Atheroscler Suppl"},{"key":"e_1_2_74_9_14_1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40463-017-0228-9","article-title":"Rheopheresis in treatment of idiopathic sensorineural sudden hearing loss","volume":"46","author":"Kostal M","year":"2017","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"e_1_2_74_9_15_1","first-page":"572","article-title":"Plasmapheresis in autoimmune inner ear disease: long\u2010term follow\u2010up","volume":"18","author":"Luetje CM","year":"1997","journal-title":"Am J Otol"},{"key":"e_1_2_74_9_16_1","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1468-1331.2011.03627.x","article-title":"Susac syndrome: clinical characteristics and treatment in 29 new cases","volume":"19","author":"Mateen FJ","year":"2012","journal-title":"Eur J Neurol"},{"key":"e_1_2_74_9_17_1","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00405-008-0823-5","article-title":"Rheopheresis for idiopathic sudden hearing loss: results from a large prospective, multicenter, randomized, controlled clinical trial","volume":"266","author":"M\u00f6sges R","year":"2009","journal-title":"Eur Arch Otorhinolarygol"},{"key":"e_1_2_74_9_18_1","unstructured":"National Institute for Health and Care Excellence (NICE) guideline: hearing loss in adults: assessment and management. Published: 21 June 2018 (Last updated 2 October 2023) Available at:https:\/\/www.nice.org.uk\/guidance\/ng98(accessed November 1 2025)."},{"key":"e_1_2_74_9_19_1","doi-asserted-by":"crossref","DOI":"10.1002\/jca.22098","article-title":"Therapeutic plasma exchange in refractory Susac's syndrome: A brief report","volume":"39","author":"Salazar RD","year":"2024","journal-title":"J Clin Apheresis"},{"key":"e_1_2_74_9_20_1","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(02)11768-5","article-title":"Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomized multicentre trial","volume":"360","author":"Suckfull M.","year":"2002","journal-title":"Lancet"},{"key":"e_1_2_74_9_21_1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/PL00007510","article-title":"Heparin\u2010induced extracorporeal low\u2010density\u2010lipoprotien precipitation (H.E.L.P.) to improve the recovery of hearing loss in patients with sudden idiopathic hearing loss","volume":"257","author":"Suckfull M","year":"2000","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"e_1_2_74_9_22_1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00129492-200205000-00013","article-title":"Hyperfibrinogenemia as a risk factor for sudden hearing loss","volume":"23","author":"Suckfull M","year":"2002","journal-title":"Otol Neurotol"},{"key":"e_1_2_74_9_23_1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/00016489950180397","article-title":"Clinical utility of LDL\u2010apheresis in the treatment of sudden hearing loss: a prospective, randomized study","volume":"119","author":"Suckfull M","year":"1999","journal-title":"Acta Otolaryngol"},{"key":"e_1_2_74_9_24_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/jca.20001","article-title":"Improved treatment of sudden hearing loss by specific fibrinogen aphaeresis","volume":"19","author":"Ullrich H","year":"2004","journal-title":"J Clin Apheresis"},{"key":"e_1_2_75_9_1_1","first-page":"5350960","article-title":"Therapeutic plasma exchange as management of complicated systemic lupus erythematosus and other autoimmune diseases","volume":"2019","author":"Aguirre\u2010Valencia D","year":"2019","journal-title":"Autoimm Dis"},{"key":"e_1_2_75_9_2_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/TCRM.S252592","article-title":"Emerging B\u2010cell therapies in systemic lupus erythematosus","volume":"17","author":"Bag\u2010Ozbek A","year":"2021","journal-title":"Ther Clin Risk Management"},{"key":"e_1_2_75_9_3_1","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/ndt\/15.9.1367","article-title":"Immunoadsorption onto protein A induces remission in severe systemic lupus erythematosus","volume":"15","author":"Braun N","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_75_9_4_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis A","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_75_9_5_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update on the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis A","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_75_9_6_1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex286","article-title":"The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults","volume":"57","author":"Gordon C","year":"2018","journal-title":"Rheumatology"},{"key":"e_1_2_75_9_7_1","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn BH","year":"2012","journal-title":"Arthritis Care Res"},{"key":"e_1_2_75_9_8_1","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1007\/s10067-016-3354-2","article-title":"Rapid reduction of antibodies and improvement of disease activity by immunoadsorption in Chinese patients with severe systemic lupus erythematosus","volume":"35","author":"Huang J","year":"2016","journal-title":"Clin Rheumatol"},{"key":"e_1_2_75_9_9_1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.autrev.2015.08.010","article-title":"Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review","volume":"15","author":"Kronbichler A","year":"2016","journal-title":"Autoimmun Rev."},{"key":"e_1_2_75_9_10_1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/jca.2920070314","article-title":"Plasmapheresis therapy is ineffective in SLE. Lupus Nephritis Collaborative Study Group","volume":"7","author":"Lewis EJ","year":"1992","journal-title":"J Clin Apher"},{"key":"e_1_2_75_9_11_1","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJM199205213262101","article-title":"A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group","volume":"326","author":"Lewis EJ","year":"1992","journal-title":"N Engl J Med"},{"key":"e_1_2_75_9_12_1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jca.21408","article-title":"Therapeutic effect of double\u2010filtration plasmapheresis combined with methylprednisolone to treat diffuse proliferative lupus nephritis","volume":"31","author":"Li M","year":"2016","journal-title":"J Clin Apher"},{"key":"e_1_2_75_9_13_1","doi-asserted-by":"crossref","first-page":"7757","DOI":"10.62347\/SSTO6670","article-title":"Efficacy of double filtration plasmapheresis combined with immunosuppressive agents in the treatment of severe lupus nephritis","volume":"16","author":"Lin X","year":"2024","journal-title":"Am J Transl Res"},{"key":"e_1_2_75_9_14_1","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.998328","article-title":"Pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus: a review","volume":"10","author":"Liu Y","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"e_1_2_75_9_15_1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.transci.2010.10.003","article-title":"Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis","volume":"43","author":"Loo CY","year":"2010","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_75_9_16_1","article-title":"Management and treatment of children, young people and adults with systemic lupus erythematosus: British Society for Rheumatology guideline scope","volume":"7","author":"Md Yusof MY","year":"2023","journal-title":"Rheumatol Adv Pract."},{"key":"e_1_2_75_9_17_1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1526-0968.2003.00032.x","article-title":"The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus","volume":"7","author":"Neuwelt CM","year":"2003","journal-title":"Ther Apher Dial"},{"key":"e_1_2_75_9_18_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.semarthrit.2020.12.004","article-title":"Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: a systematic review","volume":"51","author":"Papachristos DA","year":"2021","journal-title":"Sem Arthritis Rheum"},{"key":"e_1_2_75_9_19_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.kint.2023.09.001","article-title":"Executive summary of the KDIGO 2024 clinical practice guideline for the management of lupus nephritis","volume":"105","author":"Rovin BH","year":"2024","journal-title":"Kidney Int"},{"key":"e_1_2_75_9_20_1","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/annrheumdis-2019-215098","article-title":"Fatigue in SLE: diagnostic and pathogenic impact of anti\u2010N\u2010methyl\u2010D\u2010aspartate receptor (NMDAR) autoantibodies","volume":"78","author":"Schwarting A","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_75_9_21_1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.5152\/eurjrheum.2017.17088","article-title":"Therapeutic plasma exchange for refractory SLE: a comparison of outcomes between different sub\u2010phenotypes","volume":"5","author":"Soyu\u00f6z A","year":"2018","journal-title":"Eur J Rheumatol"},{"key":"e_1_2_75_9_22_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0140-6736(83)91561-1","article-title":"Randomized trial of plasma exchange in mild systemic lupus erythematosus","volume":"1","author":"Wei N","year":"1983","journal-title":"Lancet"},{"key":"e_1_2_75_9_23_1","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1007\/s10067-020-05156-7","article-title":"Meta\u2010analysis on the efficacy and safety of immunoadsorption for systemic lupus erythematosus among Chinese population","volume":"39","author":"Yang M","year":"2020","journal-title":"Clin Rheumatol"},{"key":"e_1_2_75_9_24_1","doi-asserted-by":"crossref","first-page":"1035150","DOI":"10.3389\/fmed.2022.1035150","article-title":"The development of immunosorbents for the treatment of systemic lupus erythematosus via hemoperfusion","volume":"9","author":"Yu Y","year":"2023","journal-title":"Front Med (Lausanne)."},{"key":"e_1_2_76_9_1_1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/03009748809105267","article-title":"Visceral improvement following combined plasmapheresis and immunosuppressive drug therapy in progressive systemic sclerosis","volume":"17","author":"Akesson A","year":"1988","journal-title":"Scand J Rheumatol"},{"key":"e_1_2_76_9_2_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2024.104036","volume":"64","author":"Bano S","year":"2025","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_76_9_3_1","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1093\/ndt\/gfs317","article-title":"Prognosis of scleroderma renal crisis: a long\u2010term observational study","volume":"27","author":"Cozzi F","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_76_9_4_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1473-0502(01)00078-7","article-title":"Long\u2010term therapy with plasma exchange in systemic sclerosis: effects on laboratory markers reflecting disease activity","volume":"25","author":"Cozzi F","year":"2001","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_76_9_5_1","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/art.1780240903","article-title":"Plasmapheresis and immunosuppressive drug therapy in scleroderma","volume":"24","author":"Dau PC","year":"1981","journal-title":"Arthritis Rheum"},{"key":"e_1_2_76_9_6_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo F","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_76_9_7_1","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15530","article-title":"Extracorporeal photopheresis for systemic sclerosis: a meta\u2010analysis of randomized clinical trials","volume":"35","author":"Delbruck C","year":"2022","journal-title":"Dermatol Ther"},{"key":"e_1_2_76_9_8_1","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1093\/rheumatology\/kew224","article-title":"BSR and BSHPR guideline for the treatment of systemic sclerosis","volume":"55","author":"Denton CP","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_76_9_9_1","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0190-9622(99)70246-X","article-title":"Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis)","volume":"41","author":"Enomoto DN","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_76_9_10_1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/039139889001300213","article-title":"Treatment of progressive systemic sclerosis by plasma exchange: long\u2010term results in 40 patients","volume":"13","author":"Guillevin L","year":"1990","journal-title":"Int J Artif Organs"},{"key":"e_1_2_76_9_11_1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/2397198318758606","article-title":"Therapeutic plasma exchange for the treatment of systemic sclerosis: a comprehensive review and analysis","volume":"3","author":"Harris ES","year":"2018","journal-title":"J Scleroderma Relat Disord"},{"key":"e_1_2_76_9_12_1","first-page":"1","article-title":"Plasmapheresis in Raynaud's phenomenon in systemic sclerosis: a microcirculatory study","volume":"10","author":"Jacobs MJ","year":"1991","journal-title":"Int J Microcirc Clin Exp"},{"key":"e_1_2_76_9_13_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jdv.12311","article-title":"Guidelines on the use of extracorporeal photopheresis","volume":"28","author":"Knobler R","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_76_9_14_1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jaad.2005.11.1091","article-title":"A randomized, double\u2010blind, placebo\u2010controlled trial of photopheresis in systemic sclerosis","volume":"54","author":"Knobler RM","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_76_9_15_1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/jca.2920010404","article-title":"Plasma exchange: a controlled study of the effect in patients with Raynaud's phenomenon and scleroderma","volume":"1","author":"McCune MA","year":"1983","journal-title":"J Clin Apher"},{"key":"e_1_2_76_9_16_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2133.2005.06857.x","article-title":"Evidence\u2010based practice of photopheresis 1987\u20132001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group","volume":"154","author":"McKenna KE","year":"2006","journal-title":"Br J Dermatol"},{"key":"e_1_2_76_9_17_1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.clim.2011.09.014","article-title":"Immunomodulatory effects of extracorporeal photo\u2010chemotherapy in systemic sclerosis","volume":"142","author":"Papp G","year":"2012","journal-title":"Clin Immunol"},{"key":"e_1_2_76_9_18_1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12026-015-8678-5","article-title":"The assessment of immune\u2010regulatory effects of extracorporeal photopheresis in systemic sclerosis: a long\u2010term follow\u2010up study","volume":"62","author":"Papp G","year":"2016","journal-title":"Immunol Res"},{"key":"e_1_2_76_9_19_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2022.100174","article-title":"Favorable long term effects of intensified immunosuppression combined with therapeutic plasma exchange in patients with early\u2010onset progressive systemic sclerosis\u2010related interstitial lung disease","volume":"5","author":"Potjewijd J","year":"2022","journal-title":"J Transl Autoimmun."},{"key":"e_1_2_76_9_20_1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.tmrv.2014.09.004","article-title":"National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: scientific opportunities in extracorporeal photopheresis","volume":"29","author":"Ratcliffe N","year":"2015","journal-title":"Transfus Med Rev."},{"key":"e_1_2_76_9_21_1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archderm.1992.01680130051005","article-title":"Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial","volume":"128","author":"Rook AH","year":"1992","journal-title":"Arch Dermatol"},{"key":"e_1_2_76_9_22_1","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019301","article-title":"Therapeutic efficacy of combined glucocorticoid, intravenous cyclophosphamide, and double\u2010filtration plasmapheresis for skin sclerosis in diffuse systemic sclerosis","volume":"99","author":"Suga K","year":"2020","journal-title":"Medicine"},{"key":"e_1_2_76_9_23_1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10067-008-1062-2","article-title":"Combined plasmapheresis and high\u2010dose intravenous immunoglobulin treatment in systemic sclerosis for 12\u2009months: follow\u2010up of immunopathological and clinical effects","volume":"28","author":"Szekanecz Z","year":"2009","journal-title":"Clin Rheumatol"},{"key":"e_1_2_76_9_24_1","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.autrev.2018.03.012","article-title":"Therapy of scleroderma renal crisis: State of the art","volume":"17","author":"Zanatta E","year":"2018","journal-title":"Autoimmun Rev."},{"key":"e_1_2_76_9_25_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11926-017-0662-8","article-title":"Photopheresis: advances and use in systemic sclerosis","volume":"19","author":"Zhou XA","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"e_1_2_77_9_1_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.leukres.2017.03.008","article-title":"The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: a case\u2010based review","volume":"58","author":"Boddu P","year":"2017","journal-title":"Leuk Res"},{"key":"e_1_2_77_9_2_1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/ejh.12759","volume":"97","author":"Buxhofer\u2010Ausch V","year":"2016","journal-title":"Eur J Haematol"},{"key":"e_1_2_77_9_3_1","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell PJ","year":"2012","journal-title":"Blood"},{"key":"e_1_2_77_9_4_1","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/jca.21644","article-title":"Therapeutic white blood cells and platelet depletions using the spectra OPTIA system continuous mononuclear cell protocol","volume":"33","author":"Cates NC","year":"2018","journal-title":"J Clin Apher"},{"key":"e_1_2_77_9_5_1","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.athoracsur.2011.02.050","article-title":"Thrombocytapheresis: managing essential thrombocythemia in a surgical patient","volume":"92","author":"Das SS","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"e_1_2_77_9_6_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.transci.2012.09.009","article-title":"Managing uncontrolled postsplenectomy reactive thrombocytosis in idiopathic thrombocytopenic purpura: role of thrombocytapheresis","volume":"49","author":"Das SS","year":"2013","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_77_9_7_1","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s00432-015-1983-5","article-title":"Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973\u20132011","volume":"141","author":"Deadmond MA","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"e_1_2_77_9_8_1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.14443","article-title":"Approach to patients with essential thrombocythaemia and very high platelets count: what is the evidence of treatment?","volume":"176","author":"Falchi L","year":"2017","journal-title":"Br J Haematol"},{"key":"e_1_2_77_9_9_1","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.1111\/hae.12152","article-title":"Acquired von Willebrand's disease in myelofibrosis and essential thrombocythemia","volume":"19","author":"Goyal J","year":"2013","journal-title":"Hemophilia"},{"key":"e_1_2_77_9_10_1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2014.1.348","article-title":"Management of MPN beyond JAK2","author":"Harrison CN","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"e_1_2_77_9_11_1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.762419","article-title":"Therapeutic plateletpheresis in patients with thrombocytosis: gender, hemoglobin before apheresis significantly affect collection efficiency","volume":"8","author":"Jiang H","year":"2021","journal-title":"Front Med"},{"key":"e_1_2_77_9_12_1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/jca.21558","article-title":"Trouble\u2010shooting the collect concentration monitor alarm in therapeutic thrombocytapheresis","volume":"33","author":"Linn N","year":"2018","journal-title":"J Clin Apher"},{"key":"e_1_2_77_9_13_1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","article-title":"Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic","volume":"107","author":"Mesa RA","year":"2006","journal-title":"Cancer"},{"key":"e_1_2_77_9_14_1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia J","year":"2013","journal-title":"N Eng J Med"},{"key":"e_1_2_77_9_15_1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4103\/0973-6247.150961","article-title":"Therapeutic platelet reduction: use in postsplenectomy thrombocytosis","volume":"9","author":"Negi G","year":"2015","journal-title":"Asian J Transfus Sci"},{"key":"e_1_2_77_9_16_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/jca.21847","article-title":"Therapeutic thrombocytapheresis in myeloproliferative neoplasms: a single\u2010institution experience","volume":"36","author":"Nguyen TH","year":"2021","journal-title":"J Clin Apher"},{"key":"e_1_2_77_9_17_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/1744-9987.12635","article-title":"Therapeutic thrombocytapheresis for symptomatic thrombocytosis in hemato\u2010oncology patients","volume":"22","author":"Prakash S","year":"2018","journal-title":"Ther Apher Dial"},{"key":"e_1_2_77_9_18_1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ajh.23635","article-title":"Pregnancy complications predict thrombotic events in young women with essential thrombocythemia","volume":"89","author":"Randi ML","year":"2014","journal-title":"Am J Hematol"},{"key":"e_1_2_77_9_19_1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/jca.21254","article-title":"Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim","volume":"28","author":"Raval JS","year":"2013","journal-title":"J Clin Apher"},{"key":"e_1_2_77_9_20_1","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.mayocp.2015.05.014","article-title":"Essential thrombocythemia and polycythemia vera: focus on clinical practice","volume":"90","author":"Tefferi A","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_77_9_21_1","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk\u2010stratification and management","volume":"95","author":"Tefferi A","year":"2020","journal-title":"Am J Hematol"},{"key":"e_1_2_77_9_22_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejogrb.2011.04.040","article-title":"Essential thrombocythemia and pregnancy","volume":"158","author":"Valera MC","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"e_1_2_77_9_23_1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/MOH.0000000000000402","article-title":"Polycythemia vera and essential thrombocythemia: algorithmic approach","volume":"25","author":"Vannucchi AM","year":"2018","journal-title":"Curr Opin Hematol"},{"key":"e_1_2_78_9_1_1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/1744-9987.12503","article-title":"Successful treatment of atypical hemolytic uremic syndrome with therapeutic plasma exchange in a 3.8\u2010kg neonate","volume":"21","author":"Almoshary MA","year":"2017","journal-title":"Ther Apher Dial"},{"key":"e_1_2_78_9_2_1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10157-022-02293-y","article-title":"Comparison of outcomes after plasma therapy or eculizumab in pediatric patients with atypical hemolytic uremic syndrome","volume":"27","author":"Ashida A","year":"2023","journal-title":"Clin Exp Nephrol"},{"key":"e_1_2_78_9_3_1","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1681\/ASN.2017010031","article-title":"The phenotypic spectrum of nephropathies associated with mutations in diacylglycerol kinase epsilon","volume":"28","author":"Azukaitis K","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_78_9_4_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12882-016-0420-6","article-title":"Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients","volume":"18","author":"Besbas N","year":"2017","journal-title":"BMC Nephrology"},{"key":"e_1_2_78_9_5_1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013050453","article-title":"Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome","volume":"25","author":"Bu F","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_78_9_6_1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/ckj\/sfv025","article-title":"Posttransplant outcome of atypical haemolytic uraemic syndrome in a patient with thrombomodulin mutation: a case without recurrence","volume":"8","author":"Caroti L","year":"2015","journal-title":"Clin Kidney J"},{"issue":"10","key":"e_1_2_78_9_7_1","first-page":"1038","article-title":"Adolescence\u2010onset atypical hemolytic uremic syndrome: is it different from infant\u2010onset? Clin Exp Nephrol. 2024;28(10):1027\u20131037","volume":"28","author":"Celegen K","year":"2024","journal-title":"Erratum in: Clin Exp Nephrol."},{"key":"e_1_2_78_9_8_1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic\u2010uremic syndrome","volume":"361","author":"Delvaeye M","year":"2009","journal-title":"N Engl J Med"},{"key":"e_1_2_78_9_9_1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41581-021-00424-4","article-title":"Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics","volume":"17","author":"Fakhouri F","year":"2021","journal-title":"Nat Rev. Nephrology"},{"key":"e_1_2_78_9_10_1","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.938896","article-title":"Atypical hemolytic uremic syndrome in a pregnant patient with a thrombomodulin gene variant treated with plasma exchange and eculizumab","volume":"24","author":"Kannan L.","year":"2023","journal-title":"Am J Case Rep."},{"key":"e_1_2_78_9_11_1","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bjh.15062","volume":"180","author":"Keragala CB","year":"2018","journal-title":"Br J Haematol"},{"key":"e_1_2_78_9_12_1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/cge.12240","article-title":"Early infantile onset of atypical hemolytic\u2010uremic syndrome is caused by recessive mutations in DGKE","volume":"84","author":"Lee JW","year":"2013","journal-title":"Clin Genet"},{"key":"e_1_2_78_9_13_1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic\u2010uremic syndrome","volume":"45","author":"Lemaire M","year":"2013","journal-title":"Nat Genet"},{"key":"e_1_2_78_9_14_1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood-2017-12-768994","article-title":"Exploring traditional and nontraditional roles for thrombomodulin","volume":"132","author":"Loghmani H","year":"2018","journal-title":"Blood"},{"key":"e_1_2_78_9_15_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4285\/kjt.22.0050","article-title":"The first successful eculizumab rescue therapy of a kidney transplant recipient with atypical hemolytic uremic syndrome in South Korea: a case report","volume":"37","author":"Min EK","year":"2023","journal-title":"Korean J Transplant."},{"key":"e_1_2_78_9_16_1","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1160\/TH15-01-0007","article-title":"Atypical haemolytic uraemic syndrome in a Japanese patient with DGKE genetic mutations","volume":"114","author":"Miyata T","year":"2015","journal-title":"Thromb Haemost"},{"key":"e_1_2_78_9_17_1","volume-title":"Genetic Atypical Hemolytic\u2010Uremic Syndrome. 2007 Nov 16 [Updated 2021 Sep 23]. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. GeneReviews [Internet]","author":"Noris M","year":"1993"},{"key":"e_1_2_78_9_18_1","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris M","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"e_1_2_78_9_19_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1681\/ASN.2012090903","article-title":"DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN","volume":"24","author":"Ozaltin F","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_78_9_20_1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/ng.2622","article-title":"DGKE and atypical HUS","volume":"45","author":"Quaggin SE","year":"2013","journal-title":"Nat Genet"},{"key":"e_1_2_78_9_21_1","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2215\/CJN.01640214","article-title":"Complement mutations in diacylglycerol kinase\u2010\u03b5\u2010associated atypical hemolytic uremic syndrome","volume":"9","author":"Sanchez Chinchilla D","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"e_1_2_78_9_22_1","doi-asserted-by":"crossref","first-page":"E177","DOI":"10.1111\/petr.12151","article-title":"Post\u2010transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation","volume":"17","author":"Sinibaldi S","year":"2013","journal-title":"Pediatr Transplant"},{"key":"e_1_2_78_9_23_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jim.2018.07.006","article-title":"Atypical hemolytic uremic syndrome: review of clinical presentation, diagnosis, and management","volume":"461","author":"Sridharan M","year":"2018","journal-title":"J Immunol Methods"},{"key":"e_1_2_78_9_24_1","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1681\/ASN.2019040331","article-title":"Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome","volume":"30","author":"Zuber J","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"e_1_2_79_9_1_1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.kint.2020.10.046","article-title":"The long\u2010acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"100","author":"Ariceta G","year":"2021","journal-title":"Kidney Int"},{"key":"e_1_2_79_9_2_1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.chest.2017.03.055","article-title":"Expert statements on the standard of care in critically ill adult patients with atypical hemolytic uremic syndrome","volume":"152","author":"Azoulay E","year":"2017","journal-title":"Chest"},{"key":"e_1_2_79_9_3_1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.kint.2017.04.028","article-title":"Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland","volume":"92","author":"Brocklebank V","year":"2017","journal-title":"Kidney Int"},{"key":"e_1_2_79_9_4_1","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2215\/CJN.00280117","article-title":"Hemolytic uremic syndrome in pregnancy and postpartum","volume":"12","author":"Bruel A","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"e_1_2_79_9_5_1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000492865","article-title":"Eculizumab modifies outcomes in adults with atypical hemolytic uremic syndrome with acute kidney injury","volume":"48","author":"Cao M","year":"2018","journal-title":"Am J Nephrol"},{"key":"e_1_2_79_9_6_1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/jcpt.13642","article-title":"Ravulizumab 100\u2009mg\/mL formulation reduces infusion time and frequency, improving the patient and caregiver experience in the treatment of atypical haemolytic uraemic syndrome","volume":"47","author":"Dixon BP","year":"2022","journal-title":"J Clin Pharm Ther."},{"key":"e_1_2_79_9_7_1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2016.99","article-title":"Anti\u2010complement factor H\u2010associated glomerulopathies","volume":"12","author":"Durey MAD","year":"2016","journal-title":"Nat Rev. Nephrol"},{"key":"e_1_2_79_9_8_1","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1182\/blood.2022017860","article-title":"How I diagnose and treat atypical hemolytic uremic syndrome","volume":"141","author":"Fakhouri F","year":"2023","journal-title":"Blood"},{"key":"e_1_2_79_9_9_1","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00467-018-4039-7","article-title":"Extra\u2010renal manifestations of atypical hemolytic uremic syndrome","volume":"34","author":"Formeck C","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"e_1_2_79_9_10_1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/nep.13234","article-title":"Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand","volume":"23","author":"Fox LC","year":"2018","journal-title":"Nephrology (Carlton)."},{"key":"e_1_2_79_9_11_1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.transci.2016.09.017","article-title":"Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: a single center experience from Turkey","volume":"55","author":"Gediz F","year":"2016","journal-title":"Tranfus Apher Sci"},{"key":"e_1_2_79_9_12_1","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jca.21412","article-title":"Efficacy and safety of therapeutic plasma exchange by using apheresis devices in pediatric atypical hemolytic uremic syndrome patients","volume":"31","author":"Hans R","year":"2016","journal-title":"J Clin Apher"},{"key":"e_1_2_79_9_13_1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/jca.21711","article-title":"Membrane\u2010filtration based plasma exchanges for atypical hemolytic uremic syndrome: Audit of efficacy and safety","volume":"34","author":"Khandelwal P","year":"2019","journal-title":"J Clin Apher"},{"key":"e_1_2_79_9_14_1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/1744-9987.12641","article-title":"Atypical hemolytic uremic syndrome: a meta\u2010analysis of case reports confirms the prevalence of genetic mutations and the shift of treatment regimens","volume":"22","author":"Krishnappa V","year":"2018","journal-title":"Ther Aph Dial"},{"key":"e_1_2_79_9_15_1","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic\u2010uremic syndrome","volume":"368","author":"Legendre CM","year":"2013","journal-title":"N Engl J Med"},{"key":"e_1_2_79_9_16_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat C","year":"2016","journal-title":"Pedatri Nephrol"},{"key":"e_1_2_79_9_17_1","first-page":"311","article-title":"Genetic atypical hemolytic uremic syndrome in children: a 20\u2010year experience from a tertiary center","volume":"43","author":"Maximiano C","year":"2021","journal-title":"J Bras Nefrol"},{"key":"e_1_2_79_9_18_1","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris M","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"e_1_2_79_9_19_1","doi-asserted-by":"crossref","first-page":"986","DOI":"10.24953\/turkjped.2021.06.006","article-title":"Could plasma based therapies still be considered in selected cases with atypical hemolytic uremic syndrome?","volume":"63","author":"\u00d6zl\u00fc SG","year":"2021","journal-title":"Turk J Pediatr"},{"key":"e_1_2_79_9_20_1","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/ki.2013.373","article-title":"Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti\u2010factor H autoantibody\u2010associated hemolytic uremic syndrome in children","volume":"85","author":"Sinha A","year":"2014","journal-title":"Kidney Int"},{"key":"e_1_2_79_9_21_1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40265-021-01481-6","article-title":"Ravulizumab: a review in atypical haemolytic uraemic syndrome","volume":"81","author":"Syed YY","year":"2021","journal-title":"Drugs"},{"key":"e_1_2_79_9_22_1","first-page":"419","article-title":"Anti\u2010compliment Factor H antibody associated hemolytic uremic syndrome in children with abbreviated plasma exchanges: a 12\u2010Month follow\u2010up study","volume":"15","author":"Tiewsoh K","year":"2021","journal-title":"Iran J Kidney Dis"},{"key":"e_1_2_79_9_23_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tracli.2021.10.001","article-title":"Role of Therapeutic Plasma Exchange in managing complement mediated thrombotic microangiopathy\u2014Case series","volume":"29","author":"Vaidya A","year":"2022","journal-title":"Transfus Clin Biol"},{"key":"e_1_2_79_9_24_1","article-title":"Recommendations for diagnosis and treatment of Atypical Hemolytic Uremic Syndrome (aHUS): an expert consensus statement from the Rare Diseases Committee of the Brazilian Society of Nephrology (COMDORA\u2010SBN)","volume":"47","author":"Vaisbich MH","year":"2025","journal-title":"J Bras Nefrol."},{"key":"e_1_2_79_9_25_1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/CLEP.S245642","article-title":"Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review","volume":"12","author":"Yan K","year":"2020","journal-title":"Clin Epidemiol"},{"issue":"10","key":"e_1_2_80_9_1_1","volume":"7","author":"Attucci I","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"key":"e_1_2_80_9_2_1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/bjh.12303","article-title":"Ticlopidine\u2010associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR)","volume":"161","author":"Bennett CL","year":"2013","journal-title":"Br J Haematol"},{"key":"e_1_2_80_9_3_1","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1182\/blood-2015-04-643148","article-title":"Mechanism of quinine\u2010dependent monoclonal antibody binding to platelet glycoprotein IIb\/IIIa","volume":"126","author":"Bougie DW","year":"2015","journal-title":"Blood"},{"key":"e_1_2_80_9_4_1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41408-024-01182-9","article-title":"Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review","volume":"14","author":"Chen C","year":"2024","journal-title":"Blood Cancer J."},{"key":"e_1_2_80_9_5_1","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-239091","article-title":"Carfilzomib\u2010induced atypical haemolytic uraemic syndrome: a diagnostic challenge and therapeutic success","volume":"26","author":"Darwin A","year":"2021","journal-title":"BMJ Case Rep"},{"key":"e_1_2_80_9_6_1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/bcp.13808","article-title":"Thrombotic microangiopathy associated with gemcitabine use: presentation and outcome in a national French retrospective cohort","volume":"85","author":"Daviet F","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_80_9_7_1","doi-asserted-by":"crossref","first-page":"274","DOI":"10.14740\/jmc3932","article-title":"Carfilzomib\u2010induced thrombotic microangiopathy: focus on pathogenesis","volume":"13","author":"Eigbire\u2010Molen O","year":"2022","journal-title":"J Med Cases"},{"key":"e_1_2_80_9_8_1","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.3390\/jcm11123355","article-title":"Genetic and functional evidence of complement dysregulation in multiple myeloma patients with carfilzomib\u2010induced thrombotic microangiopathy compared to controls","volume":"11","author":"Gavriilaki E","year":"2022","journal-title":"J Clin Med."},{"key":"e_1_2_80_9_9_1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5414\/CNP71130","article-title":"Gemcitabine nephrotoxicity and haemolytic uremic syndrome: a report of 29 cases from a single institution","volume":"71","author":"Glezerman I","year":"2009","journal-title":"Clin Nephrol"},{"key":"e_1_2_80_9_10_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jca.20213","article-title":"Is therapeutic plasma exchange indicated for patients with gemcitabine\u2010induced hemolytic uremic syndrome?","volume":"24","author":"Gore EM","year":"2009","journal-title":"J Clin Apher"},{"key":"e_1_2_80_9_11_1","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00280-010-1258-4","article-title":"Rapid and complete resolution of chemotherapy\u2010induced thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome (TTP\/HUS) with rituximab","volume":"65","author":"Gourley BL","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"e_1_2_80_9_12_1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1188\/14.ONF.551-553","article-title":"Gemcitabine\u2010associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome","volume":"41","author":"Held\u2010Warmkessel J.","year":"2014","journal-title":"Oncol Nurs Forum"},{"key":"e_1_2_80_9_13_1","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1055\/s-0032-1328894","article-title":"Ticlopidine\u2010, clopidogrel\u2010, and prasugrel\u2010associated thrombotic thrombocytopenic purpura: a 20\u2010year review from the Southern Network on Adverse Reactions (SONAR)","volume":"38","author":"Jacob S","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_80_9_14_1","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1093\/ndt\/gfae096","article-title":"Carfilzomib\u2010associated thrombotic microangiopathy: clinical features and outcomes","volume":"39","author":"Joseph A","year":"2024","journal-title":"Nephrol Dial Transplant."},{"key":"e_1_2_80_9_15_1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1055\/s-0032-1328886","article-title":"Drug\u2010associated thrombotic microangiopathies","volume":"38","author":"Kreuter J","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_80_9_16_1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1179\/1973947813Y.0000000122","article-title":"Gemcitabine\u2010related thrombotic microangiopathy: a single\u2010centre retrospective series","volume":"26","author":"Leal F","year":"2014","journal-title":"J Chemother"},{"key":"e_1_2_80_9_17_1","doi-asserted-by":"crossref","first-page":"1088031","DOI":"10.3389\/fphar.2022.1088031","article-title":"Drug\u2010induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management","volume":"13","author":"Mazzierli T","year":"2023","journal-title":"Front Pharmacol."},{"key":"e_1_2_80_9_18_1","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1053\/j.ajkd.2017.05.023","article-title":"Quinine\u2010induced thrombotic microangiopathy: a report of 19 patients","volume":"70","author":"Page EP","year":"2017","journal-title":"Am J Kidney Disease"},{"key":"e_1_2_80_9_19_1","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/j.ajkd.2010.11.030","article-title":"Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors","volume":"57","author":"Pelle G","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_80_9_20_1","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ajh.23960","article-title":"Drug\u2010induced thrombotic microangiopathy: experience of the Oklahoma Registry and the Blood Center of Wisconsin","volume":"90","author":"Reese JA","year":"2015","journal-title":"Am J Hematol"},{"key":"e_1_2_80_9_21_1","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/imj.12261","article-title":"Gemcitabine\u2010induced thrombotic microangiopathy","volume":"43","author":"Richmond J","year":"2013","journal-title":"Intern Med J"},{"key":"e_1_2_80_9_22_1","doi-asserted-by":"crossref","first-page":"E241","DOI":"10.1002\/ajh.25208","article-title":"Drug\u2010induced thrombotic microangiopathy: an updated systematic review, 2014\u20132018","volume":"93","author":"Saleem R","year":"2018","journal-title":"Am J Hematol"},{"key":"e_1_2_80_9_23_1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/hematolrep14020018","article-title":"Unique presentation of bortezomib\u2010associated thrombotic microangiopathy responsive to therapeutic plasma exchange and eculizumab therapy","volume":"14","author":"Sterner RC","year":"2022","journal-title":"Hematol Rep"},{"key":"e_1_2_80_9_24_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.thromres.2023.02.012","article-title":"Eculizumab in the management of drug\u2010induced thrombotic microangiopathy: a scoping review of the literature","volume":"224","author":"Zafar A","year":"2023","journal-title":"Thromb Res"},{"key":"e_1_2_81_9_1_1","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.ijmm.2018.08.007","article-title":"Complement depletion and Coombs positivity in pneumococcal hemolytic uremic syndrome (pnHUS). Case series and plea to revisit an old pathogenetic concept","volume":"308","author":"Bitzan M","year":"2018","journal-title":"Int J Med Microbiol"},{"key":"e_1_2_81_9_2_1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pcl.2018.09.011","article-title":"Hemolytic uremic syndrome","volume":"66","author":"Cody EM","year":"2019","journal-title":"Pediatr Clin North Am"},{"key":"e_1_2_81_9_3_1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00431-021-04200-1","article-title":"Neurological involvement in children with hemolytic uremic syndrome","volume":"181","author":"Costigan C","year":"2022","journal-title":"Eur J Pediatr"},{"key":"e_1_2_81_9_4_1","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0140-6736(99)01251-9","article-title":"Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire \n                     Escherichia coli\n                   O157:H7 outbreak","volume":"354","author":"Dundas S","year":"1999","journal-title":"Lancet"},{"key":"e_1_2_81_9_5_1","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1106483","article-title":"Epidemic profile of Shiga\u2010toxin\u2010producing \n                     Escherichia coli\n                   O104:H4 outbreak in Germany","volume":"365","author":"Frank C","year":"2011","journal-title":"N Engl J Med"},{"key":"e_1_2_81_9_6_1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0272-6386(12)70316-5","article-title":"Plasma exchange in children with hemolytic\u2010uremic syndrome at risk of poor outcome","volume":"22","author":"Gianviti A","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_81_9_7_1","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S0140-6736(11)61253-1","article-title":"Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with \n                     Escherichia coli\n                   O 104:H4\u2010associated hemolytic uraemic syndrome: a prospective trial","volume":"378","author":"Greinacher A","year":"2011","journal-title":"Lancet"},{"key":"e_1_2_81_9_8_1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/1744-9987.12768","article-title":"Is plasma exchange efficacious in Shiga toxin\u2010associated hemolytic uremic syndrome? A narrative review of current evidence","volume":"23","author":"Keenswijk W","year":"2019","journal-title":"Ther Apher Dial"},{"key":"e_1_2_81_9_9_1","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","volume":"27","author":"Kielstein JT","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_81_9_10_1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3389\/fcimb.2020.00273","article-title":"Recent updates on outbreaks of Shiga toxin\u2010producing \n                     Escherichia coli\n                   and its potential reservoirs","volume":"10","author":"Kim JS","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"e_1_2_81_9_11_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7861\/clinmed.2021-0791","article-title":"Dengue infection: global importance, immunopathology and management","volume":"22","author":"Kularatne SA","year":"2022","journal-title":"Clin Med (Lond)"},{"key":"e_1_2_81_9_12_1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF00858677","article-title":"Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Pediatric Nephrology","volume":"2","author":"Loirat C","year":"1988","journal-title":"Pediatr Nephrol"},{"key":"e_1_2_81_9_13_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e4565","article-title":"Validation of treatment strategies for enterohaemorrhagic \n                     Escherichia coli\n                   O104:H4 induced haemolytic uraemic syndrome: case\u2013control study","volume":"345","author":"Menne J","year":"2012","journal-title":"BMJ"},{"issue":"3","key":"e_1_2_81_9_14_1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/infdis\/jix305","article-title":"Streptococcus pneumoniae\n                   from patients with hemolytic uremic syndrome binds human plasminogen via the surface protein PspC and uses plasmin to damage human endothelial cells","volume":"217","author":"Meinel C","year":"2018","journal-title":"J Infect Dis."},{"key":"e_1_2_81_9_15_1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.arcped.2022.05.011","article-title":"Outbreak of hemolytic uremic syndrome with unusually severe clinical presentation caused by Shiga toxin\u2010producing \n                     Escherichia coli\n                   O26:H11 in France","volume":"29","author":"Minary K","year":"2022","journal-title":"Arch Pediatr"},{"key":"e_1_2_81_9_16_1","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2215\/CJN.08921209","article-title":"Acute neurological involvement in diarrhea associated hemolytic uremic syndrome","volume":"5","author":"Nathanson S","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"e_1_2_81_9_17_1","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12824","article-title":"Successful treatment of thrombotic microangiopathy associated with dengue infection: a case report and literature review","author":"Nieto\u2010R\u00edos JF","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"e_1_2_81_9_18_1","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00467-018-3903-9","article-title":"Eculizumab treatment in severe pediatric STEC\u2010HUS: a multicenter retrospective study","volume":"33","author":"Percheron L","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"e_1_2_81_9_19_1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0022-3476(88)80071-4","article-title":"Plasma infusion for hemolytic\u2010uremic syndrome in children: results of a multicenter controlled trial","volume":"112","author":"Rizzoni G","year":"1988","journal-title":"J Pediatr"},{"key":"e_1_2_81_9_20_1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4103\/ajts.ajts_227_23","article-title":"Role of therapeutic plasma exchange in dengue\u2010related microangiopathy","volume":"19","author":"Sahni A","year":"2024","journal-title":"Asian J Transfus Sci"},{"key":"e_1_2_81_9_21_1","first-page":"1","article-title":"Differential diagnosis of thrombotic microangiopathy: overlapping features of thrombotic thrombocytopenic purpura and complement\u2010mediated thrombotic microangiopahty in a dengue\u2010infected patient","volume":"2","author":"Sartori Pacini G","year":"2025","journal-title":"Nephron"},{"key":"e_1_2_81_9_22_1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/1744-9987.13474","article-title":"Therapeutic plasma exchange in pediatric intensive care: Indications, results and complications","volume":"24","author":"S\u0131k G","year":"2020","journal-title":"Ther Apher Dial"},{"key":"e_1_2_81_9_23_1","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00467-019-04342-3","article-title":"New insights into the pathogenesis of \n                     Streptococcus pneumoniae\n                  \u2010associated hemolytic uremic syndrome","volume":"35","author":"Scobell RR","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"e_1_2_81_9_24_1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jpeds.2007.03.055","article-title":"Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience","volume":"151","author":"Waters AM","year":"2007","journal-title":"J Pediatr"},{"key":"e_1_2_82_9_1_1","doi-asserted-by":"crossref","first-page":"S1059","DOI":"10.1016\/j.ajog.2020.09.038","article-title":"Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome","volume":"226","author":"Burwick RM","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"e_1_2_82_9_2_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.atherosclerosissup.2019.08.028","article-title":"Apheresis as emerging treatment option in severe early onset preeclampsia","volume":"40","author":"Contini C","year":"2019","journal-title":"Atheroscler Suppl"},{"key":"e_1_2_82_9_3_1","doi-asserted-by":"crossref","first-page":"11082","DOI":"10.3390\/ijms252011082","article-title":"Alteration in sB7\u2010H4 serum levels and placental biomarker expression after therapeutic plasma exchange in early\u2010onset preeclampsia patients","volume":"25","author":"Duan L","year":"2024","journal-title":"Int J Mol Sci"},{"key":"e_1_2_82_9_4_1","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-228709","article-title":"Eculizumab, a novel potential treatment for acute kidney injury associated with preeclampsia\/HELLP syndrome","volume":"12","author":"Elabd H","year":"2019","journal-title":"BMJ Case Rep"},{"key":"e_1_2_82_9_5_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103248","article-title":"The effect of therapeutic plasma exchange on management of HELLP Syndrome: The report of 47 patients","volume":"60","author":"Erkurt MA","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_82_9_6_1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/107602960501100211","article-title":"The role of plasma exchange in HELLP syndrome","volume":"11","author":"Eser B","year":"2005","journal-title":"Clin Appl Thromb Hemost"},{"key":"e_1_2_82_9_7_1","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s40620-021-01025-x","article-title":"Pregnancy\u2010triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis","volume":"34","author":"Fakhouri F","year":"2021","journal-title":"J Nephrol"},{"key":"e_1_2_82_9_8_1","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood.2020005221","article-title":"Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group","volume":"136","author":"Fakhouri F","year":"2020","journal-title":"Blood"},{"key":"e_1_2_82_9_9_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/10641955.2016.1218505","article-title":"Hemolysis, elevated liver enzymes, and low platelet syndrome: outcomes for patients admitted to intensive care at a tertiary referral center","volume":"36","author":"Gedik E","year":"2017","journal-title":"Hypertens Pregnancy"},{"key":"e_1_2_82_9_10_1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jca.21899","article-title":"Therapeutic plasma exchange and dextran\u2010sulfate plasma adsorption as extracorporeal treatments of extremely preterm preeclampsia with fetal growth restriction","volume":"36","author":"Gubensek J","year":"2021","journal-title":"J Clin Apher"},{"key":"e_1_2_82_9_11_1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/AOG.0000000000003554","article-title":"Pregnancy\u2010associated atypical hemolytic uremic syndrome: a systematic review","volume":"135","author":"Gupta M","year":"2020","journal-title":"Obstet Gynecol"},{"key":"e_1_2_82_9_12_1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejogrb.2018.09.009","article-title":"LDL\u2010apheresis to decrease sFlt\u20101 during early severe preeclampsia: report of two cases from a discontinued phase II trial","volume":"231","author":"Haddad B","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"e_1_2_82_9_13_1","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.3390\/jcm12134289","article-title":"Therapeutic plasma exchange in early\u2010onset preeclampsia: a 7\u2010year monocentric experience","volume":"12","author":"Iannaccone A","year":"2023","journal-title":"J Clin Med"},{"key":"e_1_2_82_9_14_1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3389\/fimmu.2020.00548","article-title":"Eculizumab treatment for postpartum HELLP syndrome and aHUS\u2010Case report","volume":"11","author":"Lokki AI","year":"2020","journal-title":"Front Immunol"},{"key":"e_1_2_82_9_15_1","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/0002-9378(95)91470-6","article-title":"Postpartum plasma exchange for atypical preeclampsia\u2010eclampsia as HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome","volume":"172","author":"Martin JN","year":"1995","journal-title":"Am J Obstet Gynecol"},{"key":"e_1_2_82_9_16_1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/jca.2920090302","article-title":"Plasma exchange for preeclampsia: unsuccessful antepartum utilization for severe preeclampsia with or without HELLP syndrome","volume":"9","author":"Martin JN","year":"1994","journal-title":"J Clin Apher"},{"key":"e_1_2_82_9_17_1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.transci.2012.05.016","article-title":"Postpartum thrombotic microangiopathic syndrome","volume":"48","author":"Owens MY","year":"2013","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_82_9_18_1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/bjh.12494","article-title":"ADAMTS13 deficiency in severe postpartum HELLP syndrome","volume":"163","author":"Pourrat O","year":"2013","journal-title":"Br J Haematol"},{"key":"e_1_2_82_9_19_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.transci.2014.12.009","article-title":"Early identification of women with HELLP syndrome who need plasma exchange after delivery","volume":"52","author":"Simetka O","year":"2015","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_82_9_20_1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1681\/ASN.2015020157","article-title":"Removal of soluble Fms\u2010like tyrosine kinase 1 by dextran sulfate apheresis in preeclampsia","volume":"27","author":"Thadani R","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_82_9_21_1","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1161\/CIRCULATIONAHA.111.034793","article-title":"Pilot study of extracorporeal removal of soluble Fms\u2010like tyrosine kinase 1 in preeclampsia","volume":"124","author":"Thadani R","year":"2011","journal-title":"Circulation"},{"key":"e_1_2_82_9_22_1","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1080\/14767058.2020.1755650","article-title":"A review of the alternative pathway of complement and its relation to HELLP syndrome: is it time to consider HELLP syndrome a disease of the alternative pathway","volume":"35","author":"Vaught AJ","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"key":"e_1_2_82_9_23_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100623","article-title":"Pregnancy\u2010associated renal cortical necrosis and nonenhanced functional magnetic resonance imaging: a case series","volume":"5","author":"Wang R","year":"2023","journal-title":"Kidney Medicine"},{"key":"e_1_2_82_9_24_1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.transci.2006.05.010","article-title":"Heparin\u2010mediated extracorporeal low density lipoprotein precipitation as a possible therapeutic approach in preeclampsia","volume":"35","author":"Wang Y","year":"2006","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_82_9_25_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.preghy.2024.101128","article-title":"Comparison of double\u2010filtration plasmapheresis (DFPP) versus heparin\u2010mediated extracorporeal LDL\u2010precipitation (HELP)\u2010apheresis in early\u2010onset preeclampsia","volume":"36","author":"Winkler K","year":"2024","journal-title":"Pregnancy Hypertens"},{"key":"e_1_2_83_9_1_1","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMoa2402567","article-title":"Recombinant ADAMTS13 for immune thrombotic thrombocytopenic purpura","volume":"390","author":"Bendapudi PK","year":"2024","journal-title":"N Engl J Med"},{"key":"e_1_2_83_9_2_1","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi PK","year":"2017","journal-title":"Lancet Haematol"},{"key":"e_1_2_83_9_3_1","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3324\/haematol.2011.049676","article-title":"Thrombotic Microangiopathies Reference Center. Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency\u2010associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"97","author":"Benhamou Y","year":"2012","journal-title":"Haematologica"},{"key":"e_1_2_83_9_4_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-3148.2006.00720.x","article-title":"A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura","volume":"17","author":"Brunskill SJ","year":"2007","journal-title":"Transfusion Med"},{"key":"e_1_2_83_9_5_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103168","article-title":"Caplacizumab use in immune\u2010mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project)","volume":"82","author":"Coppo P","year":"2025","journal-title":"EClinicalMedicine"},{"key":"e_1_2_83_9_6_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00005792-200301000-00003","article-title":"High\u2010dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura\/hemolytic\u2010uremic syndrome","volume":"82","author":"Coppo P","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"e_1_2_83_9_7_1","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/bjh.13654","article-title":"The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry","volume":"171","author":"Hassan S","year":"2015","journal-title":"Br J Haematol"},{"key":"e_1_2_83_9_8_1","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1016\/S2352-3026(17)30024-8","article-title":"The PLASMIC score for thrombotic thrombocytopenic purpura","volume":"4","author":"Jamme M","year":"2017","journal-title":"Lancet Haematol"},{"key":"e_1_2_83_9_9_1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/jca.21600","article-title":"Treatment of acquired thrombotic thrombocytopenic purpura in the U.S. remains heterogeneous: current and future points of clinical equipoise","volume":"33","author":"Mazepa MA","year":"2018","journal-title":"J Clin Apher"},{"key":"e_1_2_83_9_10_1","doi-asserted-by":"crossref","first-page":"107602961882530","DOI":"10.1177\/1076029618825309","article-title":"Comparison of the long\u2010term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta\u2010analysis","volume":"25","author":"Owattanapanich W","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"e_1_2_83_9_11_1","first-page":"369","article-title":"Rituximab in the treatment of immune\u2010mediated thrombotic thrombocytopenic purpura","volume":"21","author":"\u00d6zpolat HT","year":"2023","journal-title":"Blood Transfus"},{"key":"e_1_2_83_9_12_1","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi F","year":"2016","journal-title":"N Engl J Med"},{"key":"e_1_2_83_9_13_1","first-page":"2206","article-title":"Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era","volume":"141","author":"Prasannan N","year":"2023","journal-title":"Blood"},{"key":"e_1_2_83_9_14_1","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/trf.15901","article-title":"Therapeutic plasma exchange taper does not decrease exacerbations in immune thrombotic thrombocytopenic purpura patients","volume":"60","author":"Raval JS","year":"2020","journal-title":"Transfusion"},{"key":"e_1_2_83_9_15_1","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1182\/bloodadvances.2023012451","article-title":"Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab\u2010treated Japanese patients with iTTP","volume":"8","author":"Saito K","year":"2024","journal-title":"Blood Adv"},{"key":"e_1_2_83_9_16_1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.thromres.2022.04.020","article-title":"Thrombotic thrombocytopenic purpura (TTP) after COVID\u201019 vaccination: a systematic review of reported cases","volume":"214","author":"Saluja P","year":"2022","journal-title":"Thromb Res"},{"issue":"4","key":"e_1_2_83_9_17_1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully M","year":"2019","journal-title":"N Engl J Med"},{"key":"e_1_2_83_9_18_1","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully M","year":"2011","journal-title":"Blood"},{"key":"e_1_2_83_9_19_1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jca.21336","article-title":"Safety and efficacy of cryoprecipitate\u2010poor plasma as a replacement fluid for therapeutic plasma exchange in thrombotic thrombocytopenic purpura: a single center retrospective evaluation","volume":"29","author":"Stefanello B","year":"2014","journal-title":"J Clin Apher"},{"key":"e_1_2_83_9_20_1","first-page":"1381","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost 2020;18:2486\u20132495. Erratum in","volume":"19","author":"Zheng XL","year":"2021","journal-title":"J Thromb Haemost"},{"key":"e_1_2_83_9_21_1","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1016\/j.jtha.2025.06.002","article-title":"2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura","volume":"23","author":"Zheng XL","year":"2025","journal-title":"J Thromb Haemost"},{"key":"e_1_2_84_9_1_1","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ekir.2024.12.031","article-title":"Early thrombotic microangiopathy after ABO\u2010incompatible living donor kidney transplantation","volume":"10","author":"Bertrand D","year":"2024","journal-title":"Kidney Int Rep"},{"key":"e_1_2_84_9_2_1","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.bbmt.2017.08.019","article-title":"Thrombotic microangiopathy after allogeneic stem cell transplantation: a comparison of eculizumab therapy and conventional therapy","volume":"23","author":"Bohl SR","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"e_1_2_84_9_3_1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1076029615599439","article-title":"Eculizumab in Transplant\u2010Associated Thrombotic Microangiopathy","volume":"23","author":"Dhakal P","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"key":"e_1_2_84_9_4_1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fped.2019.00133","article-title":"Transplant\u2010associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: a practical approach to diagnosis and management","volume":"7","author":"Dvorak CC","year":"2019","journal-title":"Front Pediatr"},{"key":"e_1_2_84_9_5_1","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1111\/trf.14263","article-title":"Impact of treatment and outcomes for patients with posttransplant drug\u2010associated thrombotic microangiopathy","volume":"57","author":"Epperla N","year":"2017","journal-title":"Transfusion"},{"key":"e_1_2_84_9_6_1","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood.2023022526","article-title":"A prospective multi\u2010institutional study of eculizumab to treat high\u2010risk stem cell transplantation\u2010associated TMA","volume":"143","author":"Jodele S","year":"2024","journal-title":"Blood"},{"key":"e_1_2_84_9_7_1","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation\u2010associated thrombotic microangiopathy","volume":"20","author":"Jodele S","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_84_9_8_1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of HSCT\u2010associated thrombotic microangiopathy as multi\u2010system endothelial injury","volume":"29","author":"Jodele S","year":"2015","journal-title":"Blood Rev."},{"key":"e_1_2_84_9_9_1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1537-2995.2012.03776.x","article-title":"Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant\u2010associated thrombotic microangiopathy?","volume":"53","author":"Jodele S","year":"2013","journal-title":"Transfusion"},{"key":"e_1_2_84_9_10_1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/j.seminhematol.2018.04.003","article-title":"Complement in pathophysiology and treatment of transplant\u2010associated thrombotic microangiopathies","volume":"55","author":"Jodele S.","year":"2018","journal-title":"Semin Hematol"},{"key":"e_1_2_84_9_11_1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/bmt.2009.233","article-title":"Transplantation\u2010associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange","volume":"45","author":"Kennedy GA","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_84_9_12_1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/bmt.2017.207","article-title":"Hematopoietic stem cell transplant\u2010associated thrombotic microangiopathy: current paradigm and novel therapies","volume":"53","author":"Khosla J","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_84_9_13_1","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/trf.12859","article-title":"Hematopoietic stem cell transplant\u2010associated thrombotic microangiopathy: review of pharmacologic treatment options","volume":"55","author":"Kim SS","year":"2015","journal-title":"Transfusion"},{"key":"e_1_2_84_9_14_1","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2011-02-321315","article-title":"Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation\u2010associated thrombotic microangiopathy","volume":"118","author":"Laskin BL","year":"2011","journal-title":"Blood"},{"key":"e_1_2_84_9_15_1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/hematology.2024000545","article-title":"Transplant\u2010associated TMA: the conundrum of diagnosis and treatment","volume":"2024","author":"Li A","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"8","key":"e_1_2_84_9_16_1","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1007\/s12094-023-03129-1","article-title":"Clinical characteristics of pediatric allogeneic hematopoietic stem cell transplantation\u2010associated thrombotic microangiopathy (TA\u2010TMA): a retrospective single\u2010center analysis","volume":"25","author":"Luo L","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"e_1_2_84_9_17_1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/jca.21352","article-title":"Outcomes of plasma exchange in patients with transplant\u2010associated thrombotic microangiopathy based on time of presentation since transplant","volume":"30","author":"Mulay S","year":"2015","journal-title":"J Clin Apher"},{"key":"e_1_2_84_9_18_1","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s12288-020-01269-w","article-title":"Therapeutic plasma exchange (TPE) for liver transplant associated\u2010thrombotic microangiopathy (TA\u2010TMA) in a 5\u2010month\u2010old infant","volume":"36","author":"Pandey P","year":"2020","journal-title":"Indian J Hematol Blood Transfus"},{"key":"e_1_2_84_9_19_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2018.08.016","article-title":"Therapeutic plasma exchange does not improve renal function in hematopoietic stem cell transplantation\u2010associated thrombotic microangiopathy: an institutional experience","volume":"25","author":"Sartain S","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_84_9_20_1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","article-title":"Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation\u2010associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia\u2010Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research","volume":"29","author":"Schoettler ML","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"e_1_2_84_9_21_1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/bjh.17430","article-title":"Transplant\u2010associated thrombotic microangiopathy and immune hematological complications following intestine\u2010containing organ transplantation: experience from over 100 consecutive cases","volume":"193","author":"Thomas W","year":"2021","journal-title":"Br J Haematol"},{"key":"e_1_2_84_9_22_1","doi-asserted-by":"crossref","first-page":"266.e1","DOI":"10.1016\/j.jtct.2022.01.009","article-title":"Incidence and risk factors of transplantation\u2010associated thrombotic microangiopathy: a systematic review and meta\u2010analysis","volume":"28","author":"Van Benschoten V","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"e_1_2_84_9_23_1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.blre.2014.09.001","article-title":"De novo thrombotic microangiopathy after non\u2010renal solid organ transplantation","volume":"28","author":"Verbiest A","year":"2014","journal-title":"Blood Rev."},{"key":"e_1_2_84_9_24_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00277-022-05069-2","article-title":"Comparison of multiple treatments in the management of transplant\u2010related thrombotic microangiopathy: a network meta\u2010analysis","volume":"102","author":"Yang J","year":"2023","journal-title":"Ann Hematol"},{"key":"e_1_2_84_9_25_1","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s41409-022-01581-1","article-title":"Treatment outcome and efficacy of therapeutic plasma exchange for transplant\u2010associated microangiopathy in a large real\u2010world cohort study","volume":"57","author":"Yang L","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_84_9_26_1","article-title":"Survival analysis of transplant\u2010associated thrombotic microangiopathy under different diagnostic criteria and the efficacy of plasma exchange","volume":"28","author":"Xu Y","year":"2023","journal-title":"Ann Transplant"},{"key":"e_1_2_85_9_1_1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000486957","article-title":"2018 European thyroid association guidelines for the management of amiodarone\u2010associated thyroid dysfunction","volume":"7","author":"Bartalena L","year":"2018","journal-title":"Eur Thyroid J"},{"key":"e_1_2_85_9_2_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/CCM.0000000000004078","article-title":"Thyroid storm in the ICU: a retrospective multicenter study","volume":"48","author":"Bourcier S","year":"2020","journal-title":"Crit Care Med"},{"key":"e_1_2_85_9_3_1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0889-8529(18)30165-8","article-title":"Life\u2010threatening thyrotoxicosis. Thyroid storm","volume":"22","author":"Burch HB","year":"1993","journal-title":"Endocrinol Metab Clin North Am."},{"key":"e_1_2_85_9_4_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jca.20244","article-title":"Plasma filtration in the treatment of Graves' ophthalmopathy: a randomized study","volume":"25","author":"Cap J","year":"2010","journal-title":"J Clin Apheresis"},{"key":"e_1_2_85_9_5_1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/0885066613498053","article-title":"Thyroid storm: an updated review","volume":"30","author":"Chiha M","year":"2015","journal-title":"J Intensive Care Med"},{"key":"e_1_2_85_9_6_1","first-page":"366","article-title":"Clinical review and update on the management of thyroid storm","volume":"119","author":"De Almeida R","year":"2022","journal-title":"Mo Med"},{"key":"e_1_2_85_9_7_1","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(16)00278-6","volume":"388","author":"De Leo S","year":"2016","journal-title":"Hyperthyroidism. Lancet"},{"key":"e_1_2_85_9_8_1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1080\/09513590600842372","article-title":"Severe hyperthyroidism requiring therapeutic plasmapheresis in a patient with hydatidiform mole","volume":"22","author":"Erbil Y","year":"2006","journal-title":"Gynecol Endocrinol"},{"key":"e_1_2_85_9_9_1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jca.20200","article-title":"Preoperative therapeutic plasma exchange in patients with thyrotoxicosis","volume":"24","author":"Ezer A","year":"2009","journal-title":"J Clin Apher"},{"key":"e_1_2_85_9_10_1","first-page":"4135940","article-title":"Severe hyperthyroidism complicated by agranulocytosis treated with therapeutic plasma exchange: a case report and review of the literature","author":"Garla V","year":"2018","journal-title":"Case Rep Endocrinol"},{"key":"e_1_2_85_9_11_1","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.2147\/TCRM.S4110","article-title":"A thyrotoxicosis outbreak due to dietary pills in Paris","volume":"4","author":"Ioos V","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_2_85_9_12_1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000490384","article-title":"2018 European thyroid association guideline for the management of Graves' hyperthyroidism","volume":"7","author":"Kahaly GJ","year":"2018","journal-title":"Eur Thyroid J"},{"key":"e_1_2_85_9_13_1","article-title":"Two perPLEXing cases of Hashimoto's encephalopathy unresponsive to steroid and intravenous immunoglobulin therapy","volume":"14","author":"Karan A","year":"2022","journal-title":"Cureus"},{"key":"e_1_2_85_9_14_1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40618-022-01897-1","article-title":"Therapeutic plasma exchange in hyperthyroidism prior to surgery","volume":"46","author":"Kirkizlar HO","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"e_1_2_85_9_15_1","doi-asserted-by":"crossref","first-page":"E55","DOI":"10.1111\/j.1525-1594.2009.00924.x","article-title":"Treatment of thyrotoxic crisis with plasmapheresis and a single pass albumin dialysis: a case report","volume":"34","author":"Koball S","year":"2010","journal-title":"Artif Organs"},{"key":"e_1_2_85_9_16_1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/jca.20282","article-title":"Successful preoperative treatment of a Graves' disease patient with agranulocytosis and hemophagocytosis using double filtration plasmapheresis","volume":"26","author":"Lew WH","year":"2011","journal-title":"J Clin Apher"},{"key":"e_1_2_85_9_17_1","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1744-9987.2011.01003.x","article-title":"Role of plasma exchange in the thyroid storm","volume":"15","author":"Muller C","year":"2011","journal-title":"Ther Apher Dial"},{"key":"e_1_2_85_9_18_1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1046\/j.1526-0968.2001.005002142.x","article-title":"Two cases of refractory endocrine ophthalmopathy successfully treated with extracorporeal immunoadsorption","volume":"5","author":"Prophet H","year":"2001","journal-title":"Ther Apheresis"},{"key":"e_1_2_85_9_19_1","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hypethyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross DS","year":"2016","journal-title":"Thyroid"},{"key":"e_1_2_85_9_20_1","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.2169\/internalmedicine.50.6078","article-title":"A case of thyroid storm with multiple organ failure effectively treated with plasma exchange","volume":"50","author":"Sasaki K","year":"2011","journal-title":"Intern Med"},{"key":"e_1_2_85_9_21_1","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1507\/endocrj.EJ16-0336","article-title":"2016 Guidelines for the management of thyroid storm from the Japan Thyroid Association and Japan Endocrine Society (First Edition)","volume":"63","author":"Satoh T","year":"2016","journal-title":"Endocr J"},{"key":"e_1_2_85_9_22_1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/jca.21536","article-title":"Iatrogenic thyrotoxicosis and the role of therapeutic plasma exchange","volume":"32","author":"Shah KK","year":"2017","journal-title":"J Clin Apher"},{"key":"e_1_2_85_9_23_1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s12020-018-1661-x","article-title":"Therapeutic plasmapheresis in thyrotoxic patients","volume":"62","author":"Simsir YI","year":"2018","journal-title":"Endocrine"},{"key":"e_1_2_85_9_24_1","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","volume":"375","author":"Smith TJ","year":"2016","journal-title":"Graves' disease. New Engl J Med"},{"key":"e_1_2_85_9_25_1","first-page":"346","article-title":"Preoperative therapeutic plasma exchange and surgical treatment in thyrotoxicosis patients: a single\u2010center retrospective cohort study","volume":"17","author":"Yabanoglu H","year":"2022","journal-title":"Acta Endocrinol"},{"key":"e_1_2_86_9_1_1","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1159\/000517088","article-title":"Sequential blood purification for pediatric fatal toxic epidermal necrolysis: a case series","volume":"51","author":"Cui Y","year":"2022","journal-title":"Blood Purif"},{"key":"e_1_2_86_9_2_1","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s13555-024-01180-6","article-title":"Evaluation of the factors influencing mortality in patients with Stevens\u2010Johnson syndrome and toxic epidermal necrolysis: a multicenter study of 166 patients","volume":"14","author":"Erduran F","year":"2024","journal-title":"Dermat Ther (Heidelb)"},{"key":"e_1_2_86_9_3_1","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s001340051063","article-title":"Lack of significant treatment effect of plasma exchange in the treatment of drug\u2010induced toxic epidermal necrolysis?","volume":"25","author":"Furubacke A","year":"1999","journal-title":"Intensive Care Med"},{"key":"e_1_2_86_9_4_1","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis","volume":"126","author":"Guegan S","year":"2006","journal-title":"J Invest Dermatol"},{"key":"e_1_2_86_9_5_1","doi-asserted-by":"crossref","DOI":"10.1097\/GOX.0000000000001221","article-title":"Management of toxic epidermal necrolysis with plasmapheresis and cyclosporine A: our 10\u2009years' experience","volume":"5","author":"Giudice G","year":"2017","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"e_1_2_86_9_6_1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jcrc.2017.07.002","article-title":"Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study","volume":"42","author":"Han F","year":"2017","journal-title":"J Crit Care"},{"key":"e_1_2_86_9_7_1","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.12968\/jowc.2021.30.12.1012","article-title":"Stevens\u2010Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta\u2010analysis","volume":"30","author":"Houschyar KS","year":"2021","journal-title":"J Wound Care"},{"key":"e_1_2_86_9_8_1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.braindev.2013.05.010","article-title":"Plasmapheresis as adjuvant therapy in Stevens\u2010Johnson syndrome and hepatic encephalopathy","volume":"36","author":"Hung PC","year":"2014","journal-title":"Brain Dev"},{"key":"e_1_2_86_9_9_1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/jca.21213","article-title":"Beneficial effect of plasma exchange in the treatment of toxic epidermal necrolysis: a series of four cases","volume":"27","author":"Kostal M","year":"2012","journal-title":"J Clin Apher"},{"key":"e_1_2_86_9_10_1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.burns.2021.11.004","volume":"48","author":"Krajewski A","year":"2022","journal-title":"Burns"},{"key":"e_1_2_86_9_11_1","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jbcr\/irz073","article-title":"Toxic epidermal necrolysis therapy with TPE and IVIG\u201010\u2009years of experience of the burns treatment center","volume":"40","author":"Krajewski A","year":"2019","journal-title":"J Burn Care Res"},{"key":"e_1_2_86_9_12_1","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15416","article-title":"An extremely rare mucocutaneous adverse reaction following COVID\u201019 vaccination: toxic epidermal necrolysis","volume":"35","author":"Mardani M","year":"2022","journal-title":"Dermatol Ther"},{"key":"e_1_2_86_9_13_1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamadermatol.2023.0035","article-title":"Evaluation of plasmapheresis vs. immunoglobulin as first treatment after ineffective systemic corticosteroid therapy for patients with Stevens\u2010Johnson syndrome and toxic epidermal necrolysis","volume":"159","author":"Miyamoto Y","year":"2023","journal-title":"JAMA Dermatol"},{"key":"e_1_2_86_9_14_1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1346-8138.2010.01154.x","article-title":"Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: Is cytokine expression analysis useful in predicting its therapeutic efficacy?","volume":"38","author":"Narita YM","year":"2011","journal-title":"J Dermatol"},{"key":"e_1_2_86_9_15_1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.5301\/ejo.5000923","article-title":"Plasmapheresis, intravenous immunoglobulins, and autologous serum eyedrops in the acute eye complications of toxic epidermal necrolysis","volume":"27","author":"Pinna A","year":"2017","journal-title":"Eur J Ophthalmol"},{"key":"e_1_2_86_9_16_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jaad.2013.05.002","article-title":"Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment","volume":"69","author":"Schwartz RA","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_86_9_17_1","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1038\/s41598-024-53653-5","article-title":"Effectiveness of early treatment with plasma exchange in patients with Stevens\u2010Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Senda A","year":"2024","journal-title":"Scientific Reports"},{"key":"e_1_2_86_9_18_1","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/jbcr\/irac046","volume":"43","author":"Stru\u017cyna J","year":"2022","journal-title":"J Burn Care Res"},{"key":"e_1_2_86_9_19_1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/jca.21997","article-title":"The role of treatment with plasma exchange therapy in two pediatric toxic epidermal necrolysis cases related to COVID\u201019","volume":"37","author":"Varol F","year":"2022","journal-title":"J Clin Apher"},{"key":"e_1_2_86_9_20_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ajem.2024.04.001","article-title":"High risk and low prevalence diseases: Stevens Johnson syndrome and toxic epidermal necrolysis","volume":"81","author":"Nispen C","year":"2024","journal-title":"Am J Emerg Med"},{"key":"e_1_2_86_9_21_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.alit.2020.11.004","article-title":"Mortality and risk factors on admission in toxic epidermal necrolysis: a cohort study of 59 patients","volume":"70","author":"Watanabe T","year":"2021","journal-title":"Allergol Int"},{"key":"e_1_2_86_9_22_1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1744-9987.2008.00609.x","article-title":"Status of plasmapheresis for the treatment of toxic epidermal necrolysis in Japan","volume":"12","author":"Yamada H","year":"2008","journal-title":"Ther Apher Dial"},{"key":"e_1_2_86_9_23_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.alit.2015.09.001","article-title":"Retrospective analysis of Stevens\u2010Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients\u2010treatment and outcome","volume":"65","author":"Yamane Y","year":"2016","journal-title":"Allergol Int"},{"key":"e_1_2_86_9_24_1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens\u2010Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta\u2010analysis","volume":"153","author":"Zimmermann S","year":"2017","journal-title":"JAMA Dermatol"},{"key":"e_1_2_86_9_25_1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s12016-021-08859-0","article-title":"Current perspectives on severe drug eruption","volume":"61","author":"Zhang J","year":"2021","journal-title":"Clin Rev. Allergy Immunol"},{"key":"e_1_2_87_9_1_1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.healun.2014.09.027","article-title":"Outcomes in highly sensitized pediatric heart transplant patients using current management strategies","volume":"34","author":"Asante\u2010Korang A","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"e_1_2_87_9_2_1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1034\/j.1399-0012.2000.140211.x","article-title":"Prophylactic photopheresis and chronic rejection: effects on graft intimal hyperplasia in cardiac transplantation","volume":"14","author":"Barr ML","year":"2000","journal-title":"Clin Transplant"},{"key":"e_1_2_87_9_3_1","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJM199812103392404","article-title":"Photopheresis for the prevention of rejection in cardiac transplantation","volume":"339","author":"Barr ML","year":"1998","journal-title":"N Engl J Med"},{"issue":"8","key":"e_1_2_87_9_4_1","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.healun.2023.03.005","article-title":"European multicenter study on the real\u2010world use and clinical impact of extracorporeal photopheresis after heart transplantation","volume":"42","author":"Barten MJ","year":"2023","journal-title":"J Heart Lung Transplant"},{"key":"e_1_2_87_9_5_1","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.healun.2014.01.863","article-title":"Single\u2010center experience with extracorporeal photopheresis in pediatric heart transplantation","volume":"33","author":"Carlo WF","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"e_1_2_87_9_6_1","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/ajt.12162","article-title":"A survey of current practice for antibody\u2010mediated rejection in heart transplantation","volume":"13","author":"Chih S","year":"2013","journal-title":"Am J Transplant"},{"issue":"139","key":"e_1_2_87_9_7_1","first-page":"553","article-title":"Sensitization in heart transplantation: emerging knowledge: a scientific statement from the American Heart Association","volume":"19","author":"Colvin MM","year":"2019","journal-title":"Circulation"},{"key":"e_1_2_87_9_8_1","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.transproceed.2012.01.086","article-title":"Steroid pulse therapy combined with plasmapheresis for clinically compromised patients after heart transplantation","volume":"44","author":"Chou HW","year":"2012","journal-title":"Transplant Proc"},{"key":"e_1_2_87_9_9_1","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/TP.0000000000002503","article-title":"Favorable outcome of an exclusively post\u2010transplant prophylactic strategy after heart transplantation in recipients with high immunological risk","volume":"103","author":"Coutance G","year":"2019","journal-title":"Transplantation"},{"key":"e_1_2_87_9_10_1","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jfma.2021.07.014","article-title":"Outcome of urgent desensitization in sensitized heart transplant recipients","volume":"121","author":"Fu HY","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"e_1_2_87_9_11_1","doi-asserted-by":"crossref","first-page":"10320","DOI":"10.3389\/ti.2022.10320","article-title":"Extracorporeal photopheresis with low\u2010dose immunosuppression in high\u2010risk heart transplant patients\u2010A pilot study","volume":"35","author":"G\u00f6kler J","year":"2022","journal-title":"Transpl Int"},{"key":"e_1_2_87_9_12_1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1749-8090-8-48","article-title":"Profound hyperacute cardiac allograft rejection rescue with biventricular mechanical circulatory support and plasmapheresis, intravenous immunoglobulin, and rituximab therapy","volume":"8","author":"Kaczorowski DJ","year":"2013","journal-title":"J Cardiothorac Surg"},{"key":"e_1_2_87_9_13_1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.healun.2005.10.004","article-title":"Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis","volume":"25","author":"Kirklin JK","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"e_1_2_87_9_14_1","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.healun.2008.06.004","article-title":"Peri\u2010operative alemtuzumab (Campath\u20101H) and plasmapheresis for high\u2010PRA positive lymphocyte crossmatch heart transplant: a strategy to shorten left ventricular assist device support","volume":"27","author":"Lick SD","year":"2008","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"e_1_2_87_9_15_1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.healun.2024.11.014","article-title":"Therapeutic plasma exchange is associated with increased survival in heart transplant recipients experiencing severe primary graft dysfunction","volume":"44","author":"Manla Y","year":"2025","journal-title":"J Heart Lung Transplant."},{"key":"e_1_2_87_9_16_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21926\/obm.transplant.2101130","article-title":"Management of the sensitized cardiac transplantation recipient","volume":"5","author":"Mazzei M","year":"2021","journal-title":"OBM Transplantation"},{"key":"e_1_2_87_9_17_1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/TP.0000000000005201","article-title":"Extracorporeal photopheresis enhances the frequency and function of highly suppressive FoxP3+ Treg subsets in heart transplanted individuals","volume":"109","author":"Mottola M","year":"2025","journal-title":"Transplantation"},{"key":"e_1_2_87_9_18_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/0974-2069.197063","article-title":"Early primary graft failure after a pediatric heart transplant and successful rescue with plasmapheresis, immunoglobulins, and alemtuzumab. Ann","volume":"10","author":"Raj S","year":"2017","journal-title":"Pediatr Cardiol"},{"key":"e_1_2_87_9_19_1","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.transci.2017.07.009","article-title":"Extracorporeal photochemotherapy in heart transplant rejection: a single\u2010center experience","volume":"56","author":"Savignano C","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_87_9_20_1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/jca.21338","article-title":"Therapeutic plasma exchange rapidly improves cardiac allograft function in patients with presumed antibody\u2010mediated rejection","volume":"29","author":"Singh N","year":"2014","journal-title":"J Clin Apher"},{"key":"e_1_2_87_9_21_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ctr.14333","article-title":"Extracorporeal photopheresis and its role in heart transplant rejection: prophylaxis and treatment","volume":"35","author":"Slomovich S","year":"2021","journal-title":"Clin Transplant"},{"key":"e_1_2_87_9_22_1","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/ajt.17060","article-title":"Heart transplantation across preformed donor\u2010specific antibody barriers using a perioperative desensitization protocol","volume":"22","author":"Sommer W","year":"2022","journal-title":"Am J Transplant"},{"key":"e_1_2_87_9_23_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trim.2020.101274","article-title":"Serum dilutions as a predictive biomarker for peri\u2010operative desensitization: an exploratory approach to transplanting sensitized heart candidates","volume":"60","author":"Timofeeva OA","year":"2020","journal-title":"Transpl Immunol"},{"key":"e_1_2_87_9_24_1","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.healun.2016.06.014","article-title":"A multi\u2010institutional evaluation of antibody\u2010mediated rejection utilizing the Pediatric Heart Transplant database: incidence, therapies, and outcomes","volume":"35","author":"Thrush PT","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"e_1_2_87_9_25_1","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1016\/j.transproceed.2006.10.060","article-title":"Effect of plasmapheresis for acute humoral rejection after heart transplantation","volume":"38","author":"Wang SS","year":"2006","journal-title":"Transplant Proc"},{"key":"e_1_2_88_9_1_1","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood.V98.6.1687","article-title":"Delayed donor red cell chimerism and pure red cell aplasia following major ABO\u2010incompatible nonmyeloablative hematopoietic stem cell transplantation","volume":"98","author":"Bolan CD","year":"2001","journal-title":"Blood"},{"key":"e_1_2_88_9_2_1","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.bbmt.2013.03.018","article-title":"Clinical guide to ABO\u2010incompatible allogeneic stem cell transplantation","volume":"19","author":"Booth GS","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_88_9_3_1","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.bbmt.2018.04.022","article-title":"Eltrombopag for the treatment of refractory pure RBC aplasia after major ABO incompatible hematopoietic stem cell transplantation","volume":"24","author":"Busca A","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_88_9_4_1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/jca.21680","article-title":"Efficacy of three consecutive therapeutic plasma exchanges in major ABO\u2010incompatible hematopoietic stem cell transplantation","volume":"34","author":"Choi SS","year":"2018","journal-title":"J Clin Apher"},{"key":"e_1_2_88_9_5_1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/ejh.13668","article-title":"Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility","volume":"107","author":"Crysandt M","year":"2021","journal-title":"Eur J Haematol"},{"key":"e_1_2_88_9_6_1","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1111\/trf.12529","article-title":"Prophylactic red blood cell exchange for ABO\u2010mismatched hematopoietic progenitor cell transplants","volume":"54","author":"Cunard R","year":"2014","journal-title":"Transfusion"},{"key":"e_1_2_88_9_7_1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1537-2995.2011.03295.x","article-title":"Outcomes after major or bidirectional ABO\u2010mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor\u2010type secretor plasma with or without plasma exchange","volume":"52","author":"Curley C","year":"2012","journal-title":"Transfusion"},{"key":"e_1_2_88_9_8_1","first-page":"150","article-title":"The processing of stem cell concentrates from the bone marrow in ABO\u2010incompatible transplants: how and when","volume":"12","author":"Daniele N","year":"2014","journal-title":"Blood Transfus"},{"key":"e_1_2_88_9_9_1","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1537-2995.2011.03069.x","article-title":"How do I approach ABO\u2010incompatible hematopoietic progenitor cell transplantation?","volume":"51","author":"Daniel\u2010Johnson J","year":"2011","journal-title":"Transfusion"},{"issue":"24","key":"e_1_2_88_9_10_1","doi-asserted-by":"crossref","first-page":"5604","DOI":"10.12998\/wjcc.v12.i24.5604","article-title":"Seven\u2010years post allogeneic hematopoietic stem cell transplantation pure red cell aplastic anemia cured with daratumumab: A case report and review of literature","volume":"12","author":"Deng B","year":"2024","journal-title":"World J Clin Cases."},{"key":"e_1_2_88_9_11_1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.585628","article-title":"Antigen\u2010specific immunoadsorption with Glycosorb ABO immunoadsorption system as a novel treatment modality in pure red cell aplasia following major and bidirectional ABO\u2010incompatible allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Handisurya A","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"e_1_2_88_9_12_1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00277-007-0304-8","article-title":"Pure red cell aplasia following major and bi\u2010directional ABO\u2010incompatible allogeneic stem cell transplantation: recovery of donor\u2010derived erythropoiesis after long\u2010term treatment using different therapeutic strategies","volume":"86","author":"Helbig G","year":"2007","journal-title":"Ann Hematol"},{"key":"e_1_2_88_9_13_1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.bmt.1702121","article-title":"Anti\u2010A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO\u2010incompatible allogeneic bone marrow transplantation","volume":"25","author":"Lee JH","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_88_9_14_1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41409-020-01124-6","article-title":"Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question","volume":"56","author":"Marco\u2010Ayala J","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_88_9_15_1","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V96.3.1150","article-title":"Graft versus\u2010host disease and donor\u2010directed hemagglutinin titers after ABO\u2010mismatched related and unrelated marrow allografts: evidence for a graft\u2010versus\u2010plasma cell effect","volume":"96","author":"Mielcarek M","year":"2000","journal-title":"Blood"},{"key":"e_1_2_88_9_16_1","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/bloodadvances.2021006279","article-title":"Post\u2010hematopoietic stem cell transplantation immune\u2010mediated anemia: a literature review and novel therapeutics","volume":"6","author":"Migady Y","year":"2022","journal-title":"Blood Adv"},{"key":"e_1_2_88_9_17_1","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2169\/internalmedicine.36.487","article-title":"Apheresis therapy for prolonged red cell aplasia after major ABO\u2010mismatched bone marrow transplantation","volume":"36","author":"Ohta S","year":"1997","journal-title":"Intern Med"},{"key":"e_1_2_88_9_18_1","first-page":"99","article-title":"Treatment of pure red\u2010cell aplasia following major ABO\u2010mismatched T\u2010cell\u2010depleted bone marrow transplantation. Two case reports with successful response to plasmapheresis","volume":"4","author":"Or R","year":"1991","journal-title":"Transpl Int"},{"key":"e_1_2_88_9_19_1","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/bmt.2011.135","article-title":"Red blood cell\u2010incompatible allogeneic hematopoietic progenitor cell transplantation","volume":"46","author":"Rowley SD","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_88_9_20_1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/jca.21553","article-title":"Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplant","volume":"33","author":"Sackett K","year":"2018","journal-title":"J Clin Apher"},{"key":"e_1_2_88_9_21_1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3324\/haematol.13356","article-title":"Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti\u2010donor isoagglutinins","volume":"94","author":"Stussi G","year":"2009","journal-title":"Haematologica"},{"key":"e_1_2_88_9_22_1","first-page":"397","article-title":"Haemolysis, pure red cell aplasia, and red cell antibody formation associated with major and bidirectional ABO incompatible hematopoietic stem cell transplantation","volume":"16","author":"Tomac G","year":"2018","journal-title":"Blood Transfus"},{"key":"e_1_2_88_9_23_1","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S1607-551X(09)70096-8","article-title":"Pure red cell aplasia after ABO major\u2010mismatch allogeneic peripheral blood stem cell transplantation successfully treated with plasma exchange and low\u2010dose steroid: two case reports","volume":"20","author":"Tsai HJ","year":"2004","journal-title":"Kaohsiung J Med Sci"},{"key":"e_1_2_88_9_24_1","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/j.1537-2995.2007.01289.x","article-title":"Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO\u2010mismatched allogeneic peripheral blood progenitor cell transplantation after reduced\u2010intensity conditioning","volume":"47","author":"Worel N","year":"2007","journal-title":"Transfusion"},{"key":"e_1_2_88_9_25_1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1432-2277.2003.tb00303.x","article-title":"ABO\u2010incompatible organ and bone marrow transplantation: current status","volume":"16","author":"Wu A","year":"2003","journal-title":"Transpl Int"},{"key":"e_1_2_89_9_1_1","doi-asserted-by":"crossref","first-page":"e689","DOI":"10.1097\/MPH.0000000000002357","article-title":"The impact of panel reactive antibodies and different desensitization methods on pediatric allogeneic hematopoietic stem cell transplantation outcomes","volume":"44","author":"Akinci B","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"key":"e_1_2_89_9_2_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.674658","article-title":"Management of donor\u2010specific antibodies in haploidentical transplant: multicenter experience from the Madrid Group of Hematopoietic Transplant","volume":"12","author":"Bail\u00e9n R","year":"2021","journal-title":"Front Immunol"},{"key":"e_1_2_89_9_3_1","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood.V74.5.1477.1477","article-title":"Antibody\u2010mediated marrow failure after bone marrow transplantation","volume":"74","author":"Barge AJ","year":"1989","journal-title":"Blood"},{"issue":"8","key":"e_1_2_89_9_4_1","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1097\/00007890-200004270-00040","article-title":"Successful transplantation of highly selected CD34+ peripheral blood stem cells in a HLA\u2010sensitized patient treated with immunoadsorption onto protein A","volume":"69","author":"Braun N","year":"2000","journal-title":"Transplantation"},{"key":"e_1_2_89_9_5_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-015-0182-9","article-title":"Donor\u2010specific anti\u2010human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets","volume":"8","author":"Chang YJ","year":"2015","journal-title":"J Hematol Oncol"},{"key":"e_1_2_89_9_6_1","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/j.bbmt.2018.10.018","article-title":"Bortezomib and immune globulin have limited effects on donor\u2010specific HLA antibodies in haploidentical cord blood stem cell transplantation: detrimental effect of persistent haploidentical donor\u2010specific HLA antibodies","volume":"25","author":"Choe H","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_89_9_7_1","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/TP.0b013e3181b9d710","article-title":"High risk of graft failure in patients with anti\u2010HLA antibodies undergoing haploidentical stem\u2010cell transplantation","volume":"88","author":"Ciurea SO","year":"2009","journal-title":"Transplantation"},{"key":"e_1_2_89_9_8_1","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1182\/bloodadvances.2021004862","article-title":"Treatment of allosensitized patients receiving allogeneic transplantation","volume":"5","author":"Ciurea SO","year":"2021","journal-title":"Blood Advances"},{"key":"e_1_2_89_9_9_1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41409-017-0062-8","article-title":"The European society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor\u2010specific anti\u2010HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation","volume":"53","author":"Ciurea SO","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_89_9_10_1","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.bbmt.2015.05.001","article-title":"Complement\u2010binding donor\u2010specific anti\u2010HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation","volume":"21","author":"Ciurea SO","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_89_9_11_1","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1080\/10428194.2024.2376172","article-title":"Pretransplant desensitization of donor\u2010specific anti\u2010HLA antibodies with plasmapheresis and immunoglobulin produces equivalent outcomes to patients with no donor specific antibodies in haploidentical hematopoietic cell transplant","volume":"65","author":"Cochran HC","year":"2024","journal-title":"Leuk Lymphoma."},{"key":"e_1_2_89_9_12_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1365-2141.2010.08305.x","article-title":"Overcoming HLA\u2010DPB1 donor specific antibody\u2010mediated hematopoietic graft failure","volume":"151","author":"Costa LJ","year":"2010","journal-title":"Br J Hematol"},{"key":"e_1_2_89_9_13_1","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.bbmt.2013.01.016","article-title":"Partially mismatched transplantation and human leukocyte antigen donor\u2010specific antibodies","volume":"19","author":"Gladstone DE","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_89_9_14_1","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1097\/TP.0b013e318293fcda","article-title":"Rapid hematopoietic recovery with high levels of DSA in an unmanipulated haploidentical transplant patient","volume":"95","author":"Ishiyama K","year":"2013","journal-title":"Transplantation."},{"key":"e_1_2_89_9_15_1","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jtct.2024.09.005","article-title":"ASTCT consensus recommendations on testing and treatment of patients with donor\u2010specific anti\u2010HLA antibodies","volume":"30","author":"Kongtim P","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"e_1_2_89_9_16_1","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/s41409-019-0497-1","article-title":"Anti\u2010HLA donor\u2010specific antibodies in allogeneic stem cell transplantation: management and desensitization protocol","volume":"54","author":"La Rocca U","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_89_9_17_1","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/bmt.2014.331","article-title":"Donor HLA\u2010specific Abs: to BMT or not to BMT?","volume":"50","author":"Leffell MS","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_89_9_18_1","doi-asserted-by":"crossref","first-page":"e15625","DOI":"10.1111\/tan.15625","article-title":"A simple predictor for donor\u2010specific anti\u2010HLA antibody desensitization in haploidentical hematopoietic stem cell transplantation","volume":"104","author":"Li JM","year":"2024","journal-title":"HLA"},{"issue":"12","key":"e_1_2_89_9_19_1","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29993","article-title":"Outcomes of patients who underwent treatment for anti\u2010HLA donor\u2010specific antibodies before receiving a haploidentical hematopoietic cell transplant","volume":"69","author":"Lipsitt A","year":"2022","journal-title":"Pediatr Blood Cancer."},{"key":"e_1_2_89_9_20_1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/bjh.19046","article-title":"Double filtration plasmapheresis combined with rituximab for donor\u2010specific antibody desensitization in haploidentical hematopoietic stem cell transplantation","volume":"203","author":"Liu L","year":"2023","journal-title":"Br J Haematol"},{"key":"e_1_2_89_9_21_1","first-page":"397","article-title":"Donor\u2010HLA\u2010incompatible marrow transplantation with an anti\u2010donor cytotoxic antibody in the serum of the patient","volume":"7","author":"Maruta A","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_89_9_22_1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.trim.2011.06.001","article-title":"Immune modulation to prevent antibody\u2010mediated rejection after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Norlander A","year":"2011","journal-title":"Transplant Immunol"},{"key":"e_1_2_89_9_23_1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.humimm.2003.12.010","article-title":"Clinical significance of recipient antibodies to stem cell donor mismatched class I HLA antigens","volume":"65","author":"Pollack M","year":"2004","journal-title":"Hum Immunol"},{"key":"e_1_2_89_9_24_1","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/bmt.2017.10","article-title":"Effective desensitization of donor\u2010specific HLA antibodies using platelet transfusion bearing targeted HLA in a case of HLA\u2010mismatched allogeneic stem cell transplantation","volume":"52","author":"Yamashita T","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_89_9_25_1","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/bmt.2011.131","article-title":"Risk and prevention of graft failure in patients with preexisting donor\u2010specific HLA antibodies undergoing unmanipulated haploidentical SCT","volume":"47","author":"Yoshihara S","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_90_9_1_1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.transproceed.2025.01.002","article-title":"Trends in perioperative practices for immunological assessment and immunosuppression strategies for patients undergoing intestinal transplantation at American transplant centers","volume":"57","author":"Abusuliman M","year":"2025","journal-title":"Transplant Proc"},{"key":"e_1_2_90_9_2_1","first-page":"056","article-title":"Therapeutic plasma exchange in small bowel transplant recipients","volume":"6","author":"Bobr A","year":"2020","journal-title":"Int J Transplant Res Med"},{"key":"e_1_2_90_9_3_1","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/TP.0000000000001391","article-title":"Prevalence and clinical impact of donor\u2010specific alloantibody among intestinal transplant recipients","volume":"101","author":"Cheng EY","year":"2017","journal-title":"Transplantation"},{"key":"e_1_2_90_9_4_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/MOT.0000000000000393","article-title":"The impact of antibodies and virtual crossmatching on intestinal transplant outcomes","volume":"22","author":"Cheng EY","year":"2017","journal-title":"Curr Opin Organ Transplant"},{"key":"e_1_2_90_9_5_1","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1111\/ajt.13183","article-title":"Eculizumab salvage therapy for antibody\u2010mediated rejection in a desensitization\u2010resistant intestinal re\u2010transplant patient","volume":"15","author":"Fan J","year":"2015","journal-title":"Am J Transplant"},{"key":"e_1_2_90_9_6_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4240\/wjgs.v8.i1.101","article-title":"Successful living donor intestinal transplantation in crossmatch positive recipients: Initial experience. World","volume":"8","author":"Garcia\u2010Roca Tzvetanov IG","year":"2016","journal-title":"J Gastrointest Surg"},{"key":"e_1_2_90_9_7_1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/tri.12250","article-title":"Clinical relevance of the de novo production of anti\u2010HLA antibodies following intestinal and multivisceral transplantation","volume":"27","author":"Gerlach UA","year":"2014","journal-title":"Transpl Int"},{"key":"e_1_2_90_9_8_1","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1097\/01.tp.0000226078.94635.76","article-title":"Pretransplant immunomodulation of highly sensitized small bowel transplant candidates with intravenous immune globulin","volume":"81","author":"Gondolesi G","year":"2006","journal-title":"Transplantation"},{"key":"e_1_2_90_9_9_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5152\/turkjsurg.2017.3544","article-title":"Advances in small bowel transplantation","volume":"33","author":"Gurkan A.","year":"2017","journal-title":"Turk J Surg"},{"key":"e_1_2_90_9_10_1","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/MOT.0000000000000855","article-title":"Long\u2010term outcomes of intestinal transplantation","volume":"26","author":"Hind JM","year":"2021","journal-title":"Curr Opin Organ Transplant"},{"key":"e_1_2_90_9_11_1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/TP.0000000000003065","article-title":"New insights into the indications for intestinal transplantation: consensus in the year 2019","volume":"104","author":"Kaufman SS","year":"2020","journal-title":"Transplantation"},{"key":"e_1_2_90_9_12_1","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1097\/TP.0000000000000614","article-title":"Prospective monitoring of donor\u2010specific anti\u2010HLA antibodies after intestine\/multivisceral transplantation: Significance of de novo antibodies","volume":"99","author":"Kubal C","year":"2015","journal-title":"Transplantation"},{"issue":"10","key":"e_1_2_90_9_13_1","doi-asserted-by":"crossref","first-page":"1074577","DOI":"10.3389\/fped.2022.1074577","article-title":"Antibody\u2010removal therapies for de novo DSA in pediatric intestinal recipients: Why, when, and how? A single\u2010center experience","volume":"2","author":"Lasa\u2010L\u00e1zaro M","year":"2023","journal-title":"Frontiers in Pediatrics"},{"key":"e_1_2_90_9_14_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2024.111160","article-title":"Unlocking the promise of mesenchymal stem cells and extracorporeal photopheresis to address rejection and graft failure in intestinal transplant recipients","volume":"85","author":"Levitte S","year":"2024","journal-title":"Human Immunol"},{"key":"e_1_2_90_9_15_1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MOG.0000000000000358","article-title":"Intestinal transplantation: a review","volume":"33","author":"Loo L","year":"2017","journal-title":"Curr Opin Gastroenterol"},{"key":"e_1_2_90_9_16_1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MOT.0000000000000853","article-title":"Donor\u2010specific antibody and sensitized patients in intestinal transplantation","volume":"26","author":"Matsumoto CS","year":"2021","journal-title":"Curr Opin Organ Transplant"},{"key":"e_1_2_90_9_17_1","doi-asserted-by":"crossref","DOI":"10.1111\/petr.12847","article-title":"Impacts of donor\u2010specific anti\u2010HLA antibodies and antibody\u2010mediated rejection on outcomes after intestinal transplantation in children","volume":"21","author":"Petit LM","year":"2017","journal-title":"Pediatr Transplant"},{"key":"e_1_2_90_9_18_1","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1111\/ajt.14685","article-title":"Antibody\u2010mediated rejection in pediatric small bowel transplantation: capillaritis is a major determinant of C4d positivity in intestinal transplant biopsies","volume":"18","author":"Rabant M","year":"2018","journal-title":"Am J Transplant"},{"key":"e_1_2_90_9_19_1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/MOT.0000000000000075","article-title":"Updates on acute and chronic rejection in small bowel and multivisceral allografts","volume":"19","author":"Ruiz P.","year":"2014","journal-title":"Curr Opin Organ Transplant"},{"key":"e_1_2_90_9_20_1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/1526924819855088","article-title":"Is there a role for desensitization in intestinal transplantation?","volume":"29","author":"Santeusanio AD","year":"2019","journal-title":"Prog Transpl"},{"key":"e_1_2_90_9_21_1","doi-asserted-by":"crossref","DOI":"10.1002\/jca.70028","article-title":"Expanding Horizons: Single\u2010center insights on extracorporeal photopheresis (ECP) in non\u2010lung solid organ transplantation","volume":"40","author":"Sethapati VR","year":"2025","journal-title":"J Clin Apher"},{"key":"e_1_2_90_9_22_1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/TP.0b013e318229f752","article-title":"Association between donor\u2010specific antibodies and acute rejection and resolution in small bowel and multivisceral transplantation","volume":"92","author":"Tsai HL","year":"2011","journal-title":"Transplantation"},{"issue":"1","key":"e_1_2_90_9_23_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/ajts.ajts_18_21","article-title":"Passenger lymphocyte syndrome as a rare cause of hemolysis in a patient after small intestine transplantation, a case report and review of the literature","volume":"16","author":"Zarei E","year":"2022","journal-title":"Asian J Transfus Sci"},{"issue":"15","key":"e_1_2_91_9_1_1","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.3390\/jcm12154927","article-title":"Current therapies in kidney transplant rejection","volume":"12","author":"Alasfar S","year":"2023","journal-title":"J Clin Med"},{"key":"e_1_2_91_9_2_1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/ctr.12491","article-title":"Treatment of antibody\u2010mediated rejection in renal transplant patients: a clinical practice survey","volume":"29","author":"Burton SA","year":"2015","journal-title":"Clin Transplant"},{"key":"e_1_2_91_9_3_1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/1744-9987.13937","article-title":"A comparison of methods of plasmapheresis for the treatment of late antibody mediated rejection in kidney transplant recipients","volume":"3","author":"Caliskan Y","year":"2023","journal-title":"Ther Apher Dial"},{"key":"e_1_2_91_9_4_1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.humimm.2019.04.005","article-title":"Proactive treatment of angiotensin receptor antibodies in kidney transplantation with plasma exchange and\/or candesartan is safe and associated with excellent graft survival at 4\u2009years: a single centre Australian experience","volume":"80","author":"Carroll RP","year":"2019","journal-title":"Hum Immunol"},{"key":"e_1_2_91_9_5_1","first-page":"998","article-title":"Outcomes of kidney transplantation in highly HLA\u2010sensitized patients treated with intravenous immunoglobulin, plasmapheresis and rituximab: a meta\u2010analysis","volume":"8","author":"Chandramohan D","year":"2024","journal-title":"Life (Basel)"},{"key":"e_1_2_91_9_6_1","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2215\/CJN.11991019","article-title":"Evaluation and treatment of acute rejection in kidney allografts","volume":"15","author":"Cooper JE","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"e_1_2_91_9_7_1","first-page":"547","article-title":"Photopheresis abates the anti\u2010HLA antibody titer and renal failure progression in chronic antibody\u2010mediated rejection","volume":"10","author":"Gregorini M","year":"2021","journal-title":"Biology (Basel)"},{"issue":"7","key":"e_1_2_91_9_8_1","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.15383","article-title":"A randomized trial comparing imlifidase to plasmapheresis in kidney transplant recipients with antibody\u2010mediated rejection","volume":"38","author":"Halleck F","year":"2024","journal-title":"Clin Transplant."},{"key":"e_1_2_91_9_9_1","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1097\/TP.0000000000003551","article-title":"A comprehensive overview of the clinical relevance and treatment options for antibody\u2010mediated rejection associated with non\u2010HLA antibodies","volume":"105","author":"Kardol\u2010Hoefnagel T","year":"2021","journal-title":"Transplantation"},{"issue":"8","key":"e_1_2_91_9_10_1","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1016\/j.transproceed.2011.08.061","article-title":"Extracorporeal photopheresis as an antirejection prophylaxis in kidney transplant recipients: preliminary results","volume":"43","author":"Kusztal M","year":"2011","journal-title":"Transplant Proc"},{"issue":"10","key":"e_1_2_91_9_11_1","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/01.tp.0000261635.30578.d8","article-title":"Induction of regulatory T cells after prophylactic treatment with photopheresis in renal transplant recipients","volume":"83","author":"Lamioni A","year":"2007","journal-title":"Transplantation"},{"key":"e_1_2_91_9_12_1","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1600-6143.2009.02591.x","volume":"9","author":"Lefaucheur C","year":"2009","journal-title":"Am J Transplant"},{"key":"e_1_2_91_9_13_1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1012376","article-title":"Desensitization in HLA\u2010incompatible kidney recipients and survival","volume":"365","author":"Montgomery RA","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"e_1_2_91_9_14_1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ajt.2023.10.016","article-title":"The Banff 2022 kidney meeting report: reappraisal of microvascular inflammation and the role of biopsy\u2010based transcript diagnostics","volume":"24","author":"Naesens M","year":"2024","journal-title":"Am J Transplant"},{"key":"e_1_2_91_9_15_1","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.transproceed.2019.01.126","article-title":"Clearance of intra\u2010graft donor specific anti\u2010HLA antibodies in the early stage of antibody\u2010mediated rejection following rituximab and apheresis therapy in renal transplantation","volume":"51","author":"Nakamura T","year":"2019","journal-title":"Transplantat Proc"},{"issue":"6","key":"e_1_2_91_9_16_1","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3390\/jcm10061316","article-title":"Apheresis efficacy and tolerance in the setting of HLA\u2010incompatible kidney transplantation","volume":"10","author":"Noble J","year":"2021","journal-title":"J Clin Med"},{"key":"e_1_2_91_9_17_1","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1056\/NEJMoa1508380","article-title":"Survival benefit with kidney transplants from HLA\u2010incompatible live donors","volume":"374","author":"Orandi BJ","year":"2016","journal-title":"N Engl J Med"},{"key":"e_1_2_91_9_18_1","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/1744-9987.13467","article-title":"Renal transplantation in HLA sensitized patients: traversing the immunological barrier","volume":"24","author":"Pandey P","year":"2020","journal-title":"Ther Apher Dial"},{"key":"e_1_2_91_9_19_1","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s00467-015-3295-z","article-title":"Management of sensitized pediatric patients prior to renal transplantation","volume":"31","author":"Pirojsakul K","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"e_1_2_91_9_20_1","first-page":"328","article-title":"Intensive plasmapheresis and intravenous immunoglobulin for treatment of antibody\u2010mediated rejection after kidney transplant","volume":"12","author":"Ruangkanchanasetr P","year":"2014","journal-title":"Exp Clin Transplant"},{"key":"e_1_2_91_9_21_1","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended treatment for antibody\u2010mediated rejection after kidney transplantation: the 2019 expert consensus from the transplantation society working group","volume":"104","author":"Schinstock CA","year":"2020","journal-title":"Transplantation"},{"issue":"4","key":"e_1_2_91_9_22_1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.transci.2019.06.031","article-title":"Extracorporeal photopheresis for the treatment of graft rejection in 33 adult kidney transplant recipients","volume":"58","author":"Tamain M","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_91_9_23_1","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.transproceed.2017.02.059","article-title":"Outcome of pretransplantation therapeutic plasma exchange in highly sensitized deceased\u2010donor kidney transplant recipients","volume":"49","author":"Tipjaiaue P","year":"2017","journal-title":"Transplant Proc"},{"key":"e_1_2_92_9_1_1","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1111\/ajt.16712","article-title":"Characterization of ABH\u2010subtype donor\u2010specific antibodies in ABO\u2010A\u2010incompatible kidney transplantation","volume":"21","author":"Bentall A","year":"2021","journal-title":"Am J Transplant"},{"key":"e_1_2_92_9_2_1","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2215\/CJN.02940311","article-title":"Incompatible live\u2010donor kidney transplantation in the United States: results of a national survey","volume":"6","author":"Garonzik Wang JM","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"e_1_2_92_9_3_1","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.transproceed.2020.01.152","article-title":"Outcome of ABO blood type\u2013incompatible living\u2010related donor kidney transplantation under a contemporary immunosuppression strategy in Japan","volume":"52","author":"Hamano I","year":"2020","journal-title":"Transplant Proc"},{"key":"e_1_2_92_9_4_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41100-019-0204-0","article-title":"Efficacy of selective plasma exchange as pre\u2010transplant apheresis in ABO\u2010incompatible kidney transplantation","volume":"5","author":"Hanaoka A","year":"2019","journal-title":"Ren Replace Ther"},{"key":"e_1_2_92_9_5_1","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/tri.12979","article-title":"Korean Organ Transplantation Registry Study Group. Clinical outcomes of ABO\u2010and HLA\u2010incompatible kidney transplantation: a nationwide cohort study","volume":"30","author":"Ko EJ","year":"2017","journal-title":"Transpl Int"},{"key":"e_1_2_92_9_6_1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/TP.0000000000004789","article-title":"A multicenter retrospective cohort study on management protocols and clinical outcomes after ABO\u2010incompatible kidney transplantation in India","volume":"108","author":"Kute VB","year":"2024","journal-title":"Transplantation"},{"key":"e_1_2_92_9_7_1","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.transproceed.2020.09.001","article-title":"Long\u2010term follow\u2010up of ABO\u2010incompatible kidney transplantation in Freiburg, Germany: a single\u2010center outcome report","volume":"53","author":"Langhorst C","year":"2021","journal-title":"Transplant Proc"},{"issue":"7","key":"e_1_2_92_9_8_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100843","article-title":"A2\/A2B deceased donor kidney transplant using A2 titers improves access to kidney transplantation: a single\u2010center study","volume":"6","author":"Lum EL","year":"2024","journal-title":"Kidney Med"},{"key":"e_1_2_92_9_9_1","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1053\/j.ajkd.2020.03.029","article-title":"Impact of ABO\u2010incompatible living donor kidney transplantation on patient survival","volume":"76","author":"Massie AB","year":"2020","journal-title":"AJKD"},{"key":"e_1_2_92_9_10_1","doi-asserted-by":"crossref","first-page":"12263","DOI":"10.3389\/ti.2024.12263","article-title":"Non\u2010antigen specific immunoadsorption is a risk factor for sever postoperative infections in ABO\u2010incompatible kidney transplant recipients","volume":"37","author":"Matuschik L","year":"2024","journal-title":"Transpl Int."},{"issue":"1","key":"e_1_2_92_9_11_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2023.103844","article-title":"Therapeutic apheresis in renal transplantation: an update","volume":"63","author":"Melexopoulou C","year":"2024","journal-title":"Transfus Apher Sci."},{"key":"e_1_2_92_9_12_1","doi-asserted-by":"crossref","first-page":"1504495","DOI":"10.3389\/fimmu.2024.1504495","article-title":"Outcomes of ABO\u2010incompatible kidney transplants with very high isoagglutinin titers: a single\u2010center experience and literature review","volume":"15","author":"Naciri Bennani H","year":"2024","journal-title":"Front Immunol"},{"key":"e_1_2_92_9_13_1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/jca.21860","article-title":"Outcome of desensitization in human leukocyte antigen and ABO incompatible living donor kidney transplantation: single center experience of first 200 incompatible transplants","volume":"36","author":"Pandey P","year":"2021","journal-title":"J Clin Apher"},{"key":"e_1_2_92_9_14_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2054358120962586","article-title":"The first North American experience using glycosorb immunoadsorption columns for blood group\u2013incompatible kidney transplantation","volume":"7","author":"Pavenski K","year":"2020","journal-title":"Can J Kidney Health Dis"},{"key":"e_1_2_92_9_15_1","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(18)32091-9","article-title":"Clinical outcomes after ABO\u2010incompatible renal transplantation: a systematic review and meta\u2010analysis","volume":"393","author":"Scurt FG","year":"2019","journal-title":"Lancet"},{"key":"e_1_2_92_9_16_1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jamcollsurg.2018.12.023","article-title":"A2 to B kidney transplantation in the post\u2010kidney allocation system era: a 3\u2010year experience with anti\u2010A titers, outcomes, and cost","volume":"228","author":"Shaffer D","year":"2019","journal-title":"J Am Coll Surg"},{"key":"e_1_2_92_9_17_1","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/tri.13482","article-title":"Outcomes and complications following ABO\u2010incompatible kidney transplantation performed after desensitization by semi\u2010selective immunoadsorption\u2010a retrospective study","volume":"32","author":"Speer C","year":"2019","journal-title":"Transpl Int"},{"key":"e_1_2_92_9_18_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/1319-2442.252937","article-title":"Comparative analysis of ABO\u2010incompatible kidney transplantation with ABO\u2010compatible transplantation: a single\u2010center experience from Eastern India","volume":"30","author":"Thukral S","year":"2019","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"e_1_2_92_9_19_1","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.1600-6143.2010.03103.x","article-title":"ABO antibody titer and risk of antibody\u2010mediated rejection in ABO\u2010incompatible renal transplantation","volume":"10","author":"Tobian AA","year":"2010","journal-title":"Am J Transplant"},{"key":"e_1_2_92_9_20_1","first-page":"1","article-title":"Transplant outcomes of 100 cases of living\u2010donor ABO\u2010incompatible kidney transplantation","author":"Yin S","year":"2022","journal-title":"Chin Med J"},{"key":"e_1_2_93_9_1_1","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1097\/TP.0000000000004883","article-title":"High number of plasma exchanges increases the risk of bacterial infection in ABO\u2010incompatible living donor liver transplantation","volume":"108","author":"Choi MC","year":"2024","journal-title":"Transplantation"},{"key":"e_1_2_93_9_2_1","doi-asserted-by":"crossref","first-page":"13232","DOI":"10.3389\/ti.2024.13232","article-title":"Antibody\u2010mediated rejection in liver transplantation: immuno\u2010pathological characteristics and long\u2010term follow\u2010up","volume":"37","author":"Cicalese L","year":"2024","journal-title":"Transpl Int."},{"key":"e_1_2_93_9_3_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2021.101476","article-title":"Clinical outcomes after ABO\u2010incompatible liver transplantation: a systematic review and meta\u2010analysis","volume":"69","author":"Gan K","year":"2021","journal-title":"Transpl Immunol"},{"key":"e_1_2_93_9_4_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2023.101340","article-title":"ABO incompatible living donor liver transplantation in children: a single centre experience from India","volume":"14","author":"Gautam V","year":"2024","journal-title":"J Clin Exp Hepatol"},{"key":"e_1_2_93_9_5_1","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.6002\/ect.2021.0064","article-title":"Therapeutic plasma exchange for management of early allograft dysfunction after living donor liver transplant: an unmatched cohort study","volume":"19","author":"Hakeem AR","year":"2021","journal-title":"Exp Clin Transplant"},{"key":"e_1_2_93_9_6_1","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1007\/s00595-023-02678-w","article-title":"Long\u2010term outcomes following ABO\u2010incompatible living donor liver transplantation for acute liver failure: a single\u2010center experience of over 20\u2009years","volume":"53","author":"Hirukawa K","year":"2023","journal-title":"Surg Today"},{"key":"e_1_2_93_9_7_1","volume":"25","author":"Hsu SC","year":"2020","journal-title":"Ann Transplant"},{"key":"e_1_2_93_9_8_1","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jceh.2022.12.008","article-title":"Strategies for ABO incompatible liver transplantation","volume":"13","author":"Jadaun SS","year":"2023","journal-title":"J Clin Exp Hepatol"},{"key":"e_1_2_93_9_9_1","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1097\/TP.0000000000002154","article-title":"ABO\u2010incompatible living donor liver transplantation with rituximab and total plasma exchange does not increase hepatocellular carcinoma recurrence","volume":"201","author":"Kim JM","year":"2018","journal-title":"Transplantation"},{"key":"e_1_2_93_9_10_1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/TP.0b013e31825c591e","article-title":"Safety of blood group A2\u2010to\u2010O liver transplantation: an analysis of the United Network of Organ Sharing database","volume":"94","author":"Kluger MD","year":"2012","journal-title":"Transplantation"},{"key":"e_1_2_93_9_11_1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.transproceed.2021.11.022","volume":"54","author":"Komagone M","year":"2022","journal-title":"Transplant Proc"},{"key":"e_1_2_93_9_12_1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.transproceed.2015.02.004","article-title":"Results of ABO\u2010incompatible liver transplantation using a simplified protocol at a single institution","volume":"47","author":"Lee J","year":"2015","journal-title":"Transplant Proc"},{"key":"e_1_2_93_9_13_1","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.transproceed.2025.03.017","article-title":"MELD score before and after plasmapheresis in recipients of ABO\u2010incompatible living donor liver transplantation","volume":"57","author":"Lee JE","year":"2025","journal-title":"Transplant Proc"},{"key":"e_1_2_93_9_14_1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.6002\/ect.2021.0025","article-title":"ABO\u2010incompatible living donor liver transplantation with a simplified desensitization and immunosuppression protocol: a single\u2010center retrospective study","volume":"19","author":"Lee TB","year":"2021","journal-title":"Exp Clin Transplant"},{"key":"e_1_2_93_9_15_1","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14555","article-title":"Quick preparation of ABO\u2010incompatible living donor liver transplantation for acute liver failure","volume":"36","author":"Lee WC","year":"2022","journal-title":"Clin Transplant"},{"key":"e_1_2_93_9_16_1","doi-asserted-by":"crossref","first-page":"1092412","DOI":"10.3389\/fped.2023.1092412","article-title":"Outcomes after ABO incompatible pediatric liver transplantation are comparable to ABO identical\/compatible transplant","volume":"11","author":"Lemoine CP","year":"2023","journal-title":"Front Pediatr"},{"key":"e_1_2_93_9_17_1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.transci.2017.07.008","article-title":"Extracorporeal photopheresis and liver transplantation: our experience and preliminary data","volume":"56","author":"Mazzoni A","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_93_9_18_1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/petr.12445","article-title":"The impact of rituximab in ABO\u2010incompatible pediatric living donor liver transplantation: the experience of a single center","volume":"19","author":"Okada N","year":"2015","journal-title":"Pediatr Transplant"},{"key":"e_1_2_93_9_19_1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/ajt.13476","article-title":"Proposed diagnostic criteria for chronic antibody\u2010mediated rejection in liver allografts","volume":"16","author":"O'Leary LG","year":"2016","journal-title":"Am J Transplant"},{"key":"e_1_2_93_9_20_1","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/ajt.12667","article-title":"The role of donor\u2010specific HLA alloantibodies in liver transplantation","volume":"14","author":"O'Leary LG","year":"2014","journal-title":"Am J Transplant"},{"key":"e_1_2_93_9_21_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/ajt.13444","article-title":"ABO\u2010incompatible adult living donor liver transplantation under the desensitization protocol with rituximab","volume":"16","author":"Song GW","year":"2016","journal-title":"Am J Transplant"},{"key":"e_1_2_93_9_22_1","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000000932","article-title":"Bortezomib against refractory antibody\u2010mediated rejection after ABO\u2010incompatible living\u2010donor liver transplantation: dramatic effect in acute\u2010phase?","volume":"5","author":"Tajima T","year":"2019","journal-title":"Transplant Direct"},{"key":"e_1_2_93_9_23_1","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/tri.12552","article-title":"Liver transplantation with deceased ABO\u2010incompatible donors is life\u2010saving but associated with increased risk of rejection and post\u2010transplant complications","volume":"28","author":"Thorsen T","year":"2015","journal-title":"Transpl Int"},{"key":"e_1_2_93_9_24_1","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.3390\/jcm11164834","article-title":"The new challenge in pediatric liver transplantation: chronic antibody\u2010mediated rejection","volume":"11","author":"Uebayashi EY","year":"2022","journal-title":"J Clin Med"},{"issue":"589","key":"e_1_2_93_9_25_1","first-page":"402","article-title":"ABO\u2010incompatible adult living donor liver transplantation in the era of rituximab: a systematic review and meta\u2010analysis","volume":"8","author":"Yadav DK","year":"2019","journal-title":"Gastroenterol Res Pract"},{"key":"e_1_2_93_9_26_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/TP.0000000000001956","article-title":"Feasibility of monotherapy by rituximab without additional desensitization in ABO\u2010incompatible living\u2010donor liver transplantation","volume":"102","author":"Yamamoto H","year":"2018","journal-title":"Transplantation"},{"key":"e_1_2_93_9_27_1","doi-asserted-by":"crossref","first-page":"14304","DOI":"10.3389\/ti.2025.14304","article-title":"Number of pretransplant therapeutic plasma exchange sessions increase the recurrence risk of hepatocellular carcinoma in ABO\u2010incompatible living donor liver transplantation","volume":"38","author":"Yoo YJ","year":"2025","journal-title":"Transpl Int"},{"key":"e_1_2_94_9_1_1","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1111\/ajt.16707","article-title":"Long\u2010term outcomes of sensitized lung transplant recipients after peri\u2010operative desensitization","volume":"21","author":"Aversa M","year":"2021","journal-title":"Am J Transplant"},{"key":"e_1_2_94_9_2_1","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.healun.2014.04.020","article-title":"Efficacy of extracorporeal photopheresis in clearance of antibodies to donor\u2010specific and lung\u2010specific antigens in lung transplant recipients","volume":"33","author":"Baskaran G","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"e_1_2_94_9_3_1","doi-asserted-by":"crossref","first-page":"2400733","DOI":"10.1183\/13993003.00733-2024","article-title":"Extracorporeal photopheresis for the prevention of rejection after lung transplantation: a prospective randomized controlled trial","volume":"65","author":"Benazzo A","year":"2025","journal-title":"Eur Respira J"},{"key":"e_1_2_94_9_4_1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000508170","article-title":"Outcome of extracorporeal photopheresis as an add\u2010on therapy for antibody\u2010mediated rejection in lung transplant recipients","volume":"47","author":"Benazzo A","year":"2020","journal-title":"Transfus Med Hemother"},{"key":"e_1_2_94_9_5_1","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1097\/TP.0b013e31818bc024","article-title":"Extracorporeal photopheresis after lung transplantation: a 10\u2010year single\u2010center experience","volume":"86","author":"Benden C","year":"2008","journal-title":"Transplantation"},{"key":"e_1_2_94_9_6_1","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.healun.2021.07.021","volume":"40","author":"Chambers DC","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"e_1_2_94_9_7_1","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1513\/AnnalsATS.201812-869OC","article-title":"Clinical outcomes of lung transplantation in the presence of donor\u2010specific antibodies","volume":"16","author":"Courtwright AM","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"e_1_2_94_9_8_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhlto.2025.100302","article-title":"Clinical utility of 1:16 serum dilution as a predictor of response to therapeutic plasma exchange for HLA antibody\u2010mediated rejection treatment and overall survival in lung transplant recipients: a two center study","volume":"9","author":"Elrefaei M","year":"2025","journal-title":"JHLT Open"},{"key":"e_1_2_94_9_9_1","first-page":"11","article-title":"Extracorporeal photopheresis (ECP) in the treatment of chronic lung allograft dysfunction (CLAD): a prospective, multicentre, open\u2010label, randomized controlled trial studying the addition of ECP to standard care in the treatment of bilateral lung transplant patients with CLAD (E\u2010CLAD UK). BMJ Open","author":"Fisher AJ","year":"2024","journal-title":"Respir Res"},{"key":"e_1_2_94_9_10_1","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/ajt.12155","article-title":"Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients","volume":"13","author":"Greer M","year":"2013","journal-title":"Am J Transplant"},{"key":"e_1_2_94_9_11_1","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/TP.0000000000002168","article-title":"Extracorporeal photopheresis for bronchiolitis obliterans syndrome after lung transplantation","volume":"102","author":"Hachem R","year":"2018","journal-title":"Transplantation"},{"key":"e_1_2_94_9_12_1","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.ajt.2023.04.034","article-title":"Lung transplantation despite preformed donor\u2010specific antihuman leukocyte antigen antibodies: a 9\u2010year single\u2010center experience","volume":"23","author":"Heise EL","year":"2023","journal-title":"Am J Transplant"},{"key":"e_1_2_94_9_13_1","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.healun.2012.05.002","article-title":"A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation","volume":"31","author":"Jaksch P","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"e_1_2_94_9_14_1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.healun.2016.01.1223","article-title":"Antibody\u2010mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation","volume":"35","author":"Levine DJ","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"e_1_2_94_9_15_1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.healun.2017.03.017","article-title":"Comparison of extracorporeal photopheresis and alemtuzumab for the treatment of chronic lung allograft dysfunction","volume":"37","author":"Moniodis A","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"e_1_2_94_9_16_1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.healun.2009.08.029","article-title":"The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation","volume":"29","author":"Morrell MR","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"e_1_2_94_9_17_1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/10600280211012410","article-title":"Antibody\u2010mediated rejection management following lung transplantation","volume":"56","author":"Neuhaus K","year":"2022","journal-title":"Ann Pharmacother"},{"key":"e_1_2_94_9_18_1","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.ajt.2023.04.031","article-title":"The first successful case of ABO\u2010incompatible living\u2010donor lobar lung transplantation following desensitization therapy","volume":"23","author":"Nakajima D","year":"2023","journal-title":"Am J Transplant"},{"key":"e_1_2_94_9_19_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2025.102261","article-title":"Efficacy of waitlist desensitization for lung candidates is limited by antibody rebound","volume":"92","author":"Pinelli D","year":"2025","journal-title":"Transpl Immunol"},{"key":"e_1_2_94_9_20_1","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2017.14429","article-title":"Cessation of extracorporeal photopheresis in chronic lung allograft dysfunction: effects on clinical outcome in adults","volume":"147","author":"Robinson C","year":"2017","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_94_9_21_1","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.healun.2023.10.003","article-title":"Impact of intraoperative therapeutic plasma exchange on bleeding in lung transplantation","volume":"43","author":"Saddoughi SA","year":"2024","journal-title":"J Heart Lung Transplant"},{"key":"e_1_2_94_9_22_1","doi-asserted-by":"crossref","DOI":"10.1002\/jca.70016","article-title":"Effect of therapeutic plasma exchange\u2010containing regimens on donor specific antibodies in patients with antibody mediated rejection of pulmonary transplant","volume":"40","author":"Velez JM","year":"2025","journal-title":"J Clin Apher"},{"key":"e_1_2_94_9_23_1","first-page":"15","article-title":"Intentional lung transplantation due to ABO incompatibility: a case report","author":"Var\u00f3n\u2010Vega F","year":"2023","journal-title":"Cureus"},{"key":"e_1_2_94_9_24_1","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1097\/TP.0000000000004413","article-title":"Safety of crossing donor\u2010specific antibodies in lung transplantation","volume":"107","author":"Wang M","year":"2023","journal-title":"Transplantation"},{"key":"e_1_2_94_9_25_1","doi-asserted-by":"crossref","DOI":"10.1002\/jca.22151","article-title":"Efficacy of a standardized regimen of therapeutic plasma exchange and IVIG for treatment of antibody\u2010mediated rejection in lung transplant recipients","volume":"39","author":"Wodajo A","year":"2024","journal-title":"J Clin Apher"},{"key":"e_1_2_94_9_26_1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/MOT.0000000000000878","article-title":"Desensitization and management of allograft rejection","volume":"26","author":"Zaffiri L.","year":"2021","journal-title":"Curr Opin Organ Transplant"},{"key":"e_1_2_95_9_1_1","article-title":"COVID\u201019 vaccine\u2010induced thrombotic thrombocytopenia: a case series","volume":"13","author":"Alalwan AA","year":"2021","journal-title":"Cureus"},{"key":"e_1_2_95_9_2_1","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1136\/jnnp-2021-326984","article-title":"Ischaemic stroke as a presenting feature of ChAdOx1 nCoV\u201019 vaccine\u2010induced immune thrombotic thrombocytopenia","volume":"92","author":"Al\u2010Mayhani T","year":"2021","journal-title":"J Neurol Neurosurg Pyschiatry"},{"key":"e_1_2_95_9_3_1","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1182\/bloodadvances.2022007766","article-title":"The clinical and laboratory diagnosis of vaccine\u2010induced immune thrombotic thrombocytopenia","volume":"6","author":"Bissola AL","year":"2022","journal-title":"Blood Adv"},{"key":"e_1_2_95_9_4_1","unstructured":"Bussel J Cines D Dunbar C et al. American Society for Hematology (ASH) 2022. Vaccine\u2010induced immune thrombotic thrombocytopenia. Available online:https:\/\/www.hematology.org\/covid-19\/vaccine-induced-immune-thrombotic-thrombocytopenia(Accessed November 12 2025)."},{"key":"e_1_2_95_9_5_1","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1016\/j.vaccine.2023.03.071","article-title":"Vaccine\u2010induced immune thrombotic thrombocytopenia post dose 2 ChAdOx1 nCoV19 vaccination: less severe but remains a problem","volume":"41","author":"Clarke L","year":"2023","journal-title":"Vaccine"},{"key":"e_1_2_95_9_6_1","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1182\/blood.2021014684","article-title":"Natural history of PF4 antibodies in vaccine\u2010induced immune thrombocytopenia and thrombosis","volume":"139","author":"Craven B","year":"2022","journal-title":"Blood"},{"key":"e_1_2_95_9_7_1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/kjm2.12549","article-title":"Therapeutic plasma exchange for refractory vaccine\u2010induced immune thrombotic thrombocytopenia","volume":"38","author":"Fan SB","year":"2022","journal-title":"Kaohsiung J Med Sci"},{"key":"e_1_2_95_9_8_1","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov\u201019 vaccination","volume":"384","author":"Greinacher A","year":"2021","journal-title":"N Engl J Med"},{"key":"e_1_2_95_9_9_1","unstructured":"International society of Thrombosis and Hemostasis (ISTH)2021.Available online:https:\/\/www.isth.org\/news\/561406\/The-ISTH-Releases-Interim-Guidance-on-Vaccine-Induced-Immune-Thrombotic-Thrombocytopenia-VITT-.htm(Accessed November 12 2025)."},{"key":"e_1_2_95_9_10_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/jca.21945","article-title":"Refractory vaccine\u2010induced immune thrombotic thrombocytopenia (VITT) managed with delayed therapeutic plasma exchange (TPE)","volume":"37","author":"Major A","year":"2022","journal-title":"J Clin Apher"},{"issue":"2","key":"e_1_2_95_9_11_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/antib13020035","article-title":"Antibodies against platelet glycoproteins in clinically suspected VITT patients","volume":"13","author":"Meier RT","year":"2024","journal-title":"Antibodies (Basel)"},{"key":"e_1_2_95_9_12_1","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1016\/j.vaccine.2022.06.014","article-title":"Brazillian VITT Investigative Collaboration Group. Vaccine\u2010induced immune thrombotic thrombocytopenia after COVID\u201019 vaccination: description of a series of 39 cases in Brazil","volume":"40","author":"Nunes Mouta","year":"2022","journal-title":"Vaccine"},{"key":"e_1_2_95_9_13_1","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/jth.15341","article-title":"Recommendations for the clinical and laboratory diagnosis of VITT against COVID\u201019: communication from the ISTH SSC Subcommittee on Platelet Immunology","volume":"19","author":"Nazy I","year":"2021","journal-title":"J Thromb Haemost"},{"key":"e_1_2_95_9_14_1","doi-asserted-by":"crossref","first-page":"E223","DOI":"10.1002\/ajh.26542","article-title":"COVID\u201019 mRNA\u20101273 vaccine induces production of vaccine\u2010induced immune thrombotic thrombocytopenia antibodies","volume":"97","author":"Padmanabhan A","year":"2022","journal-title":"Am J Hematol"},{"key":"e_1_2_95_9_15_1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1056\/NEJMc2109465","article-title":"Therapeutic plasma exchange in vaccine\u2010induced immune thrombotic thrombocytopenia","volume":"385","author":"Patriquin CJ","year":"2021","journal-title":"N Engl J Med"},{"key":"e_1_2_95_9_16_1","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine\u2010induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord S","year":"2021","journal-title":"N Engl J Med"},{"key":"e_1_2_95_9_17_1","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1001\/jamaneurol.2021.3619","article-title":"Characteristics and outcomes of patients with cerebral venous sinus thrombosis in SARS\u2010CoV\u20102 vaccine\u2010induced immune thrombotic thrombocytopenia","volume":"78","author":"Sanchez van Kammen M","year":"2021","journal-title":"JAMA Neurol"},{"key":"e_1_2_95_9_18_1","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2021014214","article-title":"Most anti\u2010PF4 antibodies in vaccine\u2010induced immune thrombotic thrombocytopenia are transient","volume":"139","author":"Sch\u00f6nborn L","year":"2022","journal-title":"Blood"},{"key":"e_1_2_95_9_19_1","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV\u201019 vaccination","volume":"384","author":"Schultz NH","year":"2021","journal-title":"N Engl J Med"},{"key":"e_1_2_95_9_20_1","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV\u201019 vaccination","volume":"384","author":"Scully M","year":"2021","journal-title":"N Engl J Med"},{"key":"e_1_2_95_9_21_1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M21-4502","article-title":"Case series of thrombosis with thrombocytopenia syndrome after COVID\u201019 vaccination\u2010United States, December 2020 to August 2021","volume":"175","author":"See I","year":"2022","journal-title":"Ann Intern Med"},{"key":"e_1_2_95_9_22_1","article-title":"The clinicopathological features of thrombosis with thrombocytopenia syndrome following ChAdOx1\u2010S (AZD1222) vaccination and case outcomes in Australia: a population\u2010based study","volume":"40","author":"Tran HA","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"e_1_2_95_9_23_1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jtha.2023.12.020","article-title":"Biophysical studies do not reveal direct interactions between human PF4 and Ad26.COV2.S vaccine","volume":"22","author":"Neut Kolfschoten M","year":"2024","journal-title":"J Thromb Haemost."},{"key":"e_1_2_95_9_24_1","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/bcp.15116","article-title":"A case series of vaccine\u2010induced thrombotic thrombocytopenia in a London teaching hospital","volume":"88","author":"Watts I","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"e_1_2_95_9_25_1","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/jcm13041012","article-title":"Vaccine\u2010induced immune thrombotic thrombocytopenia: clinicopathologic features and new perspectives on anti\u2010PF4 antibody\u2010mediated disorders","volume":"13","author":"Zhang Y","year":"2024","journal-title":"J Clin Med"},{"key":"e_1_2_96_9_1_1","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody\u2010associated vasculitis","volume":"73","author":"Chung SA","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_96_9_2_1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ekir.2023.01.039","article-title":"Renal recovery for patients with ANCA\u2010associated vasculitis and low eGFR in the ADVOCATE trial of Avacopan","volume":"8","author":"Cortazar FB","year":"2023","journal-title":"Kidney Int Rep"},{"key":"e_1_2_96_9_3_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jaut.2015.08.003","article-title":"Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice","volume":"65","author":"Luna G","year":"2015","journal-title":"J Autoimmunity"},{"key":"e_1_2_96_9_4_1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","article-title":"Evidence\u2010based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Emmi G","year":"2023","journal-title":"Nat Rev. Rheumatol"},{"key":"e_1_2_96_9_5_1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12969-017-0150-8","article-title":"Lung involvement in childhood onset granulomatosis with polyangiitis","volume":"15","author":"Filocamo G","year":"2017","journal-title":"Pediatric Rheumatology"},{"key":"e_1_2_96_9_6_1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.kint.2023.10.009","article-title":"Executive summary of the KDIGO 2024 clinical practice guideline for the management of ANCA\u2010associated vasculitis","volume":"105","author":"Floege J","year":"2024","journal-title":"Kidney Int"},{"key":"e_1_2_96_9_7_1","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1164\/rccm.202308-1426OC","article-title":"Alveolar hemorrhage in antineutrophil cytoplasmic antibody\u2010associated vasculitis. Results of an international randomized controlled trial (PEXIVAS)","volume":"209","author":"Fussner LA","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_96_9_8_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA\u2010associated vasculitis: 2022 update","volume":"83","author":"Hellmich B","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_96_9_9_1","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high\u2010dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne DRW","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_96_9_10_1","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA\u2010associated vasculitis","volume":"384","author":"Jayne DRW","year":"2021","journal-title":"N Engl J Med"},{"key":"e_1_2_96_9_11_1","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.ard.2025.06.2131","article-title":"Two\u2010year efficacy and safety of anti\u2010interleukin\u20105\/receptor therapy for eosinophilic granulomatosis with polyangiitis","volume":"84","author":"Merkel PA","year":"2025","journal-title":"Ann RheumDis"},{"key":"e_1_2_96_9_12_1","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1681\/ASN.2021060771","article-title":"Kidney histopathology can predict kidney function in ANCA\u2010asscociated vasculitides with acute kidney injury treated with plasma exchanges","volume":"33","author":"Nezam D","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_96_9_13_1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.kint.2024.11.029","article-title":"The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA\u2010associated vasculitis in the PEXIVAS trial","volume":"107","author":"Odler B","year":"2025","journal-title":"Kidney Int"},{"key":"e_1_2_96_9_14_1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2215\/CJN.03680412","article-title":"Intravenous cyclphosphamide and plasmapheresis in dialysis\u2010dependent ANCA\u2010associated vasculitis","volume":"8","author":"Pepper RJ","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"e_1_2_96_9_15_1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/ki.1991.272","article-title":"Plasma exchange in focal necrotizing glomerulonephritis without anti\u2010GBM antibodies","volume":"40","author":"Pusey CD","year":"1991","journal-title":"Kidney Int"},{"key":"e_1_2_96_9_16_1","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1093\/ndt\/gfu084","article-title":"ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA\u2010associated glomerulonephritis","volume":"29","author":"Quintana LF","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_96_9_17_1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/jca.21415","article-title":"Plasmapheresis therapy in ANCA\u2010associated vasculitides: A single\u2010center retrospective analysis of renal outcome and mortality","volume":"31","author":"Solar\u2010Cafaggi D","year":"2016","journal-title":"J Clin Apher"},{"key":"e_1_2_96_9_18_1","doi-asserted-by":"crossref","first-page":"sfae389","DOI":"10.1093\/ckj\/sfae389","article-title":"Top ten tips in managing ANCA vasculitis","volume":"18","author":"Tan MH","year":"2025","journal-title":"Clin Kidney J"},{"key":"e_1_2_96_9_19_1","first-page":"33","article-title":"Antineutrophil cytoplasmic antibody\u2010associated vasculitis with active kidney involvement in the United States: 2016\u20132020","volume":"4","author":"Tao J","year":"2024","journal-title":"Glomerular Dis"},{"key":"e_1_2_96_9_20_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196009","article-title":"Effect of plasma exchange on in\u2010hospital mortality in patients with pulmonary hemorrhage secondary to antineutrophil cytoplasmic antibody\u2010associated vasculitis: a propensity\u2010matched analysis using a nationwide administrative database","volume":"13","author":"Uechi E","year":"2018","journal-title":"PLoS ONE"},{"key":"e_1_2_96_9_21_1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/ki.2013.131","article-title":"Long\u2010term follow\u2010up of patients with severe ANCA\u2010associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear","volume":"84","author":"Walsh M","year":"2013","journal-title":"Kidney Int"},{"key":"e_1_2_96_9_22_1","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1053\/j.ajkd.2010.10.049","article-title":"Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta\u2010analysis","volume":"57","author":"Walsh M","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_96_9_23_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-064604","article-title":"The effects of plasma exchange in patients with ANCA\u2010associated vasculitis: an updated systematic review and meta\u2010analysis","volume":"376","author":"Walsh M","year":"2022","journal-title":"BMJ"},{"key":"e_1_2_96_9_24_1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA\u2010associated vasculitis","volume":"382","author":"Walsh M","year":"2020","journal-title":"N Engl J Med"},{"key":"e_1_2_96_9_25_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-064597","article-title":"Plasma exchange and glucocorticoid dosing for patients with ANCA\u2010associated vasculitis: a clinical practice guideline","volume":"376","author":"Zeng L","year":"2022","journal-title":"BMJ"},{"key":"e_1_2_97_9_1_1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1053\/j.ajkd.2011.12.015","article-title":"Addition of plasma exchange to glucocorticosteroids for the treatment of severe Henoch\u2010Sch\u00f6nlein purpura in adults: a case series","volume":"59","author":"Augusto JF","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_97_9_2_1","first-page":"S176","article-title":"Plasma exchange therapy for severe gastrointestinal involvement of Henoch Sch\u00f6nlein purpura in children","volume":"33","author":"Ba\u015faran \u00d6","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_97_9_3_1","doi-asserted-by":"crossref","first-page":"6621","DOI":"10.3390\/jcm13216621","article-title":"IgA vasculitis (Henoch\u2010 Sch\u00f6nlein purpura): an update on treatment","volume":"13","author":"Castaneda S","year":"2024","journal-title":"J Clin Med"},{"key":"e_1_2_97_9_4_1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s004670000477","article-title":"Cerebral vasculitis in Henoch\u2010Sch\u00f6nlein purpura: a case report with sequential magnetic resonance imaging changes treated with plasmapheresis alone","volume":"15","author":"Chen CL","year":"2000","journal-title":"Pediatr Nephrol"},{"key":"e_1_2_97_9_5_1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5414\/CNP61213","article-title":"Successful treatment of crescentic glomerulonephritis associated with adult\u2010onset Henoch\u2010Sch\u00f6nlein purpura by double\u2010filtration plasmapheresis","volume":"61","author":"Chen TC","year":"2004","journal-title":"Clin Nephrol"},{"key":"e_1_2_97_9_6_1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000223237","article-title":"Life\u2010threatening or organ\u2010impairing Henoch\u2010Sch\u00f6nlein purpura: plasmapheresis saves lives and limits organ damage","volume":"219","author":"Donghi D","year":"2009","journal-title":"Dermatology"},{"key":"e_1_2_97_9_7_1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1046\/j.1442-200X.2003.01748.x","article-title":"Cerebral vasculitis in Henoch\u2010Sch\u00f6nlein purpura: MRI and MRA findings, treated with plasmapheresis alone","volume":"45","author":"Eun SH","year":"2003","journal-title":"Pediatr Int"},{"key":"e_1_2_97_9_8_1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/adc.75.3.186","article-title":"Retrospective study of plasma exchange in patients with idiopathic rapidly progressive glomerulonephritis and vasculitis","volume":"75","author":"Gianviti A","year":"1996","journal-title":"Arch Dis Child"},{"key":"e_1_2_97_9_9_1","first-page":"CD005128","article-title":"Interventions for preventing and treating kidney disease in IgA vasculitis","volume":"2","author":"Hahn D","year":"2023","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_97_9_10_1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0272-6386(99)70178-2","article-title":"Plasmapheresis as the sole therapy for rapidly progressive Henoch\u2010Sch\u00f6nlein purpura nephritis in children","volume":"33","author":"Hattori M","year":"1999","journal-title":"Am J Kid Dis"},{"key":"e_1_2_97_9_11_1","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s00467-004-1514-0","article-title":"Plasmapheresis therapy for rapidly progressive Henoch\u2010Sch\u00f6nlein nephritis","volume":"19","author":"Kawasaki Y","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"e_1_2_97_9_12_1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1600-6143.2007.02022.x","article-title":"Successful treatment of recurrent Henoch\u2010Sch\u00f6nlein purpura in a renal allograft with plasmapheresis","volume":"8","author":"Lee J","year":"2008","journal-title":"Am J Transplant"},{"key":"e_1_2_97_9_13_1","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0140-6736(79)92505-4","article-title":"IgA immune complexes in Henoch\u2010Sch\u00f6nlein purpura","volume":"2","author":"Levinsky RJ","year":"1979","journal-title":"Lancet"},{"key":"e_1_2_97_9_14_1","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.3390\/ijms24043977","article-title":"Efficacy and safety of plasma exchange as an adjunctive therapy for rapidly progressive IgA nephropathy and Henoch\u2010 Sch\u00f6nlein purpura nephritis: a systematic review","volume":"24","author":"Nguyen B","year":"2023","journal-title":"Int J. Mol. Sci"},{"key":"e_1_2_97_9_15_1","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/ndt\/gfae009","article-title":"Outcome of immunosuppression in children with IgA vasculitis\u2010related nephritis","volume":"39","author":"Rohner K","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_97_9_16_1","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/apa.17552","article-title":"Plasmapheresis for the treatment of IgA vasculitis nephritis in children: a case series","volume":"114","author":"Rohner K","year":"2025","journal-title":"Acta Paediatr"},{"key":"e_1_2_97_9_17_1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin BH","year":"2021","journal-title":"Kidney Int"},{"key":"e_1_2_97_9_18_1","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00467-007-0498-y","article-title":"Treating severe Henoch\u2010 Sch\u00f6nlein and IgA nephritis with plasmapheresis alone","volume":"22","author":"Shenoy M","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"e_1_2_98_9_1_1","first-page":"498","article-title":"The role of therapeutic plasma exchange (TPE) in multisystem inflammatory syndrome in children (MIS\u2010C)","volume":"8","author":"Atay G","year":"2021","journal-title":"Children (Basel)"},{"key":"e_1_2_98_9_2_1","first-page":"119","article-title":"Hepatitis B viremia manifesting as polyarteritis nodosa and secondary membranous nephropathy","volume":"5","author":"Balwani MR","year":"2016","journal-title":"J Nephropharmacol"},{"key":"e_1_2_98_9_3_1","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/art.41776","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of polyarteritis","volume":"73","author":"Chung SA","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_98_9_4_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103119","article-title":"Therapeutic plasma exchange: a potential management strategy for critically ill MIS\u2010C patients in the pediatric intensive care unit","volume":"60","author":"Emeksiz S","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_98_9_5_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11926-025-01182-z","article-title":"Update on multi\u2010system inflammatory syndrome in children","volume":"27","author":"Goel AR","year":"2025","journal-title":"Curr Rheumatol Rep"},{"key":"e_1_2_98_9_6_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11926-024-01167-4","article-title":"An update on Kawasaki disease","volume":"27","author":"Goel AR","year":"2025","journal-title":"Curr Rheumatol Rep"},{"key":"e_1_2_98_9_7_1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41586-025-08697-6","article-title":"TGF\u00df links EBV to multisystem inflammatory syndrome in children","volume":"640","author":"Goetzke CC","year":"2025","journal-title":"Nature"},{"key":"e_1_2_98_9_8_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2020.104034","article-title":"Treatment of systemic necrotizing vasculitides: the 40\u2010year experience of the French Vasculitis Study Group","volume":"49","author":"Guillevin L.","year":"2020","journal-title":"Presse Med"},{"key":"e_1_2_98_9_9_1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.md.0000180792.80212.5e","article-title":"Hepatitis B virus associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients","volume":"84","author":"Guillevin L","year":"2005","journal-title":"Medicine"},{"key":"e_1_2_98_9_10_1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1002\/art.42062","article-title":"American College of Rheumatology clinical guidance for MIS\u2010C associated with SARS\u2013CoV\u20102 and hyperinflammation in pediatric COVID\u201019: version 3","volume":"74","author":"Henderson LA","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_98_9_11_1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1442-200X.2011.03487.x","article-title":"Long\u2010term efficacy of plasma exchange treatment for refractory Kawasaki disease","volume":"54","author":"Hokosaki T","year":"2012","journal-title":"Pediatr Int"},{"key":"e_1_2_98_9_12_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill Consensus Conference nomenclature of vasculitides","volume":"65","author":"Jennette JC","year":"2013","journal-title":"Arthritis Rheum"},{"key":"e_1_2_98_9_13_1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/jca.21971","article-title":"Early is superior to late plasma exchange for severe multisystem inflammatory syndrome in children","volume":"37","author":"Katlan B","year":"2022","journal-title":"J Clin Apher"},{"key":"e_1_2_98_9_14_1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/INF.0000000000002982","article-title":"Kawasaki disease and Kawasaki disease shock syndrome hospitalization rates in the United States, 2006\u20132018","volume":"40","author":"Maddox RA","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"e_1_2_98_9_15_1","doi-asserted-by":"crossref","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","volume":"135","author":"McCrindle BW","year":"2017","journal-title":"Circulation"},{"key":"e_1_2_98_9_16_1","first-page":"272","volume":"3","author":"Michailides C","year":"2024","journal-title":"Infez Med"},{"key":"e_1_2_98_9_17_1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/s10165-003-0264-3","article-title":"Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma\u2010globulin","volume":"14","author":"Mori M","year":"2004","journal-title":"Mod Rheumatol"},{"key":"e_1_2_98_9_18_1","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1097\/INF.0000000000003974","article-title":"Overview of guidelines for the medical treatment of acute Kawasaki disease in Japan (2020 Revised Version) and positioning of plasma exchange therapy in the acute phase","volume":"42","author":"Mori M","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"e_1_2_98_9_19_1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.16420","article-title":"Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS\u2010CoV\u20102","volume":"4","author":"Payne AB","year":"2021","journal-title":"JAMA Netw Open"},{"key":"e_1_2_98_9_20_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2021.105320","article-title":"Polyarteritis nodosa: state of the art","volume":"89","author":"Puechal X.","year":"2022","journal-title":"Joint Bone Spine"},{"key":"e_1_2_98_9_21_1","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/1744-9987.13486","article-title":"Impact of infliximab administration before plasma exchange therapy on patients with Kawasaki disease","volume":"24","author":"Shimada S","year":"2020","journal-title":"Ther Apher Dial"},{"key":"e_1_2_98_9_22_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2102605","volume":"385","author":"Son MBF","year":"2021","journal-title":"N Engl J Med"},{"key":"e_1_2_98_9_23_1","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jpeds.2014.01.020","article-title":"Infliximab plus plasma exchange rescue therapy in Kawasaki disease","volume":"164","author":"Sonoda K","year":"2014","journal-title":"J Pediatr"},{"key":"e_1_2_98_9_24_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/ajts.ajts_70_22","article-title":"Interesting rare case of polyarteritis nodosa related to hepatitis B virus and plasma exchange role? \u2013 A case report and review of the literature","volume":"17","author":"Tripathi PP","year":"2023","journal-title":"Asian J Transfus Sci"},{"key":"e_1_2_98_9_25_1","doi-asserted-by":"crossref","first-page":"16668","DOI":"10.3390\/ijms242316668","article-title":"Polyarteritis nodosa: old disease, new etiologies","volume":"24","author":"Wolff L","year":"2023","journal-title":"Int J Mol Sci"},{"key":"e_1_2_99_9_1_1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","article-title":"Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management","volume":"92","author":"Abboud H","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_99_9_2_1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/CND.0000000000000460","article-title":"Systematic review of the clinical characteristics and management of Isaac syndrome","volume":"25","author":"Al\u2010Chalabi M","year":"2023","journal-title":"J Clin Neuromuscul Dis"},{"key":"e_1_2_99_9_3_1","first-page":"2589","volume":"13","author":"Braczkowski M","year":"2023","journal-title":"Autoimmune encephalitis with antibodies. Diagnostics (Basel)"},{"key":"e_1_2_99_9_4_1","doi-asserted-by":"crossref","DOI":"10.1002\/jca.22112","article-title":"Suspected autoimmune encephalitis: a retrospective study of patients referred for therapeutic plasma exchange","volume":"39","author":"Crowe EP","year":"2024","journal-title":"J Clin Apher"},{"key":"e_1_2_99_9_5_1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s13311-022-01210-1","article-title":"Autoimmune neurological disorders with IgG4 antibodies: a distinct disease spectrum with unique IgG4 functions responding to anti\u2010B cell therapies","volume":"19","author":"Dalakas MC","year":"2022","journal-title":"Neurotherapeutics"},{"key":"e_1_2_99_9_6_1","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody\u2010mediated encephalitis","volume":"378","author":"Dalmau J","year":"2018","journal-title":"N Engl J Med"},{"key":"e_1_2_99_9_7_1","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/WCO.0000000000000963","article-title":"Neuromuscular hyperexcitability syndromes","volume":"34","author":"De Wei B","year":"2021","journal-title":"Curr Opin Neurol"},{"key":"e_1_2_99_9_8_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000207","article-title":"Immunoadsorption therapy in autoimmune encephalitis","volume":"3","author":"Dogan\u2010Onugoren M","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_2_99_9_9_1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.seizure.2015.04.007","article-title":"Retrospective case series of the clinical features, management and outcomes of patients with autoimmune epilepsy","volume":"29","author":"Dubey D","year":"2015","journal-title":"Seizure"},{"key":"e_1_2_99_9_10_1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.atherosclerosissup.2017.05.041","article-title":"Immunoadsorption for autoimmune encephalitis","volume":"30","author":"Fassbender C","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"e_1_2_99_9_11_1","first-page":"386","article-title":"Clinical features of 28 cases of anti\u2010leucine\u2010rich glioma\u2010inactivated protein 1 encephalitis and anti\u2010contactin\u2010associated protein\u2010like 2 encephalitis","volume":"48","author":"Feng J","year":"2023","journal-title":"Zong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"e_1_2_99_9_12_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s42466-020-0053-x","article-title":"Antibody\u2010related movement disorders\u2010 comprehensive review of phenotype\u2010autoantibody correlations and a guide to testing","volume":"2","author":"G\u00f6vert F","year":"2020","journal-title":"Neurol Res Pract"},{"key":"e_1_2_99_9_13_1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus F","year":"2016","journal-title":"Lancet Neurol"},{"key":"e_1_2_99_9_14_1","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s00415-016-8277-y","article-title":"Immunoadsorption or plasma exchange in the treatment of autoimmune encephalitis: a pilot study","volume":"263","author":"Heine J","year":"2016","journal-title":"J Neurol"},{"key":"e_1_2_99_9_15_1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/jca.21233","article-title":"Winters JL Plasma exchange as a therapeutic option in patients with neurologic symptoms due to antibodies to voltage\u2010gated potassium channels: a report of five cases and review of the literature","volume":"27","author":"Jaben EA","year":"2012","journal-title":"J Clin Apher"},{"key":"e_1_2_99_9_16_1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1212\/CPJ.0000000000000268","article-title":"Clinical utility of seropositive voltage\u2010gated potassium channel\u2010complex antibody","volume":"6","author":"Jammoul A","year":"2016","journal-title":"Neurol Clin Pract"},{"key":"e_1_2_99_9_17_1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/ene.12389","article-title":"Tryptophan immunoadsorption for the treatment of autoimmune encephalitis","volume":"22","author":"K\u00f6hler W","year":"2015","journal-title":"Eur J Neurol"},{"key":"e_1_2_99_9_18_1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jnnp-2016-314758","article-title":"Intracellular and non\u2010neuronal targets of voltage\u2010gated potassium channel complex antibodies","volume":"88","author":"Lang B","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_99_9_19_1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/jca.21395","article-title":"Therapeutic plasma exchange as a steroid\u2010sparing therapy in a patient with limbic encephalitis due to antibodies to voltage\u2010gated potassium channels","volume":"31","author":"Martin IW","year":"2016","journal-title":"J Clin Apher."},{"key":"e_1_2_99_9_20_1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1176\/appi.neuropsych.13020022","article-title":"Treatment of VGKC complex antibody\u2010associated limbic encephalitis: a systematic review","volume":"25","author":"Radja GK","year":"2013","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"e_1_2_99_9_21_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00415-025-13032-0","article-title":"Intravenous immunoglobulin as first\u2010line acute treatment in adults with autoimmune encephalitis caused by antibodies to NMDAR, LGI1, and CASPR2","volume":"272","author":"Rittel JC","year":"2025","journal-title":"J Neurol"},{"key":"e_1_2_99_9_22_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42466-019-0048-7","article-title":"SOP: antibody\u2010associated autoimmune encephalitis","volume":"2","author":"R\u00f6ssling R","year":"2020","journal-title":"Neurol Res Pract"},{"key":"e_1_2_99_9_23_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acn3.51494","article-title":"Clinical features, investigations, and outcomes of pediatric limbic encephalitis: a multicenter study","volume":"9","author":"Sabanathan S","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"e_1_2_99_9_24_1","first-page":"1","article-title":"Isaacs' syndrome: clinical and paraclinical perspectives in a series of cases","volume":"23","author":"Sarraf P","year":"2024","journal-title":"Curr J Neurol."},{"key":"e_1_2_99_9_25_1","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/jnnp.2009.178293","article-title":"An effective immunotherapy regimen for VGKC antibody positive limbic encephalitis","volume":"81","author":"Wong SH","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_100_9_1_1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12072-019-09938-3","article-title":"AARC\u2010ACLF score: best predictor of outcome in children and adolescents with decompensated Wilson disease","volume":"13","author":"Alam S","year":"2019","journal-title":"Hepatol Int"},{"key":"e_1_2_100_9_2_1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/lt.25703","article-title":"Outcomes of acute liver injury in adults due to Wilson's disease: Is survival without transplant possible?","volume":"26","author":"Camarata MA","year":"2020","journal-title":"Liver Transpl"},{"key":"e_1_2_100_9_3_1","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1002\/lt.21553","article-title":"Use of the molecular adsorbents recirculating system as a treatment for acute decompensated Wilson disease","volume":"14","author":"Chiu A","year":"2008","journal-title":"Liver Transpl"},{"key":"e_1_2_100_9_4_1","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/hep.30323","article-title":"Reversal of acute liver failure due to Wilson disease by a regimen of high\u2010volume plasma exchange and penicillamine","volume":"69","author":"Damsgaard J","year":"2019","journal-title":"Hepatology"},{"key":"e_1_2_100_9_5_1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jceh.2019.02.006","article-title":"Wilson disease presenting with acute on chronic liver failure: a single\u2010center experience of outcome and predictors of mortality in 68 patients","volume":"9","author":"Devarbhavi H","year":"2019","journal-title":"J Clin Exp Hepatol"},{"key":"e_1_2_100_9_6_1","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.12998\/wjcc.v9.i14.3273","article-title":"Pediatric Wilson disease presenting as acute liver failure: prognostic indices","volume":"9","author":"Fang WY","year":"2021","journal-title":"World J Clin Cases"},{"key":"e_1_2_100_9_7_1","doi-asserted-by":"crossref","first-page":"1003887","DOI":"10.3389\/fped.2022.1003887","article-title":"Screening for Wilson's disease in acute liver failure: a new scoring system in children","volume":"10","author":"Feng CX","year":"2022","journal-title":"Front Pediatr"},{"key":"e_1_2_100_9_8_1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/hepr.12711","article-title":"Plasma exchange and chelator therapy rescues acute liver failure in Wilson disease without liver transplantation","volume":"47","author":"Kido J","year":"2017","journal-title":"Hepatol Res"},{"key":"e_1_2_100_9_9_1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s13760-022-01872-w","article-title":"Liver transplantation as a treatment for Wilson's disease with neurological presentation: a systematic literature review","volume":"122","author":"Litwin T","year":"2022","journal-title":"Acta Neurol Belg"},{"key":"e_1_2_100_9_10_1","first-page":"221","article-title":"Wilson disease: novel diagnostic and therapeutic approaches","volume":"45","author":"Marino Z","year":"2024","journal-title":"Semin Liver Dis"},{"key":"e_1_2_100_9_11_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.21037\/tgh-2020-02","article-title":"Recent advances in Wilson disease","volume":"6","author":"Moini M","year":"2021","journal-title":"Transl Gastroenterol Hepatol"},{"key":"e_1_2_100_9_12_1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/jca.21239","article-title":"Therapeutic plasma exchange for fulminant hepatic failure secondary to Wilson's disease","volume":"27","author":"Morgan SM","year":"2012","journal-title":"J Clin Apher"},{"key":"e_1_2_100_9_13_1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/ped.12291","article-title":"Successful treatment of fulminant Wilson's disease without liver transplantation","volume":"56","author":"Motobayashi M","year":"2014","journal-title":"Pediatr Int"},{"key":"e_1_2_100_9_14_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jca.21848","article-title":"Ninety days transplant\u2010free survival with high\u2010volume plasma exchange in Wilson disease presenting as acute liver failure","volume":"36","author":"Pawaria A","year":"2021","journal-title":"J Clin Apher"},{"key":"e_1_2_100_9_15_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/jca.21396","article-title":"Report of the ASFA apheresis registry study on Wilson's disease","volume":"31","author":"Pham HP","year":"2016","journal-title":"J Clin Apher"},{"key":"e_1_2_100_9_16_1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/MPG.0000000000002894","article-title":"Fulminant Wilson disease in children: recovery after plasma exchange without transplantation","volume":"71","author":"Proost R","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_100_9_17_1","first-page":"253","article-title":"Copper removal strategies for Wilson's disease crisis in the ICU","volume":"42","author":"Reynolds HV","year":"2014","journal-title":"Anaesth Intensive Care"},{"key":"e_1_2_100_9_18_1","first-page":"CD012267","article-title":"Biomarkers for diagnosis of Wilson's disease","volume":"11","author":"Ryan A","year":"2019","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_100_9_19_1","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3390\/biomedicines9091100","article-title":"Wilson's disease: facing the challenge of diagnosing a rare disease","volume":"9","author":"Sanchez\u2010Monteagudo A","year":"2021","journal-title":"Biomedicines"},{"key":"e_1_2_100_9_20_1","article-title":"Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomized, open\u2010label, non\u2010inferiority, phase 3 trial","author":"Schilsky ML","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"e_1_2_100_9_21_1","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/hep.32805","article-title":"A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases","volume":"77","author":"Schilsky ML","year":"2023","journal-title":"Hepatology"},{"key":"e_1_2_100_9_22_1","doi-asserted-by":"crossref","first-page":"732","DOI":"10.21037\/atm-20-3090","article-title":"Therapeutic strategies in Wilson disease: pathophysiology and mode of action","volume":"9","author":"Stremmel W","year":"2021","journal-title":"Ann Transl Med"},{"key":"e_1_2_100_9_23_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12519-015-0026-2","article-title":"Diagnosis and management of fulminant Wilson's disease: a single center's experience","volume":"12","author":"Tian Y","year":"2016","journal-title":"World J Pediatr"},{"key":"e_1_2_100_9_24_1","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s12072-025-10821-7","article-title":"Plasma exchange improves survival with native liver in Wilson disease with new Wilson's index \u2265\u200911 & early hepatic encephalopathy","volume":"19","author":"Verma S","year":"2025","journal-title":"Hepatol Int"},{"key":"e_1_2_100_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-025-10867-7"}],"container-title":["Journal of Clinical Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.70141","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jca.70141","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.70141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:10:08Z","timestamp":1789567808000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jca.70141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":2247,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/jca.70141"],"URL":"https:\/\/doi.org\/10.1002\/jca.70141","archive":["Portico"],"relation":{},"ISSN":["0733-2459","1098-1101"],"issn-type":[{"value":"0733-2459","type":"print"},{"value":"1098-1101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70141"}}